

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.



Overview for Request: cder_mpl1r_wp217

Request ID: cder_mpl1r_wp217_nsdp_v02_r01

<u>Request Description</u>: In this study we examined the trends in diagnosis of congenital cytomegalovirus disease (cCMV) or CMV infection (CMV). We also assessed clinical characteristics, laboratory tests performed for CMV diagnosis, hearing loss and hematologic outcomes among infants with CMV and those who used valganciclovir/ganciclovir treatment. A companion report contains assessment of follow-up time and distribution of valganciclovir/ganciclovir treatment in individuals with cCMV (see Sentinel_Report_cder_mpl1r_wp217_nsdp_v02_r02).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 11.0.0

Data Source: We distributed this request to 12 Sentinel Data Partners on December 9, 2021. These Data Partners are a subset of the Sentinel Distributed Database (SDD). The study period included data from January 1, 2008 through May 31, 2021. Please see Appendix A for a list of dates of available data for each Data Partner.

<u>Study Design</u>: We identified occurrence of cCMV or CMV, as well as prevalent valganciclovir/ganciclovir treatment among infants between 0 and 45 days old. This is a Type 2 analysis in the Query Request Package (QRP) documentation.

Event of Interest: We defined three cohorts as follows:

Infants with CMV: We identified individuals with evidence of cCMV or CMV during the query period.

<u>Infants with valganciclovir use within 45 days from CMV diagnosis</u>: We identified individuals with evidence of valganciclovir treatment within 45 days from cCMV or CMV diagnosis.

<u>Infants with valganciclovir use within 180 days from CMV diagnosis</u>: We identified individuals with evidence of valganciclovir treatment within 180 days from cCMV or CMV diagnosis.

In each of the above cohorts we only included the first qualifying (index) cCMV or CMV diagnosis in any care setting for each infant; cohort re-entry was not allowed. Please see Appendix D for a list of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes used to define cCMV or CMV events in this report.

<u>Outcome of Interest</u>: Among the cohort of infants with CMV described above, we examined valganciclovir/ganciclovir dispensings within 180 days from cCMV or CMV diagnosis. We defined valganciclovir/ganciclovir outcome using National Drug Codes (NDCs). Please see Appendix C for a list of generic and brand names of medical products used to define valganciclovir/ganciclovir use in this report.

<u>Cohort Eligibility Criteria</u>: We required members to be enrolled in health plans with medical and drug coverage on the index date. We included individuals between 0 and 45 days of age. We defined four separate groups with the following requirements: a) <u>Cohort A (Infants with CMV)</u>: To evaluate rates of CMV diagnosis, we identified individuals with evidence of cCMV or CMV during the query period. We also examined these individuals stratified by disease severity.

b) <u>Cohort A with valganciclovir treatment (Infants with CMV events and valganciclovir/gancilovir outcome)</u>: To evaluate rates of valganciclovir/ganciclovir use in infants with CMV, we identified individuals with evidence of cCMV or CMV. Then, we assessed valganciclovir/ganciclovir use within 180 days from cCMV or CMV diagnosis.

c) <u>Two sensitivity analysis cohorts</u>: We performed sensitivity anayses assessing valganciclovir/ganciclovir use among infants with cCMV or CMV. We defined the analysis cohorts as follows:

- Valganciclovir use within 45 days: We included infants with valganciclovir/ganciclovir use within 45 days from cCMV or CMV diagnosis
- Valganciclovir use within 180 days: We included infants with valganciclovir/ganciclovir use within 180 days from cCMV or CMV diagnosis

To define disease severity for the cohort of infants with CMV, we identified four sub-cohorts based on hearing loss and selected clinical characteristics. We defined these disease severity sub-cohorts as follows:

a) <u>Hearing loss absent, clinical characteristics absent</u>: To be included in this cohort, we required members to have no history of hearing loss or clinical characteristics at any time prior to index date and up to 15 days after the index date.

b) <u>Hearing loss present, clinical characteristics absent</u>: To be included in this cohort, we required members to have a history of hearing loss, but no clinical characteristics at any time prior to the index date and up to 15 days after the index date.



Overview for Request: cder_mpl1r_wp217

c) <u>Hearing loss absent, clinical characteristics present</u>: To be included in this cohort, we required members to have no history of hearing loss, but have a history of any of the select clinical characteristics at any time prior to the index date and up to 15 days after the index date.

d) <u>Hearing loss present, clinical characteristics present</u>: To be included in this cohort, we required members to have a history of hearing loss, and a history of any of the select clinical characteristics at any time prior to the index date and up to 15 days after the index date.

See Appendix G for specifications of parameters describing different cohorts identified in this request. See Appendix H for diagrams detailing the design for this request.

Baseline Characteristics: We assessed the following characteristics: age, year, sex, geographic region (as defined by the census bureau), race, and ethnicity. In addition, we assessed the following at any time prior to the index date and up to 30 days after the index date: head computed tomography, brain abnormality, other brain abnormality, brain magnetic resonance imaging (MRI), and head ultrasound. We assessed the following clinical tests at any time prior to the index date and up to 15 days after the index date: CMV polymerase chain reaction (PCR) lab test, CMV antigen lab test, and CMV culture lab test. We assessed the following clinical characteristics at any time prior to the index date: jaundice, petechiae, splenomegaly, microcephaly, thrombocytopenia, chloriotinitis, and hepatomegaly; we also assessed the following clinical characteristics at any time prior to the index date: neutropenia, receipt of red blood cell (RBC) transfusion, receipt of platelet transfusion, and receipt of granulocyte colony-stimulating factor (GCSF) transfusion.

We identified disease severity cohorts using the following clincal characteristics: hearing loss, jaundice, petechiae, hepatomegaly, splenomegaly, microcephaly, thrombocytopenia, chorioretinitis, and brain abnormality; and the following hematologic outcomes: neutropenia, receipt of RBC transfusion, receipt of platelet transfusion, and receipt of GCSF transfusion.

See Appendix B for the list of states and territories included in each census bureau region.

See Appendix E for ICD-9-CM, ICD-10-CM, Current Procedural Terminology, Fourth Edition (CPT-4), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) codes used to define inclusion and exclusion criteria in this request.

See Appendix F for CPT-4, ICD-9-CM, ICD-10-CM, ICD-10-PCS and Healthcare Common Procedure Coding System, Level II (HCPCS) codes used to define baseline characteristics and hematologic outcomes in this request.

<u>Limitations</u>: Algorithms to define exposures, inclusion, and exclusion criteria are imperfect and may result in misclassification. Therefore, data should be interpreted with this limitation in mind.

<u>Notes:</u> Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).



	Table of Contents
Glossary	Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module
<u>Table 1a</u>	Aggregated Baseline Characteristics of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), Overall in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1b</u>	Aggregated Baseline Characteristics of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Absent, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1c</u>	Aggregated Baseline Characteristics of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Present, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1d</u>	Aggregated Baseline Characteristics of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Absent, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1e</u>	Aggregated Baseline Characteristics of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Present, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1f</u>	Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), Overall in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1g</u>	Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Absent, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1h</u>	Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Present, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1i</u>	Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Absent, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1j</u>	Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Present, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1k</u>	Aggregated Baseline Characteristics of Infants with Valganciclovir Treatment Within 45 Days from Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) Diagnosis in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 1l</u>	Aggregated Baseline Characteristics of Infants with Valganciclovir Treatment Within 180 Days from Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) Diagnosis in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 2</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021
<u>Table 3</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Sex
<u>Table 4</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Year
<u>Table 5</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Race



	Table of Contents
<u>Table 6</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Hispanic Origin
<u>Table 7</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Census Bureau Region
<u>Table 8</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Sex and Year
<u>Table 9</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Census Bureau Region and Year
<u>Table 10</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Race and Year
<u>Table 11</u>	Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021, by Hispanic Origin and Year
Appendix A	Start and End Dates for Each Data Partner (DP) as of Request Distribution Date (December 9, 2021)
Appendix B	List of States and Territories Included in Each Census Bureau Region
<u>Appendix C</u>	List of Generic and Brand Names of Medical Products Used to Define Outcome and Inclusion Criteria in this Request
<u>Appendix D</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) Events in this Request
<u>Appendix E</u>	List of Current Procedural Terminology, Fourth Edition (CPT-4), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion and Exclusion Criteria in this Request
<u>Appendix F</u>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics and Hematologic Outcomes in this Request
<u>Appendix G</u> <u>Appendix H</u>	Specifications Defining Parameters for this Request Diagrams Detailing the Design for this Request



Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Patients - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level). **Exposure Episode Length** - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.



Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered. **Minimum Episode Duration** - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug

dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report



Patient Characteristics	Number	
Unique patients	1,500	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	7.59	11.51
Age (Days)	Number	Percent
≤ 45	1,500	100.0%
ex		
Female	691	46.1%
Male	809	53.9%
lace ¹		
American Indian or Alaska Native	0	0.0%
Asian	13	0.9%
Black or African American	86	5.7%
Native Hawaiian or Other Pacific Islander	8	0.5%
Unknown	1,300	86.7%
White	93	6.2%
lispanic origin		
Yes	12	0.8%
No	151	10.1%
Unknown	1,337	89.1%
ear	_,	
2008	101	6.7%
2009	89	5.9%
2010	106	7.1%
2011	79	5.3%
2012	81	5.4%
2013	96	6.4%
2014	122	8.1%
2015	119	7.9%
2016	147	9.8%
2017	164	10.9%
2018	139	9.3%
2019	139	9.9%
2020	94	
2021	94 14	6.3% 0.9%
lealth Characteristics	14	0.9%
ype of CMV Diagnosis Code		
Congenital CMV (cCMV)	1,176	78.4%
Cytomegalovirus (CMV) Infection		
ver, Prior to and Up to 15 Days After Index	619	41.3%
aundice	704	40 70/
	731	48.7%
etechiae	84	5.6%
lepatomegaly	73	4.9%
plenomegaly	53	3.5%
Aicrocephaly	123	8.2%
hrombocytopenia	542	36.1%
Chlorioretinitis	44	2.9%
learing Loss, Hearing Aid, Cochlear Implant	132	8.8%

Table 1a. Aggregated Baseline Characteristics of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), Overall in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021



Table 1a. Aggregated Baseline Characteristics of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), Overall in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	277	18.5%
Other Brain Abnormality	2	0.1%
Within 60 Days From Index		
Neutropenia	210	14.0%
Receipt of RBC transfusion	118	7.9%
Receipt of platelet transfusion	85	5.7%
Receipt of GCSF transfusion	6	0.4%
Hearing Loss, Hearing Aid, Cochlear Implant	204	13.6%
Within 180 Days From Index		
Neutropenia	244	16.3%
Receipt of RBC transfusion	122	8.1%
Receipt of platelet transfusion	90	6.0%
Receipt of GCSF transfusion	12	0.8%
Hearing Loss, Hearing Aid, Cochlear Implant	318	21.2%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	387	25.8%
Ever, Prior to and Up to Index Date		
Jaundice	683	45.5%
Petechiae	82	5.5%
Hepatomegaly	65	4.3%
Splenomegaly	49	3.3%
Microcephaly	112	7.5%
Thrombocytopenia	529	35.3%
Chlorioretinitis	36	2.4%
Brain Abnormality	237	15.8%
Other Brain Abnormality	2	0.1%
Hearing Loss, Hearing Aid, Cochlear Implant	93	6.2%
Ever, Prior to and Up to 45 Days After Index		
Jaundice	741	49.4%
Petechiae	85	5.7%
Hepatomegaly	80	5.3%
Splenomegaly	59	3.9%
Microcephaly	131	8.7%
Thrombocytopenia	546	36.4%
Chlorioretinitis	53	3.5%
Brain Abnormality	283	18.9%
Other Brain Abnormality	2	0.1%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	254	16.9%
CMV Antigen or Antibody Testing	65	4.3%
CMV Culture	110	7.3%
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	326	21.7%



Table 1a. Aggregated Baseline Characteristics of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), Overall in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Radiology Tests (Ever, Prior to and Up to 30 Days After Index)		
Head computed tomography (CT)	142	9.5%
Brain MRI	282	18.8%
Head Ultrasound	37	2.5%



Patient Characteristics	Number	
Unique patients	405	N/A
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	10.76	11.69
Age (Days)	Number	Percent
≤ 45	405	100.0%
Sex		
Female	216	53.3%
Male	189	46.7%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	2	0.5%
Black or African American	31	7.7%
Native Hawaiian or Other Pacific Islander	1	0.2%
Unknown	346	85.4%
White	25	6.2%
Hispanic origin		
Yes	3	0.7%
No	50	12.3%
Unknown	352	86.9%
Year		
2008	35	8.6%
2009	29	7.2%
2010	35	8.6%
2011	31	7.7%
2012	15	3.7%
2013	29	7.2%
2014	35	8.6%
2015	24	5.9%
2016	36	8.9%
2017	38	9.4%
2018	29	7.2%
2019	38	9.4%
2020	26	6.4%
2021	5	1.2%
Health Characteristics		
Type of CMV Diagnosis Code		
Congenital CMV (cCMV)	309	76.3%
Cytomegalovirus (CMV) Infection	149	36.8%
Ever, Prior to and Up to 15 Days After Index		
Jaundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
Splenomegaly	0	0.0%
Microcephaly	0	0.0%
Thrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Hearing loss, Hearing Aid, Cochlear Implant	0	0.0%

 Table 1b. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss:

 Absent, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021



Table 1b. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss:
Absent, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	4	1.0%
Other Brain Abnormality	0	0.0%
Within 60 Days From Index		
Neutropenia	18	4.4%
Receipt of RBC transfusion	6	1.5%
Receipt of platelet transfusion	0	0.0%
Receipt of GCSF transfusion	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	14	3.5%
Within 180 Days From Index		
Neutropenia	20	4.9%
Receipt of RBC transfusion	7	1.7%
Receipt of platelet transfusion	1	0.2%
Receipt of GCSF transfusion	1	0.2%
Hearing Loss, Hearing Aid, Cochlear Implant	37	9.1%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	57	14.1%
Ever, Prior to and Up to Index Date		
laundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
Splenomegaly	0	0.0%
Microcephaly	0	0.0%
Thrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Brain Abnormality	0	0.0%
Other Brain Abnormality	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	0	0.0%
Ever, Prior to and Up to 45 Days After Index		
Jaundice	5	1.2%
Petechiae	0	0.0%
Hepatomegaly	1	0.2%
Splenomegaly	0	0.0%
Microcephaly	2	0.5%
Thrombocytopenia	3	0.7%
Chlorioretinitis	2	0.5%
Brain Abnormality	5	1.2%
Other Brain Abnormality	0	0.0%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	78	19.3%
CMV Antigen or Antibody Testing	20	4.9%
CMV Culture	22	5.4%
		••••



 Table 1b. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss:

 Absent, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Radiology Tests (Ever, Prior to and Up to 30 Days After Index)		
Head computed tomography (CT)	13	3.2%
Brain MRI	24	5.9%
Head Ultrasound	4	1.0%



Patient Characteristics	Number	
Unique patients	38	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	22.82	14.46
Age (Days)	Number	Percent
≤ 45	38	100.0%
Sex		
Female	19	50.0%
Male	19	50.0%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	1	2.6%
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	1	2.6%
Unknown	34	89.5%
White	2	5.3%
Hispanic origin		
Yes	0	0.0%
No	4	10.5%
Unknown	34	89.5%
Year		
2008	0	0.0%
2009	3	7.9%
2010	3	7.9%
2011	0	0.0%
2012	4	10.5%
2013	2	5.3%
2014	1	2.6%
2015	2	5.3%
2016	3	7.9%
2017	6	15.8%
2018	7	18.4%
2019	3	7.9%
2020	4	10.5%
2021	0	0.0%
Health Characteristics		
Type of CMV Diagnosis Code		
Congenital CMV (cCMV)	29	76.3%
Cytomegalovirus (CMV) Infection	19	50.0%
Ever, Prior to and Up to 15 Days After Index		
Jaundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
Splenomegaly	0	0.0%
Microcephaly	0	0.0%
Thrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Hearing loss, Hearing Aid, Cochlear Implant	38	100.0%

 Table 1c. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Present,

 Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021



 Table 1c. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Present,

 Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	0	0.0%
Other Brain Abnormality	0	0.0%
Within 60 Days From Index		
Neutropenia	3	7.9%
Receipt of RBC transfusion	0	0.0%
Receipt of platelet transfusion	0	0.0%
Receipt of GCSF transfusion	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	35	92.1%
Within 180 Days From Index		
Neutropenia	3	7.9%
Receipt of RBC transfusion	0	0.0%
Receipt of platelet transfusion	0	0.0%
Receipt of GCSF transfusion	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	37	97.4%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	37	97.4%
Ever, Prior to and Up to Index Date		
Jaundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
Splenomegaly	0	0.0%
Microcephaly	0	0.0%
Thrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Brain Abnormality	0	0.0%
Other Brain Abnormality	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	29	76.3%
Ever, Prior to and Up to 45 Days After Index		
Jaundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
Splenomegaly	0	0.0%
Microcephaly	0	0.0%
Thrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Brain Abnormality	0	0.0%
Other Brain Abnormality	0	0.0%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	13	34.2%
CMV Antigen or Antibody Testing	2	5.3%
CMV Culture	6	15.8%
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	16	42.1%



 Table 1c. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Present,

 Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	4	10.5%
Brain MRI	3	7.9%
Head Ultrasound	0	0.0%



Patient Characteristics	Number	
Unique patients	963	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	5.25	10.1
Age (Days)	Number	Percent
≤ 45	963	100.0%
Sex		
Female	416	43.2%
Male	547	56.8%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	10	1.0%
Black or African American	50	5.2%
Native Hawaiian or Other Pacific Islander	4	0.4%
Unknown	840	87.2%
White	59	6.1%
Hispanic origin		
Yes	7	0.7%
No	89	9.2%
Unknown	867	90.0%
Year		
2008	59	6.1%
2009	49	5.1%
2010	59	6.1%
2011	44	4.6%
2012	60	6.2%
2013	62	6.4%
2014	78	8.1%
2015	81	8.4%
2016	100	10.4%
2017	115	11.9%
2018	96	10.0%
2019	95	9.9%
2020	58	6.0%
2021	7	0.7%
Health Characteristics		
Type of CMV Diagnosis Code		
Congenital CMV (cCMV)	757	78.6%
Cytomegalovirus (CMV) Infection	400	41.5%
Ever, Prior to and Up to 15 Days After Index	400	41.370
Jaundice	693	70.8%
Petechiae	682 69	70.8%
	65	6.7%
Hepatomegaly		
Splenomegaly Microsophaly	50	5.2%
Microcephaly	103	10.7%
Thrombocytopenia Chloricasticitia	500	51.9%
Chlorioretinitis	40	4.2%
Hearing loss, Hearing Aid, Cochlear Implant	0	0.0%

 Table 1d. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Absent,

 Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021



 Table 1d. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Absent,

 Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	227	23.6%
Other Brain Abnormality	2	0.2%
Within 60 Days From Index		
Neutropenia	173	18.0%
Receipt of RBC transfusion	105	10.9%
Receipt of platelet transfusion	82	8.5%
Receipt of GCSF transfusion	5	0.5%
Hearing Loss, Hearing Aid, Cochlear Implant	63	6.5%
Within 180 Days From Index		
Neutropenia	200	20.8%
Receipt of RBC transfusion	108	11.2%
Receipt of platelet transfusion	86	8.9%
Receipt of GCSF transfusion	10	1.0%
Hearing Loss, Hearing Aid, Cochlear Implant	152	15.8%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	200	20.8%
Ever, Prior to and Up to Index Date		
Jaundice	638	66.3%
Petechiae	67	7.0%
Hepatomegaly	58	6.0%
Splenomegaly	46	4.8%
Microcephaly	94	9.8%
Thrombocytopenia	489	50.8%
Chlorioretinitis	36	3.7%
Brain Abnormality	202	21.0%
Other Brain Abnormality	2	0.2%
Hearing Loss, Hearing Aid, Cochlear Implant	0	0.0%
Ever, Prior to and Up to 45 Days After Index		
Jaundice	687	71.3%
Petechiae	70	7.3%
Hepatomegaly	71	7.4%
Splenomegaly	55	5.7%
Microcephaly	109	11.3%
Thrombocytopenia	501	52.0%
Chlorioretinitis	45	4.7%
Brain Abnormality	232	24.1%
Other Brain Abnormality	2	0.2%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	129	13.4%
CMV Antigen or Antibody Testing	34	3.5%
CMV Culture	67	7.0%
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	177	18.4%



 Table 1d. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Absent,

 Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	102	10.6%
Brain MRI	221	22.9%
Head Ultrasound	29	3.0%



Patient Characteristics	Number	
Unique patients	94	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	11.78	14.33
Age (Days)	Number	Percent
≤ 45	94	100.0%
Sex		
Female	40	42.6%
Male	54	57.4%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	5	5.3%
Native Hawaiian or Other Pacific Islander	2	2.1%
Unknown	80	85.1%
White	7	7.4%
Hispanic origin		
Yes	2	2.1%
No	8	8.5%
Unknown	84	89.4%
Year		
2008	7	7.4%
2009	8	8.5%
2010	9	9.6%
2011	4	4.3%
2012	2	2.1%
2013	3	3.2%
2014	8	8.5%
2015	12	12.8%
2016	8	8.5%
2017	5	5.3%
2018	7	7.4%
2019	13	13.8%
2020	6	6.4%
2021	2	2.1%
Health Characteristics		
Type of CMV Diagnosis Code		
Congenital CMV (cCMV)	81	86.2%
Cytomegalovirus (CMV) Infection	51	54.3%
Ever, Prior to and Up to 15 Days After Index	51	54.570
Jaundice	49	52.1%
Petechiae	49 15	52.1% 16.0%
Hepatomegaly	8	8.5%
	8 3	8.5% 3.2%
Splenomegaly Microsophaly	3 20	3.2% 21.3%
Microcephaly	20 42	
Thrombocytopenia Chloriorativitic		44.7%
Chlorioretinitis	4	4.3%
Hearing loss, Hearing Aid, Cochlear Implant	94	100.0%

 Table 1e. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Present,

 Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021



 Table 1e. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Present, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	46	48.9%
Other Brain Abnormality	0	0.0%
Within 60 Days From Index		
Neutropenia	16	17.0%
Receipt of RBC transfusion	7	7.4%
Receipt of platelet transfusion	3	3.2%
Receipt of GCSF transfusion	1	1.1%
Hearing Loss, Hearing Aid, Cochlear Implant	92	97.9%
Within 180 Days From Index		
Neutropenia	21	22.3%
Receipt of RBC transfusion	7	7.4%
Receipt of platelet transfusion	3	3.2%
Receipt of GCSF transfusion	1	1.1%
Hearing Loss, Hearing Aid, Cochlear Implant	92	97.9%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	93	98.9%
Ever, Prior to and Up to Index Date		
Jaundice	45	47.9%
Petechiae	15	16.0%
Hepatomegaly	7	7.4%
Splenomegaly	3	3.2%
Microcephaly	18	19.1%
Thrombocytopenia	40	42.6%
Chlorioretinitis	0	0.0%
Brain Abnormality	35	37.2%
Other Brain Abnormality	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	64	68.1%
Ever, Prior to and Up to 45 Days After Index		
Jaundice	49	52.1%
Petechiae	15	16.0%
Hepatomegaly	8	8.5%
Splenomegaly	4	4.3%
Microcephaly	20	21.3%
Thrombocytopenia	42	44.7%
Chlorioretinitis	6	6.4%
Brain Abnormality	46	48.9%
Other Brain Abnormality	0	0.0%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	34	36.2%
CMV Antigen or Antibody Testing	9	9.6%
CMV Culture	15	16.0%
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	39	41.5%



 Table 1e. Aggregated Baseline Characteristic of Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) (Hearing Loss: Present, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	23	24.5%
Brain MRI	34	36.2%
Head Ultrasound	4	4.3%



Patient Characteristics	Number	
Unique patients	1,496	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	7.55	11.48
Age (Days)	Number	Percent
≤ 45	1,496	100.0%
Sex		
Female	688	46.0%
Male	808	54.0%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	13	0.9%
Black or African American	86	5.7%
Native Hawaiian or Other Pacific Islander	8	0.5%
Unknown	1,296	86.6%
White	93	6.2%
Hispanic origin		
Yes	12	0.8%
No	151	10.1%
Unknown	1,333	89.1%
Year		
2008	101	6.8%
2009	89	5.9%
2010	106	7.1%
2011	79	5.3%
2012	80	5.3%
2013	96	6.4%
2014	122	8.2%
2015	118	7.9%
2016	145	9.7%
2017	164	11.0%
2018	139	9.3%
2019	149	10.0%
2020	94	6.3%
2021	14	0.9%
Health Characteristics		
Type of CMV Diagnosis Code		
Congenital CMV (cCMV)	1,173	78.4%
Cytomegalovirus (CMV) Infection	616	41.2%
	010	41.2%
Ever, Prior to and Up to 15 Days After Index	720	40 70/
Jaundice	728	48.7%
Petechiae	83	5.5%
Hepatomegaly	73	4.9%
Splenomegaly Microachalu	53	3.5%
Microcephaly	123	8.2%
Thrombocytopenia Chlasia activitie	541	36.2%
Chlorioretinitis	44	2.9%
Hearing loss, Hearing Aid, Cochlear Implant	131	8.8%

 Table 1f. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or

 Congenital CMV (cCMV), Overall in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021



Table 1f. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or
Congenital CMV (cCMV), Overall in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	275	18.4%
Other Brain Abnormality	2	0.1%
Within 60 Days From Index		
Neutropenia	209	14.0%
Receipt of RBC transfusion	118	7.9%
Receipt of platelet transfusion	85	5.7%
Receipt of GCSF transfusion	5	0.3%
Hearing Loss, Hearing Aid, Cochlear Implant	202	13.5%
Within 180 Days From Index		
Neutropenia	243	16.2%
Receipt of RBC transfusion	122	8.2%
Receipt of platelet transfusion	90	6.0%
Receipt of GCSF transfusion	11	0.7%
Hearing Loss, Hearing Aid, Cochlear Implant	316	21.1%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	385	25.7%
Ever, Prior to and Up to Index Date		
Jaundice	680	45.5%
Petechiae	81	5.4%
Hepatomegaly	65	4.3%
Splenomegaly	49	3.3%
Microcephaly	112	7.5%
Thrombocytopenia	528	35.3%
Chlorioretinitis	36	2.4%
Brain Abnormality	235	15.7%
Other Brain Abnormality	2	0.1%
Hearing Loss, Hearing Aid, Cochlear Implant	92	6.1%
Ever, Prior to and Up to 45 Days After Index		
Jaundice	738	49.3%
Petechiae	84	5.6%
Hepatomegaly	80	5.3%
Splenomegaly	59	3.9%
Microcephaly	131	8.8%
Thrombocytopenia	545	36.4%
Chlorioretinitis	53	3.5%
Brain Abnormality	281	18.8%
Other Brain Abnormality	2	0.1%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	253	16.9%
CMV Antigen or Antibody Testing	65	4.3%
CMV Culture	110	7.4%
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	325	21.7%



Table 1f. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or
Congenital CMV (cCMV), Overall in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	141	9.4%
Brain MRI	281	18.8%
Head Ultrasound	37	2.5%



Table 1g. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Absent, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Patient Characteristics	Number	
Unique patients	405	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	10.76	11.69
Age (Days)	Number	Percent
≤ 45	405	100.0%
Sex		
Female	216	53.3%
Male	189	46.7%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	2	0.5%
Black or African American	31	7.7%
Native Hawaiian or Other Pacific Islander	1	0.2%
Unknown	346	85.4%
White	25	6.2%
Hispanic origin	-	
Yes	3	0.7%
No	50	12.3%
Unknown	352	86.9%
Year		
2008	35	8.6%
2009	29	7.2%
2010	35	8.6%
2011	31	7.7%
2012	15	3.7%
2013	29	7.2%
2014	35	8.6%
2015	24	5.9%
2016	36	8.9%
2017	38	9.4%
2018	29	7.2%
2019	38	9.4%
2020	26	6.4%
2021	5	1.2%
Health Characteristics		1.270
Type of CMV Diagnosis Code		
Congenital CMV (cCMV)	309	76.3%
Cytomegalovirus (CMV) Infection	149	36.8%
Ever, Prior to and Up to 15 Days After Index		
Jaundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
	0	0.0%
Splenomegaly Microsophaly		
Microcephaly	0	0.0%
Thrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Hearing loss, Hearing Aid, Cochlear Implant	0	0.0%



Table 1g. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Absent, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	4	1.0%
Other Brain Abnormality	0	0.0%
Within 60 Days From Index		
Neutropenia	18	4.4%
Receipt of RBC transfusion	6	1.5%
Receipt of platelet transfusion	0	0.0%
Receipt of GCSF transfusion	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	14	3.5%
Nithin 180 Days From Index		
Neutropenia	20	4.9%
Receipt of RBC transfusion	7	1.7%
Receipt of platelet transfusion	1	0.2%
Receipt of GCSF transfusion	1	0.2%
Hearing Loss, Hearing Aid, Cochlear Implant	37	9.1%
Nithin 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	57	14.1%
Ever, Prior to and Up to Index Date		
aundice	0	0.0%
Petechiae	0	0.0%
lepatomegaly	0	0.0%
plenomegaly	0	0.0%
Лісгосерhaly	0	0.0%
⁻ hrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Brain Abnormality	0	0.0%
Other Brain Abnormality	0	0.0%
learing Loss, Hearing Aid, Cochlear Implant	0	0.0%
ver, Prior to and Up to 45 Days After Index		
aundice	5	1.2%
Petechiae	0	0.0%
lepatomegaly	1	0.2%
plenomegaly	0	0.0%
Aicrocephaly	2	0.5%
⁻ hrombocytopenia	3	0.7%
Chlorioretinitis	2	0.5%
Brain Abnormality	5	1.2%
Other Brain Abnormality	0	0.0%
Medical Product Use		
ab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	78	19.3%
CMV Antigen or Antibody Testing	20	4.9%
CMV Culture	22	5.4%
MV PCR, CMV Antigen/Antibody Testing, or CMV Culture	94	23.2%



Table 1g. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection orCongenital CMV (cCMV), (Hearing Loss: Absent, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) betweenJanuary 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	13	3.2%
Brain MRI	24	5.9%
Head Ultrasound	4	1.0%



Table 1h. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Present, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Patient Characteristics	Number	
Unique patients	38	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	22.82	14.46
Age (Days)	Number	Percent
≤ 45	38	100.0%
Sex		
Female	19	50.0%
Male	19	50.0%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	1	2.6%
Black or African American	0	0.0%
Native Hawaiian or Other Pacific Islander	1	2.6%
Unknown	34	89.5%
White	2	5.3%
Hispanic origin		
Yes	0	0.0%
No	4	10.5%
Unknown	34	89.5%
Year		
2008	0	0.0%
2009	3	7.9%
2010	3	7.9%
2011	0	0.0%
2012	4	10.5%
2013	2	5.3%
2014	1	2.6%
2015	2	5.3%
2016	3	7.9%
2017	6	15.8%
2018	7	18.4%
2019	3	7.9%
2020	4	10.5%
2021	0	0.0%
Health Characteristics		
Type of CMV Diagnosis Code		
Congenital CMV (cCMV)	29	76.3%
Cytomegalovirus (CMV) Infection	19	50.0%
Ever, Prior to and Up to 15 Days After Index		
Jaundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
Splenomegaly	0	0.0%
Microcephaly	0	0.0%
Thrombocytopenia Chlorianstinitia	0	0.0%
Chlorioretinitis	0	0.0%
Hearing loss, Hearing Aid, Cochlear Implant	38	100.0%



Table 1h. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Present, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	0	0.0%
Other Brain Abnormality	0	0.0%
Within 60 Days From Index		
Neutropenia	3	7.9%
Receipt of RBC transfusion	0	0.0%
Receipt of platelet transfusion	0	0.0%
Receipt of GCSF transfusion	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	35	92.1%
Within 180 Days From Index		
Neutropenia	3	7.9%
Receipt of RBC transfusion	0	0.0%
Receipt of platelet transfusion	0	0.0%
Receipt of GCSF transfusion	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	37	97.4%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	37	97.4%
Ever, Prior to and Up to Index Date		
laundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
Splenomegaly	0	0.0%
Microcephaly	0	0.0%
Thrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Brain Abnormality	0	0.0%
Other Brain Abnormality	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	29	76.3%
Ever, Prior to and Up to 45 Days After Index		
Jaundice	0	0.0%
Petechiae	0	0.0%
Hepatomegaly	0	0.0%
Splenomegaly	0	0.0%
Microcephaly	0	0.0%
Thrombocytopenia	0	0.0%
Chlorioretinitis	0	0.0%
Brain Abnormality	0	0.0%
, Other Brain Abnormality	0	0.0%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	13	34.2%
CMV Antigen or Antibody Testing	2	5.3%
CMV Culture	6	15.8%
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	16	42.1%



 Table 1h. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or

 Congenital CMV (cCMV), (Hearing Loss: Present, Clinical Characteristics: Absent) in the Sentinel Distributed Database (SDD) between

 January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	4	10.5%
Brain MRI	3	7.9%
Head Ultrasound	0	0.0%



 Table 1i. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or

 Congenital CMV (cCMV), (Hearing Loss: Absent, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between

 January 1, 2008 and May 31, 2021

Unique patients 960 Demographic Characteristics Mean Standard Deviation Mean Age (Days) 5.19 10.02 Age (Days) 5.19 10.02 Sex 960 100.0% Female 413 43.0% Male 547 57.0% Race ¹ 0 0.0% American Indian or Alaska Native 0 0.0% Asian 10 1.0% Black or African American 50 5.2% Native Havaian or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Vesr 7 0.7% 2008 59 6.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3	Patient Characteristics	Number	
Mean Age (Days) 5.19 10.02 Age (Days) 960 100.0% Sex 960 100.0% Female 413 43.0% Male 547 57.0% Race ¹ 0 0.0% American Indian or Alaska Native 0 0.0% Aran 10 1.0% Black or African American 50 5.2% Native Hawaiian or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% Yes 7 0.7% 2008 59 6.1% 2010 49 5.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 99 1.03 2016 99 10.3% 2017 115 12.0%	Unique patients	960	
Age (Days) Number Percent Sex 960 100.0% Female 413 43.0% Male 547 57.0% Race ¹ 0 0.0% American Indian or Alaska Native 0 0.0% Asian 10 1.0% Black or African American 50 5.2% Native Hawaiian or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% Yes 7 0.7% 2008 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0%	Demographic Characteristics	Mean	Standard Deviation
s 45 960 100.0% Sex - <	Mean Age (Days)	5.19	10.02
Sex Female 413 43.0% Male 547 57.0% Race ¹ - - American Indian or Alaska Native 0 0.0% Asian 10 10% Black or African American 50 5.2% Native Hawaiian or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hisparic origin - - Yes 7 0.7% No 864 90.0% Year - - 2008 59 6.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 80 8.3% 2015 80 8.3% 2016 99 10.3% 2017 7 0.7% Pact fort V Diagnosis Code 58 6.0% </td <td>Age (Days)</td> <td>Number</td> <td>Percent</td>	Age (Days)	Number	Percent
Female 413 43.0% Male 547 57.0% Race ¹ 0 0.0% Anerican Indian or Alaska Native 0 0.0% Asian 10 1.0% Black or African American 50 5.2% Native Hawaiian or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.13 Hispanic origin 7 0.7% Yes 7 0.7% No 89 9.3% Unknown 864 90.0% Year 2008 59 6.1% 2010 59 6.1% 2011 2010 59 6.1% 2012 2013 62 6.5% 2014 466 2015 80 8.3% 2015 208 6.0% 2016 99 10.3% 2016 2% 2% 2013 7 0.7% 2015 28.6.0%	≤ 45	960	100.0%
Male Race*54757.0%Race*00.0%Alan101.0%Black or African American101.0%Black or African American505.2%Native Hawaiian or Other Pacific Islander40.4%Unknown837837.2%White596.1%Hispanic origin70.7%Yes70.7%No86490.0%Year2008596.1%2009495.1%2010596.1%2011444.6%2012596.1%2013626.5%2014788.1%2015808.3%20169910.3%201711512.0%20189610.0%2020586.0%202170.7%Peath Charcteristic7Type of CMV Diagnosis Code597.8.6%Cytomegalovius (CMV) Infection39841.5%Ever, Prior to and Up to 15 Days After Index70.7%Heath Openial607.2%Hepatomegaly505.2%Microcephaly505.2%Microcephaly505.2%Microcephaly505.2%Microcephaly505.2%Microcephaly505.2%Microcephaly505.2%Microcephaly505.2%Microcephaly505.2%	Sex		
Race ¹ 0 0.0% Asian 0 0.0% Asian 0 0.0% Black or African American 50 5.2% Native Hawaiian or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% Yes 7 0.7% No 89 9.3% Unknown 864 90.0% Year 2008 59 6.1% 2010 59 6.1% 2012 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 99 9.5 2020 58 6.0% 2021 7 0.7%	Female	413	43.0%
American Indian or Alaska Native 0 0.0% Asian 10 1.0% Black or African American 50 5.2% Native Hawailan or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% Yes 7 0.7% No 864 90.0% Year 2008 59 6.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 78 6.6% 2020 58 6.0% 2021 7 7.7% Heath Characteristis 59 59.9%	Male	547	57.0%
American Indian or Alaska Native 0 0.0% Asian 10 1.0% Black or African American 50 5.2% Native Hawailan or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% Yes 7 0.7% No 864 90.0% Year 2008 59 6.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 78 6.6% 2020 58 6.0% 2021 7 7.7% Heath Characteristis 59 59.9%	Race ¹		
Black or African American 50 5.2% Native Hawaiian or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% Yes 7 0.7% No 89 9.3% Unknown 864 90.0% Year 7 0.7% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 25 9.9% 2020 7 0.7% Healt Characteristics		0	0.0%
Native Hawailan or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% No 89 9.3% Unknown 864 90.0% Year 7 0.7% 2008 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 58 6.0% 2020 58 6.0% 2021 7 0.7% Heith Characteristics 7 0.7% Type of CMV Diagnosis Code 7 78.6% Cytomegalovirus (CM	Asian	10	1.0%
Native Hawaiian or Other Pacific Islander 4 0.4% Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% Yes 7 0.7% No 89 9.3% Unknown 864 90.0% Year 7 0.1% 2009 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 58 6.0% 2020 58 6.0% 2021 7 0.7% Heith Characteristics 7 0.7% Cytomegalovirus (CMV) Infection	Black or African American	50	5.2%
Unknown 837 87.2% White 59 6.1% Hispanic origin 7 0.7% No 89 9.3% Unknown 864 90.0% Year 2008 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 55 9.9% 2020 58 6.0% 2021 7 0.7% Heath Characteristics	Native Hawaiian or Other Pacific Islander		
White 59 6.1% Hispanic origin Yes 7 0.7% No 89 9.3% Unknown 864 90.0% Year 2008 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2020 58 6.0% 2021 7 0.7% Health Characteristics ************************************	Unknown	837	
Hispanic origin Yes 7 0.7% No 864 90.0% Year 7 0.7% 2008 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics 7 0.7% Ever, Prior to and Up to 15 Days After Index 75 78.6% Splenomegaly 50 5.2% Microcephaly 50 5.2% Microcephaly 50 5.2% Microcephaly 500 5.21%			
Yes 7 0.7% No 89 9.3% Unknown 864 90.0% Year 2008 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 80 8.3% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 25 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics 7 7 Type of CMV Diagnosis Code 7 7 Ever, Prior to and Up to 15 Days After Index 680 70.8% Petechiae 69 7.2% Hepatomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 5.21% Microcephaly 103 10.7%			
No 89 9.3% Unknown 864 90.0% Year		7	0.7%
Unknown 864 90.0% Year			
Year 2008 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2020 58 6.0% 2021 7 0.7% Healt Characteristics			
2008 59 6.1% 2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) 755 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Ever, Prior to and Up to 15 Days After Index Jaundice 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500			50.070
2009 49 5.1% 2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics T Type of CMV Diagnosis Code 58 6.0% 2020 58 6.0% 2021 Congenital CMV (cCMV) 755 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Ever, Prior to and Up to 15 Days After Index 50 5.2% Jaundice 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103		59	6.1%
2010 59 6.1% 2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Ever, Prior to and Up to 15 Days After Index Ever, Prior to and Up to 15 Days After Index Jaundice 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
2011 44 4.6% 2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) 755 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Jaundice Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 5.21% Chlorioretinitis 40 4.2%			
2012 59 6.1% 2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) 75 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Ver, Prior to and Up to 15 Days After Index Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
2013 62 6.5% 2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) 755 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Ever, Prior to and Up to 15 Days After Index Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
2014 78 8.1% 2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) 755 Cytomegalovirus (CMV) Infection 755 Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% 5plenomegaly Splenomegaly 50 5.2% Microcephaly 10.3 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
2015 80 8.3% 2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics			
2016 99 10.3% 2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) 755 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Fver, Prior to and Up to 15 Days After Index Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
2017 115 12.0% 2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) Cytomegalovirus (CMV) Infection 398 41.5% Ever, Prior to and Up to 15 Days After Index Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
2018 96 10.0% 2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) Cytomegalovirus (CMV) Infection 755 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Ever, Prior to and Up to 15 Days After Index Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
2019 95 9.9% 2020 58 6.0% 2021 7 0.7% Health Characteristics Type of CMV Diagnosis Code Congenital CMV (cCMV) 755 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Ever, Prior to and Up to 15 Days After Index Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
2020586.0%202170.7%Health CharacteristicsType of CMV Diagnosis CodeCongenital CMV (cCMV)75578.6%Cytomegalovirus (CMV) Infection75578.6%Ever, Prior to and Up to 15 Days After IndexJaundice68070.8%Petechiae697.2%Hepatomegaly656.8%Splenomegaly505.2%Microcephaly10310.7%Thrombocytopenia50052.1%Chlorioretinitis404.2%			
202170.7%Health CharacteristicsType of CMV Diagnosis CodeCongenital CMV (cCMV)75578.6%Cytomegalovirus (CMV) Infection39841.5%Ever, Prior to and Up to 15 Days After IndexJaundice68070.8%Petechiae697.2%Hepatomegaly656.8%Splenomegaly505.2%Microcephaly10310.7%Thrombocytopenia50052.1%Chlorioretinitis404.2%			
Health CharacteristicsType of CMV Diagnosis CodeCongenital CMV (cCMV)75578.6%Cytomegalovirus (CMV) Infection39841.5%Ever, Prior to and Up to 15 Days After IndexJaundice68070.8%Petechiae697.2%Hepatomegaly656.8%Splenomegaly505.2%Microcephaly10310.7%Thrombocytopenia50052.1%Chlorioretinitis404.2%			
Type of CMV Diagnosis CodeCongenital CMV (cCMV)75578.6%Cytomegalovirus (CMV) Infection39841.5%Ever, Prior to and Up to 15 Days After IndexJaundice68070.8%Petechiae697.2%Hepatomegaly656.8%Splenomegaly505.2%Microcephaly10310.7%Thrombocytopenia50052.1%Chlorioretinitis404.2%		,	0.776
Congenital CMV (cCMV) 755 78.6% Cytomegalovirus (CMV) Infection 398 41.5% Ever, Prior to and Up to 15 Days After Index 50 70.8% Jaundice 69 7.2% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
Cytomegalovirus (CMV) Infection39841.5%Ever, Prior to and Up to 15 Days After Index5070.8%Jaundice68070.8%Petechiae697.2%Hepatomegaly656.8%Splenomegaly505.2%Microcephaly10310.7%Thrombocytopenia50052.1%Chlorioretinitis404.2%		755	78.6%
Ever, Prior to and Up to 15 Days After Index Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
Jaundice 680 70.8% Petechiae 69 7.2% Hepatomegaly 65 6.8% Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
Petechiae697.2%Hepatomegaly656.8%Splenomegaly505.2%Microcephaly10310.7%Thrombocytopenia50052.1%Chlorioretinitis404.2%		680	70.8%
Hepatomegaly656.8%Splenomegaly505.2%Microcephaly10310.7%Thrombocytopenia50052.1%Chlorioretinitis404.2%			
Splenomegaly 50 5.2% Microcephaly 103 10.7% Thrombocytopenia 500 52.1% Chlorioretinitis 40 4.2%			
Microcephaly10310.7%Thrombocytopenia50052.1%Chlorioretinitis404.2%			
Thrombocytopenia50052.1%Chlorioretinitis404.2%			
Chlorioretinitis 40 4.2%		500	
Hearing loss, Hearing Aid, Cochlear Implant00.0%		40	4.2%
	Hearing loss, Hearing Aid, Cochlear Implant	0	0.0%



Table 1i. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Absent, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	225	23.4%
Other Brain Abnormality	2	0.2%
Within 60 Days From Index		
Neutropenia	173	18.0%
Receipt of RBC transfusion	105	10.9%
Receipt of platelet transfusion	82	8.5%
Receipt of GCSF transfusion	5	0.5%
Hearing Loss, Hearing Aid, Cochlear Implant	62	6.5%
Within 180 Days From Index		
Neutropenia	200	20.8%
Receipt of RBC transfusion	108	11.3%
Receipt of platelet transfusion	86	9.0%
Receipt of GCSF transfusion	10	1.0%
Hearing Loss, Hearing Aid, Cochlear Implant	151	15.7%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	199	20.7%
Ever, Prior to and Up to Index Date		
laundice	636	66.3%
Petechiae	67	7.0%
Hepatomegaly	58	6.0%
Splenomegaly	46	4.8%
Microcephaly	94	9.8%
Thrombocytopenia	489	50.9%
Chlorioretinitis	36	3.8%
Brain Abnormality	200	20.8%
Other Brain Abnormality	2	0.2%
Hearing Loss, Hearing Aid, Cochlear Implant	0	0.0%
Ever, Prior to and Up to 45 Days After Index		
laundice	685	71.4%
Petechiae	70	7.3%
Hepatomegaly	71	7.4%
Splenomegaly	55	5.7%
Microcephaly	109	11.4%
Thrombocytopenia	501	52.2%
Chlorioretinitis	45	4.7%
Brain Abnormality	230	24.0%
Other Brain Abnormality	2	0.2%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	128	13.3%
CMV Antigen or Antibody Testing	34	3.5%
CMV Culture	67	7.0%
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	176	18.3%



Table 1i. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Absent, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	101	10.5%
Brain MRI	220	22.9%
Head Ultrasound	29	3.0%



Table 1j. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Present, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Patient Characteristics	Number	
Unique patients	93	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	11.73	14.40
Age (Days)	Number	Percent
≤ 45	93	100.0%
Sex		
Female	40	43.0%
Male	53	57.0%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	5	5.4%
Native Hawaiian or Other Pacific Islander	2	2.2%
Unknown	79	84.9%
White	7	7.5%
Hispanic origin		
Yes	2	2.2%
No	- 8	8.6%
Unknown	83	89.2%
Year	65	00.270
2008	7	7.5%
2009	8	8.6%
2010	9	9.7%
2011	4	4.3%
2012	2	2.2%
2012	3	3.2%
2013	8	8.6%
2014 2015	8 12	
		12.9%
2016	7	7.5%
2017	5	5.4%
2018	7	7.5%
2019	13	14.0%
2020	6	6.5%
2021	2	2.2%
Health Characteristics		
Type of CMV Diagnosis Code Congenital CMV (cCMV)	80	86.0%
Cytomegalovirus (CMV) Infection	50	53.8%
Ever, Prior to and Up to 15 Days After Index	50	55.870
Jaundice	48	51.6%
Petechiae	14	15.1%
Hepatomegaly	8	8.6%
Splenomegaly	3	3.2%
Microcephaly	20	21.5%
Thrombocytopenia	41	44.1%
Chlorioretinitis	4	4.3%
Hearing loss, Hearing Aid, Cochlear Implant	93	100.0%
с ,, с ,,		



Table 1j. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV), (Hearing Loss: Present, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	46	49.5%
Other Brain Abnormality	0	0.0%
Within 60 Days From Index		
Neutropenia	15	16.1%
Receipt of RBC transfusion	7	7.5%
Receipt of platelet transfusion	3	3.2%
Receipt of GCSF transfusion	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	91	97.8%
Within 180 Days From Index		
Neutropenia	20	21.5%
Receipt of RBC transfusion	7	7.5%
Receipt of platelet transfusion	3	3.2%
Receipt of GCSF transfusion	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	91	97.8%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	92	98.9%
Ever, Prior to and Up to Index Date		
laundice	44	47.3%
Petechiae	14	15.1%
Hepatomegaly	7	7.5%
Splenomegaly	3	3.2%
Microcephaly	18	19.4%
Thrombocytopenia	39	41.9%
Chlorioretinitis	0	0.0%
Brain Abnormality	35	37.6%
Other Brain Abnormality	0	0.0%
Hearing Loss, Hearing Aid, Cochlear Implant	63	67.7%
Ever, Prior to and Up to 45 Days After Index		
Jaundice	48	51.6%
Petechiae	14	15.1%
Hepatomegaly	8	8.6%
Splenomegaly	4	4.3%
Microcephaly	20	21.5%
Thrombocytopenia	41	44.1%
Chlorioretinitis	6	6.5%
Brain Abnormality	46	49.5%
Other Brain Abnormality	0	0.0%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)	<u></u>	
CMV PCR (Blood, urine, saliva)	34	36.6%
CMV Antigen or Antibody Testing	9 15	9.7% 16.1%
CMV Culture	1 -	



Table 1j. Aggregated Baseline Characteristics of Valganciclovir Treatment for Infants with Cytomegalovirus (CMV) Infection orCongenital CMV (cCMV), (Hearing Loss: Present, Clinical Characteristics: Present) in the Sentinel Distributed Database (SDD) betweenJanuary 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	23	24.7%
Brain MRI	34	36.6%
Head Ultrasound	4	4.3%

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.



Patient Characteristics	Number	
Unique patients	221	
Demographic Characteristics	Mean	Standard Deviation
Mean Age (Days)	8.97	12.34
Age (Days)	Number	Percent
≤ 45	221	100.0%
Sex		
Female	105	47.5%
Male	116	52.5%
Race ¹		
American Indian or Alaska Native	0	0.0%
Asian	1	0.5%
Black or African American	15	6.8%
Native Hawaiian or Other Pacific Islander	2	0.9%
Unknown	185	83.7%
White	18	8.1%
Hispanic origin		
Yes	2	0.9%
No	27	12.2%
Unknown	192	86.9%
Year		
2008	2	0.9%
2009	1	0.5%
2010	3	1.4%
2011	5	2.3%
2012	11	5.0%
2013	11	5.0%
2014	16	7.2%
2015	28	12.7%
2016	32	14.5%
2017	30	13.6%
2018	25	11.3%
2019	31	14.0%
2020	23	10.4%
2021	3	1.4%
Health Characteristics		
Type of CMV Diagnosis Code		
Congenital CMV (cCMV)	208	94.1%
Cytomegalovirus (CMV) Infection	90	40.7%
Ever, Prior to and Up to 15 Days After Index		
Jaundice	105	47.5%
Deteching	22	1 / 00/

 Table 1k. Aggregated Baseline Characteristics of Infants with Valganciclovir Treatment Within 45 Days from Cytomegalovirus (CMV)

 Infection or Congenital CMV (cCMV) Diagnosis in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

cytomegalovilus (civity) intection	50	40.770
Ever, Prior to and Up to 15 Days After Index		
Jaundice	105	47.5%
Petechiae	33	14.9%
Hepatomegaly	18	8.1%
Splenomegaly	18	8.1%
Microcephaly	36	16.3%
Thrombocytopenia	97	43.9%
Chlorioretinitis	13	5.9%
Hearing loss, Hearing Aid, Cochlear Implant	49	22.2%



Health Characteristics	Number	Percent
Ever, Prior to and Up to 30 Days After Index		
Brain Abnormality	74	33.5%
Other Brain Abnormality	1	0.5%
Within 60 Days From Index		
Neutropenia	41	18.6%
Receipt of RBC transfusion	7	3.2%
Receipt of platelet transfusion	14	6.3%
Receipt of GCSF transfusion	3	1.4%
Hearing Loss, Hearing Aid, Cochlear Implant	87	39.4%
Within 180 Days From Index		
Neutropenia	57	25.8%
Receipt of RBC transfusion	7	3.2%
Receipt of platelet transfusion	14	6.3%
Receipt of GCSF transfusion	7	3.2%
Hearing Loss, Hearing Aid, Cochlear Implant	124	56.1%
Within 365 Days From Index		
Hearing Loss, Hearing Aid, Cochlear Implant	138	62.4%
Ever, Prior to and Up to Index Date		
laundice	99	44.8%
Petechiae	32	14.5%
Hepatomegaly	15	6.8%
Splenomegaly	16	7.2%
Microcephaly	31	14.0%
Thrombocytopenia	95	43.0%
Chlorioretinitis	10	4.5%
Brain Abnormality	55	24.9%
Other Brain Abnormality	1	0.5%
Hearing Loss, Hearing Aid, Cochlear Implant	33	14.9%
Ever, Prior to and Up to 45 Days After Index		
laundice	107	48.4%
Petechiae	34	15.4%
Hepatomegaly	19	8.6%
Splenomegaly	21	9.5%
Microcephaly	38	17.2%
Thrombocytopenia	97	43.9%
Chlorioretinitis	17	7.7%
Brain Abnormality	77	34.8%
Other Brain Abnormality	1	0.5%
Medical Product Use		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)		
CMV PCR (Blood, urine, saliva)	69	31.2%
CMV Antigen or Antibody Testing	10	4.5%
CMV Culture	16	7.2%
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	73	33.0%

 Table 1k. Aggregated Baseline Characteristics of Infants with Valganciclovir Treatment Within 45 Days from Cytomegalovirus (CMV)

 Infection or Congenital CMV (cCMV) Diagnosis in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021



 Table 1k. Aggregated Baseline Characteristics of Infants with Valganciclovir Treatment Within 45 Days from Cytomegalovirus (CMV)

 Infection or Congenital CMV (cCMV) Diagnosis in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	26	11.8%
Brain MRI	72	32.6%
Head Ultrasound	4	1.8%

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.



Patient Characteristics	Number		
Unique patients	301		
Demographic Characteristics	Mean	Standard Deviation	
Mean Age (Days)	8.02	11.84	
Age (Days)	Number	Percent	
≤ 45	301	100.0%	
Sex			
Female	142	47.2%	
Male	159	52.8%	
Race ¹			
American Indian or Alaska Native	0	0.0%	
Asian	1	0.3%	
Black or African American	24	8.0%	
Native Hawaiian or Other Pacific Islander	3	1.0%	
Unknown	246	81.7%	
White	27	9.0%	
Hispanic origin			
Yes	2	0.7%	
No	43	14.3%	
Unknown	256	85.0%	
Year			
2008	7	2.3%	
2009	4	1.3%	
2010	5	1.7%	
2011	11	3.7%	
2012	11	3.7%	
2013	15	5.0%	
2014	24	8.0%	
2015	35	11.6%	
2016	45	15.0%	
2017	43	14.3%	
2018	32	10.6%	
2019	39	13.0%	
2020	27	9.0%	
2021	3	1.0%	
Health Characteristics	-		
Type of CMV Diagnosis Code			
Congenital CMV (cCMV)	279	92.7%	
Cytomegalovirus (CMV) Infection	125	41.5%	
Ever, Prior to and Up to 15 Days After Index			
Jaundice	144	47.8%	
Petechiae	37	12.3%	
Hepatomegaly	24	8.0%	
Splenomegaly	25	8.3%	
Microcopholy	го	10 00/	

Microcephaly

Chlorioretinitis

Thrombocytopenia

Hearing loss, Hearing Aid, Cochlear Implant

 Table 1I. Aggregated Baseline Characteristics of Infants with Valganciclovir Treatment Within 180 Days from Cytomegalovirus (CMV)

 Infection or Congenital CMV (cCMV) Diagnosis in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

16.6%

46.8%

5.3%

19.3%

50

141

16

58



 Table 1I. Aggregated Baseline Characteristics of Infants with Valganciclovir Treatment Within 180 Days from Cytomegalovirus (CMV)

 Infection or Congenital CMV (cCMV) Diagnosis in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Health Characteristics	Number	Percent	
Ever, Prior to and Up to 30 Days After Index			
Brain Abnormality	95	31.6%	
Other Brain Abnormality	1	0.3%	
Within 60 Days From Index			
Neutropenia	64	21.3%	
Receipt of RBC transfusion	17	5.6%	
Receipt of platelet transfusion	23	7.6%	
Receipt of GCSF transfusion	4	1.3%	
Hearing Loss, Hearing Aid, Cochlear Implant	103	34.2%	
Within 180 Days From Index			
Neutropenia	85	28.2%	
Receipt of RBC transfusion	19	6.3%	
Receipt of platelet transfusion	24	8.0%	
Receipt of GCSF transfusion	8	2.7%	
Hearing Loss, Hearing Aid, Cochlear Implant	155	51.5%	
Within 365 Days From Index			
Hearing Loss, Hearing Aid, Cochlear Implant	175	58.1%	
Ever, Prior to and Up to Index Date			
laundice	137	45.5%	
Petechiae	36	12.0%	
Hepatomegaly	20	6.6%	
Splenomegaly	22	7.3%	
Microcephaly	45	15.0%	
Thrombocytopenia	136	45.2%	
Chlorioretinitis	13	4.3%	
Brain Abnormality	72	23.9%	
Other Brain Abnormality	1	0.3%	
Hearing Loss, Hearing Aid, Cochlear Implant	39	13.0%	
Ever, Prior to and Up to 45 Days After Index			
Jaundice	149	49.5%	
Petechiae	38	12.6%	
Hepatomegaly	25	8.3%	
Splenomegaly	28	9.3%	
Microcephaly	53	17.6%	
Thrombocytopenia	142	47.2%	
Chlorioretinitis	22	7.3%	
Brain Abnormality	99	32.9%	
Other Brain Abnormality	1	0.3%	
Medical Product Use	-		
Lab Tests (Ever, Prior to and Up to 15 Days After Index)			
CMV PCR (Blood, urine, saliva)	80	26.6%	
CMV Antigen or Antibody Testing	13	4.3%	
CMV Culture	21	7.0%	
CMV PCR, CMV Antigen/Antibody Testing, or CMV Culture	86	28.6%	



 Table 1I. Aggregated Baseline Characteristics of Infants with Valganciclovir Treatment Within 180 Days from Cytomegalovirus (CMV)

 Infection or Congenital CMV (cCMV) Diagnosis in the Sentinel Distributed Database (SDD) between January 1, 2008 and May 31, 2021

Medical Product Use	Number	Percent
Medical Product Use		
Head computed tomography (CT)	36	12.0%
Brain MRI	98	32.6%
Head Ultrasound	6	2.0%

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.



New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants			
Cytomegalovirus (CMV) Infection or Cong	Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV)							
Overall								
1,500	5,947,422	3,368.4	2.2	0	0.0			
Hearing Loss: Absent, Clinical Characteris	tics: Absent							
405	4,142,341	969.4	2.4	0	0.0			
Hearing Loss: Present, Clinical Characteri	stics: Absent							
38	25,229	79.6	2.1	0	0.0			
Hearing Loss: Absent, Clinical Characteris	tics: Present							
963	1,812,140	2,080.7	2.2	0	0.0			
Hearing Loss: Present, Clinical Characteri	stics: Present							
94	15,600	238.6	2.5	0	0.0			
Valganciclovir Treatment for Infants with	CMV or cCMV							
Overall								
1,496	5,947,422	506.7	0.3	295	1,971.9			
Hearing Loss: Absent, Clinical Characteris	tics: Absent							
405	4,142,341	152.6	0.4	39	963.0			
Hearing Loss: Present, Clinical Characteri	stics: Absent							
38	25,229	10.8	0.3	11	2,894.7			
Hearing Loss: Absent, Clinical Characteris	tics: Present							
960	1,812,140	320.5	0.3	199	2,072.9			
Hearing Loss: Present, Clinical Characteri	stics: Present							
93	15,600	22.8	0.2	46	4,946.2			
Treatment Within 45 Days from Diagnosi	S							
221	275	468.8	2.1	0	0.0			
Treatment Within 180 Days from Diagnos	sis							
301	474	677.7	2.3	0	0.0			

¹Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

²Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



Cyclonegalovirus (CMV) Infection or Congenital CMV (cCMV) Overail Fermale 591 2,890,509 1,524.8 2.2 0 0.0 Male 809 3,056,281 1,843.6 2.3 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Absent Fermale 216 2,039,435 528.7 2.4 0 0.0 Male 189 2,102,458 440.8 2.3 0 0.0 Hearing Loss: Present, Clinical Characteristics: Absent 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Absent, Clinical Characteristics: Absent 1.3 0.4 0.4 0.2	Sex	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Female 691 2,890,509 1,524.8 2.2 0 0.0 Male 809 3,056,281 1,843.6 2.3 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Absent	Cytomegalovir	us (CMV) Infection	or Congenital CMV (cCN	/IV)			
Male 809 3,056,281 1,843.6 2.3 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Absent, 0 0.0 Male 189 2,102,458 440.8 2.3 0 0.0 Male 189 2,102,458 440.8 2.3 0 0.0 Hearing Loss: Present, Clinical Characteristics: Absent 0 0.0 0.0 Male 19 11,443 48.1 2.5 0 0.0 0.0 Male 19 13,781 31.4 1.7 0 0.0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present 0 0.0 0.0 Male 547 959,134 1,221.3 2.2 0 0.0 0.0 Male 547 959,134 1,221.3 2.8 0 0.0 0.0 Male 54 8,680 150.1 2.8 0 0.0 0.0 Male 54 8,680	Overall						
Hearing Loss: Absent, Clinical Characteristics: Absent Image Clinical Characteristics: Absent Female 216 2,039,435 528.7 2.4 0 0.0 Male 189 2,102,458 440.8 2.3 0 0.0 Hearing Loss: Present, Clinical Characteristics: Absent 0 0.0 Male 19 11,443 48.1 2.5 0 0.0 Male 19 13,781 31.4 1.7 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Male 547 959,134 1,221.3 2.2 0 0.0 Male 547 856.6 2.2 0 0.0 0.0 Male 54 8.660 150.1 2.8 0 0.0 Veganciclo	Female	691	2,890,509	1,524.8	2.2	0	0.0
Female 216 2,039,435 528.7 2.4 0 0.0 Male 189 2,102,458 440.8 2.3 0 0.0 Hearing Loss: Present, Clinical Characteristics: Absent 0 0.0 Male 19 11,443 48.1 2.5 0 0.0 Male 19 13,781 31.4 1.7 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Male 54 8,680 150.1 2.8 0 0.0 Valganciclovir Treatment for Infants with CMV or cCMV 0 0.0 0.0 Male 54 8,680 127.5 0.3 158 1.995.4 <td>Male</td> <td>809</td> <td>3,056,281</td> <td>1,843.6</td> <td>2.3</td> <td>0</td> <td>0.0</td>	Male	809	3,056,281	1,843.6	2.3	0	0.0
Male 189 2,102,458 440.8 2.3 0 0.0 Hearing Loss: Present, Clinical Characteristics: Absent Female 19 13,781 31.4 1.7 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present Female 416 852,826 859.4 2.1 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 2.2 0 0.0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 2.2 0 0.0 0.0 Male 50 150.1 2.8 0 0.0 0.0 Valganciclovir Treattwert for Infants with CMV or CMV CMV 2.8 0 0.0 Male 88 3.050,281 277.5 0.3 158 1.991.3 <td>Hearing Loss: A</td> <td>Absent, Clinical Cha</td> <td>racteristics: Absent</td> <td></td> <td></td> <td></td> <td></td>	Hearing Loss: A	Absent, Clinical Cha	racteristics: Absent				
Hearing Loss: Present, Clinical Characteristics: Absent Female 19 11,443 48.1 2.5 0 0.0 Male 19 13,781 31.4 1.7 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present	Female	216	2,039,435	528.7	2.4	0	0.0
Female 19 11,443 48.1 2.5 0 0.0 Male 19 13,781 31.4 1.7 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present 0 0.0 Male 547 959,134 1,221.3 2.2 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Male 54 8,680 150.1 2.8 0 0.0 Valganciclovir Treatment for Infants with CMV or CCMV 0 0.0 Overall 1,991.3 1,991.3 Male 808 3,056,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent 1,269.8 1,991.3 Male 189 2,102,458 71.5 0.4 24 1,269.8	Male	189	2,102,458	440.8	2.3	0	0.0
Male 19 13,781 31.4 1.7 0 0.0 Hearing Loss: Absent, Clinical Characteristics: Present 0 0.0 Male 416 852,826 859.4 2.1 0 0.0 Male 547 959,134 1,21.3 2.2 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 Male 54 8,680 150.1 2.8 0 0.0 Valganciclovi Treatments with CMV or CMV CMV CMV 0 0.0 Valganciclovi Treatments with CMV or CMV CMV 0.3 137 1,991.3 Male 808 3,056,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent Female 216 0,393,435 81.1 0.4 15 6	Hearing Loss: A	Present, Clinical Cha	racteristics: Absent				
Hearing Loss: Absent, Clinical Characteristics: Present Female 416 852,826 859.4 2.1 0 0.0 Male 547 959,134 1,221.3 2.2 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 0.0 Male 54 8,680 150.1 2.8 0 0.0 Valganciclovir Treatment for Infants with CMV or cCMV 0 0.0 0.0 Valganciclovir Treatment for Infants with CMV or cCMV 0 0.0 Male 688 2,890,509 229.2 0.3 137 1,991.3 Male 808 3,056,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Cha	Female	19	11,443	48.1	2.5	0	0.0
Female 416 852,826 859.4 2.1 0 0.0 Male 547 959,134 1,221.3 2.2 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0 0.0 0.0 Male 54 8,680 150.1 2.8 0 0.0 Valganciclovir Treatment for Infants with CMV or cCMV 0 0.0 0.0 Valganciclovir Treatment for Infants with CMV or cCMV 0 0.3 137 1,991.3 Male 808 3,056,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent 15 694.4 Yale 2,16 2,039,435 81.1 0.4 15 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent 15	Male	19	13,781	31.4	1.7	0	0.0
Male 547 959,134 1,221.3 2.2 0 0.0 Hearing Loss: Present, Clinical Characteristics: Present 0.0 0.0 Male 40 6,916 88.6 2.2 0 0.0 0.0 Male 54 8,680 150.1 2.8 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 <td>Hearing Loss: A</td> <td>Absent, Clinical Cha</td> <td>racteristics: Present</td> <td></td> <td></td> <td></td> <td></td>	Hearing Loss: A	Absent, Clinical Cha	racteristics: Present				
Hearing Loss: Present, Clinical Characteristics: Present Female 40 6,916 88.6 2.2 0 0.0 Male 54 8,680 150.1 2.8 0 0.0 Valganciclovir Treatment for Infants with CMV or cCMV Overall Female 688 2,890,509 229.2 0.3 137 1,991.3 Male 808 3,056,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent 15 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Absent, Clinical Characteristics: Absent 15 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent 16 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 2,631.6 3,157.9	Female	416	852,826	859.4	2.1	0	0.0
Female 40 6,916 88.6 2.2 0 0.0 Male 54 8,680 150.1 2.8 0 0.0 Valganciclovir Treatment for Infants with CMV or cCMV V V V V Overall	Male	547	959,134	1,221.3	2.2	0	0.0
Male 54 8,680 150.1 2.8 0 0.0 Valganciclovir Treatment for Infants with CMV or CCMV V </td <td>Hearing Loss: A</td> <td>Present, Clinical Cha</td> <td>racteristics: Present</td> <td></td> <td></td> <td></td> <td></td>	Hearing Loss: A	Present, Clinical Cha	racteristics: Present				
Valganciclovir Treatment for Infants with CMV or cCMV Overall Female 688 2,890,509 229.2 0.3 137 1,991.3 Male 808 3,056,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent 15 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent Female 19 11,443 5.6 0.3 5 2,631.6 Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 3,157.9 Male 19 13,781 5.2 0.3 1	Female	40	6,916	88.6	2.2	0	0.0
Overall Female 688 2,890,509 229.2 0.3 137 1,991.3 Male 808 3,056,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent 155 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent 2,631.6 Male 19 11,443 5.6 0.3 5 2,631.6 Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 2,348.7 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 2,348.7 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 3,157.9 3,102 1,864.7 Male 547 959,134 187.2 0.3	Male	54	8,680	150.1	2.8	0	0.0
Female 688 2,890,509 229.2 0.3 137 1,991.3 Male 808 3,056,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent	Valganciclovir	Treatment for Infar	nts with CMV or cCMV				
Male 808 3,05,281 277.5 0.3 158 1,955.4 Hearing Loss: Absent, Clinical Characteristics: Absent 216 2,039,435 81.1 0.4 15 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent V 2 2,631.6 3,157.9 Female 19 11,443 5.6 0.3 5 2,631.6 Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present V 2,631.6 3,157.9 2,348.7 Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present V V 3,157.9 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present V V 20.2 5,000.0	Overall						
Hearing Loss: Absent, Clinical Characteristics: Absent Female 216 2,039,435 81.1 0.4 15 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent 5.6 0.3 5 2,631.6 Male 19 11,443 5.6 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 2,348.7 3,164.7 Hearing Loss: Present, Clinical Characteristics: Present 102 1,864.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present 5,000.0 5,000.0	Female	688	2,890,509	229.2	0.3	137	1,991.3
Female 216 2,039,435 81.1 0.4 15 694.4 Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent 2,631.6 Female 19 11,443 5.6 0.3 5 2,631.6 Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 413 852,826 133.4 0.3 97 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present 40 6,916 9.2 0.2 20 5,000.0	Male	808	3,056,281	277.5	0.3	158	1,955.4
Male 189 2,102,458 71.5 0.4 24 1,269.8 Hearing Loss: Present, Clinical Characteristics: Absent 1,269.8 Female 19 11,443 5.6 0.3 5 2,631.6 Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 3,157.9 Female 413 852,826 133.4 0.3 97 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present	Hearing Loss: A	Absent, Clinical Cha	racteristics: Absent				
Hearing Loss: Present, Clinical Characteristics: Absent Female 19 11,443 5.6 0.3 5 2,631.6 Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present Female 413 852,826 133.4 0.3 97 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present V V V V V Female 413 852,826 133.4 0.3 97 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present V V V V V Female 40 6,916 9.2 0.2 20 5,000.0	Female	216	2,039,435	81.1	0.4	15	694.4
Female 19 11,443 5.6 0.3 5 2,631.6 Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present Female 413 852,826 133.4 0.3 97 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present Female 40 6,916 9.2 0.2 20 5,000.0	Male	189	2,102,458	71.5	0.4	24	1,269.8
Male 19 13,781 5.2 0.3 6 3,157.9 Hearing Loss: Absent, Clinical Characteristics: Present 3,157.9 Female 413 852,826 133.4 0.3 97 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present V V 20 5,000.0	Hearing Loss: F	Present, Clinical Cha	racteristics: Absent				
Hearing Loss: Absent, Clinical Characteristics: Present Female 413 852,826 133.4 0.3 97 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present 97 2,348.7 102 1,864.7 Female 40 6,916 9.2 0.2 20 5,000.0	Female	19	11,443	5.6	0.3	5	2,631.6
Female 413 852,826 133.4 0.3 97 2,348.7 Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present 97 2,348.7 20 5,000.0	Male	19	13,781	5.2	0.3	6	3,157.9
Male 547 959,134 187.2 0.3 102 1,864.7 Hearing Loss: Present, Clinical Characteristics: Present 9.2 0.2 20 5,000.0	Hearing Loss: A	Absent, Clinical Cha	racteristics: Present				
Hearing Loss: Present, Clinical Characteristics: PresentFemale406,9169.20.2205,000.0	Female	413	852,826	133.4	0.3	97	2,348.7
Female 40 6,916 9.2 0.2 20 5,000.0	Male	547	959,134	187.2	0.3	102	1,864.7
Female 40 6,916 9.2 0.2 20 5,000.0	Hearing Loss: A	Present, Clinical Cha	racteristics: Present				
Male 53 8,680 13.6 0.3 26 4,905.7				9.2	0.2	20	5,000.0
	Male	53	8,680	13.6	0.3	26	4,905.7



Sex	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants	
Valganciclovir Treatment for Infants with CMV or cCMV							
Treatment Wit	hin 45 Days from D	iagnosis					
Female	105	134	209.1	2.0	0	0.0	
Male	116	141	259.8	2.2	0	0.0	
Treatment Wit	hin 180 Days from I	Diagnosis					
Female	142	231	298.6	2.1	0	0.0	
Male	159	243	379.1	2.4	0	0.0	

¹Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

²Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



Year	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Cytomegalovirus	(CMV) Infection	or Congenital CMV (cC	MV)			
Overall						
2008	101	557,288	308.5	3.1	0	0.0
2009	89	526,114	267.4	3.0	0	0.0
2010	106	466,006	362.2	3.4	0	0.0
2011	79	440,362	261.5	3.3	0	0.0
2012	81	425,161	246.2	3.0	0	0.0
2013	96	485,284	266.9	2.8	0	0.0
2014	122	505,232	328.3	2.7	0	0.0
2015	119	520,647	293.4	2.5	0	0.0
2016	147	535,835	316.2	2.2	0	0.0
2017	164	521,359	309.3	1.9	0	0.0
2018	139	504,080	207.0	1.5	0	0.0
2019	149	478,833	152.2	1.0	0	0.0
2020	94	402,715	47.1	0.5	0	0.0
2021	14	52,420	2.2	0.2	0	0.0
Hearing Loss: Ab	sent, Clinical Cha	racteristics: Absent				
2008	35	400,692	119.8	3.4	0	0.0
2009	29	367,909	92.2	3.2	0	0.0
2010	35	324,206	119.6	3.4	0	0.0
2011	31	309,501	93.1	3.0	0	0.0
2012	15	299,620	43.2	2.9	0	0.0
2013	29	343,332	95.6	3.3	0	0.0
2014	35	354,217	86.6	2.5	0	0.0
2015	24	364,651	57.3	2.4	0	0.0
2016	36	369,744	84.0	2.3	0	0.0
2017	38	354,431	81.0	2.1	0	0.0
2018	29	339,615	46.6	1.6	0	0.0
2019	38	321,940	35.7	0.9	0	0.0
2020	26	268,708	14.2	0.5	0	0.0
2021	5	36,305	0.5	0.1	0	0.0



Year	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants			
Hearing Loss:	Present, Clinical Cha	aracteristics: Absent							
2008	0	2,965	0.0	-	0	NaN			
2009	3	2,662	13.4	4.5	0	0.0			
2010	3	2,357	11.3	3.8	0	0.0			
2011	0	2,217	0.0	-	0	NaN			
2012	4	1,958	9.4	2.4	0	0.0			
2013	2	2,147	10.6	5.3	0	0.0			
2014	1	2,305	0.0	0.0	0	0.0			
2015	2	2,093	6.0	3.0	0	0.0			
2016	3	1,840	4.3	1.4	0	0.0			
2017	6	1,686	12.0	2.0	0	0.0			
2018	7	1,625	10.1	1.4	0	0.0			
2019	3	1,460	0.6	0.2	0	0.0			
2020	4	1,313	2.0	0.5	0	0.0			
2021	0	131	0.0	-	0	NaN			
Hearing Loss:	Absent, Clinical Cha	racteristics: Present							
2008	59	155,995	152.8	2.6	0	0.0			
2009	49	157,906	129.6	2.6	0	0.0			
2010	59	141,727	218.3	3.7	0	0.0			
2011	44	130,843	154.7	3.5	0	0.0			
2012	60	125,743	184.2	3.1	0	0.0			
2013	62	142,324	158.7	2.6	0	0.0			
2014	78	151,124	204.9	2.6	0	0.0			
2015	81	156,586	194.6	2.4	0	0.0			
2016	100	166,822	209.2	2.1	0	0.0			
2017	115	167,751	202.2	1.8	0	0.0			
2018	96	165,265	140.8	1.5	0	0.0			
2019	95	157,854	99.7	1.0	0	0.0			
2020	58	134,778	29.8	0.5	0	0.0			
2021	7	16,175	1.1	0.2	0	0.0			



Year	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Pro	esent, Clinical Cha	aracteristics: Present				
2008	7	1,777	35.9	5.1	0	0.0
2009	8	1,660	32.2	4.0	0	0.0
2010	9	1,434	13.0	1.4	0	0.0
2011	4	1,323	13.6	3.4	0	0.0
2012	2	1,299	9.4	4.7	0	0.0
2013	3	1,262	1.9	0.6	0	0.0
2014	8	1,426	36.8	4.6	0	0.0
2015	12	1,258	35.5	3.0	0	0.0
2016	8	1,138	18.7	2.3	0	0.0
2017	5	1,139	14.2	2.8	0	0.0
2018	7	1,055	9.5	1.4	0	0.0
2019	13	957	16.2	1.2	0	0.0
2020	6	783	1.1	0.2	0	0.0
2021	2	91	0.6	0.3	0	0.0
Valganciclovir Tr	eatment for Infai	nts with CMV or cCMV				
Overall						
2008	101	557,288	38.3	0.4	7	693.1
2009	89	526,114	36.3	0.4	4	449.4
2010	106	466,006	43.8	0.4	5	471.7
2011	79	440,362	30.7	0.4	11	1,392.4
2012	80	425,161	30.6	0.4	10	1,250.0
2013	96	485,284	34.1	0.4	15	1,562.5
2014	122	505,232	41.9	0.3	23	1,885.2
2015	118	520,647	36.9	0.3	34	2,881.4
2016	145	535,835	43.4	0.3	42	2,896.6
2017	164	521,359	53.4	0.3	43	2,622.0
2018	139	504,080	45.1	0.3	32	2,302.2
2019	149	478,833	46.3	0.3	39	2,617.4
2020	94	402,715	24.1	0.3	27	2,872.3
2021	14	52,420	1.7	0.1	3	2,142.9



Year	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: A	Absent, Clinical Cha	racteristics: Absent				
2008	35	400,692	12.2	0.3	1	285.7
2009	29	367,909	11.4	0.4	0	0.0
2010	35	324,206	14.5	0.4	0	0.0
2011	31	309,501	11.9	0.4	5	1,612.9
2012	15	299,620	6.3	0.4	0	0.0
2013	29	343,332	10.5	0.4	4	1,379.3
2014	35	354,217	14.7	0.4	0	0.0
2015	24	364,651	10.3	0.4	1	416.7
2016	36	369,744	14.0	0.4	5	1,388.9
2017	38	354,431	14.0	0.4	6	1,578.9
2018	29	339,615	10.8	0.4	4	1,379.3
2019	38	321,940	14.7	0.4	5	1,315.8
2020	26	268,708	7.0	0.3	7	2,692.3
2021	5	36,305	0.3	0.1	1	2,000.0
Hearing Loss: P	Present, Clinical Cha	aracteristics: Absent				
2008	0	2,965	0.0	-	0	NaN
2009	3	2,662	1.2	0.4	0	0.0
2010	3	2,357	1.5	0.5	0	0.0
2011	0	2,217	0.0	-	0	NaN
2012	4	1,958	2.0	0.5	0	0.0
2013	2	2,147	0.6	0.3	1	5,000.0
2014	1	2,305	0.0	0.0	0	0.0
2015	2	2,093	0.3	0.2	1	5,000.0
2016	3	1,840	0.6	0.2	2	6,666.7
2017	6	1,686	1.2	0.2	3	5,000.0
2018	7	1,625	2.2	0.3	2	2,857.1
2019	3	1,460	0.6	0.2	0	0.0
2020	4	1,313	0.5	0.1	2	5,000.0
2021	0	131	0.0	-	0	NaN



Year	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Ab	osent, Clinical Cha	racteristics: Present				
2008	59	155,995	23.1	0.4	5	847.5
2009	49	157,906	20.6	0.4	3	612.2
2010	59	141,727	23.6	0.4	5	847.5
2011	44	130,843	17.4	0.4	5	1,136.4
2012	59	125,743	22.2	0.4	8	1,355.9
2013	62	142,324	22.1	0.4	9	1,451.6
2014	78	151,124	26.0	0.3	16	2,051.3
2015	80	156,586	23.4	0.3	26	3,250.0
2016	99	166,822	28.0	0.3	30	3,030.3
2017	115	167,751	37.8	0.3	29	2,521.7
2018	96	165,265	30.5	0.3	22	2,291.7
2019	95	157,854	29.3	0.3	24	2,526.3
2020	58	134,778	15.8	0.3	15	2,586.2
2021	7	16,175	0.8	0.1	2	2,857.1
Hearing Loss: Pr	esent, Clinical Cha	aracteristics: Present				
2008	7	1,777	3.0	0.4	1	1,428.6
2009	8	1,660	3.1	0.4	1	1,250.0
2010	9	1,434	4.3	0.5	0	0.0
2011	4	1,323	1.4	0.3	1	2,500.0
2012	2	1,299	0.1	0.1	2	10,000.0
2013	3	1,262	0.9	0.3	1	3,333.3
2014	8	1,426	1.1	0.1	7	8,750.0
2015	12	1,258	2.9	0.2	6	5,000.0
2016	7	1,138	0.9	0.1	5	7,142.9
2017	5	1,139	0.5	0.1	5	10,000.0
2018	7	1,055	1.7	0.2	4	5,714.3
2019	13	957	1.6	0.1	10	7,692.3
2020	6	783	0.7	0.1	3	5,000.0
2021	2	91	0.6	0.3	0	0.0



Year	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Treatment Within	n 45 Days from D	Diagnosis				
2008	2	3	21.7	10.9	0	0.0
2009	1	4	0.4	0.4	0	0.0
2010	3	4	7.6	2.5	0	0.0
2011	5	8	24.7	4.9	0	0.0
2012	11	12	34.4	3.1	0	0.0
2013	11	15	27.2	2.5	0	0.0
2014	16	19	45.0	2.8	0	0.0
2015	28	37	76.3	2.7	0	0.0
2016	32	40	88.6	2.8	0	0.0
2017	30	40	58.1	1.9	0	0.0
2018	25	28	36.5	1.5	0	0.0
2019	31	44	34.1	1.1	0	0.0
2020	23	27	13.6	0.6	0	0.0
2021	3	3	0.7	0.2	0	0.0
Treatment Within	n 180 Days from	Diagnosis				
2008	7	14	38.1	5.4	0	0.0
2009	4	13	15.8	3.9	0	0.0
2010	5	17	18.5	3.7	0	0.0
2011	11	17	45.0	4.1	0	0.0
2012	11	19	34.4	3.1	0	0.0
2013	15	27	30.4	2.0	0	0.0
2014	24	39	73.3	3.1	0	0.0
2015	35	57	99.2	2.8	0	0.0
2016	45	67	122.9	2.7	0	0.0
2017	43	69	89.6	2.1	0	0.0
2018	32	45	50.3	1.6	0	0.0
2019	39	66	43.0	1.1	0	0.0
2020	27	37	16.7	0.6	0	0.0
2021	3	3	0.7	0.2	0	0.0

¹Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

²Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



Race	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Cytomegalovirus (CMV) Infec	ction or Conge	enital CMV (cCMV)				
Overall						
American Indian or Alaska Native	0	7,426	0.0	-	0	N/A
Asian	13	49,380	30.2	2.3	0	0.0
Black or African American	86	166,054	261.8	3.0	0	0.0
Native Hawaiian or Other Pacific Islander	8	16,909	28.2	3.5	0	0.0
Unknown	1,300	5,275,903	2,674.6	2.1	0	0.0
White	93	431,750	373.5	4.0	0	0.0
Hearing Loss: Absent, Clinical	l Characteristi	ics: Absent				
American Indian or Alaska Native	0	5,211	0.0	-	0	N/A
Asian	2	27,334	2.3	1.1	0	0.0
Black or African American	31	132,973	97.2	3.1	0	0.0
Native Hawaiian or Other Pacific Islander	1	8,756	2.9	2.9	0	0.0
Unknown	346	3,670,194	763.6	2.2	0	0.0
White	25	297,873	103.5	4.1	0	0.0
Hearing Loss: Present, Clinica	l Characterist	tics: Absent				
American Indian or Alaska Native	0	38	0.0	-	0	N/A
Asian	1	219	3.8	3.8	0	0.0
Black or African American	0	492	0.0		0	N/A
Native Hawaiian or Other Pacific Islander	1	164	3.0	3.0	0	0.0
Unknown	34	22,827	62.7	1.8	0	0.0
White	2	1,489	10.1	5.1	0	0.0



Race	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Absent, Clinica	l Characteristi	ics: Present				
American Indian or Alaska Native	0	2,218	0.0	-	0	N/A
Asian	10	22,167	24.0	2.4	0	0.0
Black or African American	50	33,338	150.2	3.0	0	0.0
Native Hawaiian or Other Pacific Islander	4	8,133	12.3	3.1	0	0.0
Unknown	840	1,611,463	1,666.2	2.0	0	0.0
White	59	134,821	227.9	3.9	0	0.0
Hearing Loss: Present, Clinica	al Characterist	tics: Present				
American Indian or Alaska Native	0	20	0.0	-	0	N/A
Asian	0	237	0.0	-	0	N/A
Black or African American	5	285	14.4	2.9	0	0.0
Native Hawaiian or Other Pacific Islander	2	159	10.1	5.0	0	0.0
Unknown	80	13,966	182.2	2.3	0	0.0
White	7	933	32.0	4.6	0	0.0
Valganciclovir Treatment for	Infants with	CMV or cCMV				
Overall						
American Indian or Alaska Native	0	7,426	0.0	-	0	N/A
Asian	13	49,380	5.7	0.4	1	769.2
Black or African American	86	166,054	29.0	0.3	24	2,790.7
Native Hawaiian or Other Pacific Islander	8	16,909	2.7	0.3	3	3,750.0
Unknown	1,296	5,275,903	436.6	0.3	240	1,851.9
White	93	431,750	32.8	0.4	27	2,903.2



Race	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Absent, Clinica	l Characteristi	cs: Absent				
American Indian or Alaska Native	0	5,211	0.0	-	0	N/A
Asian	2	27,334	1.0	0.5	0	0.0
Black or African American	31	132,973	12.5	0.4	5	1,612.9
Native Hawaiian or Other Pacific Islander	1	8,756	0.1	0.1	1	10,000.0
Unknown	346	3,670,194	129.1	0.4	30	867.1
White	25	297,873	9.9	0.4	3	1,200.0
Hearing Loss: Present, Clinica	al Characterist	ics: Absent				
American Indian or Alaska Native	0	38	0.0	-	0	N/A
Asian	1	219	0.1	0.1	1	10,000.0
Black or African American	0	492	0.0		0	N/A
Native Hawaiian or Other Pacific Islander	1	164	0.1	0.1	1	10,000.0
Unknown	34	22,827	10.0	0.3	8	2,352.9
White	2	1,489	0.6	0.3	1	5,000.0
Hearing Loss: Absent, Clinical	l Characteristi	cs: Present				
American Indian or Alaska Native	0	2,218	0.0	-	0	N/A
Asian	10	22,167	4.6	0.5	0	0.0
Black or African American	50	33,338	15.5	0.3	16	3,200.0
Native Hawaiian or Other Pacific Islander	4	8,133	1.9	0.5	0	0.0
Unknown	837	1,611,463	277.5	0.3	165	1,971.3
White	59	134,821	21.0	0.4	18	3,050.8



Race	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Present, Clinica	al Characterist	ics: Present				
American Indian or Alaska Native	0	20	0.0	-	0	N/A
Asian	0	237	0.0	-	0	N/A
Black or African American	5	285	0.9	0.2	3	6,000.0
Native Hawaiian or Other Pacific Islander	2	159	0.5	0.3	1	5,000.0
Unknown	79	13,966	20.0	0.3	37	4,683.5
White	7	933	1.3	0.2	5	7,142.9
Treatment Within 45 Days fro	om Diagnosis					
American Indian or Alaska Native	0	0	0.0	-	0	N/A
Asian	1	2	3.8	3.8	0	0.0
Black or African American	15	18	44.8	3.0	0	0.0
Native Hawaiian or Other Pacific Islander	2	3	3.0	1.5	0	0.0
Unknown	185	227	352.7	1.9	0	0.0
White	18	25	64.6	3.6	0	0.0
Treatment Within 180 Days f	rom Diagnosis	5				
American Indian or Alaska Native	0	0	0.0	-	0	N/A
Asian	1	3	3.8	3.8	0	0.0
Black or African American	24	29	72.9	3.0	0	0.0
Native Hawaiian or Other Pacific Islander	3	6	5.9	2.0	0	0.0
Unknown	246	394	497.1	2.0	0	0.0
White	27	42	98.0	3.6	0	0.0

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

³Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



Hispanic Origin	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Cytomegalovirus (CN	/IV) Infection or Co	ngenital CMV (cCMV)				
Overall						
Yes	12	56,193	31.7	2.6	0	0.0
No	151	543,509	583.9	3.9	0	0.0
Unknown	1,337	5,347,720	2,752.7	2.1	0	0.0
Hearing Loss: Absent	t, Clinical Character	ristics: Absent				
Yes	3	36,210	13.7	4.6	0	0.0
No	50	381,403	182.0	3.6	0	0.0
Unknown	352	3,724,728	773.7	2.2	0	0.0
Hearing Loss: Presen	t, Clinical Characte	eristics: Absent				
Yes	0	228	0.0	-	0	N/A
No	4	1,872	16.9	4.2	0	0.0
Unknown	34	23,129	62.7	1.8	0	0.0
Hearing Loss: Absent	t, Clinical Character	ristics: Present				
Yes	7	20,040	15.4	2.2	0	0.0
No	89	163,195	338.9	3.8	0	0.0
Unknown	867	1,628,905	1,726.4	2.0	0	0.0
Hearing Loss: Presen	t, Clinical Characte	eristics: Present				
Yes	2	175	2.6	1.3	0	0.0
No	8	1,270	46.1	5.8	0	0.0
Unknown	84	14,155	189.9	2.3	0	0.0
Valganciclovir Treatr	nent for Infants wi	th CMV or cCMV				
Overall						
Yes	12	56,193	5.0	0.4	2	1,666.7
No	151	543,509	54.2	0.4	43	2,847.7
Unknown	1,333	5,347,720	447.5	0.3	250	1,875.5
Hearing Loss: Absent	, Clinical Character	ristics: Absent				
Yes	3	36,210	1.0	0.3	1	3,333.3
No	50	381,403	20.0	0.4	8	1,600.0
Unknown	352	3,724,728	131.6	0.4	30	852.3



	•					
Hispanic Origin	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Present	t, Clinical Characte	ristics: Absent				
Yes	0	228	0.0	-	0	N/A
No	4	1,872	0.8	0.2	3	7,500.0
Unknown	34	23,129	10.0	0.3	8	2,352.9
Hearing Loss: Absent	, Clinical Characte	ristics: Present				
Yes	7	20,040	3.4	0.5	0	0.0
No	89	163,195	31.4	0.4	27	3,033.7
Unknown	864	1,628,905	285.7	0.3	172	1,990.7
Hearing Loss: Present	t, Clinical Characte	ristics: Present				
Yes	2	175	0.5	0.3	1	5,000.0
No	8	1,270	2.0	0.3	5	6,250.0
Unknown	83	14,155	20.2	0.2	40	4,819.3
Treatment Within 45	Days from Diagno	sis				
Yes	2	3	3.9	2.0	0	0.0
No	27	37	85.5	3.2	0	0.0
Unknown	192	235	379.4	2.0	0	0.0
Treatment Within 18	0 Days from Diagn	osis				
Yes	2	4	3.9	2.0	0	0.0
No	43	62	138.3	3.2	0	0.0
Unknown	256	408	535.4	2.1	0	0.0

¹Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

²Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Cytomegalovirus	(CMV) Infection	or Congenital CMV (cCN	VIV)			
Overall						
Midwest	317	1,273,190	581.6	1.8	0	0.0
Northeast	177	706,647	325.0	1.8	0	0.0
South	753	2,558,253	1,904.4	2.5	0	0.0
West	233	1,247,290	517.4	2.2	0	0.0
Invalid	8	53,261	32.2	4.0	0	0.0
Missing	12	107,992	7.8	0.7	0	0.0
Other	0	789	0.0	-	0	N/A
learing Loss: Ab	sent, Clinical Cha	racteristics: Absent				
Midwest	70	855,895	144.6	2.1	0	0.0
Northeast	58	535,728	98.0	1.7	0	0.0
South	211	1,758,587	587.0	2.8	0	0.0
West	58	862,030	118.1	2.0	0	0.0
Invalid	2	42,226	16.1	8.1	0	0.0
Missing	6	87,215	5.5	0.9	0	0.0
Other	0	660	0.0	-	0	N/A
Hearing Loss: Pro	esent, Clinical Cha	racteristics: Absent				
Midwest	6	5,158	12.1	2.0	0	0.0
Northeast	13	4,168	27.2	2.1	0	0.0
South	13	10,931	22.2	1.7	0	0.0
West	6	4,428	18.1	3.0	0	0.0
Invalid	0	95	0.0	-	0	N/A
Missing	0	449	0.0	-	0	N/A
Other	0	0	0.0	-	0	N/A
learing Loss: Ab	sent, Clinical Cha	racteristics: Present				
Midwest	219	419,446	369.7	1.7	0	0.0
Northeast	95	171,214	180.0	1.9	0	0.0
South	497	801,964	1,205.8	2.4	0	0.0
West	143	387,339	308.1	2.2	0	0.0
Invalid	6	11,105	16.0	2.7	0	0.0
Missing	3	20,933	1.1	0.4	0	0.0
Other	0	139	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Pr	esent, Clinical Cha	racteristics: Present				
Midwest	22	3,168	55.2	2.5	0	0.0
Northeast	11	2,035	19.7	1.8	0	0.0
South	32	6,963	89.4	2.8	0	0.0
West	26	3,167	73.1	2.8	0	0.0
Invalid	0	67	0.0	-	0	N/A
Missing	3	199	1.2	0.4	0	0.0
Other	0	1	0.0	-	0	N/A
/alganciclovir Tı	reatment for Infar	nts with CMV or cCMV				
Overall						
Midwest	317	1,273,190	104.2	0.3	70	2,208.2
Northeast	176	706,647	60.3	0.3	31	1,761.4
South	752	2,558,253	255.2	0.3	152	2,021.3
West	231	1,247,290	80.8	0.3	40	1,731.6
Invalid	8	53,261	3.3	0.4	0	0.0
Missing	12	107,992	2.9	0.2	2	1,666.7
Other	0	789	0.0	-	0	N/A
learing Loss: Ab	osent, Clinical Cha	racteristics: Absent				
Midwest	70	855,895	28.3	0.4	4	571.4
Northeast	58	535,728	19.6	0.3	4	689.7
South	211	1,758,587	82.9	0.4	22	1,042.7
West	58	862,030	19.5	0.3	9	1,551.7
Invalid	2	42,226	1.0	0.5	0	0.0
Missing	6	87,215	1.4	0.2	0	0.0
Other	0	660	0.0	-	0	N/A
learing Loss: Pr	esent, Clinical Cha	racteristics: Absent				
Midwest	6	5,158	1.6	0.3	3	5,000.0
Northeast	13	4,168	4.2	0.3	1	769.2
South	13	10,931	3.3	0.3	5	3,846.2
West	6	4,428	1.7	0.3	2	3,333.3
Invalid	0	95	0.0	-	0	N/A
Missing	0	449	0.0	-	0	N/A
Other	0	0	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Ab	sent, Clinical Chai	racteristics: Present				
Midwest	219	419,446	69.9	0.3	50	2,283.1
Northeast	94	171,214	34.5	0.4	18	1,914.9
South	496	801,964	161.0	0.3	109	2,197.6
West	142	387,339	52.0	0.4	21	1,478.9
Invalid	6	11,105	2.3	0.4	0	0.0
Missing	3	20,933	0.8	0.3	1	3,333.3
Other	0	139	0.0	-	0	N/A
Hearing Loss: Pro	esent, Clinical Cha	racteristics: Present				
Midwest	22	3,168	4.5	0.2	13	5,909.1
Northeast	11	2,035	1.9	0.2	8	7,272.7
South	32	6,963	8.0	0.2	16	5,000.0
West	25	3,167	7.7	0.3	8	3,200.0
Invalid	0	67	0.0	-	0	N/A
Missing	3	199	0.7	0.2	1	3,333.3
Other	0	1	0.0	-	0	N/A
Treatment With	in 45 Days from D	iagnosis				
Midwest	55	68	104.3	1.9	0	0.0
Northeast	24	31	37.2	1.6	0	0.0
South	103	129	233.4	2.3	0	0.0
West	37	45	93.6	2.5	0	0.0
Invalid	0	0	0.0	-	0	N/A
Missing	2	2	0.3	0.1	0	0.0
Other	0	0	0.0	-	0	N/A
Treatment With	in 180 Days from I	Diagnosis				
Midwest	70	108	139.8	2.0	0	0.0
Northeast	33	53	52.4	1.6	0	0.0
South	154	229	380.0	2.5	0	0.0
West	42	80	105.2	2.5	0	0.0
Invalid	0	1	0.0	-	0	N/A
Missing	2	3	0.3	0.1	0	0.0
Other	0	0	0.0	-	0	N/A

¹Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

²Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Cytomegalovir	us (CMV) Infection	or Congenital CMV (cC	MV)			
Overall						
Female						
2008	49	270,320	127.2	2.6	0	0.0
2009	40	255,371	141.3	3.5	0	0.0
2010	53	226,069	187.3	3.5	0	0.0
2011	41	213,394	117.2	2.9	0	0.0
2012	35	206,077	104.4	3.0	0	0.0
2013	43	235,352	127.3	3.0	0	0.0
2014	53	245,651	117.7	2.2	0	0.0
2015	55	252,935	133.1	2.4	0	0.0
2016	72	260,661	146.9	2.0	0	0.0
2017	74	253,871	139.6	1.9	0	0.0
2018	59	246,015	96.8	1.6	0	0.0
2019	68	233,144	66.2	1.0	0	0.0
2020	46	196,004	19.5	0.4	0	0.0
2021	3	25,529	0.3	0.1	0	0.0
Male						
2008	52	286,920	181.3	3.5	0	0.0
2009	49	270,695	126.1	2.6	0	0.0
2010	53	239,905	174.9	3.3	0	0.0
2011	38	226,948	144.3	3.8	0	0.0
2012	46	219,041	141.8	3.1	0	0.0
2013	53	249,897	139.6	2.6	0	0.0
2014	69	259,530	210.7	3.1	0	0.0
2015	64	267,673	160.3	2.5	0	0.0
2016	75	275,104	169.4	2.3	0	0.0
2017	90	267,436	169.7	1.9	0	0.0
2018	80	258,023	110.2	1.4	0	0.0
2019	81	245,601	86.0	1.1	0	0.0
2020	48	206,620	27.6	0.6	0	0.0
2021	11	26,884	1.8	0.2	0	0.0



200818196,69744.82.500.0200916180,92658.03.600.0201019159,51584.04.400.0201122151,99360.62.800.020128147,40926.63.300.0201315168,48751.73.400.0201414174,65036.22.600.0201514179,25939.92.900.0201622182,25046.12.100.0201720174,95735.01.700.0201817168,19723.31.400.0202014132,3636.90.500.02021117,9400.00.00.00.0		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Hearing Loss:	Absent, Clinical Cha	racteristics: Absent				
2009 16 180,926 58.0 3.6 0 0.0 2010 19 159,515 84.0 4.4 0 0.0 2011 22 151,993 60.6 2.8 0 0.0 2012 8 147,409 26.6 3.3 0 0.0 2013 15 168,487 51.7 3.4 0 0.0 2014 14 179,550 36.2 2.6 0 0.0 2015 14 179,259 39.9 2.9 0 0.0 2016 22 182,250 46.1 2.1 0 0.0 2018 17 168,197 23.3 1.4 0 0.0 2019 16 158,708 15.5 1.0 0 0.0 2020 14 132,363 6.9 0.5 0 0.0 2021 16 158,708 15.5 1.0 0 0.0 <	Female						
2010 19 159,515 84.0 4.4 0 0.0 2011 22 151,993 60.6 2.8 0 0.0 2012 8 147,409 2.6.6 3.3 0 0.0 2013 15 168,487 51.7 3.4 0 0.0 2014 14 174,550 36.2 2.6 0 0.0 2015 14 179,259 39.9 2.9 0 0.0 2016 22 182,250 46.1 2.1 0 0.0 2017 20 174,957 35.0 1.7 0 0.0 2018 17 168,197 2.3 1.4 0 0.0 2020 14 132,363 6.9 0.5 0 0.0 2021 1 17,940 0.0 0.0 0.0 0.0 2010 15 166,666 35.7 2.2 0 0.0 <t< td=""><td>2008</td><td>18</td><td>196,697</td><td>44.8</td><td>2.5</td><td>0</td><td>0.0</td></t<>	2008	18	196,697	44.8	2.5	0	0.0
2011 22 151,993 60.6 2.8 0 0.0 2012 8 147,409 26.6 3.3 0 0.0 2013 15 168,487 51.7 3.4 0 0.0 2014 14 174,650 36.2 2.6 0 0.0 2015 14 179,259 39.9 2.9 0 0.0 2016 22 182,250 46.1 2.1 0 0.0 2018 17 168,197 23.3 1.4 0 0.0 2019 16 158,708 15.5 1.0 0 0.0 2020 14 132,363 6.9 0.5 0 0.0 2021 1 17,940 0.0 0.0 0.0 0.0 2012 7 152,182 16.6 2.4 0 0.0 2014 16 164,666 35.7 2.2 0 0.0 <td< td=""><td>2009</td><td>16</td><td>180,926</td><td>58.0</td><td>3.6</td><td>0</td><td>0.0</td></td<>	2009	16	180,926	58.0	3.6	0	0.0
2012 8 147,409 26.6 3.3 0 0.0 2013 15 168,487 51.7 3.4 0 0.0 2014 14 174,650 36.2 2.6 0 0.0 2015 14 179,259 39.9 2.9 0 0.0 2016 22 182,250 46.1 2.1 0 0.0 2017 20 174,957 35.0 1.7 0 0.0 2018 17 168,197 23.3 1.4 0 0.0 2020 14 132,363 6.9 0.5 0 0.0 2021 1 17,940 0.0 0.0 0.0 0.0 2020 13 186,957 34.1 2.6 0 0.0 2010 16 154,666 35.7 2.2 0 0.0 2011 9 157,489 32.5 3.6 0 0.0 <td< td=""><td>2010</td><td>19</td><td>159,515</td><td>84.0</td><td>4.4</td><td>0</td><td>0.0</td></td<>	2010	19	159,515	84.0	4.4	0	0.0
2013 15 168,487 51.7 3.4 0 0.0 2014 14 174,650 36.2 2.6 0 0.0 2015 14 179,259 39.9 2.9 0 0.0 2016 22 182,250 46.1 2.1 0 0.0 2017 20 174,957 35.0 1.7 0 0.0 2018 17 168,197 23.3 1.4 0 0.0 2019 16 158,708 15.5 1.0 0 0.0 2021 1 17,940 0.0 0.0 0.0 0.0 2021 1 17,940 0.0 0.0 0.0 0.0 2021 1 17,940 0.0 0.0 0.0 0.0 2010 13 186,957 34.1 2.6 0 0.0 2011 9 157,489 32.5 3.6 0 0.0 <td< td=""><td>2011</td><td>22</td><td>151,993</td><td>60.6</td><td>2.8</td><td>0</td><td>0.0</td></td<>	2011	22	151,993	60.6	2.8	0	0.0
2014 14 174,650 36.2 2.6 0 0.0 2015 14 179,259 39.9 2.9 0 0.0 2016 22 182,250 46.1 2.1 0 0.0 2017 20 174,957 35.0 1.7 0 0.0 2018 17 168,197 23.3 1.4 0 0.0 2019 16 158,708 15.5 1.0 0 0.0 2020 14 132,363 6.9 0.5 0 0.0 2021 1 17,940 0.0 0.0 0.0 0.0 2021 1 17,940 0.0 0.0 0.0 0.0 2010 16 164,666 35.7 2.2 0 0.0 0.0 2011 9 157,482 16.6 2.4 0 0.0 0.0 2012 7 152,182 16.6 2.4 0 <t< td=""><td>2012</td><td>8</td><td>147,409</td><td>26.6</td><td>3.3</td><td>0</td><td>0.0</td></t<>	2012	8	147,409	26.6	3.3	0	0.0
201514179,25939.92.900.0201622182,25046.12.100.0201720174,95735.01.700.0201817168,19723.31.400.0201916158,70815.51.000.0202014132,3636.90.500.02021117,9400.00.000.02021117,9407.04.400.0200817203,9617.5.04.400.0201918164,66635.72.200.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.90.00.0202012136,2807.30.600.0	2013	15	168,487	51.7	3.4	0	0.0
201622182,25046.12.100.0201720174,95735.01.700.0201817168,19723.31.400.0201916158,70815.51.000.0202014132,3636.90.500.02021117,9400.00.000.0Male200817203,96175.04.400.0201016164,66635.72.200.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.020181217,13002.31.900.0201922163,17020.20.900.0201212136,2807.30.600.0	2014	14	174,650	36.2	2.6	0	0.0
201720174,95735.01.700.0201817168,19723.31.400.0201916158,70815.51.000.0202014132,3636.90.500.02021117,9400.00.00.00.0MaleNo0.00.00.00.0200913186,95734.12.600.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2015	14	179,259	39.9	2.9	0	0.0
201817168,19723.31.400.0201916158,70815.51.000.0202014132,3636.90.500.02021117,9400.00.000 Male 200817203,96175.04.400.0200913186,95734.12.600.0201016164,66635.72.200.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.020181217,3902.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2016	22	182,250	46.1	2.1	0	0.0
201916158,70815.51.000.0202014132,3636.90.500.02021117,9400.00.000.0Male </td <td>2017</td> <td>20</td> <td>174,957</td> <td>35.0</td> <td>1.7</td> <td>0</td> <td>0.0</td>	2017	20	174,957	35.0	1.7	0	0.0
202014132,3636.90.500.02021117,9400.00.000.0Male200817203,96175.04.400.0200913186,95734.12.600.0201016164,66635.72.200.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0	2018	17	168,197	23.3	1.4	0	0.0
2021117,9400.00.0000.0Male200817203,96175.04.400.0200913186,95734.12.600.0201016164,66635.72.200.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0202012136,2807.30.600.0	2019	16	158,708	15.5	1.0	0	0.0
Male 2008 17 203,961 75.0 4.4 0 0.0 2009 13 186,957 34.1 2.6 0 0.0 2010 16 164,666 35.7 2.2 0 0.0 2011 9 157,489 32.5 3.6 0 0.0 2012 7 152,182 16.6 2.4 0 0.0 2013 14 174,820 43.9 3.1 0 0.0 2014 21 179,532 50.4 2.4 0 0.0 2015 10 185,362 17.4 1.7 0 0.0 2016 14 187,442 37.9 2.7 0 0.0 2017 18 179,435 46.0 2.6 0 0.0 2018 12 171,390 23.3 1.9 0 0.0 2019 22 163,170 20.2 0.9 0 0.0 </td <td>2020</td> <td>14</td> <td>132,363</td> <td>6.9</td> <td>0.5</td> <td>0</td> <td>0.0</td>	2020	14	132,363	6.9	0.5	0	0.0
200817203,96175.04.400.0200913186,95734.12.600.0201016164,66635.72.200.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2021	1	17,940	0.0	0.0	0	0.0
200913186,95734.12.600.0201016164,66635.72.200.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	Male						
201016164,66635.72.200.020119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2008	17	203,961	75.0	4.4	0	0.0
20119157,48932.53.600.020127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2009	13	186,957	34.1	2.6	0	0.0
20127152,18216.62.400.0201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2010	16	164,666	35.7	2.2	0	0.0
201314174,82043.93.100.0201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2011	9	157,489	32.5	3.6	0	0.0
201421179,53250.42.400.0201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2012	7	152,182	16.6	2.4	0	0.0
201510185,36217.41.700.0201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2013	14	174,820	43.9	3.1	0	0.0
201614187,44237.92.700.0201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2014	21	179,532	50.4	2.4	0	0.0
201718179,43546.02.600.0201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2015	10	185,362	17.4	1.7	0	0.0
201812171,39023.31.900.0201922163,17020.20.900.0202012136,2807.30.600.0	2016	14	187,442	37.9	2.7	0	0.0
2019 22 163,170 20.2 0.9 0 0.0 2020 12 136,280 7.3 0.6 0 0.0	2017	18	179,435	46.0	2.6	0	0.0
2020 12 136,280 7.3 0.6 0 0.0	2018	12	171,390	23.3	1.9	0	0.0
	2019	22	163,170	20.2	0.9	0	0.0
2021 4 18,361 0.5 0.1 0 0.0	2020	12	136,280	7.3	0.6	0	0.0
	2021	4	18,361	0.5	0.1	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: P	Present, Clinical Cha	aracteristics: Absent				
Female						
2008	0	1,358	0.0	-	0	N/A
2009	2	1,208	12.3	6.2	0	0.0
2010	2	1,103	10.4	5.2	0	0.0
2011	0	1,024	0.0	-	0	N/A
2012	1	881	6.3	6.3	0	0.0
2013	0	969	0.0	-	0	N/A
2014	1	1,076	0.0	0.0	0	0.0
2015	2	928	6.0	3.0	0	0.0
2016	2	828	2.4	1.2	0	0.0
2017	1	754	0.3	0.3	0	0.0
2018	5	731	9.4	1.9	0	0.0
2019	1	671	0.3	0.3	0	0.0
2020	2	588	0.7	0.4	0	0.0
2021	0	53	0.0	-	0	N/A
Male						
2008	0	1,607	0.0	-	0	N/A
2009	1	1,453	1.1	1.1	0	0.0
2010	1	1,254	0.8	0.8	0	0.0
2011	0	1,193	0.0	-	0	N/A
2012	3	1,076	3.1	1.0	0	0.0
2013	2	1,177	10.6	5.3	0	0.0
2014	0	1,229	0.0	-	0	N/A
2015	0	1,165	0.0	-	0	N/A
2016	1	1,011	1.9	1.9	0	0.0
2017	5	931	11.7	2.3	0	0.0
2018	2	894	0.7	0.3	0	0.0
2019	2	789	0.3	0.2	0	0.0
2020	2	725	1.2	0.6	0	0.0
2021	0	78	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: /	Absent, Clinical Cha	racteristics: Present				
Female						
2008	29	73,191	70.1	2.4	0	0.0
2009	19	74,195	60.4	3.2	0	0.0
2010	28	66,332	83.1	3.0	0	0.0
2011	17	61,309	52.9	3.1	0	0.0
2012	26	58,669	71.5	2.8	0	0.0
2013	27	66,917	74.4	2.8	0	0.0
2014	33	70,923	64.8	2.0	0	0.0
2015	35	73,848	76.2	2.2	0	0.0
2016	42	78,596	88.9	2.1	0	0.0
2017	51	79,178	99.9	2.0	0	0.0
2018	36	78,124	61.2	1.7	0	0.0
2019	46	74,775	44.6	1.0	0	0.0
2020	25	63,886	11.1	0.4	0	0.0
2021	2	7,605	0.3	0.2	0	0.0
Male						
2008	30	82,788	82.7	2.8	0	0.0
2009	30	83,690	69.3	2.3	0	0.0
2010	31	75,388	135.2	4.4	0	0.0
2011	27	69,533	101.8	3.8	0	0.0
2012	34	67,061	112.7	3.3	0	0.0
2013	35	75,399	84.4	2.4	0	0.0
2014	45	80,185	140.1	3.1	0	0.0
2015	46	82,730	118.3	2.6	0	0.0
2016	58	88,209	120.3	2.1	0	0.0
2017	64	88,560	102.3	1.6	0	0.0
2018	60	87,127	79.6	1.3	0	0.0
2019	49	83,052	55.2	1.1	0	0.0
2020	33	70,868	18.7	0.6	0	0.0
2021	5	8,567	0.8	0.2	0	0.0



2008 2 807 12.2 6.1 0 0.0 2009 3 740 10.6 3.5 0 0.0 2010 4 650 9.8 2.4 0 0.0 2011 2 594 3.7 1.8 0 0.0 2012 0 592 0.0 - 0 N/A 2013 1 585 1.3 1.3 0 0.0 2014 5 646 16.6 3.3 0 0.0 2015 4 542 10.9 2.7 0 0.0 2016 6 482 9.5 1.6 0 0.0 2017 2 509 4.5 2.3 0 0.0 2018 1 430 2.9 2.9 0 0.0 2019 5 415 5.8 1.2 0 0.0 2020 5 350 0.8 0.2 0 0.0 2021 0 43 0.0 -<		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2008 2 807 12.2 6.1 0 0.0 2009 3 740 10.6 3.5 0 0.0 2010 4 650 9.8 2.4 0 0.0 2011 2 594 3.7 1.8 0 0.0 2012 0 592 0.0 - 0 N/A 2013 1 585 1.3 1.3 0 0.0 2014 5 646 16.6 3.3 0 0.0 2015 4 542 10.9 2.7 0 0.0 2017 2 509 4.5 2.3 0 0.0 2018 1 430 2.9 2.9 0 0.0 2020 5 350 0.8 0.2 0 0.0 2021 0 43 0.0 - 0 N/A 2020 5 920 21.5 </th <th>Hearing Loss: P</th> <th>resent, Clinical Cha</th> <th>aracteristics: Present</th> <th></th> <th></th> <th></th> <th></th>	Hearing Loss: P	resent, Clinical Cha	aracteristics: Present				
2009374010.63.500.01201046509.82.400.02201125943.71.800.01201205920.0-0N/A201315851.31.300.022014564616.63.300.022015454210.92.700.02201664829.51.600.0220172504.52.300.02201815.81.200.02202053500.80.200.022021030.0-0N/A2008597023.74.700.022011272910.05.000.02201227079.44.700.022011272910.05.000.02201127660.70.300.022014378020.26.700.022015871.524.63.100.022014366651.400.022015871.524.63.100.02201436309.73.200.022015871.524.6	Female						
201046509.82.400.0201125943.71.800.0201205920.0-0N/A201315851.31.300.02014564616.63.300.0201545420.92.700.0201664.829.51.600.0201725094.52.300.0201814302.92.900.0202053500.80.200.020210430.0-0N/A202059202.154.300.0201057843.20.600.02011272910.05.00.00.0201227079.44.700.0201437802.026.700.0201437802.026.700.0201437802.026.700.0201437802.026.700.0201587152.463.100.020143656.61.100.0201436309.73.200.0201587152.46<	2008	2	807	12.2	6.1	0	0.0
2011 2 594 3.7 1.8 0 0.0 2012 0 592 0.0 - 0 N/A 2013 1 585 1.3 1.3 0 0.0 2014 5 646 1.6 3.3 0 0.0 2015 4 542 10.9 2.7 0 0.0 2016 6 482 9.5 1.6 0 0.0 2017 2 509 4.5 2.3 0 0.0 2018 1 430 2.9 2.9 0 0.0 2019 5 415 5.8 1.2 0 0.0 2020 5 350 0.8 0.2 0 0.0 2021 0 43 0.0 - 0 0.0 2020 5 920 21.5 4.3 0 0.0 2009 5 920 21.5 <td>2009</td> <td>3</td> <td>740</td> <td>10.6</td> <td>3.5</td> <td>0</td> <td>0.0</td>	2009	3	740	10.6	3.5	0	0.0
2012 0 592 0.0 - 0 N/A 2013 1 585 1.3 1.3 0 0.0 2014 5 646 16.6 3.3 0 0.0 2015 4 542 10.9 2.7 0 0.0 2016 6 482 9.5 1.6 0 0.0 2017 2 509 4.5 2.3 0 0.0 2018 1 430 2.9 0 0.0 0.0 2019 5 350 0.8 0.2 0 0.0 2020 5 350 0.8 0.2 0 0.0 2021 0 43 0.2 0 0.0 0.0 2009 5 970 2.7 4.7 0 0.0 0.0 2011 2 784 3.2 0.6 0 0.0 0.0 2012 2 <td>2010</td> <td>4</td> <td>650</td> <td>9.8</td> <td>2.4</td> <td>0</td> <td>0.0</td>	2010	4	650	9.8	2.4	0	0.0
201315851.31.300.02014564616.63.300.02015454210.92.700.0201664829.51.600.0201725094.52.300.0201814302.92.900.0201954155.81.200.020210430.0-0N/A20210430.0-00.02016597023.74.700.0201057843.20.60.00.02011272910.05.000.0201227079.44.700.020132660.70.300.02014378020.26.63.100.02015871524.63.100.00.0201436309.73.200.00.02015871524.63.100.00.0201626569.24.600.00.0201436309.73.200.00.02015854210.41.300.00.0201626566.61.1 <td>2011</td> <td>2</td> <td>594</td> <td>3.7</td> <td>1.8</td> <td>0</td> <td>0.0</td>	2011	2	594	3.7	1.8	0	0.0
2014 5 646 16.6 3.3 0 0.0 2015 4 542 10.9 2.7 0 0.0 2016 6 482 9.5 1.6 0 0.0 2017 2 509 4.5 2.3 0 0.0 2018 1 430 2.9 2.9 0 0.0 2019 5 415 5.8 1.2 0 0.0 2020 5 350 0.8 0.2 0 0.0 2021 0 43 0.0 - 0 0.0 2020 5 350 0.8 0.2 0 0.0 2021 0 43 0.0 - 0 0.0 2021 5 920 21.5 4.3 0 0.0 2039 5 920 21.5 4.3 0 0.0 2011 2 729 10.0 5.0 0 0.0 2012 2 766 0.7 0.3<	2012	0	592	0.0	-	0	N/A
2015 4 542 10.9 2.7 0 0.0 2016 6 482 9.5 1.6 0 0.0 2017 2 509 4.5 2.3 0 0.0 2018 1 430 2.9 2.9 0 0.0 2019 5 415 5.8 1.2 0 0.0 2020 5 350 0.8 0.2 0 0.0 2021 0 43 0.0 - 0 N/A vert vert vert vert 0.0 0.0 2009 5 920 21.5 4.3 0 0.0 2011 2 729 10.0 5.0 0 0.0 2012 2 707 9.4 4.7 0 0.0 2014 3 780 20.2 6.7 0 0.0 2015 8 715 24.6	2013	1	585	1.3	1.3	0	0.0
2016 6 482 9.5 1.6 0 0.0 2017 2 509 4.5 2.3 0 0.0 2018 1 430 2.9 2.9 0 0.0 2019 5 415 5.8 1.2 0 0.0 2020 5 350 0.8 0.2 0 N/A 2021 0 43 0.0 - 0 N/A 2021 0 43 0.0 - 0 0.0 2021 0 43 0.0 - 0 0.0 2012 0 43 0.0 - 0 0.0 2009 5 920 21.5 4.3 0 0.0 0.0 2011 2 784 3.2 0.6 0 0.0 0.0 2012 2 707 9.4 4.7 0 0.0 0.0 2014	2014	5	646	16.6	3.3	0	0.0
201725094.52.300.0201814302.92.900.0201954155.81.200.0202053500.80.200.020210430.0-0N/Averticada2008597023.74.700.02010592021.54.300.02011272910.05.000.0201227079.44.700.0201226760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201866.256.61.100.02019854210.41.300.0	2015	4	542	10.9	2.7	0	0.0
2018 1 430 2.9 2.9 0 0.0 2019 5 415 5.8 1.2 0 0.0 2020 5 350 0.8 0.2 0 0.0 2021 0 43 0.0 - 0 N/A viet viet viet viet viet viet viet viet 2008 5 970 23.7 4.7 0 0.0 0.0 2009 5 920 21.5 4.3 0 0.0 0.0 2011 2 729 10.0 5.0 0 0.0 0.0 2012 2 707 9.4 4.7 0 0.0 0.0 2013 2 676 0.7 0.3 0 0.0 0.0 2014 3 780 20.2 6.7 0 0.0 0.0 2015 8 715 24.6 3.1 0 0.0 0.0 2017 3 630 9.7 <td>2016</td> <td>6</td> <td>482</td> <td>9.5</td> <td>1.6</td> <td>0</td> <td>0.0</td>	2016	6	482	9.5	1.6	0	0.0
201954155.81.200.0202053500.80.200.020210430.0-0N/AMate2008597023.74.700.02009592021.54.300.0201057843.20.600.02011272910.05.000.0201227079.44.700.0201326760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0	2017	2	509	4.5	2.3	0	0.0
202053500.80.2000.020210430.0-0N/A2008597023.74.700.02009592021.54.300.0201057843.20.600.02011272910.05.000.0201227079.44.700.0201326760.70.300.02014378020.26.700.02015871524.63.100.0201736309.73.200.0201866256.61.100.02019854210.41.300.0	2018	1	430	2.9	2.9	0	0.0
20210430.0-0N/AMale2008597023.74.700.02009592021.54.300.0201057843.20.600.02011272910.05.000.0201227079.44.700.0201326760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.300.0	2019	5	415	5.8	1.2	0	0.0
Male 0 0.0 2008 5 970 23.7 4.7 0 0.0 2009 5 920 21.5 4.3 0 0.0 2010 5 784 3.2 0.6 0 0.0 2011 2 729 10.0 5.0 0 0.0 2012 2 707 9.4 4.7 0 0.0 2013 2 676 0.7 0.3 0 0.0 2014 3 780 20.2 6.7 0 0.0 2015 8 715 24.6 3.1 0 0.0 2016 2 656 9.2 4.6 0 0.0 2017 3 630 9.7 3.2 0 0.0 2018 6 625 6.6 1.1 0 0.0 2019 8 542 10.4 1.3 0 0.0 <	2020	5	350	0.8	0.2	0	0.0
2008597023.74.700.02009592021.54.300.0201057843.20.600.02011272910.05.000.0201227079.44.700.0201326760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.300.0	2021	0	43	0.0	-	0	N/A
2009592021.54.300.0201057843.20.600.02011272910.05.000.0201227079.44.700.0201326760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.300.0	Male						
201057843.20.600.02011272910.05.000.0201227079.44.700.0201326760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.300.0	2008	5	970	23.7	4.7	0	0.0
2011272910.05.000.0201227079.44.700.0201326760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.30.30.1	2009	5	920	21.5	4.3	0	0.0
201227079.44.700.0201326760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.30.300.0	2010	5	784	3.2	0.6	0	0.0
201326760.70.300.02014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.300.0	2011	2	729	10.0	5.0	0	0.0
2014378020.26.700.02015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.30.30.1	2012	2	707	9.4	4.7	0	0.0
2015871524.63.100.0201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.300.0	2013	2	676	0.7	0.3	0	0.0
201626569.24.600.0201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.300.0	2014	3	780	20.2	6.7	0	0.0
201736309.73.200.0201866256.61.100.02019854210.41.300.0202014310.30.300.0	2015	8	715	24.6	3.1	0	0.0
2018 6 6.6 1.1 0 0.0 2019 8 542 10.4 1.3 0 0.0 2020 1 431 0.3 0.3 0 0.0	2016	2	656	9.2	4.6	0	0.0
2019 8 542 10.4 1.3 0 0.0 2020 1 431 0.3 0.3 0 0.0	2017	3	630	9.7	3.2	0	0.0
2020 1 431 0.3 0.3 0.0	2018	6	625	6.6	1.1	0	0.0
	2019	8	542	10.4	1.3	0	0.0
2021 2 48 0.6 0.3 0 0.0	2020	1	431	0.3	0.3	0	0.0
	2021	2	48	0.6	0.3	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infant
/alganciclovir	Treatment for Infai	nts with CMV or cCMV				
Overall						
Female						
2008	49	270,320	17.6	0.4	3	612.2
2009	40	255,371	15.4	0.4	3	750.0
2010	53	226,069	21.1	0.4	2	377.4
2011	41	213,394	16.8	0.4	3	731.7
2012	34	206,077	14.2	0.4	2	588.2
2013	43	235,352	14.6	0.3	8	1,860.5
2014	53	245,651	16.6	0.3	12	2,264.2
2015	54	252,935	15.8	0.3	18	3,333.3
2016	71	260,661	20.5	0.3	18	2,535.2
2017	74	253,871	25.8	0.3	16	2,162.2
2018	59	246,015	18.9	0.3	20	3,389.8
2019	68	233,144	20.6	0.3	21	3,088.2
2020	46	196,004	10.9	0.2	11	2,391.3
2021	3	25,529	0.3	0.1	0	0.0
Male						
2008	52	286,920	20.8	0.4	4	769.2
2009	49	270,695	20.8	0.4	1	204.1
2010	53	239,905	22.7	0.4	3	566.0
2011	38	226,948	14.0	0.4	8	2,105.3
2012	46	219,041	16.4	0.4	8	1,739.1
2013	53	249,897	19.5	0.4	7	1,320.8
2014	69	259,530	25.3	0.4	11	1,594.2
2015	64	267,673	21.1	0.3	16	2,500.0
2016	74	275,104	22.9	0.3	24	3,243.2
2017	90	267,436	27.6	0.3	27	3,000.0
2018	80	258,023	26.2	0.3	12	1,500.0
2019	81	245,601	25.7	0.3	18	2,222.2
2020	48	206,620	13.2	0.3	16	3,333.3
2021	11	26,884	1.3	0.1	3	2,727.3



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: A	bsent, Clinical Cha	racteristics: Absent				
Female						
2008	18	196,697	5.7	0.3	0	0.0
2009	16	180,926	6.2	0.4	0	0.0
2010	19	159,515	7.7	0.4	0	0.0
2011	22	151,993	9.2	0.4	2	909.1
2012	8	147,409	3.7	0.5	0	0.0
2013	15	168,487	5.7	0.4	1	666.7
2014	14	174,650	5.3	0.4	0	0.0
2015	14	179,259	5.7	0.4	1	714.3
2016	22	182,250	8.3	0.4	2	909.1
2017	20	174,957	7.6	0.4	2	1,000.0
2018	17	168,197	5.5	0.3	4	2,352.9
2019	16	158,708	6.8	0.4	0	0.0
2020	14	132,363	3.6	0.3	3	2,142.9
2021	1	17,940	0.0	0.0	0	0.0
Male						
2008	17	203,961	6.5	0.4	1	588.2
2009	13	186,957	5.2	0.4	0	0.0
2010	16	164,666	6.7	0.4	0	0.0
2011	9	157,489	2.7	0.3	3	3,333.3
2012	7	152,182	2.7	0.4	0	0.0
2013	14	174,820	4.8	0.3	3	2,142.9
2014	21	179,532	9.4	0.4	0	0.0
2015	10	185,362	4.5	0.5	0	0.0
2016	14	187,442	5.7	0.4	3	2,142.9
2017	18	179,435	6.4	0.4	4	2,222.2
2018	12	171,390	5.2	0.4	0	0.0
2019	22	163,170	8.0	0.4	5	2,272.7
2020	12	136,280	3.4	0.3	4	3,333.3
2021	4	18,361	0.3	0.1	1	2,500.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: P	Present, Clinical Cha	aracteristics: Absent				
Female						
2008	0	1,358	0.0	-	0	N/A
2009	2	1,208	0.7	0.4	0	0.0
2010	2	1,103	1.0	0.5	0	0.0
2011	0	1,024	0.0	-	0	N/A
2012	1	881	0.5	0.5	0	0.0
2013	0	969	0.0	-	0	N/A
2014	1	1,076	0.0	0.0	0	0.0
2015	2	928	0.3	0.2	1	5,000.0
2016	2	828	0.5	0.3	1	5,000.0
2017	1	754	0.0	0.0	1	10,000.0
2018	5	731	2.1	0.4	1	2,000.0
2019	1	671	0.3	0.3	0	0.0
2020	2	588	0.0	0.0	1	5,000.0
2021	0	53	0.0	-	0	N/A
Male						
2008	0	1,607	0.0	-	0	N/A
2009	1	1,453	0.5	0.5	0	0.0
2010	1	1,254	0.5	0.5	0	0.0
2011	0	1,193	0.0	-	0	N/A
2012	3	1,076	1.5	0.5	0	0.0
2013	2	1,177	0.6	0.3	1	5,000.0
2014	0	1,229	0.0	-	0	N/A
2015	0	1,165	0.0	-	0	N/A
2016	1	1,011	0.1	0.1	1	10,000.0
2017	5	931	1.2	0.2	2	4,000.0
2018	2	894	0.1	0.1	1	5,000.0
2019	2	789	0.3	0.2	0	0.0
2020	2	725	0.5	0.2	1	5,000.0
2021	0	78	0.0	-	0	N/A



20082973,19110.90.431,034.520091974,1957.70.431,578.920102866,33210.40.42714.320111761,3097.00.400.020122558,66910.10.42800.020132766,9178.40.372,592.620143370,92310.30.382,424.220153473,8489.00.3112,682.920175179,17818.10.4112,156.920183678,12410.80.3154,166.720194674,77512.80.3173,695.720202563,8866.50.352,000.0202127,6050.30.200.0		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2008 29 $73,191$ 10.9 0.4 3 $1,034.5$ 2009 19 $74,195$ 7.7 0.4 3 $1,578.9$ 2010 28 $66,332$ 10.4 0.4 2 714.3 2011 17 $61,309$ 7.0 0.4 0 0.0 2012 25 $58,669$ 10.1 0.4 2 800.0 2013 27 $66,917$ 8.4 0.3 7 $2,592.6$ 2014 33 $70,923$ 10.3 0.3 8 $2,424.2$ 2015 34 $73,848$ 9.0 0.3 11 $2,682.9$ 2017 51 $79,178$ 18.1 0.4 11 $2,682.9$ 2018 36 $78,124$ 10.8 0.3 15 $4,166.7$ 2019 46 $74,775$ 12.8 0.3 15 $4,060$ 2021 2 7.605 0.3 0.2 0 0.0 2021 2 7.65 0.3 0.2 0 0.0 2010 31 $75,388$ 13.2 0.4 3 967.7 2011 27 $69,533$ 10.4 0.4 5 $1,851.9$ 2012 34 $67,061$ 12.1 0.4 6 $1,764.7$ 2011 27 $69,533$ 10.4 0.4 5 $1,851.9$ 2012 34 $67,061$ 12.1 0.4 6 $1,764.7$ 2013 35 <th>Hearing Loss:</th> <th>Absent, Clinical Cha</th> <th>racteristics: Present</th> <th></th> <th></th> <th></th> <th></th>	Hearing Loss:	Absent, Clinical Cha	racteristics: Present				
2009 19 74,195 7.7 0.4 3 1,578.9 2010 28 66,332 10.4 0.4 2 714.3 2011 17 61,309 7.0 0.4 0 0.0 2012 25 58,669 10.1 0.4 2 800.0 2013 27 66,917 8.4 0.3 7 2,592.6 2014 33 70,923 10.3 0.3 13 3,823.5 2016 41 78,596 11.0 0.3 11 2,682.9 2017 51 79,178 18.1 0.4 11 2,682.9 2018 36 74,775 12.8 0.3 17 3,695.7 2020 25 63,886 6.5 0.3 20 0.0 2021 2 76,76 0.3 0.4 2 66.7 2008 30 82,788 12.3 0.4 2 66.7	Female						
2010 28 66,332 10.4 0.4 2 714.3 2011 17 61,309 7.0 0.4 0 0.0 2012 25 58,669 10.1 0.4 2 800.0 2013 27 66,917 8.4 0.3 7 2,592.6 2014 33 70,923 10.3 0.3 8 2,424.2 2015 34 73,848 9.0 0.3 11 2,682.9 2016 41 78,596 11.0 0.3 11 2,682.9 2017 51 79,178 18.1 0.4 11 2,656.9 2018 36 78,124 10.8 0.3 15 4,166.7 2020 25 63,886 6.5 0.3 17 3,695.7 2020 25 7,655 0.3 0.2 0 0.0 2021 2 7,605 0.3 0.4 2 5,667.7 </td <td>2008</td> <td>29</td> <td>73,191</td> <td>10.9</td> <td>0.4</td> <td>3</td> <td>1,034.5</td>	2008	29	73,191	10.9	0.4	3	1,034.5
2011 17 61,309 7.0 0.4 0 0.0 2012 25 58,669 10.1 0.4 2 800.0 2013 27 66,917 8.4 0.3 7 2,592.6 2014 33 70,923 10.3 0.3 8 2,424.2 2015 34 73,848 9.0 0.3 13 3,823.5 2016 41 78,596 11.0 0.3 11 2,682.9 2017 51 79,178 18.1 0.4 11 2,156.9 2018 66 74,775 12.8 0.3 15 4,166.7 2020 25 63,886 6.5 0.3 5 2,000.0 2021 25 63,869 12.9 0.4 0 0.0 2020 25 63,869 12.9 0.4 0 0.0 2014 30 86,973 10.4 0.4 5 1,851.9	2009	19	74,195	7.7	0.4	3	1,578.9
2012 25 58,669 10.1 0.4 2 800.0 2013 27 66,917 8.4 0.3 7 2,592.6 2014 33 70,923 10.3 0.3 8 2,424.2 2015 34 73,848 9.0 0.3 13 3,823.5 2016 41 78,596 11.0 0.3 11 2,682.9 2017 51 79,178 18.1 0.4 11 2,682.9 2018 36 78,124 10.8 0.3 15 4,166.7 2019 46 74,775 12.8 0.3 15 2,000.0 2021 2.5 63,866 6.5 0.3 5 2,000.0 2021 2.6 63,86 6.5 0.3 5 2,000.0 2021 2.7 63,886 12.9 0.4 0 0.0 2010 31 75,389 13.2 0.4 3 967.7<	2010	28	66,332	10.4	0.4	2	714.3
2013 27 66,917 8.4 0.3 7 2,592.6 2014 33 70,923 10.3 0.3 8 2,424.2 2015 34 73,848 9.0 0.3 13 3,823.5 2016 41 78,596 11.0 0.3 11 2,682.9 2017 51 79,178 18.1 0.4 11 2,156.9 2018 36 78,124 10.8 0.3 15 4,166.7 2019 46 74,775 12.8 0.3 5 2,000.0 2021 2 7,605 0.3 0.2 0 0.0 2021 2 7,605 0.3 0.2 0 0.0 2010 31 75,388 13.2 0.4 0 0.0 2010 31 75,389 13.7 0.4 2 51.4 2014 45 80,185 15.7 0.3 8 1,777.8	2011	17	61,309	7.0	0.4	0	0.0
2014 33 7,923 10.3 0.3 8 2,424.2 2015 34 73,848 9.0 0.3 13 3,823.5 2016 41 78,596 11.0 0.3 11 2,682.9 2017 51 79,178 18.1 0.4 11 2,156.9 2018 36 78,124 10.8 0.3 15 4,166.7 2019 46 74,775 12.8 0.3 5 2,000.0 2021 2 7,605 0.3 0.2 0 0.0 2021 2 7,605 0.3 0.2 0 0.0 2021 2 7,605 0.3 0.2 0 0.0 2021 2 7,605 0.3 0.4 0 0.0 0.0 2010 30 82,788 12.3 0.4 0 0 0.0 2011 27 69,533 10.4 0.4 5	2012	25	58,669	10.1	0.4	2	800.0
20153473,8489.00.3133,823.520164178,59611.00.3112,682.920175179,17818.10.4112,156.920183678,12410.80.3154,166.720194674,77512.80.3173,695.720202563,8666.50.352,000.0202127,6050.30.200.0verter20083082,78812.30.42666.720193175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,77.820154682,73014.40.3132,826.120165888,20917.00.3182,812.520176488,56019.70.3182,812.520186087,12719.60.371,428.620203370,8689.30.3103,030.3	2013	27	66,917	8.4	0.3	7	2,592.6
2016 41 78,596 11.0 0.3 11 2,682.9 2017 51 79,178 18.1 0.4 11 2,156.9 2018 36 78,124 10.8 0.3 15 4,166.7 2019 46 74,775 12.8 0.3 17 3,695.7 2020 25 63,866 6.5 0.3 5 2,000.0 2021 2 7,605 0.3 0.2 0 0.0 2021 2 7,605 0.3 0.4 2 666.7 2021 30 82,788 12.3 0.4 0 0.0 2008 30 82,788 13.2 0.4 0 0.0 2010 31 75,388 13.2 0.4 3 967.7 2011 27 69,533 10.4 0.4 6 1,764.7 2012 34 67,019 13.7 0.4 2 571.4	2014	33	70,923	10.3	0.3	8	2,424.2
20175179,17818.10.4117,156.920183678,12410.80.3154,166.720194674,77512.80.3173,695.720202563,8866.50.352,000.0202127,6050.50.200.020202563,8866.50.352,000.0202127,6050.30.200.0202127,6050.30.42666.720093082,78812.30.42666.720103175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.381,777.820144580,18515.70.381,777.820154682,73014.40.3132,826.120144580,18515.70.3182,825.120154682,60019.70.3182,825.120146083,65019.70.3182,825.120154682,60019.70.3182,825.120154683,65019.70.3182,825.120165888,56019.70.318	2015	34	73,848	9.0	0.3	13	3,823.5
20183678,12410.80.3154,166.720194674,77512.80.3173,695.720202563,8866.50.352,000.0202127,6050.30.200.0 Value2008 3082,78812.30.42666.720193083,69012.90.400.020103175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3193,275.920176485,6019.70.3182,812.520186087,12719.60.371,428.620194983,05216.50.371,428.620203370,8689.30.3103,030.3	2016	41	78,596	11.0	0.3	11	2,682.9
20194674,77512.80.3173,695.720202563,8866.50.352,000.0202127,6050.30.200.0Meters20083082,78812.30.42666.720193083,69012.90.400.020103175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3182,812.520176485,6019.70.3182,812.520186087,12719.60.371,428.620194983,05216.50.371,428.6	2017	51	79,178	18.1	0.4	11	2,156.9
20202563,8866.50.352,000.0202127,6050.30.200.0Male20083082,78812.30.42666.720093083,69012.90.400.020103175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2018	36	78,124	10.8	0.3	15	4,166.7
202127,6050.30.200.0Male20083082,78812.30.42666.720093083,69012.90.400.020103175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3182,812.520176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2019	46	74,775	12.8	0.3	17	3,695.7
Male 2008 30 82,788 12.3 0.4 2 666.7 2009 30 83,690 12.9 0.4 0 0.0 2010 31 75,388 13.2 0.4 3 967.7 2011 27 69,533 10.4 0.4 5 1,851.9 2012 34 67,061 12.1 0.4 6 1,764.7 2013 35 75,399 13.7 0.4 2 571.4 2014 45 80,185 15.7 0.3 8 1,777.8 2015 46 82,730 14.4 0.3 13 2,826.1 2016 58 88,209 17.0 0.3 19 3,275.9 2017 64 88,560 19.7 0.3 18 2,812.5 2018 60 87,127 19.6 0.3 7 1,166.7 2019 49 83,052 16.5 0.3 7	2020	25	63,886	6.5	0.3	5	2,000.0
20083082,78812.30.42666.720093083,69012.90.400.020103175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3182,812.520176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2021	2	7,605	0.3	0.2	0	0.0
20093083,69012.90.400.020103175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3182,812.520176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	Male						
20103175,38813.20.43967.720112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3182,812.520176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2008	30	82,788	12.3	0.4	2	666.7
20112769,53310.40.451,851.920123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3193,275.920176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2009	30	83,690	12.9	0.4	0	0.0
20123467,06112.10.461,764.720133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3193,275.920176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2010	31	75,388	13.2	0.4	3	967.7
20133575,39913.70.42571.420144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3193,275.920176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2011	27	69,533	10.4	0.4	5	1,851.9
20144580,18515.70.381,777.820154682,73014.40.3132,826.120165888,20917.00.3193,275.920176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2012	34	67,061	12.1	0.4	6	1,764.7
20154682,73014.40.3132,826.120165888,20917.00.3193,275.920176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2013	35	75,399	13.7	0.4	2	571.4
20165888,20917.00.3193,275.920176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2014	45	80,185	15.7	0.3	8	1,777.8
20176488,56019.70.3182,812.520186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2015	46	82,730	14.4	0.3	13	2,826.1
20186087,12719.60.371,166.720194983,05216.50.371,428.620203370,8689.30.3103,030.3	2016	58	88,209	17.0	0.3	19	3,275.9
2019 49 83,052 16.5 0.3 7 1,428.6 2020 33 70,868 9.3 0.3 10 3,030.3	2017	64	88,560	19.7	0.3	18	2,812.5
2020 33 70,868 9.3 0.3 10 3,030.3	2018	60	87,127	19.6	0.3	7	1,166.7
	2019	49	83,052	16.5	0.3	7	1,428.6
2021 5 8,567 0.5 0.1 2 4,000.0	2020	33	70,868	9.3	0.3	10	3,030.3
	2021	5	8,567	0.5	0.1	2	4,000.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss:	Present, Clinical Cha	aracteristics: Present				
Female						
2008	2	807	1.0	0.5	0	0.0
2009	3	740	0.9	0.3	0	0.0
2010	4	650	2.0	0.5	0	0.0
2011	2	594	0.6	0.3	1	5,000.0
2012	0	592	0.0	-	0	N/A
2013	1	585	0.5	0.5	0	0.0
2014	5	646	0.9	0.2	4	8,000.0
2015	4	542	0.7	0.2	3	7,500.0
2016	6	482	0.7	0.1	4	6,666.7
2017	2	509	0.1	0.0	2	10,000.0
2018	1	430	0.5	0.5	0	0.0
2019	5	415	0.7	0.1	4	8,000.0
2020	5	350	0.7	0.1	2	4,000.0
2021	0	43	0.0	-	0	N/A
Male						
2008	5	970	2.0	0.4	1	2,000.0
2009	5	920	2.3	0.5	1	2,000.0
2010	5	784	2.3	0.5	0	0.0
2011	2	729	0.8	0.4	0	0.0
2012	2	707	0.1	0.1	2	10,000.0
2013	2	676	0.4	0.2	1	5,000.0
2014	3	780	0.2	0.1	3	10,000.0
2015	8	715	2.3	0.3	3	3,750.0
2016	1	656	0.1	0.1	1	10,000.0
2017	3	630	0.4	0.1	3	10,000.0
2018	6	625	1.2	0.2	4	6,666.7
2019	8	542	0.9	0.1	6	7,500.0
2020	1	431	0.0	0.0	1	10,000.0
2021	2	48	0.6	0.3	0	0.0



Female 0 0.0 2008 1 1 10.6 10.6 0 0.0 2009 1 2 0.4 0.4 0 0.0 2010 1 1 2.7 2.7 0 0.0 2011 2 3 10.5 5.3 0 0.0 2012 3 4 9.7 3.2 0 0.0 2013 7 10 21.6 3.1 0 0.0 2014 8 11 19.3 2.4 0 0.0 2015 15 19 29.0 1.9 0 0.0 2015 15 19 23.3 2.9 0 0.0 2016 15 19 43.3 2.9 0 0.0 2018 15 17 21.0 1.4 0 0.0 2019 17 25 17.5 1.0 0 0.0 <tr< th=""><th></th><th>New Users</th><th>Eligible Members²</th><th>Years at Risk</th><th>Average Person-Years at Risk</th><th>New Episodes with an Event</th><th>Events per 10,000 New Infants</th></tr<>		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Treatment Within 45 Days Diagnosis							
2009 1 2 0.4 0.4 0 0.0 2010 1 1 2.7 2.7 0 0.0 2011 2 3 10.5 5.3 0 0.0 2012 3 4 9.7 3.2 0 0.0 2013 7 10 21.6 3.1 0 0.0 2014 8 11 19.3 2.4 0 0.0 2015 19 29.0 1.9 0 0.0 0.0 2016 15 19 43.3 2.9 0 0.0 2018 15 17 2.0 1.4 0 0.0 2019 17 25 17.5 1.0 0 0.0 2021 0 0 0 - 0 N/A 2021 0 0 - 0 N/A 2021 11 1.1 1.1 0 <t< td=""><td>Female</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	Female							
2010112.72.700.020112310.55.300.02012349.73.200.0201371021.63.100.0201481119.32.400.02015151929.01.900.0201615194.32.900.02017101517.61.800.02018151721.01.400.0202010115.90.600.02021000.0-0N/A202200.0-0N/A2020121.111.100.02010234.92.500.02011355.61.400.02012882.573.200.02013455.61.400.02014882.573.200.02015131847.33.600.02014882.573.200.02015131847.33.600.020141415.51.600.00.0201513186.61.200.0 <td>2008</td> <td>1</td> <td>1</td> <td>10.6</td> <td>10.6</td> <td>0</td> <td>0.0</td>	2008	1	1	10.6	10.6	0	0.0	
2011 2 3 10.5 5.3 0 0.0 2012 3 4 9.7 3.2 0 0.0 2013 7 10 21.6 3.1 0 0.0 2014 8 11 19.3 2.4 0 0.0 2015 15 19 29.0 1.9 0 0.0 2016 15 19 43.3 2.9 0 0.0 2017 10 15 17.6 1.8 0 0.0 2018 15 17 21.0 1.4 0 0.0 2020 10 11 5.9 0.6 0 0.0 2021 0 0 0.0 - 0 N/A 2020 10 11.1 11.1 0 0.0 0.0 2010 2 3 4.9 2.5 0 0.0 0.0 2011 3 5	2009	1	2	0.4	0.4	0	0.0	
2012 3 4 9.7 3.2 0 0.0 2013 7 10 21.6 3.1 0 0.0 2014 8 11 19.3 2.4 0 0.0 2015 15 19 29.0 1.9 0 0.0 2016 15 19 43.3 2.9 0 0.0 2017 10 15 17.6 1.8 0 0.0 2018 15 17 21.0 1.4 0 0.0 2019 17 25 17.5 1.0 0 0.0 2020 10 11 5.9 0.6 0 0.0 2021 0 0 0.0 - 0 N/A 2020 10 11 5.9 0.6 0 0.0 2021 0 2 0.0 - 0 0.0 2010 2 3 4.9 2.5 0 0.0 0.0 2010 2 3 4.9	2010	1	1	2.7	2.7	0	0.0	
2013 7 10 21.6 3.1 0 0.0 2014 8 11 19.3 2.4 0 0.0 2015 15 19 29.0 1.9 0 0.0 2015 15 19 43.3 2.9 0 0.0 2017 10 15 17.6 1.8 0 0.0 2018 15 17 21.0 1.4 0 0.0 2019 17 25 17.5 1.0 0 0.0 2020 10 11 5.9 0.6 0 0.0 2021 0 0 0.0 - 0 N/A 2021 0 0 - 0 N/A 2010 2 3 4.9 2.5 0 0.0 2011 3 5 14.2 4.7 0 0.0 2012 8 8 25.7 3.2	2011	2	3	10.5	5.3	0	0.0	
2014 8 11 19.3 2.4 0 0.0 2015 15 19 29.0 1.9 0 0.0 2016 15 19 43.3 2.9 0 0.0 2017 10 15 17.6 1.8 0 0.0 2018 15 17 21.0 1.4 0 0.0 2019 17 25 17.5 1.0 0 0.0 2020 10 11 5.9 0.6 0 0.0 2021 0 0 0.0 .7 0 N/A 2021 0 0 0 .0 N/A 2021 0 2 0.0 .7 0 0.0 2008 1 2 11.1 11.1 0 0.0 0.0 2010 2 3 4.9 2.5 0 0.0 0.0 2011 3 5	2012	3	4	9.7	3.2	0	0.0	
2015 15 19 29.0 1.9 0 0.0 2016 15 19 43.3 2.9 0 0.0 2017 10 15 17.6 1.8 0 0.0 2018 15 17 21.0 1.4 0 0.0 2019 17 25 17.5 1.0 0 0.0 2020 10 11 5.9 0.6 0 0.0 2021 0 0 0.0 - 0 N/A 2020 10 11 5.9 0.6 0 0.0 2021 0 0 0.0 - 0 N/A 2020 13 4.9 2.5 0 0.0 0.0 2010 2 3 4.9 2.5 0 0.0 0.0 2011 3 5 14.2 4.7 0 0.0 0.0 2012 8	2013	7	10	21.6	3.1	0	0.0	
2016 15 19 43.3 2.9 0 0.0 2017 10 15 17.6 1.8 0 0.0 2018 15 17 21.0 1.4 0 0.0 2019 17 25 17.5 1.0 0 0.0 2020 10 11 5.9 0.6 0 0.0 2021 0 0 0.0 - 0 N/A 2021 0 0 0.0 - 0 N/A 2021 0 0 0 - 0 N/A 2021 2 0.0 - 0 N/A 2010 2 3 4.9 2.5 0 0.0 2011 3 5 14.2 4.7 0 0.0 2012 8 8 25.7 3.2 0 0.0 2014 8 8 25.7 3.2 0	2014	8	11	19.3	2.4	0	0.0	
2017 10 15 17.6 1.8 0 0.0 2018 15 17 21.0 1.4 0 0.0 2019 17 25 17.5 1.0 0 0.0 2020 10 11 5.9 0.6 0 0.0 2021 0 0 0.0 - 0 N/A 2021 0 0 0.0 - 0 N/A 2021 0 0.0 - 0 0.0 . 2010 2 0.0 - 0 0.0 . 2010 2 3 4.9 2.5 0 0.0 . 2011 3 5 14.2 4.7 0 0.0 . 2012 8 8 24.7 3.1 0 0.0 . 2014 8 8 25.7 3.2 0 0.0 . 2015	2015	15	19	29.0	1.9	0	0.0	
2018151721.01.400.02019172517.51.000.0202010115.90.600.02021000.0-0N/AMale20081211.111.100.02009020.0-0N/A2010234.92.500.020113514.24.700.020128824.73.100.02013455.61.400.020148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0	2016	15	19	43.3	2.9	0	0.0	
2019172517.51.000.0202010115.90.600.02021000.0-0N/AMale	2017	10	15	17.6	1.8	0	0.0	
202010115.90.6000.02021000.0-0N/AMale20081211.111.100.02009020.0-0N/A2010234.92.500.020113514.24.700.020128824.73.100.02013455.61.400.020148825.73.200.02015131847.33.600.02017202540.62.000.02017202540.62.000.02018101115.51.600.02019141916.61.200.0	2018	15	17	21.0	1.4	0	0.0	
2021000.0-0N/AMale20081211.111.100.02009020.0-0N/A2010234.92.500.020113514.24.700.020128824.73.100.02013455.61.400.020148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2019	17	25	17.5	1.0	0	0.0	
Male20081211.111.100.02009020.0-0N/A2010234.92.500.020113514.24.700.020128824.73.100.02013455.61.400.020148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2020	10	11	5.9	0.6	0	0.0	
20081211.111.100.0 2009 020.0-0N/A 2010 234.92.500.0 2011 3514.24.700.0 2012 8824.73.100.0 2013 455.61.400.0 2014 8825.73.200.0 2015 131847.33.600.0 2017 202540.62.000.0 2018 101115.51.600.0 2019 141916.61.200.0 2020 13167.70.600.0	2021	0	0	0.0	-	0	N/A	
2009020.0-0N/A2010234.92.500.020113514.24.700.020128824.73.100.02013455.61.400.020148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	Male							
2010234.92.500.020113514.24.700.020128824.73.100.02013455.61.400.020148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2008	1	2	11.1	11.1	0	0.0	
20113514.24.700.020128824.73.100.02013455.61.400.020148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2009	0	2	0.0	-	0	N/A	
20128824.73.100.02013455.61.400.020148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2010	2	3	4.9	2.5	0	0.0	
2013455.61.400.020148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2011	3	5	14.2	4.7	0	0.0	
20148825.73.200.02015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2012	8	8	24.7	3.1	0	0.0	
2015131847.33.600.02016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2013	4	5	5.6	1.4	0	0.0	
2016172145.32.700.02017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2014	8	8	25.7	3.2	0	0.0	
2017202540.62.000.02018101115.51.600.02019141916.61.200.0202013167.70.600.0	2015	13	18	47.3	3.6	0	0.0	
2018101115.51.600.02019141916.61.200.0202013167.70.600.0	2016	17	21	45.3	2.7	0	0.0	
2019 14 19 16.6 1.2 0 0.0 2020 13 16 7.7 0.6 0 0.0	2017	20	25	40.6	2.0	0	0.0	
2020 13 16 7.7 0.6 0 0.0	2018	10	11	15.5	1.6	0	0.0	
	2019	14	19	16.6	1.2	0	0.0	
2021 3 3 0.7 0.2 0 0.0	2020	13	16	7.7	0.6	0	0.0	
	2021	3	3	0.7	0.2	0	0.0	



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Treatment Wi	thin 180 Days Diagn	osis				
Female						
2008	3	6	13.0	4.3	0	0.0
2009	3	4	15.2	5.1	0	0.0
2010	2	8	2.9	1.4	0	0.0
2011	3	6	11.3	3.8	0	0.0
2012	3	7	9.7	3.2	0	0.0
2013	8	17	22.0	2.7	0	0.0
2014	13	22	32.8	2.5	0	0.0
2015	19	29	42.8	2.3	0	0.0
2016	20	30	56.2	2.8	0	0.0
2017	16	31	31.7	2.0	0	0.0
2018	20	27	32.2	1.6	0	0.0
2019	21	37	21.9	1.0	0	0.0
2020	11	15	6.8	0.6	0	0.0
2021	0	0	0.0	-	0	N/A
Male						
2008	4	8	25.1	6.3	0	0.0
2009	1	9	0.6	0.6	0	0.0
2010	3	9	15.6	5.2	0	0.0
2011	8	11	33.6	4.2	0	0.0
2012	8	12	24.7	3.1	0	0.0
2013	7	10	8.4	1.2	0	0.0
2014	11	17	40.5	3.7	0	0.0
2015	16	28	56.3	3.5	0	0.0
2016	25	37	66.7	2.7	0	0.0
2017	27	38	57.8	2.1	0	0.0
2018	12	18	18.1	1.5	0	0.0
2019	18	29	21.1	1.2	0	0.0
2020	16	22	9.9	0.6	0	0.0
2021	3	3	0.7	0.2	0	0.0

	1
Table 8. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between January 1, 2008 and May	⁷ 31, 2021, by Sex and Year ¹

¹Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

²Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Cytomegaloviru	us (CMV) Infection	or Congenital CMV (cC	MV)			
Overall						
Midwest						
2008	20	112,555	41.7	2.1	0	0.0
2009	22	109,119	46.7	2.1	0	0.0
2010	16	100,340	27.4	1.7	0	0.0
2011	9	95,988	37.3	4.1	0	0.0
2012	16	93,947	42.4	2.7	0	0.0
2013	13	107,953	11.8	0.9	0	0.0
2014	27	108,780	54.2	2.0	0	0.0
2015	19	109,059	47.4	2.5	0	0.0
2016	32	111,682	82.8	2.6	0	0.0
2017	41	111,297	66.2	1.6	0	0.0
2018	33	108,977	53.1	1.6	0	0.0
2019	45	101,430	58.3	1.3	0	0.0
2020	22	95,403	12.1	0.5	0	0.0
2021	2	12,595	0.3	0.1	0	0.0
Northeast						
2008	10	60,076	36.5	3.6	0	0.0
2009	8	58,909	18.8	2.3	0	0.0
2010	11	55,832	33.0	3.0	0	0.0
2011	6	52,013	6.9	1.2	0	0.0
2012	13	49,620	32.9	2.5	0	0.0
2013	7	58,366	7.3	1.0	0	0.0
2014	17	62,169	36.0	2.1	0	0.0
2015	12	63,479	33.5	2.8	0	0.0
2016	19	64,064	29.9	1.6	0	0.0
2017	15	60,949	31.4	2.1	0	0.0
2018	21	58,656	28.0	1.3	0	0.0
2019	23	54,551	24.8	1.1	0	0.0
2020	13	51,789	5.9	0.5	0	0.0
2021	2	5,374	0.2	0.1	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
South						
2008	50	229,847	168.3	3.4	0	0.0
2009	42	221,723	153.6	3.7	0	0.0
2010	62	205,828	264.8	4.3	0	0.0
2011	55	194,561	194.2	3.5	0	0.0
2012	40	186,680	135.2	3.4	0	0.0
2013	54	207,348	176.2	3.3	0	0.0
2014	56	217,742	170.8	3.1	0	0.0
2015	63	231,296	151.3	2.4	0	0.0
2016	72	239,429	155.1	2.2	0	0.0
2017	84	234,122	168.1	2.0	0	0.0
2018	68	225,990	97.3	1.4	0	0.0
2019	67	215,567	52.5	0.8	0	0.0
2020	34	151,653	16.2	0.5	0	0.0
2021	6	16,815	0.7	0.1	0	0.0
West						
2008	16	96,392	48.4	3.0	0	0.0
2009	12	97,673	36.8	3.1	0	0.0
2010	16	97,904	36.8	2.3	0	0.0
2011	9	92,824	23.1	2.6	0	0.0
2012	12	90,078	35.6	3.0	0	0.0
2013	22	106,168	71.5	3.2	0	0.0
2014	21	110,038	62.7	3.0	0	0.0
2015	25	110,126	61.3	2.5	0	0.0
2016	23	112,879	47.8	2.1	0	0.0
2017	22	107,896	38.1	1.7	0	0.0
2018	16	103,401	25.5	1.6	0	0.0
2019	14	100,793	16.6	1.2	0	0.0
2020	23	97,239	12.7	0.6	0	0.0
2021	2	14,198	0.6	0.3	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Invalid						
2008	1	4,840	13.0	13.0	0	0.0
2009	2	4,796	10.1	5.1	0	0.0
2010	1	4,510	0.3	0.3	0	0.0
2011	0	3,547	0.0	-	0	N/A
2012	0	3,460	0.0	-	0	N/A
2013	0	3,288	0.0	-	0	N/A
2014	0	4,062	0.0	-	0	N/A
2015	0	4,190	0.0	-	0	N/A
2016	0	5,433	0.0	-	0	N/A
2017	2	5,065	5.5	2.8	0	0.0
2018	1	5,292	3.0	3.0	0	0.0
2019	0	5,043	0.0	-	0	N/A
2020	1	3,938	0.2	0.2	0	0.0
2021	0	268	0.0	-	0	N/A
Missing						
2008	4	53,519	0.7	0.2	0	0.0
2009	3	33,848	1.3	0.4	0	0.0
2010	0	1,531	0.0	-	0	N/A
2011	0	1,398	0.0	-	0	N/A
2012	0	1,345	0.0	-	0	N/A
2013	0	2,116	0.0	-	0	N/A
2014	1	2,400	4.7	4.7	0	0.0
2015	0	2,459	0.0	-	0	N/A
2016	1	2,310	0.7	0.7	0	0.0
2017	0	1,994	0.0	-	0	N/A
2018	0	1,715	0.0	-	0	N/A
2019	0	1,331	0.0	-	0	N/A
2020	1	2,460	0.1	0.1	0	0.0
2021	2	3,169	0.4	0.2	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Other						
2008	0	59	0.0	-	0	N/A
2009	0	46	0.0	-	0	N/A
2010	0	61	0.0	-	0	N/A
2011	0	31	0.0	-	0	N/A
2012	0	31	0.0	-	0	N/A
2013	0	45	0.0	-	0	N/A
2014	0	41	0.0	-	0	N/A
2015	0	38	0.0	-	0	N/A
2016	0	38	0.0	-	0	N/A
2017	0	36	0.0	-	0	N/A
2018	0	49	0.0	-	0	N/A
2019	0	118	0.0	-	0	N/A
2020	0	233	0.0	-	0	N/A
2021	0	1	0.0	-	0	N/A
Hearing Loss: A	bsent, Clinical Cha	racteristics: Absent				
Midwest						
2008	3	75,883	10.1	3.4	0	0.0
2009	5	71,967	15.4	3.1	0	0.0
2010	5	66,445	4.3	0.9	0	0.0
2011	3	64,687	14.8	4.9	0	0.0
2012	2	64,129	2.2	1.1	0	0.0
2013	3	74,091	0.7	0.2	0	0.0
2014	6	74,604	19.5	3.3	0	0.0
2015	3	74,177	7.2	2.4	0	0.0
2016	8	75,246	22.6	2.8	0	0.0
2017	7	73,692	14.1	2.0	0	0.0
2018	12	71,736	24.3	2.0	0	0.0
2019	10	65,509	7.9	0.8	0	0.0
2020	3	62,395	1.3	0.4	0	0.0
2021	0	8,873	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Northeast						
2008	5	47,120	22.7	4.5	0	0.0
2009	3	45,351	13.5	4.5	0	0.0
2010	6	42,962	15.8	2.6	0	0.0
2011	4	40,056	2.3	0.6	0	0.0
2012	2	38,210	0.4	0.2	0	0.0
2013	3	44,768	1.5	0.5	0	0.0
2014	6	47,391	7.2	1.2	0	0.0
2015	6	48,438	13.4	2.2	0	0.0
2016	6	48,026	8.1	1.4	0	0.0
2017	3	44,794	4.2	1.4	0	0.0
2018	4	42,642	3.1	0.8	0	0.0
2019	3	39,445	3.0	1.0	0	0.0
2020	5	37,681	2.5	0.5	0	0.0
2021	2	4,006	0.2	0.1	0	0.0
South						
2008	14	162,263	59.8	4.3	0	0.0
2009	18	152,148	46.5	2.6	0	0.0
2010	22	142,054	98.7	4.5	0	0.0
2011	22	136,890	73.0	3.3	0	0.0
2012	10	131,490	38.9	3.9	0	0.0
2013	17	145,383	67.4	4.0	0	0.0
2014	14	150,280	41.0	2.9	0	0.0
2015	12	159,237	34.3	2.9	0	0.0
2016	15	162,608	33.0	2.2	0	0.0
2017	23	157,293	55.1	2.4	0	0.0
2018	10	150,582	13.1	1.3	0	0.0
2019	21	145,932	19.2	0.9	0	0.0
2020	10	98,170	6.8	0.7	0	0.0
2021	3	11,276	0.3	0.1	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
West						
2008	8	67,820	13.5	1.7	0	0.0
2009	2	67,738	16.5	8.3	0	0.0
2010	2	68,054	0.8	0.4	0	0.0
2011	2	63,998	3.0	1.5	0	0.0
2012	1	61,981	1.7	1.7	0	0.0
2013	6	74,891	25.9	4.3	0	0.0
2014	8	76,776	14.3	1.8	0	0.0
2015	3	77,363	2.4	0.8	0	0.0
2016	7	77,424	20.3	2.9	0	0.0
2017	4	72,833	4.4	1.1	0	0.0
2018	3	68,938	6.1	2.0	0	0.0
2019	4	65,763	5.5	1.4	0	0.0
2020	8	65,224	3.7	0.5	0	0.0
2021	0	9,834	0.0	-	0	N/A
Invalid						
2008	1	3,653	13.0	13.0	0	0.0
2009	0	3,528	0.0	-	0	N/A
2010	0	3,307	0.0	-	0	N/A
2011	0	2,640	0.0	-	0	N/A
2012	0	2,651	0.0	-	0	N/A
2013	0	2,461	0.0	-	0	N/A
2014	0	3,272	0.0	-	0	N/A
2015	0	3,495	0.0	-	0	N/A
2016	0	4,599	0.0	-	0	N/A
2017	1	4,222	3.2	3.2	0	0.0
2018	0	4,408	0.0	-	0	N/A
2019	0	4,154	0.0	-	0	N/A
2020	0	3,165	0.0	-	0	N/A
2021	0	138	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Missing						
2008	4	43,905	0.7	0.2	0	0.0
2009	1	27,139	0.2	0.2	0	0.0
2010	0	1,328	0.0	-	0	N/A
2011	0	1,203	0.0	-	0	N/A
2012	0	1,135	0.0	-	0	N/A
2013	0	1,700	0.0	-	0	N/A
2014	1	1,858	4.7	4.7	0	0.0
2015	0	1,911	0.0	-	0	N/A
2016	0	1,807	0.0	-	0	N/A
2017	0	1,568	0.0	-	0	N/A
2018	0	1,265	0.0	-	0	N/A
2019	0	1,039	0.0	-	0	N/A
2020	0	1,887	0.0	-	0	N/A
2021	0	2,178	0.0	-	0	N/A
Other						
2008	0	48	0.0	-	0	N/A
2009	0	38	0.0	-	0	N/A
2010	0	56	0.0	-	0	N/A
2011	0	27	0.0	-	0	N/A
2012	0	24	0.0	-	0	N/A
2013	0	38	0.0	-	0	N/A
2014	0	36	0.0	-	0	N/A
2015	0	30	0.0	-	0	N/A
2016	0	34	0.0	-	0	N/A
2017	0	29	0.0	-	0	N/A
2018	0	44	0.0	-	0	N/A
2019	0	98	0.0	-	0	N/A
2020	0	186	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: P	resent, Clinical Cha	aracteristics: Absent				
Midwest						
2008	0	524	0.0	-	0	N/A
2009	0	499	0.0	-	0	N/A
2010	1	537	0.8	0.8	0	0.0
2011	0	482	0.0	-	0	N/A
2012	0	421	0.0	-	0	N/A
2013	0	477	0.0	-	0	N/A
2014	0	445	0.0	-	0	N/A
2015	1	436	5.7	5.7	0	0.0
2016	0	347	0.0	-	0	N/A
2017	2	325	4.0	2.0	0	0.0
2018	0	318	0.0	-	0	N/A
2019	0	318	0.0	-	0	N/A
2020	2	286	1.6	0.8	0	0.0
2021	0	29	0.0	-	0	N/A
Northeast						
2008	0	431	0.0	-	0	N/A
2009	1	461	1.1	1.1	0	0.0
2010	2	349	10.4	5.2	0	0.0
2011	0	320	0.0	-	0	N/A
2012	2	289	8.0	4.0	0	0.0
2013	0	307	0.0	-	0	N/A
2014	1	404	0.0	0.0	0	0.0
2015	0	363	0.0	-	0	N/A
2016	0	351	0.0	-	0	N/A
2017	3	324	4.2	1.4	0	0.0
2018	3	302	3.4	1.1	0	0.0
2019	1	240	0.1	0.1	0	0.0
2020	0	268	0.0	-	0	N/A
2021	0	23	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
South						
2008	0	1,481	0.0	-	0	N/A
2009	1	1,064	12.1	12.1	0	0.0
2010	0	922	0.0	-	0	N/A
2011	0	871	0.0	-	0	N/A
2012	2	777	1.4	0.7	0	0.0
2013	1	889	2.4	2.4	0	0.0
2014	0	962	0.0	-	0	N/A
2015	0	976	0.0	-	0	N/A
2016	3	866	4.3	1.4	0	0.0
2017	0	798	0.0	-	0	N/A
2018	2	772	1.1	0.6	0	0.0
2019	2	644	0.5	0.3	0	0.0
2020	2	533	0.4	0.2	0	0.0
2021	0	50	0.0	-	0	N/A
West						
2008	0	301	0.0	-	0	N/A
2009	1	459	0.2	0.2	0	0.0
2010	0	534	0.0	-	0	N/A
2011	0	535	0.0	-	0	N/A
2012	0	457	0.0	-	0	N/A
2013	1	452	8.2	8.2	0	0.0
2014	0	472	0.0	-	0	N/A
2015	1	300	0.2	0.2	0	0.0
2016	0	269	0.0	-	0	N/A
2017	1	227	3.8	3.8	0	0.0
2018	2	225	5.5	2.8	0	0.0
2019	0	253	0.0	-	0	N/A
2020	0	209	0.0	-	0	N/A
2021	0	18	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Invalid						
2008	0	19	0.0	-	0	N/A
2009	0	12	0.0	-	0	N/A
2010	0	7	0.0	-	0	N/A
2011	0	7	0.0	-	0	N/A
2012	0	8	0.0	-	0	N/A
2013	0	9	0.0	-	0	N/A
2014	0	11	0.0	-	0	N/A
2015	0	8	0.0	-	0	N/A
2016	0	5	0.0	-	0	N/A
2017	0	3	0.0	-	0	N/A
2018	0	3	0.0	-	0	N/A
2019	0	3	0.0	-	0	N/A
2020	0	8	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Missing						
2008	0	209	0.0	-	0	N/A
2009	0	167	0.0	-	0	N/A
2010	0	8	0.0	-	0	N/A
2011	0	2	0.0	-	0	N/A
2012	0	6	0.0	-	0	N/A
2013	0	13	0.0	-	0	N/A
2014	0	11	0.0	-	0	N/A
2015	0	10	0.0	-	0	N/A
2016	0	2	0.0	-	0	N/A
2017	0	9	0.0	-	0	N/A
2018	0	5	0.0	-	0	N/A
2019	0	2	0.0	-	0	N/A
2020	0	9	0.0	-	0	N/A
2021	0	11	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Other						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Hearing Loss: A	bsent, Clinical Cha	racteristics: Present				
Midwest						
2008	16	36,705	26.4	1.7	0	0.0
2009	16	37,158	29.9	1.9	0	0.0
2010	10	33,927	22.2	2.2	0	0.0
2011	5	31,348	12.8	2.6	0	0.0
2012	13	29,919	38.8	3.0	0	0.0
2013	10	33,969	11.1	1.1	0	0.0
2014	20	34,284	34.5	1.7	0	0.0
2015	11	34,975	24.2	2.2	0	0.0
2016	21	36,632	48.0	2.3	0	0.0
2017	31	37,832	44.4	1.4	0	0.0
2018	18	37,436	24.8	1.4	0	0.0
2019	30	36,139	43.2	1.4	0	0.0
2020	16	33,257	9.1	0.6	0	0.0
2021	2	3,743	0.3	0.1	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Northeast						
2008	4	12,926	12.6	3.1	0	0.0
2009	4	13,534	4.1	1.0	0	0.0
2010	2	12,892	6.2	3.1	0	0.0
2011	2	11,999	4.6	2.3	0	0.0
2012	8	11,430	16.6	2.1	0	0.0
2013	4	13,562	5.8	1.4	0	0.0
2014	9	14,753	27.3	3.0	0	0.0
2015	6	14,988	20.0	3.3	0	0.0
2016	11	15,983	20.5	1.9	0	0.0
2017	8	16,144	19.1	2.4	0	0.0
2018	13	15,994	20.2	1.6	0	0.0
2019	17	15,141	19.8	1.2	0	0.0
2020	7	14,146	3.2	0.5	0	0.0
2021	0	1,361	0.0	-	0	N/A
South						
2008	33	66,727	87.1	2.6	0	0.0
2009	20	69,387	75.6	3.8	0	0.0
2010	37	63,787	164.0	4.4	0	0.0
2011	30	57,750	117.3	3.9	0	0.0
2012	28	55,408	94.9	3.4	0	0.0
2013	34	62,194	104.8	3.1	0	0.0
2014	39	67,595	112.5	2.9	0	0.0
2015	48	72,287	110.2	2.3	0	0.0
2016	53	77,064	117.7	2.2	0	0.0
2017	59	77,065	107.7	1.8	0	0.0
2018	54	75,695	79.3	1.5	0	0.0
2019	39	70,024	25.8	0.7	0	0.0
2020	21	53,599	8.8	0.4	0	0.0
2021	2	5,544	0.2	0.1	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
West						
2008	6	28,708	26.8	4.5	0	0.0
2009	7	29,846	9.9	1.4	0	0.0
2010	9	29,692	25.6	2.8	0	0.0
2011	7	28,630	20.1	2.9	0	0.0
2012	11	27,949	34.0	3.1	0	0.0
2013	14	31,347	37.0	2.6	0	0.0
2014	10	33,152	30.6	3.1	0	0.0
2015	16	33,080	40.0	2.5	0	0.0
2016	14	35,784	22.4	1.6	0	0.0
2017	16	35,433	28.7	1.8	0	0.0
2018	10	34,791	13.4	1.3	0	0.0
2019	9	35,344	10.9	1.2	0	0.0
2020	13	32,374	8.5	0.7	0	0.0
2021	1	4,409	0.2	0.2	0	0.0
Invalid						
2008	0	1,188	0.0	-	0	N/A
2009	2	1,270	10.1	5.1	0	0.0
2010	1	1,217	0.3	0.3	0	0.0
2011	0	913	0.0	-	0	N/A
2012	0	815	0.0	-	0	N/A
2013	0	828	0.0	-	0	N/A
2014	0	789	0.0	-	0	N/A
2015	0	697	0.0	-	0	N/A
2016	0	842	0.0	-	0	N/A
2017	1	849	2.4	2.4	0	0.0
2018	1	890	3.0	3.0	0	0.0
2019	0	894	0.0	-	0	N/A
2020	1	774	0.2	0.2	0	0.0
2021	0	130	0.0	-	0	N/A



Missing		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009 0 6,702 0.0 - 0 N/A 2010 0 206 0.0 - 0 N/A 2011 0 199 0.0 - 0 N/A 2012 0 215 0.0 - 0 N/A 2013 0 417 0.0 - 0 N/A 2014 0 544 0.0 - 0 N/A 2015 0 551 0.0 - 0 N/A 2016 1 513 0.7 0.7 0 0.0 2016 1 513 0.7 0.7 0 N/A 2018 0 454 0.0 - 0 N/A 2020 0 575 0.0 - 0 N/A 2021 2 987 0.4 0.2 0 0 2014 0 10 0 - <th>Missing</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	Missing						
2010 0 206 0.0 0 N/A 2011 0 199 0.0 0 N/A 2012 0 215 0.0 0 N/A 2013 0 417 0.0 0 N/A 2014 0 544 0.0 - 0 N/A 2015 0 551 0.0 - 0 N/A 2016 1 513 0.7 0.7 0 0 0 2017 0 421 0.0 - 0 N/A 2018 0 454 0.0 - 0 N/A 2020 0 575 0.0 - 0 N/A 2021 2 987 0.4 0.2 0 0.0 2021 2 987 0.4 0.2 0 N/A 2020 0 9 0.0<	2008	0	9,730	0.0	-	0	N/A
2011 0 199 0.0 0 N/A 2012 0 215 0.0 0 N/A 2013 0 417 0.0 0 N/A 2014 0 554 0.0 0 N/A 2015 0 551 0.0 0 N/A 2016 1 513 0.7 0.7 0 0.0 0.0 2017 0 421 0.0 0 N/A 2018 0 454 0.0 0 N/A 2019 0 292 0.0 0 N/A 2020 0 575 0.0 0 N/A 2020 0 575 0.0 0 N/A 2020 0 9 0.0 0 N/A 2010 0 6 <td< td=""><td>2009</td><td>0</td><td>6,702</td><td>0.0</td><td>-</td><td>0</td><td>N/A</td></td<>	2009	0	6,702	0.0	-	0	N/A
2012 0 215 0.0 - 0 N/A 2013 0 417 0.0 - 0 N/A 2014 0 544 0.0 - 0 N/A 2015 0 551 0.0 - 0 N/A 2016 1 513 0.7 0.7 0 0.0 2017 0 421 0.0 - 0 N/A 2018 0 454 0.0 - 0 N/A 2020 0 575 0.0 - 0 N/A 2021 2 97 0.4 0.2 0 N/A 2020 0 575 0.0 - 0 N/A 2021 2 97 0.4 0.2 0 N/A 2011 0 4 0.0 - 0 N/A 2012 0 7 0.0 -	2010	0	206	0.0	-	0	N/A
2013 0 417 0.0 - 0 N/A 2014 0 544 0.0 - 0 N/A 2015 0 551 0.0 - 0 N/A 2015 0 421 0.0 - 0 N/A 2017 0 421 0.0 - 0 N/A 2018 0 454 0.0 - 0 N/A 2019 0 292 0.0 - 0 N/A 2021 2 987 0.4 0.2 0 0 2021 2 987 0.4 0.2 0 0 2021 2 987 0.4 0.2 0 0 0 2021 2 987 0.4 0.2 0 0 N/A 2010 6 0.0 - 0 N/A 2011 0 6 0.0	2011	0	199	0.0	-	0	N/A
2014 0 544 0.0 - 0 N/A 2015 0 551 0.0 - 0 N/A 2016 1 513 0.7 0.7 0 0.0 2017 0 421 0.0 - 0 N/A 2018 0 454 0.0 - 0 N/A 2019 0 292 0.0 - 0 N/A 2020 0 575 0.0 - 0 N/A 2021 2 987 0.4 0.2 0 0 2021 2 987 0.4 0.2 0 0 2021 2 987 0.0 - 0 N/A 2020 0 59 0.0 - 0 N/A 2014 0 7 0.0 - 0 N/A 2012 0 7 0.0 -	2012	0	215	0.0	-	0	N/A
2015 0 551 0.0 - 0 N/A 2016 1 513 0.7 0.7 0 0.0 2017 0 421 0.0 - 0 N/A 2018 0 451 0.0 - 0 N/A 2019 0 292 0.0 - 0 N/A 2020 0 575 0.0 - 0 N/A 2021 2 987 0.4 0.2 0 0.0 2021 2 987 0.4 0.2 0 0.0 2021 2 987 0.4 0.2 0 0.0 2021 2 987 0.4 0.2 0 0.0 0.0 2010 0 9 0.0 - 0 N/A 2011 0 4 0.0 - 0 N/A 2012 0 7 0.0<	2013	0	417	0.0	-	0	N/A
2016 1 513 0.7 0.7 0 0.0 2017 0 421 0.0 - 0 N/A 2018 0 454 0.0 - 0 N/A 2019 0 292 0.0 - 0 N/A 2020 0 575 0.0 - 0 N/A 2021 2 987 0.4 0.2 0 0 2021 2 987 0.4 0.2 0 0 2021 2 987 0.4 0.2 0 0 0 2021 2 987 0.4 0.2 0 0 0 0 0 2012 0 9 0.0 - 0 N/A 0 N/A 2010 0 6 0.0 - 0 N/A 2011 0 7 0.0 - 0 N/A	2014	0	544	0.0	-	0	N/A
2017 0 421 0.0 0 N/A 2018 0 454 0.0 0 N/A 2019 0 292 0.0 0 N/A 2020 0 575 0.0 0 N/A 2021 2 927 0.4 0.2 0 0 2021 2 927 0.4 0.2 0 0 2021 2 927 0.4 0.2 0 0 2021 2 927 0.4 0.2 0 0 2010 0 11 0.0 - 0 N/A 2010 0 6 0.0 - 0 N/A 2011 0 4 0.0 - 0 N/A 2012 0 7 0.0 - 0 N/A 2014 0 7 0.0 -	2015	0	551	0.0	-	0	N/A
2018 0 454 0.0 - 0 N/A 2019 0 292 0.0 - 0 N/A 2020 0 575 0.0 - 0 N/A 2021 2 987 0.4 0.2 0 0.0 2021 2 987 0.4 0.2 0 0.0 2021 2 987 0.4 0.2 0 0.0 2011 2 987 0.4 0.2 0 N/A 2009 0 9 0.0 - 0 N/A 2010 0 6 0.0 - 0 N/A 2011 0 4 0.0 - 0 N/A 2012 0 7 0.0 - 0 N/A 2013 0 7 0.0 - 0 N/A 2014 0 7 0.0 -	2016	1	513	0.7	0.7	0	0.0
201902920.0-0N/A202005750.0-0N/A202129870.40.200.0Other20080110.0-0N/A2009090.0-0N/A2010060.0-0N/A2011040.0-0N/A2012070.0-0N/A2013070.0-0N/A2014070.0-0N/A2015080.0-0N/A2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A	2017	0	421	0.0	-	0	N/A
202005750.0-0N/A202129870.40.200.0Other-0N/A20080110.0-0N/A2009090.0-0N/A2010060.0-0N/A2011040.0-0N/A2012070.0-0N/A2013070.0-0N/A2014070.0-0N/A2015080.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A	2018	0	454	0.0	-	0	N/A
202005750.0-0N/A202129870.40.200.0Other-0N/A20080110.0-0N/A2009090.0-0N/A2010060.0-0N/A2011040.0-0N/A2012070.0-0N/A2013070.0-0N/A2014070.0-0N/A2015080.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A	2019	0	292	0.0	-	0	N/A
Other 2008 0 11 0.0 - 0 N/A 2009 0 9 0.0 - 0 N/A 2010 0 6 0.0 - 0 N/A 2011 0 4 0.0 - 0 N/A 2012 0 7 0.0 - 0 N/A 2013 0 7 0.0 - 0 N/A 2014 0 7 0.0 - 0 N/A 2015 0 8 0.0 - 0 N/A 2016 0 4 0.0 - 0 N/A 2017 0 7 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 20 0.0 - 0 N/A 2020 0 53 0.0 -	2020	0	575	0.0	-	0	
2008 0 11 0.0 - 0 N/A 2009 0 9 0.0 - 0 N/A 2010 0 6 0.0 - 0 N/A 2011 0 4 0.0 - 0 N/A 2012 0 7 0.0 - 0 N/A 2013 0 7 0.0 - 0 N/A 2014 0 7 0.0 - 0 N/A 2015 0 8 0.0 - 0 N/A 2016 0 4 0.0 - 0 N/A 2017 0 7 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 20 0.0 - 0 N/A 2020 0 53 0.0 - 0	2021	2	987	0.4	0.2	0	0.0
2009090.0-0N/A2010060.0-0N/A2011040.0-0N/A2012070.0-0N/A2013070.0-0N/A2014070.0-0N/A2015080.0-0N/A2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A20200530.0-0N/A	Other						
2010060.0-0N/A2011040.0-0N/A2012070.0-0N/A2013070.0-0N/A2014070.0-0N/A2015080.0-0N/A2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A20200530.0-0N/A	2008	0	11	0.0	-	0	N/A
2011040.0-0N/A2012070.0-0N/A2013070.0-0N/A2014070.0-0N/A2015080.0-0N/A2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A20200530.0-0N/A	2009	0	9	0.0	-	0	N/A
2012070.0-0N/A2013070.0-0N/A2014070.0-0N/A2015080.0-0N/A2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A20200530.0-0N/A	2010	0	6	0.0	-	0	N/A
2013070.0-0N/A2014070.0-0N/A2015080.0-0N/A2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A20200530.0-0N/A	2011	0	4	0.0	-	0	N/A
2014070.0-0N/A2015080.0-0N/A2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A20200530.0-0N/A	2012	0	7	0.0	-	0	N/A
2015080.0-0N/A2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A20200530.0-0N/A	2013	0	7	0.0	-	0	N/A
2016040.0-0N/A2017070.0-0N/A2018050.0-0N/A20190200.0-0N/A20200530.0-0N/A	2014	0	7	0.0	-	0	N/A
2017 0 7 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 20 0.0 - 0 N/A 2020 0 53 0.0 - 0 N/A	2015	0	8	0.0	-	0	N/A
2018 0 5 0.0 - 0 N/A 2019 0 20 0.0 - 0 N/A 2020 0 53 0.0 - 0 N/A	2016	0	4	0.0	-	0	N/A
2019 0 20 0.0 - 0 N/A 2020 0 53 0.0 - 0 N/A	2017	0	7	0.0	-	0	N/A
2019 0 20 0.0 - 0 N/A 2020 0 53 0.0 - 0 N/A	2018	0	5	0.0	-	0	N/A
2020 0 53 0.0 - 0 N/A	2019	0	20	0.0	-	0	
	2020	0		0.0	-	0	
	2021	0	1	0.0	-	0	N/A



200812975.25.200.0200913431.41.400.0201002980.0-0N/A201112809.79.700.0201212801.41.400.0201302450.0-0N/A201412870.20.200.02015427210.22.500.02016321912.34.100.0201712093.73.700.0201832174.01.300.0201952077.11.400.0202011970.10.100.020210220.0-0N/A		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2008 1 297 5.2 5.2 0 0.0 2009 1 343 1.4 1.4 0 0 0 2010 0 298 0.0 - 0 N/A 2011 1 280 9.7 9.7 0 0.0 2012 1 280 1.4 1.4 0 0.0 2013 0 245 0.0 - 0 N/A 2014 1 287 0.2 0.2 0 0.0 2015 4 272 10.2 2.5 0 0.0 2016 3 219 12.3 4.1 0 0.0 2017 1 2.0 1.3 0 0.0 0 2018 3 2.17 4.0 1.3 0 0.0 2020 1 1.97 0.1 0.1 0 0.0 2021 0 -	Hearing Loss: P	resent, Clinical Cha	aracteristics: Present				
200913431.41.400.0201002980.0-0N/A201112809.79.700.0201212801.41.400.0201302450.0-0N/A201412870.20.200.02015427210.22.500.02016321912.34.100.0201712093.73.700.0201832174.01.300.0201952077.11.400.0202011970.10.100.020210-0N/A00.0202011710.60.600.0201101520.0-0N/A201211578.08.000.0201411.41.400.00.0201501520.0-0N/A201411641.41.400.0201501550.0-0N/A201411.641.41.400.0201501553.93.900.0201611.401.31.30	Midwest						
2010 0 298 0.0 - 0 N/A 2011 1 280 9.7 9.7 0 0.0 2012 1 280 9.7 9.7 0 0.0 2013 0 245 0.0 - 0 N/A 2014 1 287 0.2 0.2 0 0.0 2015 4 272 10.2 2.5 0 0.0 2016 3 219 1.3 4.1 0 0.0 2017 1 209 3.7 3.7 0 0.0 2018 3 217 4.0 1.3 0 0.0 2020 1 197 0.1 0.1 0 0.0 2021 0 20 0 - 0 N/A 2020 1 1.3 1.3 0 0.0 0 2020 1 7.4 0.0	2008	1	297	5.2	5.2	0	0.0
2011 1 280 9.7 9.7 0 0.0 2012 1 280 1.4 1.4 0 0.0 2013 0 245 0.0 - 0 N/A 2014 1 287 0.2 0.2 0 0.0 2015 4 272 10.2 2.5 0 0.0 2016 3 219 1.3 4.1 0 0.0 2017 1 209 3.7 3.7 0 0.0 2018 3 217 4.0 1.3 0 0.0 2019 5 207 7.1 1.4 0 0.0 2020 1 197 0.1 0.1 0 0.0 2021 0 1.4 0.1 0 0.0 0 2021 1 1.3 1.3 0 0.0 0 2010 1 1.1 0.6	2009	1	343	1.4	1.4	0	0.0
201212801.41.400.0201302450.0-0N/A201412870.20.200.02015427210.22.500.02016321912.34.100.0201712093.73.700.0201832174.01.300.0201952077.11.400.0202011970.10.100.020210220.0-0N/A202011970.10.100.020210200-0N/A202011740.0-0N/A201011710.60.600.0201101520.0-0N/A201211578.08.000.0201301760.0-0N/A201411641.41.400.020150120.600.00.020150120.600.00.0201411401.31.300.0201501.20.600.00.0201411.41.40.40<	2010	0	298	0.0	-	0	N/A
2013 0 245 0.0 - 0 N/A 2014 1 287 0.2 0.2 0 0.0 2015 4 272 10.2 2.5 0 0.0 2016 3 219 12.3 4.1 0 0.0 2017 1 209 3.7 3.7 0 0.0 2018 3 217 4.0 1.3 0 0.0 2019 5 207 7.1 1.4 0 0.0 2021 0 22 00 - 0 N/A 2021 0 22 00 - 0 N/A 2021 0 22 0.0 - 0 N/A 2021 0 1.3 1.3 0.1 0.0 0.0 2008 1 711 0.6 0 0 0.0 0.0 2010 1 171	2011	1	280	9.7	9.7	0	0.0
2014 1 287 0.2 0.2 0 0.0 2015 4 272 10.2 2.5 0 0.0 2016 3 219 12.3 4.1 0 0.0 2017 1 209 3.7 3.7 0 0.0 2018 3 217 4.0 1.3 0 0.0 2019 5 207 7.1 1.4 0 0.0 2021 0 22 0.0 - 0 N/A 2021 0 22 0.0 - 0 N/A 2021 0 1.3 1.3 0 0.0 0.0 2021 1 174 0.0 - 0 N/A 2010 152 0.0 - 0 N/A 2011 0 156 0.0 - 0 N/A 2012 1 157 8.0 8.0	2012	1	280	1.4	1.4	0	0.0
2015 4 272 10.2 2.5 0 0.0 2016 3 219 12.3 4.1 0 0.0 2017 1 209 3.7 3.7 0 0.0 2018 3 217 4.0 1.3 0 0.0 2019 5 207 7.1 1.4 0 0.0 2020 1 197 0.1 0.1 0 0.0 2021 0 22 0.0 - 0 N/A Vortheast	2013	0	245	0.0	-	0	N/A
2016 3 219 12.3 4.1 0 0.0 2017 1 209 3.7 3.7 0 0.0 2018 3 217 4.0 1.3 0 0.0 2019 5 207 7.1 1.4 0 0.0 2020 1 197 0.1 0.1 0 0.0 2021 0 22 0.0 - 0 N/A 2021 0 22 0.0 - 0 N/A 2021 0 20 0 - 0 N/A 2021 0 1.3 1.3 0 0.0 0.0 2012 1 174 0.0 - 0 N/A 2010 1 171 0.6 0.6 0 0.0 2012 1 157 8.0 8.0 0 0.0 0.0 2014 1 164	2014	1	287	0.2	0.2	0	0.0
201712093.73.700.0201832174.01.300.0201952077.11.400.0202011970.10.100.020210220.0-0N/Avertree200812011.31.300.0200901740.0-0N/A201011710.60.600.0201101520.0-0N/A201211578.08.000.0201301641.41.400.0201411641.41.400.020150-0N/A00.0201621931.20.600.0201711753.93.900.0201811401.31.300.020192201.91.000.0	2015	4	272	10.2	2.5	0	0.0
201832174.01.300.0201952077.11.400.0202011970.10.100.020210220.0-0N/AVortheast200812011.31.300.0201001740.0-0N/A200901740.60.600.0201101520.0-0N/A201211578.08.000.0201301760.0-0N/A201411541.41.400.020150120.0-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0	2016	3	219	12.3	4.1	0	0.0
201952077.11.400.0202011970.10.100.020210220.0-0N/AVortheast200812011.31.300.0200901740.0-0N/A201011710.60.600.0201101520.0-0N/A201211578.08.000.0201301760.0-0N/A201411641.41.400.02015090.0-0N/A201621931.20.600.0201711753.93.900.0201814001.31.300.0201921201.91.000.0	2017	1	209	3.7	3.7	0	0.0
202011970.10.100.020210220.0-0N/A2011.20.0-00.0200812011.31.300.0200901740.0-0N/A201011710.60.600.0201101520.0-0N/A201211578.08.000.0201301760.0-0N/A201411641.41.400.0201501.20.600.0201711753.93.900.0201811401.31.300.0201921200.10.100.0	2018	3	217	4.0	1.3	0	0.0
20210220.0-0N/AVortheast200812011.31.300.0200901740.0-0N/A201011710.60.600.0201101520.0-0N/A201211578.08.000.0201301760.0-0N/A201411641.41.400.0201501950.0-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2019	5	207	7.1	1.4	0	0.0
Northeast 2008 1 201 1.3 1.3 0 0.0 2009 0 174 0.0 - 0 N/A 2010 1 171 0.6 0.6 0 0.0 2011 0 152 0.0 - 0 N/A 2012 1 157 8.0 8.0 0 0.0 2013 0 176 0.0 - 0 N/A 2014 1 164 1.4 1.4 0 0.0 2015 0 195 0.0 - 0 N/A 2016 2 193 1.2 0.6 0 0.0 2017 1 175 3.9 3.9 0 0.0 0.0 2018 1 140 1.3 1.3 0 0.0 0.0 2019 2 120 1.9 1.0 0 0.0 0.0 <td>2020</td> <td>1</td> <td>197</td> <td>0.1</td> <td>0.1</td> <td>0</td> <td>0.0</td>	2020	1	197	0.1	0.1	0	0.0
2008 1 201 1.3 1.3 0 0.0 2009 0 174 0.0 - 0 N/A 2010 1 171 0.6 0.6 0 0.0 2011 0 152 0.0 - 0 N/A 2012 1 157 8.0 8.0 0 0.0 2013 0 176 0.0 - 0 N/A 2014 1 164 1.4 1.4 0 0.0 2015 0 195 0.0 - 0 N/A 2016 2 193 1.2 0.6 0 0.0 2017 1 175 3.9 3.9 0 0.0 0.0 2018 1 140 1.3 1.3 0 0.0 0.0 2019 2 120 1.9 1.0 0 0.0 0.0	2021	0	22	0.0	-	0	N/A
200901740.0-0N/A201011710.60.600.0201101520.0-0N/A201211578.08.000.0201301760.0-0N/A201411641.41.400.0201501950.0-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	Northeast						
201011710.60.6000.0201101520.0-0N/A201211578.08.000.0201301760.0-0N/A201411641.41.400.0201501950.0-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2008	1	201	1.3	1.3	0	0.0
201101520.0-0N/A201211578.08.000.0201301760.0-0N/A201411641.41.400.0201501950.0-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2009	0	174	0.0	-	0	N/A
201211578.08.08.000.0201301760.0-0N/A201411641.41.400.0201501950.0-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2010	1	171	0.6	0.6	0	0.0
201301760.0-0N/A201411641.41.400.0201501950.0-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2011	0	152	0.0	-	0	N/A
201411641.41.400.0201501950.0-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2012	1	157	8.0	8.0	0	0.0
20150-0N/A201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2013	0	176	0.0	-	0	N/A
201621931.20.600.0201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2014	1	164	1.4	1.4	0	0.0
201711753.93.900.0201811401.31.300.0201921201.91.000.0202011290.10.100.0	2015	0	195	0.0	-	0	N/A
201811401.31.300.0201921201.91.000.0202011290.10.100.0	2016	2	193	1.2	0.6	0	0.0
2019 2 120 1.9 1.0 0 0.0 2020 1 129 0.1 0.1 0 0.0	2017	1	175	3.9	3.9	0	0.0
2020 1 129 0.1 0.1 0.0	2018	1	140	1.3	1.3	0	0.0
	2019	2	120	1.9	1.0	0	0.0
2021 0 13 0.0 - 0 N/A	2020	1	129	0.1	0.1	0	0.0
	2021	0	13	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
South						
2008	3	942	21.4	7.1	0	0.0
2009	3	705	19.5	6.5	0	0.0
2010	3	605	2.1	0.7	0	0.0
2011	3	499	4.0	1.3	0	0.0
2012	0	472	0.0	-	0	N/A
2013	2	512	1.7	0.8	0	0.0
2014	3	605	17.4	5.8	0	0.0
2015	3	593	6.7	2.2	0	0.0
2016	1	544	0.1	0.1	0	0.0
2017	2	593	5.4	2.7	0	0.0
2018	2	539	3.7	1.8	0	0.0
2019	5	457	6.9	1.4	0	0.0
2020	1	318	0.3	0.3	0	0.0
2021	1	27	0.2	0.2	0	0.0
West						
2008	2	233	8.1	4.0	0	0.0
2009	2	345	10.1	5.1	0	0.0
2010	5	352	10.3	2.1	0	0.0
2011	0	386	0.0	-	0	N/A
2012	0	386	0.0	-	0	N/A
2013	1	323	0.3	0.3	0	0.0
2014	3	359	17.8	5.9	0	0.0
2015	5	187	18.6	3.7	0	0.0
2016	2	179	5.1	2.6	0	0.0
2017	1	159	1.1	1.1	0	0.0
2018	1	146	0.5	0.5	0	0.0
2019	1	167	0.2	0.2	0	0.0
2020	2	133	0.5	0.3	0	0.0
2021	1	25	0.4	0.4	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Invalid						
2008	0	8	0.0	-	0	N/A
2009	0	11	0.0	-	0	N/A
2010	0	7	0.0	-	0	N/A
2011	0	5	0.0	-	0	N/A
2012	0	3	0.0	-	0	N/A
2013	0	4	0.0	-	0	N/A
2014	0	8	0.0	-	0	N/A
2015	0	6	0.0	-	0	N/A
2016	0	3	0.0	-	0	N/A
2017	0	2	0.0	-	0	N/A
2018	0	9	0.0	-	0	N/A
2019	0	4	0.0	-	0	N/A
2020	0	1	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Missing						
2008	0	96	0.0	-	0	N/A
2009	2	82	1.2	0.6	0	0.0
2010	0	1	0.0	-	0	N/A
2011	0	1	0.0	-	0	N/A
2012	0	1	0.0	-	0	N/A
2013	0	2	0.0	-	0	N/A
2014	0	3	0.0	-	0	N/A
2015	0	5	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	1	0.0	-	0	N/A
2018	0	3	0.0	-	0	N/A
2019	0	2	0.0	-	0	N/A
2020	1	5	0.1	0.1	0	0.0
2021	0	4	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Other						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	1	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Valganciclovir 1	Treatment for Infai	nts with CMV or cCMV				
Overall						
Midwest						
2008	20	112,555	8.0	0.4	1	500.0
2009	22	109,119	8.5	0.4	2	909.1
2010	16	100,340	5.6	0.4	4	2,500.0
2011	9	95,988	3.6	0.4	2	2,222.2
2012	16	93,947	6.1	0.4	2	1,250.0
2013	13	107,953	4.1	0.3	1	769.2
2014	27	108,780	8.0	0.3	7	2,592.6
2015	19	109,059	5.4	0.3	5	2,631.6
2016	32	111,682	10.0	0.3	9	2,812.5
2017	41	111,297	13.1	0.3	8	1,951.2
2018	33	108,977	10.5	0.3	8	2,424.2
2019	45	101,430	15.3	0.3	13	2,888.9
2020	22	95,403	5.8	0.3	7	3,181.8
	2	12,595	0.1	0.0	1	5,000.0



20081060,0764.50.500.02009858,9093.20.400.020101155,8325.00.500.02011652,0131.90.323,333.320121249,6203.90.332,500.02013758,3662.20.334,285.720141762,1695.20.321,176.520151263,4794.30.432,500.020161964,0646.80.431,578.920171560,9495.10.332,000.020182158,6566.40.341,904.820192354,5518.70.431,304.320201351,7892.80.253,846.2202125,3740.20.100.0		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009 8 58,909 3.2 0.4 0 0.0 2010 11 55,832 5.0 0.5 0 0.0 2011 6 52,013 1.9 0.3 2 3,333.3 2012 12 49,620 3.9 0.3 3 2,500.0 2013 7 58,366 2.2 0.3 3 4,285.7 2014 17 62,169 5.2 0.3 2 1,176.5 2015 12 63,479 4.3 0.4 3 1,578.9 2016 19 64,064 6.8 0.4 3 1,504.8 2018 21 58,556 6.4 0.3 4 1,904.8 2019 23 54,551 8.7 0.4 3 1,304.3 2020 13 51,789 2.8 0.2 5 3,846.2 2021 2 0.4 6 1,200.0 1.3 1,304.3	Northeast						
2010 11 55,832 5.0 0.5 0 0.0 2011 6 52,013 1.9 0.3 2 3,333.3 2012 12 49,620 3.9 0.3 3 4,285.7 2014 17 62,169 5.2 0.3 2 1,176.5 2015 12 63,479 4.3 0.4 3 2,500.0 2016 19 64,064 6.8 0.4 3 1,578.9 2017 15 60,949 5.1 0.3 3 2,000.0 2018 21 58,656 6.4 0.3 4 1,904.8 2020 13 51,789 2.8 0.2 5 3,846.2 2021 2 5,374 0.2 0.1 0 0.0 2020 13 51,789 2.8 0.2 5 3,846.2 2021 2 5,374 0.2 0.1 0 0.0	2008	10	60,076	4.5	0.5	0	0.0
2011 6 52,013 1.9 0.3 2 3,333.3 2012 12 49,620 3.9 0.3 3 2,500.0 2013 7 58,366 2.2 0.3 3 4,285.7 2014 17 62,169 5.2 0.3 2 1,76.5 2015 12 63,479 4.3 0.4 3 2,500.0 2016 19 64,064 6.8 0.4 3 1,578.9 2017 15 60,949 5.1 0.3 3 2,000.0 2018 21 58,556 6.4 0.3 3 1,304.3 2019 23 54,551 8.7 0.4 3 1,304.3 2020 13 51,789 2.8 0.2 5 3,846.2 2021 2 5.0 0.4 3 1,200.0 1,200.0 2009 42 221,723 17.6 0.4 1 161.3 <	2009	8	58,909	3.2	0.4	0	0.0
2012 12 49,620 3.9 0.3 3 2,500.0 2013 7 58,366 2.2 0.3 3 4,285.7 2014 17 62,169 5.2 0.3 2 1,176.5 2015 12 63,479 4.3 0.4 3 2,500.0 2016 19 64,064 6.8 0.4 3 1,578.9 2017 15 60,949 5.1 0.3 3 2,000.0 2018 21 58,656 6.4 0.3 4 1,904.8 2020 13 51,789 2.8 0.2 5 3,846.2 2021 2 53,734 0.2 0.1 0 0 2020 13 51,789 2.8 0.2 5 3,846.2 2021 2 50 1,813 0.4 6 1,200.0 2008 50 229,847 18.3 0.4 1 161.3	2010	11	55,832	5.0	0.5	0	0.0
2013758,3662.20.334,285.720141762,1695.20.321,176.520151263,4794.30.432,500.020161964,0646.80.431,578.920171560,9495.10.332,000.020182158,6566.40.341,904.820192354,5518.70.431,304.320201351,7892.80.253,846.2202125,3740.20.100.0colspan="4">col	2011	6	52,013	1.9	0.3	2	3,333.3
20141762,1695.20.321,176.520151263,4794.30.432,500.020161964,0646.80.431,578.920171560,4495.10.332,000.020182158,6566.40.341,904.820192354,5518.70.431,304.320201351,7892.80.253,846.2202125,3740.20.100.0south colspan="4">south colspan="4">colspan="4">south colspan="4">colspan="4">south colspan="4">south colspan="4">south colspan="4">colspan="4">south colspan="4">south colspan="4">south colspan="4" south colspan="4">south colspan="5	2012	12	49,620	3.9	0.3	3	2,500.0
20151263,4794.30.432,500.020161964,0646.80.431,578.920171560,9495.10.332,000.020182158,6566.40.341,904.820192354,5518.70.431,304.320201351,7892.80.253,846.2202125,3740.20.100.0south200850229,87118.30.461,200.0201962205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.420178424,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,6538.10.292,647.1	2013	7	58,366	2.2	0.3	3	4,285.7
20161964,0646.80.431,578.920171560,9495.10.332,000.020182158,6566.40.341,904.820192354,5518.70.431,304.320201351,7892.80.253,846.2202125,3740.20.100.0colspan="4">colspan="4"colspan="4">colspan="4"colspan="4"colspan="4">colspan="4"colspan="4"colspan="4">colspan="4"cols	2014	17	62,169	5.2	0.3	2	1,176.5
20171560,9495.10.332,000.020182158,6566.40.341,904.820192354,5518.70.431,304.320201351,7892.80.253,846.2202125,3740.20.100.0South200850229,84718.30.461,200.0201062205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2015	12	63,479	4.3	0.4	3	2,500.0
20182158,6566.40.341,904.820192354,5518.70.431,304.320201351,7892.80.253,846.2202125,3740.20.100.0South200850229,84718.30.461,200.0200942221,72317.60.42476.2201062205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3182,647.120186825.90021.00.3182,647.1201967215,66717.90.3192,835.8202034151,6538.10.292,647.1	2016	19	64,064	6.8	0.4	3	1,578.9
20192354,5518.70.431,304.320201351,7892.80.253,846.2202125,3740.20.100.0South200850229,84718.30.461,200.0200942221,72317.60.42476.2201062205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3293,452.4201784234,12226.70.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2017	15	60,949	5.1	0.3	3	2,000.0
20201351,7892.80.253,846.2202125,3740.20.100.0South200850229,84718.30.461,200.0200942221,72317.60.42476.2201062205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3293,452.4201784234,12226.70.3182,647.1201868225,99021.00.3192,835.8202034151,6538.10.292,647.1	2018	21	58,656	6.4	0.3	4	1,904.8
202125,3740.20.100.0South200850229,84718.30.461,200.0200942221,72317.60.42476.2201062205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2019	23	54,551	8.7	0.4	3	1,304.3
South 2008 50 229,847 18.3 0.4 6 1,200.0 2009 42 221,723 17.6 0.4 2 476.2 2010 62 205,828 26.0 0.4 1 161.3 2011 55 194,561 22.2 0.4 6 1,090.9 2012 40 186,680 15.7 0.4 3 750.0 2013 54 207,348 21.1 0.4 5 925.9 2014 56 217,742 20.2 0.4 10 1,785.7 2015 62 231,296 19.0 0.3 20 3,225.8 2016 72 239,429 20.9 0.3 23 3,194.4 2017 84 234,122 26.7 0.3 29 3,452.4 2018 68 225,990 21.0 0.3 18 2,647.1 2019 67 215,567 17.9 0.3	2020	13	51,789	2.8	0.2	5	3,846.2
200850229,84718.30.461,200.0200942221,72317.60.42476.2201062205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2021	2	5,374	0.2	0.1	0	0.0
200942221,72317.60.42476.2201062205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	South						
201062205,82826.00.41161.3201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2008	50	229,847	18.3	0.4	6	1,200.0
201155194,56122.20.461,090.9201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2009	42	221,723	17.6	0.4	2	476.2
201240186,68015.70.43750.0201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2010	62	205,828	26.0	0.4	1	161.3
201354207,34821.10.45925.9201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2011	55	194,561	22.2	0.4	6	1,090.9
201456217,74220.20.4101,785.7201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2012	40	186,680	15.7	0.4	3	750.0
201562231,29619.00.3203,225.8201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2013	54	207,348	21.1	0.4	5	925.9
201672239,42920.90.3233,194.4201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2014	56	217,742	20.2	0.4	10	1,785.7
201784234,12226.70.3293,452.4201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2015	62	231,296	19.0	0.3	20	3,225.8
201868225,99021.00.3182,647.1201967215,56717.90.3192,835.8202034151,6538.10.292,647.1	2016	72	239,429	20.9	0.3	23	3,194.4
2019 67 215,567 17.9 0.3 19 2,835.8 2020 34 151,653 8.1 0.2 9 2,647.1	2017	84	234,122	26.7	0.3	29	3,452.4
2020 34 151,653 8.1 0.2 9 2,647.1	2018	68	225,990	21.0	0.3	18	2,647.1
2020 34 151,653 8.1 0.2 9 2,647.1	2019	67	215,567	17.9	0.3	19	2,835.8
2021 6 16,815 0.5 0.1 1 1,666.7	2020	34	151,653	8.1	0.2		2,647.1
	2021		16,815				1,666.7



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
West						
2008	16	96,392	6.4	0.4	0	0.0
2009	12	97,673	5.3	0.4	0	0.0
2010	16	97,904	6.9	0.4	0	0.0
2011	9	92,824	3.1	0.3	1	1,111.1
2012	12	90,078	4.8	0.4	2	1,666.7
2013	22	106,168	6.7	0.3	6	2,727.3
2014	21	110,038	8.0	0.4	4	1,904.8
2015	25	110,126	8.1	0.3	6	2,400.0
2016	21	112,879	5.2	0.2	7	3,333.3
2017	22	107,896	7.5	0.3	3	1,363.6
2018	16	103,401	6.7	0.4	2	1,250.0
2019	14	100,793	4.3	0.3	4	2,857.1
2020	23	97,239	7.1	0.3	5	2,173.9
2021	2	14,198	0.6	0.3	0	0.0
Invalid						
2008	1	4,840	0.5	0.5	0	0.0
2009	2	4,796	0.8	0.4	0	0.0
2010	1	4,510	0.3	0.3	0	0.0
2011	0	3,547	0.0	-	0	N/A
2012	0	3,460	0.0	-	0	N/A
2013	0	3,288	0.0	-	0	N/A
2014	0	4,062	0.0	-	0	N/A
2015	0	4,190	0.0	-	0	N/A
2016	0	5,433	0.0	-	0	N/A
2017	2	5,065	1.0	0.5	0	0.0
2018	1	5,292	0.5	0.5	0	0.0
2019	0	5,043	0.0	-	0	N/A
2020	1	3,938	0.2	0.2	0	0.0
2021	0	268	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Missing						
2008	4	53,519	0.7	0.2	0	0.0
2009	3	33,848	0.9	0.3	0	0.0
2010	0	1,531	0.0	-	0	N/A
2011	0	1,398	0.0	-	0	N/A
2012	0	1,345	0.0	-	0	N/A
2013	0	2,116	0.0	-	0	N/A
2014	1	2,400	0.5	0.5	0	0.0
2015	0	2,459	0.0	-	0	N/A
2016	1	2,310	0.5	0.5	0	0.0
2017	0	1,994	0.0	-	0	N/A
2018	0	1,715	0.0	-	0	N/A
2019	0	1,331	0.0	-	0	N/A
2020	1	2,460	0.0	0.0	1	10,000.0
2021	2	3,169	0.3	0.2	1	5,000.0
Other						
2008	0	59	0.0	-	0	N/A
2009	0	46	0.0	-	0	N/A
2010	0	61	0.0	-	0	N/A
2011	0	31	0.0	-	0	N/A
2012	0	31	0.0	-	0	N/A
2013	0	45	0.0	-	0	N/A
2014	0	41	0.0	-	0	N/A
2015	0	38	0.0	-	0	N/A
2016	0	38	0.0	-	0	N/A
2017	0	36	0.0	-	0	N/A
2018	0	49	0.0	-	0	N/A
2019	0	118	0.0	-	0	N/A
2020	0	233	0.0	-	0	N/A
2021	0	1	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: A	bsent, Clinical Cha	racteristics: Absent				
Midwest						
2008	3	75,883	1.5	0.5	0	0.0
2009	5	71,967	1.6	0.3	0	0.0
2010	5	66,445	2.1	0.4	0	0.0
2011	3	64,687	1.0	0.3	1	3,333.3
2012	2	64,129	1.0	0.5	0	0.0
2013	3	74,091	0.7	0.2	0	0.0
2014	6	74,604	3.0	0.5	0	0.0
2015	3	74,177	1.1	0.4	0	0.0
2016	8	75,246	3.7	0.5	0	0.0
2017	7	73,692	3.0	0.4	0	0.0
2018	12	71,736	4.4	0.4	3	2,500.0
2019	10	65,509	4.1	0.4	0	0.0
2020	3	62,395	1.1	0.4	0	0.0
2021	0	8,873	0.0	-	0	N/A
Northeast						
2008	5	47,120	2.1	0.4	0	0.0
2009	3	45,351	1.2	0.4	0	0.0
2010	6	42,962	2.5	0.4	0	0.0
2011	4	40,056	1.4	0.4	1	2,500.0
2012	2	38,210	0.4	0.2	0	0.0
2013	3	44,768	0.9	0.3	1	3,333.3
2014	6	47,391	2.1	0.3	0	0.0
2015	6	48,438	2.5	0.4	0	0.0
2016	6	48,026	2.1	0.3	0	0.0
2017	3	44,794	0.6	0.2	1	3,333.3
2018	4	42,642	0.9	0.2	0	0.0
2019	3	39,445	1.3	0.4	0	0.0
2020	5	37,681	1.5	0.3	1	2,000.0
2021	2	4,006	0.2	0.1	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
South						
2008	14	162,263	4.6	0.3	1	714.3
2009	18	152,148	7.4	0.4	0	0.0
2010	22	142,054	9.4	0.4	0	0.0
2011	22	136,890	9.3	0.4	2	909.1
2012	10	131,490	4.5	0.5	0	0.0
2013	17	145,383	7.3	0.4	1	588.2
2014	14	150,280	6.0	0.4	0	0.0
2015	12	159,237	5.6	0.5	1	833.3
2016	15	162,608	6.1	0.4	2	1,333.3
2017	23	157,293	8.7	0.4	5	2,173.9
2018	10	150,582	3.9	0.4	1	1,000.0
2019	21	145,932	7.9	0.4	4	1,904.8
2020	10	98,170	2.1	0.2	4	4,000.0
2021	3	11,276	0.1	0.0	1	3,333.3
West						
2008	8	67,820	2.9	0.4	0	0.0
2009	2	67,738	1.0	0.5	0	0.0
2010	2	68,054	0.5	0.3	0	0.0
2011	2	63,998	0.1	0.1	1	5,000.0
2012	1	61,981	0.5	0.5	0	0.0
2013	6	74,891	1.6	0.3	2	3,333.3
2014	8	76,776	3.2	0.4	0	0.0
2015	3	77,363	1.1	0.4	0	0.0
2016	7	77,424	2.1	0.3	3	4,285.7
2017	4	72,833	1.1	0.3	0	0.0
2018	3	68,938	1.5	0.5	0	0.0
2019	4	65,763	1.5	0.4	1	2,500.0
2020	8	65,224	2.3	0.3	2	2,500.0
2021	0	9,834	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Invalid						
2008	1	3,653	0.5	0.5	0	0.0
2009	0	3,528	0.0	-	0	N/A
2010	0	3,307	0.0	-	0	N/A
2011	0	2,640	0.0	-	0	N/A
2012	0	2,651	0.0	-	0	N/A
2013	0	2,461	0.0	-	0	N/A
2014	0	3,272	0.0	-	0	N/A
2015	0	3,495	0.0	-	0	N/A
2016	0	4,599	0.0	-	0	N/A
2017	1	4,222	0.5	0.5	0	0.0
2018	0	4,408	0.0	-	0	N/A
2019	0	4,154	0.0	-	0	N/A
2020	0	3,165	0.0	-	0	N/A
2021	0	138	0.0	-	0	N/A
Missing						
2008	4	43,905	0.7	0.2	0	0.0
2009	1	27,139	0.2	0.2	0	0.0
2010	0	1,328	0.0	-	0	N/A
2011	0	1,203	0.0	-	0	N/A
2012	0	1,135	0.0	-	0	N/A
2013	0	1,700	0.0	-	0	N/A
2014	1	1,858	0.5	0.5	0	0.0
2015	0	1,911	0.0	-	0	N/A
2016	0	1,807	0.0	-	0	N/A
2017	0	1,568	0.0	-	0	N/A
2018	0	1,265	0.0	-	0	N/A
2019	0	1,039	0.0	-	0	N/A
2020	0	1,887	0.0	-	0	N/A
2021	0	2,178	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Other						
2008	0	48	0.0	-	0	N/A
2009	0	38	0.0	-	0	N/A
2010	0	56	0.0	-	0	N/A
2011	0	27	0.0	-	0	N/A
2012	0	24	0.0	-	0	N/A
2013	0	38	0.0	-	0	N/A
2014	0	36	0.0	-	0	N/A
2015	0	30	0.0	-	0	N/A
2016	0	34	0.0	-	0	N/A
2017	0	29	0.0	-	0	N/A
2018	0	44	0.0	-	0	N/A
2019	0	98	0.0	-	0	N/A
2020	0	186	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Hearing Loss: P	Present, Clinical Cha	aracteristics: Absent				
Midwest						
2008	0	524	0.0	-	0	N/A
2009	0	499	0.0	-	0	N/A
2010	1	537	0.5	0.5	0	0.0
2011	0	482	0.0	-	0	N/A
2012	0	421	0.0	-	0	N/A
2013	0	477	0.0	-	0	N/A
2014	0	445	0.0	-	0	N/A
2015	1	436	0.1	0.1	1	10,000.0
2016	0	347	0.0	-	0	N/A
2017	2	325	0.5	0.3	1	5,000.0
2018	0	318	0.0	-	0	N/A
2019	0	318	0.0	-	0	N/A
2020	2	286	0.5	0.3	1	5,000.0
2021	0	29	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Northeast						
2008	0	431	0.0	-	0	N/A
2009	1	461	0.5	0.5	0	0.0
2010	2	349	1.0	0.5	0	0.0
2011	0	320	0.0	-	0	N/A
2012	2	289	1.0	0.5	0	0.0
2013	0	307	0.0	-	0	N/A
2014	1	404	0.0	0.0	0	0.0
2015	0	363	0.0	-	0	N/A
2016	0	351	0.0	-	0	N/A
2017	3	324	0.6	0.2	1	3,333.3
2018	3	302	1.1	0.4	0	0.0
2019	1	240	0.1	0.1	0	0.0
2020	0	268	0.0	-	0	N/A
2021	0	23	0.0	-	0	N/A
South						
2008	0	1,481	0.0	-	0	N/A
2009	1	1,064	0.5	0.5	0	0.0
2010	0	922	0.0	-	0	N/A
2011	0	871	0.0	-	0	N/A
2012	2	777	1.0	0.5	0	0.0
2013	1	889	0.1	0.1	1	10,000.0
2014	0	962	0.0	-	0	N/A
2015	0	976	0.0	-	0	N/A
2016	3	866	0.6	0.2	2	6,666.7
2017	0	798	0.0	-	0	N/A
2018	2	772	0.5	0.3	1	5,000.0
2019	2	644	0.5	0.3	0	0.0
2020	2	533	0.0	0.0	1	5,000.0
2021	0	50	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
West						
2008	0	301	0.0	-	0	N/A
2009	1	459	0.2	0.2	0	0.0
2010	0	534	0.0	-	0	N/A
2011	0	535	0.0	-	0	N/A
2012	0	457	0.0	-	0	N/A
2013	1	452	0.5	0.5	0	0.0
2014	0	472	0.0	-	0	N/A
2015	1	300	0.2	0.2	0	0.0
2016	0	269	0.0	-	0	N/A
2017	1	227	0.1	0.1	1	10,000.0
2018	2	225	0.6	0.3	1	5,000.0
2019	0	253	0.0	-	0	N/A
2020	0	209	0.0	-	0	N/A
2021	0	18	0.0	-	0	N/A
Invalid						
2008	0	19	0.0	-	0	N/A
2009	0	12	0.0	-	0	N/A
2010	0	7	0.0	-	0	N/A
2011	0	7	0.0	-	0	N/A
2012	0	8	0.0	-	0	N/A
2013	0	9	0.0	-	0	N/A
2014	0	11	0.0	-	0	N/A
2015	0	8	0.0	-	0	N/A
2016	0	5	0.0	-	0	N/A
2017	0	3	0.0	-	0	N/A
2018	0	3	0.0	-	0	N/A
2019	0	3	0.0	-	0	N/A
2020	0	8	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A



2008 0 209 0.0 - 0 N/A 2009 0 167 0.0 - 0 N/A 2010 0 8 0.0 - 0 N/A 2011 0 2 0.0 - 0 N/A 2012 0 6 0.0 - 0 N/A 2013 0 13 0.0 - 0 N/A 2014 0 11 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2016 0 2 0.0 - 0 N/A 2017 0 9 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 2 0.0 - 0 N/A 2020 0 9 0.0 - 0		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
200901670.0-0N/A2010080.0-0N/A2011020.0-0N/A2012060.0-0N/A20130130.0-0N/A20140110.0-0N/A20150100.0-0N/A2016020.0-0N/A2017090.0-0N/A2018050.0-0N/A2019020.0-0N/A2020090.0-0N/A2021010.0-0N/A202000.0-0N/A202100.0-0N/A202000.0-0N/A2011000.0-0N/A201200.0-0N/A201300.0-0N/A2014000.0-0N/A2015000.0-0N/A2014000.0-0N/A2015000.0-0N/A2014000.0-0N/A2015 <t< th=""><th>Missing</th><th></th><th></th><th></th><th></th><th></th><th></th></t<>	Missing						
2010080.0-0N/A2011020.0-0N/A2012060.0-0N/A20130130.0-0N/A20140110.0-0N/A20150100.0-0N/A2016020.0-0N/A2017090.0-0N/A2018050.0-0N/A2019020.0-0N/A20210110.0-0N/A20210110.0-0N/A20210110.0-0N/A20210100.0-0N/A2019000.0-0N/A201000.0-0N/A2011000.0-0N/A2012000.0-0N/A2013000.0-0N/A2014000.0-0N/A2015000.0-0N/A2014000.0-0N/A2015000.0-0N/A <trr>2014000.0-<td< td=""><td>2008</td><td>0</td><td>209</td><td>0.0</td><td>-</td><td>0</td><td>N/A</td></td<></trr>	2008	0	209	0.0	-	0	N/A
2011020.0-0N/A2012060.0-0N/A20130130.0-0N/A20140110.0-0N/A20150100.0-0N/A2016020.0-0N/A2017090.0-0N/A2018050.0-0N/A2020090.0-0N/A20210110.0-0N/A20210110.0-0N/A20210110.0-0N/A20210100.0-0N/A2019000.0-0N/A201000.0-0N/A2011000.0-0N/A2012000.0-0N/A2013000.0-0N/A2014000.0-0N/A2015000.0-0N/A2014000.0-0N/A2015000.0-0N/A2014000.0-0N/A <trr>2015000.0-<td< td=""><td>2009</td><td>0</td><td>167</td><td>0.0</td><td>-</td><td>0</td><td>N/A</td></td<></trr>	2009	0	167	0.0	-	0	N/A
2012 0 6 0.0 - 0 N/A 2013 0 13 0.0 - 0 N/A 2014 0 11 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2016 0 2 0.0 - 0 N/A 2017 0 9 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 2 0.0 - 0 N/A 2020 0 9 0.0 - 0 N/A 2021 0 1 0.0 - 0 N/A 2020 0 0 0.0 - 0 N/A 2021 0 0 0.0 - 0 N/A 2020 0 0 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 0 N	2010	0	8	0.0	-	0	N/A
2013 0 13 0.0 - 0 N/A 2014 0 11 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2015 0 2 0.0 - 0 N/A 2017 0 9 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 2 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A	2011	0	2	0.0	-	0	N/A
2014 0 11 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2016 0 2 0.0 - 0 N/A 2017 0 9 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 2 0.0 - 0 N/A 2021 0 1 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 10 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0 N/A	2012	0	6	0.0	-	0	N/A
2015 0 10 0.0 - 0 N/A 2016 0 2 0.0 - 0 N/A 2017 0 9 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 2 0.0 - 0 N/A 2020 0 9 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 0 0.0 - 0 N/A 2020 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0	2013	0	13	0.0	-	0	N/A
2016 0 2 0.0 - 0 N/A 2017 0 9 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 2 0.0 - 0 N/A 2020 0 9 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 10 0.0 - 0 N/A 2021 0 10 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0	2014	0	11	0.0	-	0	N/A
2017 0 9 0.0 - 0 N/A 2018 0 5 0.0 - 0 N/A 2019 0 2 0.0 - 0 N/A 2020 0 9 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0 N/A 2014 0 0 0.0 - 0	2015	0	10	0.0	-	0	N/A
2018 0 5 0.0 - 0 N/A 2019 0 2 0.0 - 0 N/A 2020 0 9 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A	2016	0	2	0.0	-	0	N/A
2019 0 2 0.0 - 0 N/A 2020 0 9 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A 2008 0 0 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A 2015 0 0 0.0 - 0 N/A	2017	0	9	0.0	-	0	N/A
2020 0 9 0.0 - 0 N/A 2021 0 11 0.0 - 0 N/A Other - 0 N/A 0 N/A 2008 0 0 0.0 - 0 N/A 2009 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A 2015 0 0 0.0 - 0 N/A 2017 0 0 0.0 - 0 N/A	2018	0	5	0.0	-	0	N/A
2021 0 11 0.0 - 0 N/A Other 2008 0 0 0.0 - 0 N/A 2009 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A 2015 0 0 0.0 - 0 N/A 2016 0 0 0.0 - 0 N/A 2017 0 0 0.0 - 0 N/A 2017 0 0 0.0 - 0 N/A 2018 0 0 0.0 -	2019	0	2	0.0	-	0	N/A
Other 2008 0 0 0.0 - 0 N/A 2009 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A 2015 0 0 0.0 - 0 N/A 2016 0 0 0.0 - 0 N/A 2017 0 0 0.0 - 0 N/A 2018 0 0 0.0 - 0 N/A 2019 0 0 0.0 - 0 N/A	2020	0	9	0.0	-	0	N/A
2008 0 0 0.0 - 0 N/A 2009 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 0 0 0.0 - 0 N/A 2013 0 0 0.0 - 0 N/A 2014 0 0 0.0 - 0 N/A 2015 0 0 0.0 - 0 N/A 2016 0 0 0.0 - 0 N/A 2017 0 0 0.0 - 0 N/A 2018 0 0 0.0 - 0 N/A 2019 0 0 0.0 - 0 N/A 2020 0 0 0.0 - 0	2021	0	11	0.0	-	0	N/A
2009000.0-0N/A2010000.0-0N/A2011000.0-0N/A2012000.0-0N/A2013000.0-0N/A2014000.0-0N/A2015000.0-0N/A201600.0-0N/A2017000.0-0N/A2018000.0-0N/A2019000.0-0N/A2020000.0-0N/A	Other						
2010000.0-0N/A2011000.0-0N/A2012000.0-0N/A2013000.0-0N/A2014000.0-0N/A2015000.0-0N/A201600.0-0N/A2017000.0-0N/A201800.0-0N/A201900.0-0N/A2020000.0-0N/A	2008	0	0	0.0	-	0	N/A
2011000.0-0N/A2012000.0-0N/A2013000.0-0N/A2014000.0-0N/A2015000.0-0N/A201600.0-0N/A201700.0-0N/A201800.0-0N/A201900.0-0N/A202000.0-0N/A	2009	0	0	0.0	-	0	N/A
2012000.0-0N/A2013000.0-0N/A2014000.0-0N/A2015000.0-0N/A201600.0-0N/A201700.0-0N/A201800.0-0N/A201900.0-0N/A202000.0-0N/A	2010	0	0	0.0	-	0	N/A
2013000.0-0N/A2014000.0-0N/A2015000.0-0N/A2016000.0-0N/A2017000.0-0N/A2018000.0-0N/A201900.0-0N/A2020000.0-0N/A	2011	0	0	0.0	-	0	N/A
2014000.0-0N/A2015000.0-0N/A2016000.0-0N/A2017000.0-0N/A201800.0-0N/A201900.0-0N/A202000.0-0N/A	2012	0	0	0.0	-	0	N/A
201500.0-0N/A201600.0-0N/A2017000.0-0N/A201800.0-0N/A201900.0-0N/A202000.0-0N/A	2013	0	0	0.0	-	0	N/A
2016 0 0.0 - 0 N/A 2017 0 0 0.0 - 0 N/A 2018 0 0 0.0 - 0 N/A 2019 0 0.0 - 0 N/A 2020 0 0.0 - 0 N/A	2014	0	0	0.0	-	0	N/A
2017 0 0 0.0 - 0 N/A 2018 0 0 0.0 - 0 N/A 2019 0 0 0.0 - 0 N/A 2020 0 0.0 - 0 N/A	2015	0	0	0.0	-	0	N/A
2018 0 0.0 - 0 N/A 2019 0 0 0.0 - 0 N/A 2020 0 0 0.0 - 0 N/A	2016	0	0	0.0	-	0	N/A
2019 0 0.0 - 0 N/A 2020 0 0 0.0 - 0 N/A	2017	0	0	0.0	-	0	N/A
2020 0 0.0 - 0 N/A	2018	0	0	0.0	-	0	N/A
	2019	0	0	0.0	-	0	N/A
2021 0 0.0 - 0. N/A	2020	0	0	0.0	-	0	N/A
	2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: At	osent, Clinical Cha	racteristics: Present				
Midwest						
2008	16	36,705	6.0	0.4	1	625.0
2009	16	37,158	6.4	0.4	2	1,250.0
2010	10	33,927	3.1	0.3	4	4,000.0
2011	5	31,348	2.1	0.4	1	2,000.0
2012	13	29,919	5.1	0.4	1	769.2
2013	10	33,969	3.3	0.3	1	1,000.0
2014	20	34,284	5.0	0.3	6	3,000.0
2015	11	34,975	3.2	0.3	3	2,727.3
2016	21	36,632	6.2	0.3	6	2,857.1
2017	31	37,832	9.2	0.3	6	1,935.5
2018	18	37,436	5.5	0.3	3	1,666.7
2019	30	36,139	10.5	0.4	9	3,000.0
2020	16	33,257	4.1	0.3	6	3,750.0
2021	2	3,743	0.1	0.0	1	5,000.0
Northeast						
2008	4	12,926	2.0	0.5	0	0.0
2009	4	13,534	1.6	0.4	0	0.0
2010	2	12,892	1.0	0.5	0	0.0
2011	2	11,999	0.5	0.2	1	5,000.0
2012	7	11,430	2.5	0.4	2	2,857.1
2013	4	13,562	1.3	0.3	2	5,000.0
2014	9	14,753	2.9	0.3	1	1,111.1
2015	6	14,988	1.8	0.3	3	5,000.0
2016	11	15,983	4.6	0.4	1	909.1
2017	8	16,144	3.9	0.5	0	0.0
2018	13	15,994	3.9	0.3	4	3,076.9
2019	17	15,141	7.3	0.4	1	588.2
2020	7	14,146	1.3	0.2	3	4,285.7
2021	0	1,361	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
South						
2008	33	66,727	12.7	0.4	4	1,212.1
2009	20	69,387	8.4	0.4	1	500.0
2010	37	63,787	15.2	0.4	1	270.3
2011	30	57,750	11.9	0.4	3	1,000.0
2012	28	55,408	10.2	0.4	3	1,071.4
2013	34	62,194	12.8	0.4	3	882.4
2014	39	67,595	13.5	0.3	8	2,051.3
2015	47	72,287	12.8	0.3	17	3,617.0
2016	53	77,064	14.1	0.3	19	3,584.9
2017	59	77,065	17.9	0.3	22	3,728.8
2018	54	75,695	16.5	0.3	14	2,592.6
2019	39	70,024	8.9	0.2	11	2,820.5
2020	21	53,599	5.9	0.3	3	1,428.6
2021	2	5,544	0.2	0.1	0	0.0
West						
2008	6	28,708	2.5	0.4	0	0.0
2009	7	29,846	3.4	0.5	0	0.0
2010	9	29,692	4.0	0.4	0	0.0
2011	7	28,630	2.9	0.4	0	0.0
2012	11	27,949	4.4	0.4	2	1,818.2
2013	14	31,347	4.6	0.3	3	2,142.9
2014	10	33,152	4.5	0.5	1	1,000.0
2015	16	33,080	5.6	0.4	3	1,875.0
2016	13	35,784	2.6	0.2	4	3,076.9
2017	16	35,433	6.2	0.4	1	625.0
2018	10	34,791	4.1	0.4	1	1,000.0
2019	9	35,344	2.6	0.3	3	3,333.3
2020	13	32,374	4.3	0.3	3	2,307.7
2021	1	4,409	0.2	0.2	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Invalid						
2008	0	1,188	0.0	-	0	N/A
2009	2	1,270	0.8	0.4	0	0.0
2010	1	1,217	0.3	0.3	0	0.0
2011	0	913	0.0	-	0	N/A
2012	0	815	0.0	-	0	N/A
2013	0	828	0.0	-	0	N/A
2014	0	789	0.0	-	0	N/A
2015	0	697	0.0	-	0	N/A
2016	0	842	0.0	-	0	N/A
2017	1	849	0.5	0.5	0	0.0
2018	1	890	0.5	0.5	0	0.0
2019	0	894	0.0	-	0	N/A
2020	1	774	0.2	0.2	0	0.0
2021	0	130	0.0	-	0	N/A
Missing						
2008	0	9,730	0.0	-	0	N/A
2009	0	6,702	0.0	-	0	N/A
2010	0	206	0.0	-	0	N/A
2011	0	199	0.0	-	0	N/A
2012	0	215	0.0	-	0	N/A
2013	0	417	0.0	-	0	N/A
2014	0	544	0.0	-	0	N/A
2015	0	551	0.0	-	0	N/A
2016	1	513	0.5	0.5	0	0.0
2017	0	421	0.0	-	0	N/A
2018	0	454	0.0	-	0	N/A
2019	0	292	0.0	-	0	N/A
2020	0	575	0.0	-	0	N/A
2021	2	987	0.3	0.2	1	5,000.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Other						
2008	0	11	0.0	-	0	N/A
2009	0	9	0.0	-	0	N/A
2010	0	6	0.0	-	0	N/A
2011	0	4	0.0	-	0	N/A
2012	0	7	0.0	-	0	N/A
2013	0	7	0.0	-	0	N/A
2014	0	7	0.0	-	0	N/A
2015	0	8	0.0	-	0	N/A
2016	0	4	0.0	-	0	N/A
2017	0	7	0.0	-	0	N/A
2018	0	5	0.0	-	0	N/A
2019	0	20	0.0	-	0	N/A
2020	0	53	0.0	-	0	N/A
2021	0	1	0.0	-	0	N/A
Hearing Loss: P	Present, Clinical Cha	aracteristics: Present				
Midwest						
2008	1	297	0.5	0.5	0	0.0
2009	1	343	0.5	0.5	0	0.0
2010	0	298	0.0	-	0	N/A
2011	1	280	0.5	0.5	0	0.0
2012	1	280	0.1	0.1	1	10,000.0
2013	0	245	0.0	-	0	N/A
2014	1	287	0.0	0.0	1	10,000.0
2015	4	272	1.1	0.3	1	2,500.0
2016	3	219	0.2	0.1	3	10,000.0
2017	1	209	0.3	0.3	1	10,000.0
2018	3	217	0.6	0.2	2	6,666.7
2019	5	207	0.7	0.1	4	8,000.0
2020	1	197	0.1	0.1	0	0.0
2021	0	22	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Northeast						
2008	1	201	0.5	0.5	0	0.0
2009	0	174	0.0	-	0	N/A
2010	1	171	0.5	0.5	0	0.0
2011	0	152	0.0	-	0	N/A
2012	1	157	0.1	0.1	1	10,000.0
2013	0	176	0.0	-	0	N/A
2014	1	164	0.1	0.1	1	10,000.0
2015	0	195	0.0	-	0	N/A
2016	2	193	0.1	0.1	2	10,000.0
2017	1	175	0.0	0.0	1	10,000.0
2018	1	140	0.5	0.5	0	0.0
2019	2	120	0.0	0.0	2	10,000.0
2020	1	129	0.1	0.1	1	10,000.0
2021	0	13	0.0	-	0	N/A
South						
2008	3	942	1.1	0.4	1	3,333.3
2009	3	705	1.3	0.4	1	3,333.3
2010	3	605	1.4	0.5	0	0.0
2011	3	499	0.9	0.3	1	3,333.3
2012	0	472	0.0	-	0	N/A
2013	2	512	0.9	0.4	0	0.0
2014	3	605	0.7	0.2	2	6,666.7
2015	3	593	0.6	0.2	2	6,666.7
2016	1	544	0.1	0.1	0	0.0
2017	2	593	0.1	0.1	2	10,000.0
2018	2	539	0.1	0.0	2	10,000.0
2019	5	457	0.6	0.1	4	8,000.0
2020	1	318	0.0	0.0	1	10,000.0
2021	1	27	0.2	0.2	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
West						
2008	2	233	1.0	0.5	0	0.0
2009	2	345	0.7	0.3	0	0.0
2010	5	352	2.4	0.5	0	0.0
2011	0	386	0.0	-	0	N/A
2012	0	386	0.0	-	0	N/A
2013	1	323	0.0	0.0	1	10,000.0
2014	3	359	0.2	0.1	3	10,000.0
2015	5	187	1.2	0.2	3	6,000.0
2016	1	179	0.5	0.5	0	0.0
2017	1	159	0.1	0.1	1	10,000.0
2018	1	146	0.5	0.5	0	0.0
2019	1	167	0.2	0.2	0	0.0
2020	2	133	0.5	0.3	0	0.0
2021	1	25	0.4	0.4	0	0.0
Invalid						
2008	0	8	0.0	-	0	N/A
2009	0	11	0.0	-	0	N/A
2010	0	7	0.0	-	0	N/A
2011	0	5	0.0	-	0	N/A
2012	0	3	0.0	-	0	N/A
2013	0	4	0.0	-	0	N/A
2014	0	8	0.0	-	0	N/A
2015	0	6	0.0	-	0	N/A
2016	0	3	0.0	-	0	N/A
2017	0	2	0.0	-	0	N/A
2018	0	9	0.0	-	0	N/A
2019	0	4	0.0	-	0	N/A
2020	0	1	0.0	-	0	N/A
2021	0	0	0.0	_	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Missing						
2008	0	96	0.0	-	0	N/A
2009	2	82	0.7	0.3	0	0.0
2010	0	1	0.0	-	0	N/A
2011	0	1	0.0	-	0	N/A
2012	0	1	0.0	-	0	N/A
2013	0	2	0.0	-	0	N/A
2014	0	3	0.0	-	0	N/A
2015	0	5	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	1	0.0	-	0	N/A
2018	0	3	0.0	-	0	N/A
2019	0	2	0.0	-	0	N/A
2020	1	5	0.0	0.0	1	10,000.0
2021	0	4	0.0	-	0	N/A
Other						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	1	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A



2008000.0-0N/A 2009 120.40.400.0 2010 234.92.500.0 2011 133.03.000.0 2012 224.02.000.0 2013 010.0-0N/A 2014 7811.01.600.0 2015 5821.14.200.0 2016 6823.23.900.0 2017 6710.61.800.0 2018 8117.91.000.0 2019 101213.81.400.0 2020 664.20.700.0 2021 110.20.200.0		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2008 0 0 0.0 - 0 N/A 2009 1 2 0.4 0.4 0 0.0 2010 2 3 4.9 2.5 0 0.0 2011 1 3 3.0 3.0 0 0.0 2012 2 2 4.0 2.0 0 0.0 2013 0 1 0.0 - 0 N/A 2014 7 8 11.0 1.6 0 0.0 2015 5 8 21.1 4.2 0 0.0 2016 6 8 23.2 3.9 0 0.0 2016 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 2020 6 6 4.2 0.7 0 0.0 2021 1 1 0.2 0.2	Treatment Wit	hin 45 Days from D	Diagnosis				
2009 1 2 0.4 0.4 0 0.0 2010 2 3 4.9 2.5 0 0.0 2011 1 3 3.0 3.0 0 0.0 2012 2 2 4.0 2.0 0 0.0 2013 0 1 0.0 - 0 N/A 2014 7 8 11.0 1.6 0 0.0 2015 5 8 2.1 4.2 0 0.0 2016 6 7 10.6 1.8 0 0.0 2017 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 0.0 2019 10 12 13.8 1.4 0 0.0 0.0 2020 6 6 4.2 0.7 0 N/A 2021 1 0 </td <td>Midwest</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Midwest						
2010 2 3 4.9 2.5 0 0.0 2011 1 3 3.0 3.0 0 0.0 2012 2 2 4.0 2.0 0 0.0 2013 0 1 0.0 - 0 N/A 2014 7 8 11.0 1.6 0 0.0 2015 5 8 21.1 4.2 0 0.0 2016 6 8 2.2 3.9 0 0.0 2017 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 2019 10 12 13.8 1.4 0 0.0 2020 1 1 0.2 0.2 0 0.0 2021 1 1 0.2 0.2 0 0.0 2021 0 0 0.0 - <td>2008</td> <td>0</td> <td>0</td> <td>0.0</td> <td>-</td> <td>0</td> <td>N/A</td>	2008	0	0	0.0	-	0	N/A
2011 1 3 3.0 3.0 0 0.0 2012 2 2 4.0 2.0 0 0.0 2013 0 1 0.0 - 0 N/A 2014 7 8 11.0 1.6 0 0.0 2015 5 8 21.1 4.2 0 0.0 2016 6 8 23.2 3.9 0 0.0 2017 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 2019 10 12 13.8 1.4 0 0.0 2020 6 6 4.2 0.7 0 0.0 2021 1 1 0.0 - 0 N/A 2009 0 0 0.0 - 0 N/A 2011 0 0 0.0 -	2009	1	2	0.4	0.4	0	0.0
2012 2 2 4.0 2.0 0 0.0 2013 0 1 0.0 - 0 N/A 2014 7 8 11.0 1.6 0 0.0 2015 5 8 21.1 4.2 0 0.0 2016 6 8 23.2 3.9 0 0.0 2017 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 2019 10 12 13.8 1.4 0 0.0 2020 6 6 4.2 0.7 0 0.0 2021 1 1 0.2 0.2 0 0.0 0.0 2021 0 0 0.0 - 0 N/A 2009 0 0 0.0 - 0 N/A 2011 0 0 0.0	2010	2	3	4.9	2.5	0	0.0
2013 0 1 0.0 - 0 N/A 2014 7 8 11.0 1.6 0 0.0 2015 5 8 21.1 4.2 0 0.0 2015 5 8 23.2 3.9 0 0.0 2017 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 2019 10 12 13.8 1.4 0 0.0 2020 6 6 4.2 0.7 0 0.0 2021 1 1 0.2 0 0 0 2021 1 0.0 0.0 - 0 N/A 2008 0 0 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 2011 0 0 0.0 0.0 0.0	2011	1	3	3.0	3.0	0	0.0
2014 7 8 11.0 1.6 0 0.0 2015 5 8 21.1 4.2 0 0.0 2016 6 8 23.2 3.9 0 0.0 2017 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 2019 10 12 13.8 1.4 0 0.0 2020 6 6 4.2 0.7 0 0.0 2021 1 1 0.2 0 0.0 0.0 2021 1 1 0.2 0 0.0 0.0 0.0 2021 1 1 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 2011 0 0.0 - 0 0.0 2013 1 1 1.6 1.6 0 <td>2012</td> <td>2</td> <td>2</td> <td>4.0</td> <td>2.0</td> <td>0</td> <td>0.0</td>	2012	2	2	4.0	2.0	0	0.0
2015 5 8 21.1 4.2 0 0.0 2016 6 8 23.2 3.9 0 0.0 2017 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 2019 10 12 13.8 1.4 0 0.0 2020 6 6 4.2 0.7 0 0.0 2021 1 1 0.2 0.2 0 0.0 2021 1 1 0.2 0.2 0 0.0 2021 1 1 0.2 0.2 0 0.0 2021 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 0.0 2013 1 1 1.6 1.6	2013	0	1	0.0	-	0	N/A
2016 6 8 23.2 3.9 0 0.0 2017 6 7 10.6 1.8 0 0.0 2018 8 11 7.9 1.0 0 0.0 2019 10 12 13.8 1.4 0 0.0 2020 6 6 4.2 0.7 0 0.0 2021 1 1 0.2 0.2 0 0.0 2021 1 1 0.2 0.2 0 0.0 2021 1 1 0.2 0.2 0 0.0 2021 1 1 0.2 0.7 0 0.0 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 4 4 0.9 2.7 0 0.0 2014 1 1.6 1.6 0	2014	7	8	11.0	1.6	0	0.0
20176710.61.800.020188117.91.000.02019101213.81.400.02020664.20.700.02021110.20.200.0Northest2008000.0-0N/A2010000.0-0N/A2011000.0-0N/A20124410.92.700.02014116.26.200.02015252.01.000.02016341.90.600.02017345.51.800.02018222.81.400.02019353.51.200.0	2015	5	8	21.1	4.2	0	0.0
20188117.91.000.02019101213.81.400.02020664.20.700.02021110.20.200.02021110.20.200.02021110.20.200.02021110.20.200.02011000.0-0N/A20124410.92.700.0201311.61.600.0201416.26.200.02015252.01.000.02016345.51.800.02017345.51.800.02019353.51.200.0	2016	6	8	23.2	3.9	0	0.0
2019101213.81.400.02020664.20.700.02021110.20.200.0Northeast2008000.0-0N/A2009000.0-0N/A2011000.0-0N/A20124410.92.700.02013116.26.200.0201411.61.600.02015252.01.000.02016341.90.600.02017345.51.800.02019353.51.200.02019572.70.500.0	2017	6	7	10.6	1.8	0	0.0
2020664.20.700.02021110.20.200.0Northeast2008000.0-0N/A2009000.0-0N/A2010000.0-0N/A2011000.0-0N/A20124410.92.700.0201311.61.600.0201416.26.200.02015252.01.000.02017345.51.800.02018222.81.400.02019353.51.200.0	2018	8	11	7.9	1.0	0	0.0
2021110.20.200.0Northeast2008000.0-0N/A2009000.0-0N/A2010000.0-0N/A2011000.0-0N/A20124410.92.700.02013111.61.600.02014116.26.200.02015252.01.000.02016341.90.600.02017345.51.800.02018222.81.400.02019353.51.200.02020572.70.500.0	2019	10	12	13.8	1.4	0	0.0
Northeast 2008 0 0 0.0 - 0 N/A 2009 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 4 4 10.9 2.7 0 0.0 2013 1 1 1.6 1.6 0 0.0 2014 1 1 6.2 6.2 0 0.0 2015 2 5 2.0 1.0 0 0.0 2016 3 4 1.9 0.6 0 0.0 2017 3 4 5.5 1.8 0 0.0 2018 2 2 2.8 1.4 0 0.0 2019 3 5 3.5 1.2 0 0.0 2020 5 7	2020	6	6	4.2	0.7	0	0.0
2008 0 0 0.0 - 0 N/A 2009 0 0 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 4 4 10.9 2.7 0 0.0 2013 1 1 1.6 1.6 0 0.0 2014 1 1 6.2 6.2 0 0.0 2015 2 5 2.0 1.0 0 0.0 2016 3 4 1.9 0.6 0 0.0 2017 3 4 5.5 1.8 0 0.0 2018 2 2 2.8 1.4 0 0.0 2019 3 5 3.5 1.2 0 0.0 2020 5 7 2.7 0.5	2021	1	1	0.2	0.2	0	0.0
2009000.0-0N/A2010000.0-0N/A2011000.0-0N/A20124410.92.700.0201311.61.600.0201416.26.200.02015252.01.000.02016341.90.600.02017345.51.800.02018222.81.400.02019353.51.200.02020572.70.500.0	Northeast						
201000.0-0N/A2011000.0-0N/A20124410.92.700.02013111.61.600.0201411.66.200.02015252.01.000.02016341.90.600.02018222.81.400.02019353.51.200.02020572.70.500.0	2008	0	0	0.0	-	0	N/A
2011000.0-0N/A20124410.92.700.02013111.61.600.02014116.26.200.02015252.01.000.02016341.90.600.02017345.51.800.02018222.81.400.02019353.51.200.02020572.70.500.0	2009	0	0	0.0	-	0	N/A
20124410.92.700.02013111.61.600.02014116.26.200.02015252.01.000.02016341.90.600.02017345.51.800.0201822.81.400.02019353.51.200.02020572.70.500.0	2010	0	0	0.0	-	0	N/A
2013111.61.600.02014116.26.200.02015252.01.000.02016341.90.600.02017345.51.800.0201822.81.400.02019353.51.200.02020572.70.500.0	2011	0	0	0.0	-	0	N/A
201416.26.200.02015252.01.000.02016341.90.600.02017345.51.800.0201822.81.400.02019353.51.200.02020572.70.500.0	2012	4	4	10.9	2.7	0	0.0
2015252.01.000.02016341.90.600.02017345.51.800.0201822.81.400.02019353.51.200.02020572.70.500.0	2013	1	1	1.6	1.6	0	0.0
2016341.90.600.02017345.51.800.02018222.81.400.02019353.51.200.02020572.70.500.0	2014	1	1	6.2	6.2	0	0.0
2017345.51.800.0201822.81.400.02019353.51.200.02020572.70.500.0	2015	2	5	2.0	1.0	0	0.0
201822.81.400.02019353.51.200.02020572.70.500.0	2016	3	4	1.9	0.6	0	0.0
2019 3 5 3.5 1.2 0 0.0 2020 5 7 2.7 0.5 0 0.0	2017	3	4	5.5	1.8	0	0.0
2020 5 7 2.7 0.5 0 0.0	2018	2	2	2.8	1.4	0	0.0
	2019	3	5	3.5	1.2	0	0.0
2021 0 0.0 . 0 N/A	2020	5	7	2.7	0.5	0	0.0
	2021	0	0	0.0		0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
South						
2008	2	3	21.7	10.9	0	0.0
2009	0	2	0.0	-	0	N/A
2010	1	1	2.7	2.7	0	0.0
2011	3	3	18.8	6.3	0	0.0
2012	3	4	17.0	5.7	0	0.0
2013	4	5	10.9	2.7	0	0.0
2014	5	7	16.2	3.2	0	0.0
2015	15	17	33.9	2.3	0	0.0
2016	15	19	35.7	2.4	0	0.0
2017	18	25	35.9	2.0	0	0.0
2018	14	14	24.3	1.7	0	0.0
2019	14	21	12.1	0.9	0	0.0
2020	8	9	4.1	0.5	0	0.0
2021	1	1	0.2	0.2	0	0.0
West						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	1	2	2.9	2.9	0	0.0
2012	2	2	2.5	1.2	0	0.0
2013	6	8	14.7	2.5	0	0.0
2014	3	3	11.6	3.9	0	0.0
2015	6	7	19.3	3.2	0	0.0
2016	8	9	27.8	3.5	0	0.0
2017	3	4	6.1	2.0	0	0.0
2018	1	1	1.5	1.5	0	0.0
2019	4	6	4.8	1.2	0	0.0
2020	3	4	2.4	0.8	0	0.0
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Invalid						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Missing						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	1	1	0.1	0.1	0	0.0
2021	1	1	0.2	0.2	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Other						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Treatment Wit	hin 180 Days from	Diagnosis				
Midwest						
2008	1	2	1.8	1.8	0	0.0
2009	2	4	5.1	2.5	0	0.0
2010	4	10	15.8	4.0	0	0.0
2011	2	5	3.9	1.9	0	0.0
2012	2	3	4.0	2.0	0	0.0
2013	1	6	0.4	0.4	0	0.0
2014	7	12	11.0	1.6	0	0.0
2015	5	12	21.1	4.2	0	0.0
2016	9	14	30.3	3.4	0	0.0
2017	8	10	14.9	1.9	0	0.0
2018	8	11	7.9	1.0	0	0.0
2019	13	16	18.5	1.4	0	0.0
2020	7	8	5.1	0.7	0	0.0
2021	1	1	0.2	0.2	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Northeast						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	1	0.0	-	0	N/A
2011	2	3	5.2	2.6	0	0.0
2012	4	6	10.9	2.7	0	0.0
2013	3	4	2.3	0.8	0	0.0
2014	3	4	7.6	2.5	0	0.0
2015	3	8	6.3	2.1	0	0.0
2016	3	5	1.9	0.6	0	0.0
2017	3	5	5.5	1.8	0	0.0
2018	4	4	6.4	1.6	0	0.0
2019	3	7	3.5	1.2	0	0.0
2020	5	8	2.7	0.5	0	0.0
2021	0	0	0.0	-	0	N/A
South						
2008	6	12	36.3	6.1	0	0.0
2009	2	6	10.7	5.3	0	0.0
2010	1	4	2.7	2.7	0	0.0
2011	6	7	33.0	5.5	0	0.0
2012	3	6	17.0	5.7	0	0.0
2013	5	6	13.1	2.6	0	0.0
2014	10	15	36.2	3.6	0	0.0
2015	21	29	52.5	2.5	0	0.0
2016	24	34	62.2	2.6	0	0.0
2017	29	44	63.0	2.2	0	0.0
2018	18	24	31.5	1.8	0	0.0
2019	19	34	16.3	0.9	0	0.0
2020	9	13	5.4	0.6	0	0.0
2021	1	1	0.2	0.2	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
West						
2008	0	0	0.0	-	0	N/A
2009	0	3	0.0	-	0	N/A
2010	0	2	0.0	-	0	N/A
2011	1	2	2.9	2.9	0	0.0
2012	2	3	2.5	1.2	0	0.0
2013	6	11	14.7	2.5	0	0.0
2014	4	7	18.4	4.6	0	0.0
2015	6	8	19.3	3.2	0	0.0
2016	9	14	28.6	3.2	0	0.0
2017	3	10	6.1	2.0	0	0.0
2018	2	6	4.5	2.2	0	0.0
2019	4	9	4.8	1.2	0	0.0
2020	5	7	3.4	0.7	0	0.0
2021	0	0	0.0	-	0	N/A
Invalid						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	1	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Missing						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	1	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	1	1	0.1	0.1	0	0.0
2021	1	1	0.2	0.2	0	0.0
Other						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A

¹Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

²Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Cytomegalovir	us (CMV) Infection	or Congenital CMV (cC	MV)			
Overall						
American India	an or Alaska Native					
2008	0	641	0.0	-	0	N/A
2009	0	569	0.0	-	0	N/A
2010	0	779	0.0	-	0	N/A
2011	0	951	0.0	-	0	N/A
2012	0	1,229	0.0	-	0	N/A
2013	0	1,234	0.0	-	0	N/A
2014	0	675	0.0	-	0	N/A
2015	0	395	0.0	-	0	N/A
2016	0	337	0.0	-	0	N/A
2017	0	345	0.0	-	0	N/A
2018	0	299	0.0	-	0	N/A
2019	0	311	0.0	-	0	N/A
2020	0	231	0.0	-	0	N/A
2021	0	47	0.0	-	0	N/A
Asian						
2008	0	4,679	0.0	-	0	N/A
2009	1	3,761	9.8	9.8	0	0.0
2010	1	3,631	0.3	0.3	0	0.0
2011	3	3,721	4.5	1.5	0	0.0
2012	0	3,979	0.0	-	0	N/A
2013	0	3,601	0.0	-	0	N/A
2014	1	3,841	5.6	5.6	0	0.0
2015	1	3,909	2.1	2.1	0	0.0
2016	0	4,329	0.0	-	0	N/A
2017	3	4,944	4.7	1.6	0	0.0
2018	0	4,865	0.0	-	0	N/A
2019	2	4,558	2.6	1.3	0	0.0
2020	1	3,787	0.6	0.6	0	0.0
2021	0	700	0.0	-	0	N/A



Black or African Amer 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017	3 4 8 4 5 3 7 8	16,073 15,812 15,408 16,040 16,502 16,271 15,241	12.6 4.9 63.2 21.4 13.9 15.2	4.2 1.2 7.9 5.3 2.8	0 0 0 0	0.0 0.0 0.0
2009 2010 2011 2012 2013 2014 2015 2016	4 8 4 5 3 7 8	15,812 15,408 16,040 16,502 16,271	4.9 63.2 21.4 13.9	1.2 7.9 5.3	0 0	0.0 0.0
2010 2011 2012 2013 2014 2015 2016	8 4 5 3 7 8	15,408 16,040 16,502 16,271	63.2 21.4 13.9	7.9 5.3	0	0.0
2011 2012 2013 2014 2015 2016	4 5 3 7 8	16,040 16,502 16,271	21.4 13.9	5.3		
2012 2013 2014 2015 2016	5 3 7 8	16,502 16,271	13.9		0	
2013 2014 2015 2016	3 7 8	16,271		2.8		0.0
2014 2015 2016	7 8		15.2		0	0.0
2015 2016	8	15,241	1012	5.1	0	0.0
2016		,	31.3	4.5	0	0.0
		15,170	29.2	3.6	0	0.0
2017	10	15,346	23.8	2.4	0	0.0
	12	15,091	27.1	2.3	0	0.0
2018	12	11,385	13.5	1.1	0	0.0
2019	7	10,100	4.6	0.7	0	0.0
2020	3	5,406	1.1	0.4	0	0.0
2021	0	554	0.0	-	0	N/A
Native Hawaiian or O	ther Pacific	Islander				
2008	0	1,587	0.0	-	0	N/A
2009	1	1,486	10.0	10.0	0	0.0
2010	0	1,409	0.0	-	0	N/A
2011	1	1,470	2.9	2.9	0	0.0
2012	2	1,500	9.7	4.8	0	0.0
2013	0	1,412	0.0	-	0	N/A
2014	0	1,293	0.0	-	0	N/A
2015	0	1,352	0.0	-	0	N/A
2016	0	1,496	0.0	-	0	N/A
2017	0	1,391	0.0	-	0	N/A
2018	1	1,389	3.0	3.0	0	0.0
2019	1	1,362	2.2	2.2	0	0.0
2020	2	1,245	0.5	0.3	0	0.0
2021	0	236	0.0		0	N/A



Unknown 2008 85 483,458 210.7 2.5 0 0.0 2009 77 459,818 209.7 2.7 0 0.0 2010 89 402,103 263.7 3.0 0 0.0 2011 66 374,433 201.5 3.1 0 0.0 2012 66 359,065 185.9 2.8 0 0.0 2013 87 421,917 216.0 2.5 0 0.0 2014 107 445,819 264.2 2.5 0 0.0 2015 102 463,196 227.7 2.2 0 0.0 2016 124 477,378 262.4 2.1 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2018 124 473,378 262.4 2.1 0 0.0 2019 136 440,690 140.6 1.0 0		New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009 77 459,818 209,7 2.7 0 0.0 2010 89 402,103 263,7 3.0 0 0.0 2011 66 374,433 2015 3.1 0 0.0 2012 66 359,065 185.9 2.8 0 0.0 2013 87 421,917 216.0 2.5 0 0.0 2014 107 445,819 264.2 2.5 0 0.0 2015 102 463,196 227.7 2.2 0 0.0 2015 124 477,378 262.4 2.1 0 0.0 2014 124 449,830 145.5 1.5 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2019 136 440,690 140.6 1.0 0 0.0 2021 12 48,332 1.6 0.1 0.0 0.0 </th <th>Unknown</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	Unknown						
2010 89 402,103 263.7 3.0 0 0.0 2011 66 374,433 201.5 3.1 0 0.0 2012 66 359,065 185.9 2.8 0 0.0 2013 87 421,917 216.0 2.5 0 0.0 2014 107 445,819 264.2 2.5 0 0.0 2015 102 463,196 227.7 2.2 0 0.0 2016 124 477,378 262.4 2.1 0 0.0 2017 141 464,688 263.0 1.9 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2020 86 360,697 43.3 0.5 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2021 13 50,850 85.7 5.5 0 0.0 <	2008	85	483,458	210.7	2.5	0	0.0
2011 66 374,433 201.5 3.1 0 0.0 2012 66 359,065 185.9 2.8 0 0.0 2013 87 421,917 216.0 2.5 0 0.0 2014 107 445,819 264.2 2.5 0 0.0 2015 102 463,196 227.7 2.2 0 0.0 2016 124 477,378 262.4 2.1 0 0.0 2017 141 464,688 263.0 1.9 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2020 86 380,697 43.3 0.5 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2020 86 38.0,697 43.3 5.5 0 0.0 2010 8 42,676 35.0 4.4 0 0.0 <t< td=""><td>2009</td><td>77</td><td>459,818</td><td>209.7</td><td>2.7</td><td>0</td><td>0.0</td></t<>	2009	77	459,818	209.7	2.7	0	0.0
2012 66 359,065 185.9 2.8 0 0.0 2013 87 421,917 216.0 2.5 0 0.0 2014 107 445,819 264.2 2.5 0 0.0 2015 102 463,196 227.7 2.2 0 0.0 2016 124 477,378 262.4 2.1 0 0.0 2017 141 464,688 263.0 1.9 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2019 136 440,690 140.6 1.0 0 0.0 2020 86 380,697 43.3 0.5 0 0.0 2021 12 48,32 1.6 0.1 0 0 2020 86 380,697 43.3 0.5 0 0.0 2010 13 50,850 85.1 6.5 0 0.0	2010	89	402,103	263.7	3.0	0	0.0
2013 87 421,917 216.0 2.5 0 0.0 2014 107 445,819 264.2 2.5 0 0.0 2015 102 463,196 227.7 2.2 0 0.0 2016 124 477,378 262.4 2.1 0 0.0 2017 141 464,688 263.0 1.9 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2019 136 440,690 140.6 1.0 0 0.0 2020 86 380,697 43.3 0.5 0 0.0 2021 12 48,332 1.6 0 0 0 2020 86 380,697 43.3 0.5 0 0.0 2014 12 48,332 1.6 0 0.0 0.0 2010 8 42,676 35.0 4.4 0 0.0 0.0	2011	66	374,433	201.5	3.1	0	0.0
2014 107 445,819 264.2 2.5 0 0.0 2015 102 443,196 227.7 2.2 0 0.0 2016 124 477,378 262.4 2.1 0 0.0 2017 141 464,688 263.0 1.9 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2019 136 440,690 140.6 1.0 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2021 12 48,332 1.6 0 0.0 0.0 2021 13 50,850 85.1 6.5 0 0.0 2008 13 50,850 85.1 6.5 0 0.0 2010 8 42,676 35.0 4.4 0 0.0 2011 5 43,747 31.2 6.2 0 0.0	2012	66	359,065	185.9	2.8	0	0.0
2015 102 463,196 227.7 2.2 0 0.0 2016 124 477,378 262.4 2.1 0 0.0 2017 141 464,688 263.0 1.9 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2019 136 440,690 140.6 1.0 0 0.0 2020 86 380,697 43.3 0.5 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2020 8 42,676 35.0 4.4 0 0.0 2010 8 42,676 35.0 4.4 0 0.0 2011 5 43,747 31.2 6.2 0 0.0 <	2013	87	421,917	216.0	2.5	0	0.0
2016 124 477,378 262.4 2.1 0 0.0 2017 141 464,688 263.0 1.9 0 0.0 2018 122 459,840 184.5 1.5 0 0.0 2019 136 440,690 140.6 1.0 0 0.0 2020 86 380,697 43.3 0.5 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2021 12 48,332 1.6 0.1 0 0.0 2010 8 42,676 35.0 4.4 0 0.0 2011 5 43,747 31.2 6.2 0 0.0 2012 8 42,686 36.7 4.6 0 0.0 2013 6 40,849 35.7 5.9 0 0.0 2	2014	107	445,819	264.2	2.5	0	0.0
2017141464,688263.01.900.02018122459,840184.51.500.02019136440,690140.61.000.0202086380,69743.30.500.020211248,3321.60.100.0White20081350,85085.16.500.02010842,67635.04.400.02011543,74731.26.200.02012842,86635.74.600.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2015	102	463,196	227.7	2.2	0	0.0
2018122459,840184.51.500.02019136440,690140.61.000.0202086380,69743.30.500.020211248,3321.60.100.0White20081350,85085.16.500.02010644,66833.05.500.02011543,74731.26.200.02012842,87635.75.900.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.0	2016	124	477,378	262.4	2.1	0	0.0
2019136440,690140.61.000.0202086380,69743.30.500.020211248,3321.60.100.0White20081350,85085.16.500.02009644,66833.05.500.02010842,67635.04.400.02011543,74731.26.200.02012842,88636.74.600.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02019321,8122.10.700.02019321,8122.10.700.0	2017	141	464,688	263.0	1.9	0	0.0
202086380,69743.30.500.020211248,3321.60.100.0White20081350,85085.16.500.02009644,66833.05.500.02010842,67635.04.400.02011543,74731.26.200.02012842,88636.74.600.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.02017836,94930.02.300.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2018	122	459,840	184.5	1.5	0	0.0
20211248,3321.60.100.0White20081350,85085.16.500.02009644,66833.05.500.02010842,67635.04.400.02011543,74731.26.200.02012842,88636.74.600.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2019	136	440,690	140.6	1.0	0	0.0
White 2008 13 50,850 85.1 6.5 0 0.0 2009 6 44,668 33.0 5.5 0 0.0 2010 8 42,676 35.0 4.4 0 0.0 2011 5 43,747 31.2 6.2 0 0.0 2012 8 42,886 36.7 4.6 0 0.0 2013 6 40,849 35.7 5.9 0 0.0 2014 7 38,363 27.3 3.9 0 0.0 2015 8 36,625 34.4 4.3 0 0.0 2016 13 36,949 30.0 2.3 0 0.0 2017 8 34,900 14.5 1.8 0 0.0 2018 4 26,302 6.1 1.5 0 0.0 2019 3 21,812 2.1 0.7 0 0.0 <td>2020</td> <td>86</td> <td>380,697</td> <td>43.3</td> <td>0.5</td> <td>0</td> <td>0.0</td>	2020	86	380,697	43.3	0.5	0	0.0
200813 $50,850$ 85.1 6.5 0 0.0 2009 6 $44,668$ 33.0 5.5 0 0.0 2010 8 $42,676$ 35.0 4.4 0 0.0 2011 5 $43,747$ 31.2 6.2 0 0.0 2012 8 $42,886$ 36.7 4.6 0 0.0 2013 6 $40,849$ 35.7 5.9 0 0.0 2014 7 $38,363$ 27.3 3.9 0 0.0 2015 8 $36,625$ 34.4 4.3 0 0.0 2016 13 $36,949$ 30.0 2.3 0 0.0 2017 8 $34,900$ 14.5 1.8 0 0.0 2018 4 $26,302$ 6.1 1.5 0 0.0 2019 3 $21,812$ 2.1 0.7 0 0.0 2020 2 $11,349$ 1.7 0.8 0 0.0	2021	12	48,332	1.6	0.1	0	0.0
2009644,66833.05.500.02010842,67635.04.400.02011543,74731.26.200.02012842,88636.74.600.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	White						
2010842,67635.04.400.02011543,74731.26.200.02012842,88636.74.600.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2008	13	50,850	85.1	6.5	0	0.0
2011543,74731.26.200.02012842,88636.74.600.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2009	6	44,668	33.0	5.5	0	0.0
2012842,88636.74.600.02013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2010	8	42,676	35.0	4.4	0	0.0
2013640,84935.75.900.02014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2011	5	43,747	31.2	6.2	0	0.0
2014738,36327.33.900.02015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2012	8	42,886	36.7	4.6	0	0.0
2015836,62534.44.300.020161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2013	6	40,849	35.7	5.9	0	0.0
20161336,94930.02.300.02017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2014	7	38,363	27.3	3.9	0	0.0
2017834,90014.51.800.02018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2015	8	36,625	34.4	4.3	0	0.0
2018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2016	13	36,949	30.0	2.3	0	0.0
2018426,3026.11.500.02019321,8122.10.700.02020211,3491.70.800.0	2017			14.5		0	0.0
2019 3 21,812 2.1 0.7 0 0.0 2020 2 11,349 1.7 0.8 0 0.0	2018		26,302	6.1	1.5	0	0.0
2020 2 11,349 1.7 0.8 0 0.0	2019	3				0	0.0
	2020	2	11,349	1.7	0.8	0	0.0
	2021		2,551			0	



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: A	bsent, Clinical Cha	racteristics: Absent				
American India	n or Alaska Native					
2008	0	471	0.0	-	0	N/A
2009	0	411	0.0	-	0	N/A
2010	0	576	0.0	-	0	N/A
2011	0	690	0.0	-	0	N/A
2012	0	907	0.0	-	0	N/A
2013	0	888	0.0	-	0	N/A
2014	0	458	0.0	-	0	N/A
2015	0	228	0.0	-	0	N/A
2016	0	213	0.0	-	0	N/A
2017	0	217	0.0	-	0	N/A
2018	0	187	0.0	-	0	N/A
2019	0	193	0.0	-	0	N/A
2020	0	141	0.0	-	0	N/A
2021	0	26	0.0	-	0	N/A
Asian						
2008	0	2,962	0.0	-	0	N/A
2009	0	2,200	0.0	-	0	N/A
2010	0	2,006	0.0	-	0	N/A
2011	1	2,086	1.3	1.3	0	0.0
2012	0	2,101	0.0	-	0	N/A
2013	0	1,918	0.0	-	0	N/A
2014	0	1,902	0.0	-	0	N/A
2015	0	2,106	0.0	-	0	N/A
2016	0	2,221	0.0	-	0	N/A
2017	0	2,694	0.0	-	0	N/A
2018	0	2,729	0.0	-	0	N/A
2019	1	2,523	1.0	1.0	0	0.0
2020	0	1,993	0.0	-	0	N/A
2021	0	364	0.0	-	0	N/A



Black or African		Eligible Members ³			iten spisodes mitil all stellt	Events per 10,000 New Infants
2008	4					
	1	13,692	2.2	2.2	0	0.0
2009	2	13,144	3.1	1.5	0	0.0
2010	4	12,740	31.2	7.8	0	0.0
2011	1	13,423	8.3	8.3	0	0.0
2012	4	13,670	8.1	2.0	0	0.0
2013	1	13,239	6.7	6.7	0	0.0
2014	1	12,036	5.7	5.7	0	0.0
2015	1	11,695	3.0	3.0	0	0.0
2016	5	11,716	10.2	2.0	0	0.0
2017	5	11,389	11.7	2.3	0	0.0
2018	2	8,719	3.8	1.9	0	0.0
2019	4	7,879	3.3	0.8	0	0.0
2020	0	3,988	0.0	-	0	N/A
2021	0	374	0.0	-	0	N/A
Native Hawaiian	or Other Pacific	Islander				
2008	0	984	0.0	-	0	N/A
2009	0	884	0.0	-	0	N/A
2010	0	732	0.0	-	0	N/A
2011	1	677	2.9	2.9	0	0.0
2012	0	602	0.0	-	0	N/A
2013	0	599	0.0	-	0	N/A
2014	0	519	0.0	-	0	N/A
2015	0	727	0.0	-	0	N/A
2016	0	731	0.0	-	0	N/A
2017	0	695	0.0	-	0	N/A
2018	0	750	0.0	-	0	N/A
2019	0	852	0.0	-	0	N/A
2020	0	730	0.0	-	0	N/A
2021	0	128	0.0	-	0	N/A



200831344,71987.02.800.0200922318,91466.23.000.0201029278,05287.63.000.0201125261,03567.82.700.020129252,11426.52.900.0201328298,39088.93.200.0201433314,00378.42.400.0201522325,85149.82.300.0201627330,90961.12.300.0201731316,97565.62.100.0201825310,04738.71.500.0201933295,79431.41.000.0202026254,81614.20.500.02021533,8320.50.100.0		New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009 22 318,914 66.2 3.0 0 0.0 2010 29 278,052 87.6 3.0 0 0.0 2011 25 261,035 67.8 2.7 0 0.0 2012 9 252,114 26.5 2.9 0 0.0 2013 28 298,390 88.9 3.2 0 0.0 2014 33 314,003 78.4 2.4 0 0.0 2015 22 232,581 49.8 2.3 0 0.0 2016 27 330,909 61.1 2.3 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2019 33 295,794 31.4 1.0 0 0.0 2021 5 32,356 2.9 4.6 0 0.0 2020 5 32,356 2.9 4.3 0 0.0 20	Unknown						
2010 29 278,052 87.6 3.0 0 0.0 2011 25 261,035 67.8 2.7 0 0.0 2012 9 252,114 26.5 2.9 0 0.0 2013 28 298,390 88.9 3.2 0 0.0 2014 33 314,003 78.4 2.4 0 0.0 2015 22 325,851 49.8 2.3 0 0.0 2016 27 30,099 61.1 2.3 0 0.0 2017 31 316,975 65.6 2.1 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2020 26 38,832 0.5 0.1 0 0.0 2021 5 33,832 0.5 0.1 0 0.0 2020 2 30,100 0.9 0.4 0 0.0 2	2008	31	344,719	87.0	2.8	0	0.0
2011 25 261,035 67.8 2.7 0 0.0 2012 9 252,114 26.5 2.9 0 0.0 2013 28 298,390 88.9 3.2 0 0.0 2014 33 314,003 78.4 2.4 0 0.0 2015 22 325,851 49.8 2.3 0 0.0 2016 27 330,909 61.1 2.3 0 0.0 2017 31 316,975 65.6 2.1 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2021 5 3,832 0.5 0.1 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2010 2 30,100 0.9 0.4 0 0.0 201	2009	22	318,914	66.2	3.0	0	0.0
2012 9 252,114 26.5 2.9 0 0.0 2013 28 298,390 88.9 3.2 0 0.0 2014 33 314,003 78.4 2.4 0 0.0 2015 22 232,851 49.8 2.3 0 0.0 2016 27 330,909 61.1 2.3 0 0.0 2017 31 316,975 65.6 2.1 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2019 33 295,794 31.4 1.0 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2021 5 33,82 0.5 0.1 0 0 2020 26 254,816 14.2 0.5 0 0.0 2010 3 37,864 30.6 10.2 0 0.0 201	2010	29	278,052	87.6	3.0	0	0.0
2013 28 298,390 88.9 3.2 0 0.0 2014 33 314,003 78.4 2.4 0 0.0 2015 22 325,851 49.8 2.3 0 0.0 2016 27 330,909 61.1 2.3 0 0.0 2017 31 316,975 65.6 2.1 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2019 33 295,794 31.4 1.0 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2021 5 33,832 0.5 0 0.0 0.0 2021 5 32,356 22.9 4.6 0 0.0 0.0 2010 2 30,100 0.9 4.4 0 0.0 0.0 2011 3 31,590 12.9 4.3 0 0.0	2011	25	261,035	67.8	2.7	0	0.0
2014 33 314,003 78.4 2.4 0 0.0 2015 22 325,851 49.8 2.3 0 0.0 2016 27 330,909 61.1 2.3 0 0.0 2017 31 316,975 65.6 2.1 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2019 33 295,794 31.4 1.0 0 0.0 2021 26 254,816 14.2 0.5 0 0.0 2021 26 33,832 0.5 0 0.0 0.0 2021 26 33,832 0.5 0 0.0 0.0 2010 26 33,355 22.9 4.6 0 0.0 0.0 2010 2 30,100 0.9 0.4 0 0.0 0.0 2011 3 31,590 1.2.9 4.3 0 0.	2012	9	252,114	26.5	2.9	0	0.0
2015 22 325,851 49.8 2.3 0 0.0 2016 27 330,909 61.1 2.3 0 0.0 2017 31 316,975 65.6 2.1 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2019 33 295,794 31.4 1.0 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2021 5 33,832 0.5 0.1 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2021 5 33,832 0.5 0.1 0 0.0 2020 26 254,816 14.2 0.5 0.0 0.0 2020 26 2.9 0.6 10.2 0.0 0.0 2010 2 30,100 0.9 0.4 0 0.0 2011	2013	28	298,390	88.9	3.2	0	0.0
2016 27 330,909 61.1 2.3 0 0.0 2017 31 316,975 65.6 2.1 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2019 33 295,794 31.4 1.0 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2021 5 33,832 0.5 0.1 0 0.0 2021 5 32,356 22.9 4.6 0 0.0 2008 3 37,864 30.6 10.2 0 0.0 2010 2 30,100 0.9 0.4 0 0.0 2011 3 31,590 12.9 4.3 0 0.0 2012 2 30,226 8.6 4.3 0 0.0 2013 0 28,298 0.0 - 0 0.0 2014	2014	33	314,003	78.4	2.4	0	0.0
2017 31 316,975 65.6 2.1 0 0.0 2018 25 310,047 38.7 1.5 0 0.0 2019 33 295,794 31.4 1.0 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2021 5 33,832 0.5 0 0.0 White V V 0 0.0 2009 5 32,356 22.9 4.6 0 0.0 2010 2 30,100 0.9 0.4 0 0.0 2011 3 31,590 12.9 4.3 0 0.0 2012 2 30,226 8.6 4.3 0 0.0 2013 0 28,298 0.0 - 0 N/A 2014 1 25,299 2.6 2.6 0 0.0 2015 1 24,044 4.6	2015	22	325,851	49.8	2.3	0	0.0
201825310,04738.71.500.0201933295,79431.41.000.0202026254,81614.20.500.02021533,8320.50.100.02021533,8320.50.100.0White2008337,86430.610.200.02019532,35622.94.600.02010230,1000.90.400.02011331,59012.94.300.02012230,2268.64.300.02013028,2980.0-0N/A2014125,2992.62.600.02015124,0444.64.600.02016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2016	27	330,909	61.1	2.3	0	0.0
2019 33 295,794 31.4 1.0 0 0.0 2020 26 254,816 14.2 0.5 0 0.0 2021 5 33,832 0.5 0.1 0 0.0 White 0 0.0 2008 3 37,864 30.6 10.2 0 0.0 0.0 2009 5 32,356 22.9 4.6 0 0.0 0.0 2010 2 30,100 0.9 0.4 0 0.0 0.0 2011 3 31,590 12.9 4.3 0 0.0 0.0 2012 2 30,226 8.6 4.3 0 0.0 0.0 2014 1 25,299 2.6 2.6 0 0.0 0.0 2015 1 24,044 4.6 4.6 0 0.0 0.0 2016	2017	31	316,975	65.6	2.1	0	0.0
202026254,81614.20.5000.02021533,8320.50.100.0White2008337,86430.610.200.02009532,35622.94.600.02010230,1000.90.400.02011331,59012.94.300.02012230,2268.64.300.02013028,2980.0-0N/A2014125,2992.62.600.02015124,0444.64.600.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A	2018	25	310,047	38.7	1.5	0	0.0
2021533,8320.50.100.0White2008337,86430.610.200.02009532,35622.94.600.02010230,1000.90.400.02011331,59012.94.300.02012230,2268.64.300.02013028,2980.0-0N/A2014125,2992.62.600.02015124,0444.64.600.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2019	33	295,794	31.4	1.0	0	0.0
White 0 0.0 2008 3 37,864 30.6 10.2 0 0.0 2009 5 32,356 22.9 4.6 0 0.0 2010 2 30,100 0.9 0.4 0 0.0 2011 3 31,590 12.9 4.3 0 0.0 2012 2 30,226 8.6 4.3 0 0.0 2013 0 28,298 0.0 - 0 N/A 2014 1 25,299 2.6 2.6 0 0.0 2015 1 24,044 4.6 4.6 0 0.0 2016 4 23,954 12.7 3.2 0 0.0 2017 2 22,461 3.6 1.8 0 0.0 2018 2 17,183 4.1 2.1 0 0.0 2019 0 14,699 0.0 - 0	2020	26	254,816	14.2	0.5	0	0.0
2008 3 37,864 30.6 10.2 0 0.0 2009 5 32,356 22.9 4.6 0 0.0 2010 2 30,100 0.9 0.4 0 0.0 2011 3 31,590 12.9 4.3 0 0.0 2012 2 30,226 8.6 4.3 0 0.0 2013 0 28,298 0.0 - 0 N/A 2014 1 25,299 2.6 2.6 0 0.0 2015 1 24,044 4.6 4.6 0 0.0 2016 4 23,954 12.7 3.2 0 0.0 2017 2 22,461 3.6 1.8 0 0.0 2018 2 17,183 4.1 2.1 0 N/A 2020 0 7,040 0.0 - 0 N/A	2021	5	33,832	0.5	0.1	0	0.0
2009532,35622.94.600.02010230,1000.90.400.02011331,59012.94.300.02012230,2268.64.300.02013028,2980.0-0N/A2014125,2992.62.600.02015124,0444.64.600.02016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	White						
2010230,1000.90.400.02011331,59012.94.300.02012230,2268.64.300.02013028,2980.0-0N/A2014125,2992.62.600.02015124,0444.64.600.02016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2008	3	37,864	30.6	10.2	0	0.0
2011331,59012.94.300.02012230,2268.64.300.02013028,2980.0-0N/A2014125,2992.62.600.02015124,0444.64.600.02016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2009	5	32,356	22.9	4.6	0	0.0
2012230,2268.64.300.02013028,2980.0-0N/A2014125,2992.62.600.02015124,0444.64.600.02016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2010	2	30,100	0.9	0.4	0	0.0
2013028,2980.0-0N/A2014125,2992.62.600.02015124,0444.64.600.02016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2011	3	31,590	12.9	4.3	0	0.0
2014125,2992.62.600.02015124,0444.64.600.02016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2012	2	30,226	8.6	4.3	0	0.0
2015124,0444.64.600.02016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2013	0	28,298	0.0	-	0	N/A
2016423,95412.73.200.02017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2014	1	25,299	2.6	2.6	0	0.0
2017222,4613.61.800.02018217,1834.12.100.02019014,6990.0-0N/A202007,0400.0-0N/A	2015	1	24,044	4.6	4.6	0	0.0
2018 2 17,183 4.1 2.1 0 0.0 2019 0 14,699 0.0 - 0 N/A 2020 0 7,040 0.0 - 0 N/A	2016	4	23,954	12.7	3.2	0	0.0
2019 0 14,699 0.0 - 0 N/A 2020 0 7,040 0.0 - 0 N/A	2017	2	22,461	3.6	1.8	0	0.0
2020 0 7,040 0.0 - O N/A	2018	2	17,183	4.1	2.1	0	0.0
	2019	0	14,699	0.0	-	0	N/A
2021 0 1,581 0.0 - O N/A	2020	0	7,040	0.0	-	0	N/A
	2021	0	1,581	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Pro	esent, Clinical Cha	aracteristics: Absent				
American Indian	or Alaska Native	2				
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	4	0.0	-	0	N/A
2011	0	5	0.0	-	0	N/A
2012	0	11	0.0	-	0	N/A
2013	0	6	0.0	-	0	N/A
2014	0	4	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	3	0.0	-	0	N/A
2017	0	2	0.0	-	0	N/A
2018	0	2	0.0	-	0	N/A
2019	0	5	0.0	-	0	N/A
2020	0	1	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Asian						
2008	0	25	0.0	-	0	N/A
2009	0	23	0.0	-	0	N/A
2010	0	24	0.0	-	0	N/A
2011	0	28	0.0	-	0	N/A
2012	0	13	0.0	-	0	N/A
2013	0	24	0.0	-	0	N/A
2014	0	14	0.0	-	0	N/A
2015	0	9	0.0	-	0	N/A
2016	0	13	0.0	-	0	N/A
2017	1	11	3.8	3.8	0	0.0
2018	0	15	0.0	-	0	N/A
2019	0	26	0.0	-	0	N/A
2020	0	9	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A



Black or African American		New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009 0 50 0.0 - 0 N/A 2010 0 63 0.0 - 0 N/A 2011 0 45 0.0 - 0 N/A 2012 0 44 0.0 - 0 N/A 2013 0 35 0.0 - 0 N/A 2014 0 43 0.0 - 0 N/A 2015 0 62 0.0 - 0 N/A 2016 0 49 0.0 - 0 N/A 2018 0 28 0.0 - 0 N/A 2019 0 24 0.0 - 0 N/A 2020 12 0.0 - 0 N/A 2021 0 12 0.0 - 0 N/A 2010 12 0.0 - 0 N/A	Black or Africa	an American					
2010 0 63 0.0 0 N/A 2011 0 45 0.0 0 N/A 2012 0 44 0.0 0 N/A 2013 0 35 0.0 0 N/A 2014 0 43 0.0 0 N/A 2015 0 62 0.0 0 N/A 2016 0 49 0.0 0 N/A 2017 0 31 0.0 0 N/A 2018 0 28 0.0 - 0 N/A 2019 0 24 0.0 - 0 N/A 2021 0 0 - 0 N/A 2021 0 0 - 0 N/A 2021 0 0 - 0 N/A 2	2008	0	32	0.0	-	0	N/A
2011 0 45 0.0 - 0 N/A 2012 0 44 0.0 - 0 N/A 2013 0 35 0.0 - 0 N/A 2014 0 43 0.0 - 0 N/A 2015 0 62 0.0 - 0 N/A 2016 0 49 0.0 - 0 N/A 2016 0 49 0.0 - 0 N/A 2017 0 31 0.0 - 0 N/A 2018 0 28 0.0 - 0 N/A 2020 0 12 0.0 - 0 N/A 2021 0 0 0 - 0 N/A 2020 12 0.0 - 0 N/A 2010 0 12 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A	2009	0	50	0.0	-	0	N/A
2012 0 44 0.0 - 0 N/A 2013 0 35 0.0 - 0 N/A 2014 0 43 0.0 - 0 N/A 2015 0 62 0.0 - 0 N/A 2016 0 49 0.0 - 0 N/A 2017 0 31 0.0 - 0 N/A 2018 0 24 0.0 - 0 N/A 2020 0 12 0.0 - 0 N/A 2021 0 0 0 N/A 0 N/A 2020 0 12 0.0 - 0 N/A 2020 0 12 0.0 - 0 N/A 2021 0 6 0 - 0 N/A 2010 12 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A	2010	0	63	0.0	-	0	N/A
2013 0 35 0.0 - 0 N/A 2014 0 43 0.0 - 0 N/A 2015 0 62 0.0 - 0 N/A 2015 0 49 0.0 - 0 N/A 2017 0 31 0.0 - 0 N/A 2018 0 28 0.0 - 0 N/A 2019 0 24 0.0 - 0 N/A 2020 0 12 0.0 - 0 N/A 2021 0 0 0 - 0 N/A 2021 0 0 - 0 N/A 2021 0 12 0.0 - 0 N/A 2010 12 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A	2011	0	45	0.0	-	0	N/A
2014 0 43 0.0 - 0 N/A 2015 0 62 0.0 - 0 N/A 2016 0 49 0.0 - 0 N/A 2017 0 31 0.0 - 0 N/A 2018 0 28 0.0 - 0 N/A 2019 0 24 0.0 - 0 N/A 2020 0 12 0.0 - 0 N/A 2021 0 0 0 N/A 0 N/A 2021 0 0 0 N/A 0 N/A 2021 0 0 0 N/A 0 N/A 2021 0 12 0.0 - 0 N/A 2010 12 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A	2012	0	44	0.0	-	0	N/A
2015 0 62 0.0 - 0 N/A 2016 0 49 0.0 - 0 N/A 2017 0 31 0.0 - 0 N/A 2018 0 28 0.0 - 0 N/A 2019 0 24 0.0 - 0 N/A 2020 0 12 0.0 - 0 N/A 2021 0 0 - 0 N/A 2010 12 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2012 0 10 0.0 - 0 N/A	2013	0	35	0.0	-	0	N/A
2016 0 49 0.0 - 0 N/A 2017 0 31 0.0 - 0 N/A 2018 0 28 0.0 - 0 N/A 2019 0 24 0.0 - 0 N/A 2020 0 12 0.0 - 0 N/A 2021 0 0 0.0 - 0 N/A 2010 12 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A 2014 0 10 0.0 - 0 N/A <td>2014</td> <td>0</td> <td>43</td> <td>0.0</td> <td>-</td> <td>0</td> <td>N/A</td>	2014	0	43	0.0	-	0	N/A
2017 0 31 0.0 0 N/A 2018 0 28 0.0 0 N/A 2019 0 24 0.0 0 N/A 2020 0 12 0.0 0 N/A 2021 0 0 0.0 - 0 N/A 2010 12 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2012 0 12 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A 2014 0 10 0.0 - 0 N/A	2015	0	62	0.0	-	0	N/A
2018 0 28 0.0 - 0 N/A 2019 0 24 0.0 - 0 N/A 2020 0 12 0.0 - 0 N/A 2021 0 0 0.0 - 0 N/A 2014 0 6 0.0 - 0 N/A 2009 12 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2012 0 12 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A 2014 0 10 0.0 - 0 N/A	2016	0	49	0.0	-	0	N/A
2019 0 24 0.0 0 N/A 2020 0 12 0.0 0 N/A 2021 0 0 0.0 0 N/A Netweiling of the Pacific Islander Vertific Islander 2008 0 6 0.0 - 0 N/A 2009 0 12 0.0 - 0 N/A 2010 0 19 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2012 0 12 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A 2014 0 10 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2016 0 13 0.0 - 0	2017	0	31	0.0	-	0	N/A
2020 0 12 0.0 - 0 N/A 2021 0 0 0.0 - 0 N/A Native Hawaiian or Other Pacific Islander 0 N/A 2008 0 6 0.0 - 0 N/A 2009 0 12 0.0 - 0 N/A 2010 0 19 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2012 0 12 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A 2014 0 10 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2017 0 16 0.0 - 0 N/A 2018 1 12 3.0 3.0 0	2018	0	28	0.0	-	0	N/A
2021 0 0 - 0 N/A Native Hawaiian or Other Pacific Islander N/A N/A N/A 2008 0 6 0.0 - 0 N/A 2009 0 12 0.0 - 0 N/A 2010 0 19 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2012 0 12 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A 2014 0 10 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2016 0 13 0.0 - 0 N/A 2016 0 13 0.0 - 0 N/A 2017 0 16 0.0 - 0 N/A <tr< td=""><td>2019</td><td>0</td><td>24</td><td>0.0</td><td>-</td><td>0</td><td>N/A</td></tr<>	2019	0	24	0.0	-	0	N/A
Native Hawaiian or Other Pacific Islander 2008 0 6 0.0 - 0 N/A 2009 0 12 0.0 - 0 N/A 2010 0 19 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2012 0 12 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A 2014 0 10 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2016 0 13 0.0 - 0 N/A 2017 0 16 0.0 - 0 N/A 2018 1 12 3.0 3.0 0 0 0 2019 0 26 0.0 - 0 N/A 0	2020	0	12	0.0	-	0	N/A
2008 0 6 0.0 - 0 N/A 2009 0 12 0.0 - 0 N/A 2010 0 19 0.0 - 0 N/A 2011 0 13 0.0 - 0 N/A 2012 0 12 0.0 - 0 N/A 2013 0 9 0.0 - 0 N/A 2014 0 10 0.0 - 0 N/A 2015 0 10 0.0 - 0 N/A 2016 0 13 0.0 - 0 N/A 2016 0 13 0.0 - 0 N/A 2017 0 16 0.0 - 0 N/A 2018 1 12 3.0 3.0 0 0 0 2019 0 26 0.0 - <td>2021</td> <td>0</td> <td>0</td> <td>0.0</td> <td>-</td> <td>0</td> <td>N/A</td>	2021	0	0	0.0	-	0	N/A
20090120.0-0N/A20100190.0-0N/A20110130.0-0N/A20120120.0-0N/A2013090.0-0N/A20140100.0-0N/A20150100.0-0N/A20160130.0-0N/A20170160.0-0N/A20181123.03.000.020190260.0-0N/A20200170.0-0N/A	Native Hawai	ian or Other Pacific	Islander				
20100190.0-0N/A20110130.0-0N/A20120120.0-0N/A2013090.0-0N/A20140100.0-0N/A20150100.0-0N/A20160130.0-0N/A20170160.0-0N/A20181123.03.000.020190260.0-0N/A20200170.0-0N/A	2008	0	6	0.0	-	0	N/A
20110130.0-0N/A20120120.0-0N/A2013090.0-0N/A20140100.0-0N/A20150100.0-0N/A20160130.0-0N/A20170160.0-0N/A20181123.03.000.020190260.0-0N/A20200170.0-0N/A	2009	0	12	0.0	-	0	N/A
20120120.0-0N/A2013090.0-0N/A20140100.0-0N/A20150100.0-0N/A20160130.0-0N/A20170160.0-0N/A20181123.03.000.020190260.0-0N/A20200170.0-0N/A	2010	0	19	0.0	-	0	N/A
2013090.0-0N/A20140100.0-0N/A20150100.0-0N/A20160130.0-0N/A20170160.0-0N/A20181123.03.000.020190260.0-0N/A20200170.0-0N/A	2011	0	13	0.0	-	0	N/A
20140100.0-0N/A20150100.0-0N/A20160130.0-0N/A20170160.0-0N/A20181123.03.000.020190260.0-0N/A20200170.0-0N/A	2012	0	12	0.0	-	0	N/A
2015 0 10 0.0 - 0 N/A 2016 0 13 0.0 - 0 N/A 2017 0 16 0.0 - 0 N/A 2018 1 12 3.0 3.0 0 0.0 2019 0 26 0.0 - 0 N/A 2020 0 17 0.0 - 0 N/A	2013	0	9	0.0	-	0	N/A
2016 0 13 0.0 - 0 N/A 2017 0 16 0.0 - 0 N/A 2018 1 12 3.0 3.0 0 0.0 2019 0 26 0.0 - 0 N/A 2020 0 17 0.0 - 0 N/A	2014	0	10	0.0	-	0	N/A
2017 0 16 0.0 - 0 N/A 2018 1 12 3.0 3.0 0 0.0 2019 0 26 0.0 - 0 N/A 2020 0 17 0.0 - 0 N/A	2015	0	10	0.0	-	0	N/A
2018 1 12 3.0 3.0 0 0.0 2019 0 26 0.0 - 0 N/A 2020 0 17 0.0 - 0 N/A	2016	0	13	0.0	-	0	N/A
2019 0 26 0.0 - 0 N/A 2020 0 17 0.0 - 0 N/A	2017	0	16	0.0	-	0	N/A
2020 0 17 0.0 - O N/A	2018	1	12	3.0	3.0	0	0.0
	2019	0	26	0.0	-	0	N/A
2021 0 3 0.0 - 0 N/A	2020	0	17	0.0	-	0	N/A
	2021	0	3	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	0	2,701	0.0	-	0	N/A
2009	3	2,364	13.4	4.5	0	0.0
2010	3	2,056	11.3	3.8	0	0.0
2011	0	1,959	0.0	-	0	N/A
2012	4	1,704	9.4	2.4	0	0.0
2013	1	1,916	2.4	2.4	0	0.0
2014	1	2,137	0.0	0.0	0	0.0
2015	2	1,913	6.0	3.0	0	0.0
2016	2	1,678	2.4	1.2	0	0.0
2017	5	1,557	8.1	1.6	0	0.0
2018	6	1,498	7.1	1.2	0	0.0
2019	3	1,337	0.6	0.2	0	0.0
2020	4	1,257	2.0	0.5	0	0.0
2021	0	123	0.0	-	0	N/A
White						
2008	0	201	0.0	-	0	N/A
2009	0	213	0.0	-	0	N/A
2010	0	191	0.0	-	0	N/A
2011	0	167	0.0	-	0	N/A
2012	0	174	0.0	-	0	N/A
2013	1	157	8.2	8.2	0	0.0
2014	0	97	0.0	-	0	N/A
2015	0	99	0.0	-	0	N/A
2016	1	84	1.9	1.9	0	0.0
2017	0	69	0.0	-	0	N/A
2018	0	70	0.0	-	0	N/A
2019	0	42	0.0	-	0	N/A
2020	0	17	0.0	-	0	N/A
2021	0	5	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: A	bsent, Clinical Cha	racteristics: Present				
American India	n or Alaska Native	,				
2008	0	170	0.0	-	0	N/A
2009	0	159	0.0	-	0	N/A
2010	0	201	0.0	-	0	N/A
2011	0	262	0.0	-	0	N/A
2012	0	317	0.0	-	0	N/A
2013	0	348	0.0	-	0	N/A
2014	0	216	0.0	-	0	N/A
2015	0	167	0.0	-	0	N/A
2016	0	123	0.0	-	0	N/A
2017	0	130	0.0	-	0	N/A
2018	0	110	0.0	-	0	N/A
2019	0	114	0.0	-	0	N/A
2020	0	95	0.0	-	0	N/A
2021	0	21	0.0	-	0	N/A
Asian						
2008	0	1,735	0.0	-	0	N/A
2009	1	1,559	9.8	9.8	0	0.0
2010	1	1,614	0.3	0.3	0	0.0
2011	2	1,619	3.2	1.6	0	0.0
2012	0	1,877	0.0	-	0	N/A
2013	0	1,680	0.0	-	0	N/A
2014	1	1,946	5.6	5.6	0	0.0
2015	1	1,810	2.1	2.1	0	0.0
2016	0	2,122	0.0	-	0	N/A
2017	2	2,267	0.8	0.4	0	0.0
2018	0	2,148	0.0	-	0	N/A
2019	1	2,050	1.6	1.6	0	0.0
2020	1	1,819	0.6	0.6	0	0.0
2021	0	336	0.0	-	0	N/A



Bibock or African American 2008 2 2,412 10.5 5.2 0 0.0 2009 2 2,691 1.8 0.9 0 0.0 2010 4 2,680 32.0 8.0 0 0.0 2011 3 2,634 13.1 4.4 0 0.0 2012 1 2,852 5.9 5.9 0 0.0 2013 1 3,061 7.2 7.2 0 0.0 2015 5 3,486 20.9 4.2 0 0.0 2016 5 3,629 13.6 2.7 0 0.0 2016 5 3,629 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A <th></th> <th>New Users</th> <th>Eligible Members³</th> <th>Years at Risk</th> <th>Average Person-Years at Risk</th> <th>New Episodes with an Event</th> <th>Events per 10,000 New Infants</th>		New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009 2 2,691 1.8 0.9 0 0.0 2010 4 2,680 32.0 8.0 0 0.0 2011 3 2,634 13.1 4.4 0 0.0 2012 1 2,852 5.9 5.9 0 0.0 2013 1 3,061 7.2 7.2 0 0.0 2015 5 3,486 20.9 4.2 0 0.0 2016 5 3,629 13.6 2.7 0 0.0 2017 6 3,713 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 0.0 2019 3 2,231 1.4 0.5 0 0.0 0.0 2020 3 1,419 1.1 0.4 0 N/A 2020 0 595 0.0 - 0 N/A <td< th=""><th>Black or Africa</th><th>n American</th><th></th><th></th><th></th><th></th><th></th></td<>	Black or Africa	n American					
2010 4 2,680 32.0 8.0 0 0.0 2011 3 2,634 13.1 4.4 0 0.0 2012 1 2,852 5.9 5.9 0 0.0 2013 1 3,061 7.2 7.2 0 0.0 2014 5 3,225 19.8 4.0 0 0.0 2015 5 3,486 20.9 4.2 0 0.0 2016 5 3,629 13.6 2.7 0 0.0 2016 5 3,629 13.6 2.7 0 0.0 2017 6 3,713 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A 2020 0 <t< td=""><td>2008</td><td>2</td><td>2,412</td><td>10.5</td><td>5.2</td><td>0</td><td>0.0</td></t<>	2008	2	2,412	10.5	5.2	0	0.0
201132,63413.14.400.0201212,8525.95.900.0201313,0617.27.200.0201453,22519.84.000.0201553,48620.94.200.0201653,62913.62.700.0201763,71313.42.200.02018102,6889.71.000.0201932,2311.40.500.0202031,4191.10.400.0202101810.0-0N/A200905950.0-0N/A201006740.0-0N/A201107850.0-0N/A201228879.74.800.0201307970.0-0N/A201407750.0-0N/A201506310.0-0N/A201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201806410.0-0N/A201914972.2 <t< td=""><td>2009</td><td>2</td><td>2,691</td><td>1.8</td><td>0.9</td><td>0</td><td>0.0</td></t<>	2009	2	2,691	1.8	0.9	0	0.0
2012 1 2,852 5.9 5.9 0 0.0 2013 1 3,061 7.2 7.2 0 0.0 2014 5 3,225 19.8 4.0 0 0.0 2015 5 3,486 20.9 4.2 0 0.0 2016 5 3,629 13.6 2.7 0 0.0 2017 6 3,713 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 2019 3 2,231 1.4 0.5 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A 2009 0 595 0.0 - 0 N/A 2010 0 785 0.0 - 0 N/A 2011 0 797	2010	4	2,680	32.0	8.0	0	0.0
2013 1 3,061 7.2 7.2 0 0.0 2014 5 3,225 19.8 4.0 0 0.0 2015 5 3,486 20.9 4.2 0 0.0 2016 5 3,629 13.6 2.7 0 0.0 2017 6 3,713 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 2019 3 2,231 1.4 0.5 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A 2020 3 9.55 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2010 0 775 0.0 - 0 N/A 2011 0 775	2011	3	2,634	13.1	4.4	0	0.0
2014 5 3,225 19,8 4.0 0 0.0 2015 5 3,486 20.9 4.2 0 0.0 2016 5 3,629 13.6 2.7 0 0.0 2017 6 3,713 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 2019 3 2,231 1.4 0.5 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A 2008 0 606 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 0 2014 0	2012	1	2,852	5.9	5.9	0	0.0
2015 5 3,486 20.9 4.2 0 0.0 2016 5 3,629 13.6 2.7 0 0.0 2017 6 3,713 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 2019 3 2,231 1.4 0.5 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A NATIVE Hawaiian or Other Pacific Islander 2008 0 606 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 2013 0 797 0.0 - 0 N/A	2013	1	3,061	7.2	7.2	0	0.0
2016 5 3,629 13.6 2.7 0 0.0 2017 6 3,713 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 2019 3 2,231 1.4 0.5 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A Attive Havailian or Other Pacific Islander 2008 0 606 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2011 0 775 0.0 - 0 N/A 2014 0 775 0.0 - 0 N/A 2015 0 631 0.0 - 0 N/A <td>2014</td> <td>5</td> <td>3,225</td> <td>19.8</td> <td>4.0</td> <td>0</td> <td>0.0</td>	2014	5	3,225	19.8	4.0	0	0.0
2017 6 3,713 13.4 2.2 0 0.0 2018 10 2,688 9.7 1.0 0 0.0 2019 3 2,231 1.4 0.5 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A Pattive Hawailan or Other Pacific Islander 2008 0 606 0.0 - 0 N/A 2009 0 595 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 0 2014 0 775 0.0 - 0 N/A 2015 0 631 0.0 - 0 N/A	2015	5	3,486	20.9	4.2	0	0.0
2018 10 2,688 9,7 1.0 0 0.0 2019 3 2,231 1.4 0.5 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A Netwe Hawaiian or Other Pacific Islander 0 . 0 N/A 2008 0 606 0.0 - 0 N/A 2009 0 595 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 0 2013 0 797 0.0 - 0 N/A 0 2014 0 755 0.0 - 0 N/A 2015 <td>2016</td> <td>5</td> <td>3,629</td> <td>13.6</td> <td>2.7</td> <td>0</td> <td>0.0</td>	2016	5	3,629	13.6	2.7	0	0.0
2019 3 2,231 1.4 0.5 0 0.0 2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A Description 0 606 0.0 - 0 N/A 2008 0 606 0.0 - 0 N/A 2009 0 595 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 N/A 2013 0 797 0.0 - 0 N/A 2014 0 755 0.0 - 0 N/A 2015 0 631 0.0 - 0 N/A 2015 0 641	2017	6	3,713	13.4	2.2	0	0.0
2020 3 1,419 1.1 0.4 0 0.0 2021 0 181 0.0 - 0 N/A Native Hawaiian or Other Pacific Islander 2008 0 606 0.0 - 0 N/A 2009 0 595 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 0.0 2013 0 797 0.0 - 0 N/A 0.0 N/A 2014 0 775 0.0 - 0 N/A 2015 0 631 0.0 - 0 N/A 2016 0 761 0.0 - 0 N/A 2018	2018	10	2,688	9.7	1.0	0	0.0
2021 0 181 0.0 - 0 N/A Mative Hawaiian or Other Pacific Islander - 0 N/A 2008 0 606 0.0 - 0 N/A 2009 0 595 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 2013 0 797 0.0 - 0 N/A 2014 0 775 0.0 - 0 N/A 2015 0 631 0.0 - 0 N/A 2017 0 693 0.0 - 0 N/A 2018 0 641 0.0 - 0 N/A 2019 1 497 2.2 2.2 0.4	2019	3	2,231	1.4	0.5	0	0.0
Native Hawaiian or Other Pacific Islander 2008 0 606 0.0 - 0 N/A 2009 0 595 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 2013 0 797 0.0 - 0 N/A 2014 0 775 0.0 - 0 N/A 2015 0 631 0.0 - 0 N/A 2016 0 761 0.0 - 0 N/A 2017 0 693 0.0 - 0 N/A 2018 0 641 0.0 - 0 N/A 2019 1 497 2.2 2.2 0.4 0.4 0 0.0 <td>2020</td> <td>3</td> <td>1,419</td> <td>1.1</td> <td>0.4</td> <td>0</td> <td>0.0</td>	2020	3	1,419	1.1	0.4	0	0.0
2008 0 606 0.0 - 0 N/A 2009 0 595 0.0 - 0 N/A 2010 0 674 0.0 - 0 N/A 2011 0 785 0.0 - 0 N/A 2012 2 887 9.7 4.8 0 0.0 2013 0 797 0.0 - 0 N/A 2014 0 775 0.0 - 0 N/A 2015 0 631 0.0 - 0 N/A 2016 0 761 0.0 - 0 N/A 2017 0 693 0.0 - 0 N/A 2018 0 641 0.0 - 0 N/A 2019 1 497 2.2 2.2 0 0.0 0.0	2021	0	181	0.0	-	0	N/A
200905950.0-0N/A201006740.0-0N/A201107850.0-0N/A201228879.74.800.0201307970.0-0N/A201407750.0-0N/A201506310.0-0N/A201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400.0	Native Hawaiid	n or Other Pacific	Islander				
201006740.0-0N/A201107850.0-0N/A201228879.74.800.0201307970.0-0N/A201407750.0-0N/A201506310.0-0N/A201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400	2008	0	606	0.0	-	0	N/A
201107850.0-0N/A201228879.74.800.0201307970.0-0N/A201407750.0-0N/A201506310.0-0N/A201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400.0	2009	0	595	0.0	-	0	N/A
201228879.74.800.0201307970.0-0N/A201407750.0-0N/A201506310.0-0N/A201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400.0	2010	0	674	0.0	-	0	N/A
201307970.0-0N/A201407750.0-0N/A201506310.0-0N/A201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400.0	2011	0	785	0.0	-	0	N/A
201407750.0-0N/A201506310.0-0N/A201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400.0	2012	2	887	9.7	4.8	0	0.0
201506310.0-0N/A201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400.0	2013	0	797	0.0	-	0	N/A
201607610.0-0N/A201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400.0	2014	0	775	0.0	-	0	N/A
201706930.0-0N/A201806410.0-0N/A201914972.22.200.0202015220.40.400.0	2015	0	631	0.0	-	0	N/A
201806410.0-0N/A201914972.22.200.0202015220.40.400.0	2016	0	761	0.0	-	0	N/A
201914972.22.200.0202015220.40.400.0	2017	0	693	0.0	-	0	N/A
2020 1 522 0.4 0.4 0.0	2018	0	641	0.0	-	0	N/A
	2019	1	497	2.2	2.2	0	0.0
2021 0 106 0.0 - 0 N/A	2020	1	522	0.4	0.4	0	0.0
	2021	0	106	0.0	-	0	N/A



Unknown 98.9 2.1 0 0.0 2009 45 140,540 107.9 2.4 0 0.0 2010 48 123,933 151.8 3.2 0 0.0 2011 37 113,332 120.0 3.2 0 0.0 2012 51 107.092 140.6 2.8 0 0.0 2013 56 123,833 124.1 2.2 0 0.0 2014 68 131,840 166.8 2.5 0 0.0 2015 69 137,830 146.4 2.1 0 0.0 2016 87 147,118 180.3 2.1 0 0.0 2018 85 150,515 129.6 1.5 0 0.0 2018 87 145,796 92.4 1.1 0 0.0 2020 51 126,580 26.0 0.5 0 0.0 2021 6		New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009 45 140,540 107,9 2.4 0 0.0 2010 48 123,933 151.8 3.2 0 0.0 2011 37 113,332 120.0 3.2 0 0.0 2012 51 107,092 140.6 2.8 0 0.0 2013 56 123,833 124.1 2.2 0 0.0 2014 68 137,830 166.8 2.5 0 0.0 2015 69 137,830 146.4 2.1 0 0.0 2016 87 147,118 180.3 2.1 0 0.0 2018 85 150,515 129.6 1.5 0 0.0 2019 87 145,796 92.4 1.1 0 0.0 2021 6 12,658 26.0 0.5 0 0.0 2021 6 12,658 34.1 5.7 0 0.0	Unknown						
2010 48 123,933 151.8 3.2 0 0.0 2011 37 113,322 120.0 3.2 0 0.0 2012 51 107,092 140.6 2.8 0 0.0 2013 56 123,833 124.1 2.2 0 0.0 2014 68 131,840 166.8 2.5 0 0.0 2015 69 137,830 146.4 2.1 0 0.0 2016 87 147,118 180.3 2.1 0 0.0 2017 102 148,426 180.4 1.8 0 0.0 2018 85 150,515 129.6 1.5 0 0.0 2020 51 126,580 26.0 0.5 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2020 1 12,362 10.1 10.1 0 0.0	2008	48	138,008	98.9	2.1	0	0.0
2011 37 113,332 120.0 3.2 0 0.0 2012 51 107,092 140.6 2.8 0 0.0 2013 56 123,833 124.1 2.2 0 0.0 2014 68 131,840 166.8 2.5 0 0.0 2015 69 137,830 146.4 2.1 0 0.0 2016 87 147,118 180.3 2.1 0 0.0 2017 102 148,426 180.4 1.8 0 0.0 2018 85 150,515 129.6 1.5 0 0.0 2020 51 126,580 26.0 0.5 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2020 51 126,580 26.0 0.5 0 0.0 2010 6 12,362 10.1 10.1 0 0.0	2009	45	140,540	107.9	2.4	0	0.0
201251107,092140.62.800.0201356123,833124.12.200.0201468131,840166.82.500.0201569137,830146.42.100.0201687147,118180.32.100.02017102148,426180.41.800.0201885150,515129.61.500.0201987145,79692.41.100.0202051126,58026.00.500.02021614,5610.90.200.0202051126,58026.00.500.02021612,62534.15.700.02009112,36210.110.100.02011212,21118.39.200.02012612,62534.15.700.02013512,60527.55.500.02014413,12212.73.200.02015612,6227.61.500.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.500.00.0201937,166 <td>2010</td> <td>48</td> <td>123,933</td> <td>151.8</td> <td>3.2</td> <td>0</td> <td>0.0</td>	2010	48	123,933	151.8	3.2	0	0.0
2013 56 123,833 124.1 2.2 0 0.0 2014 68 131,840 166.8 2.5 0 0.0 2015 69 137,830 146.4 2.1 0 0.0 2016 87 147,118 180.3 2.1 0 0.0 2017 102 148,426 180.4 1.8 0 0.0 2018 85 150,515 129.6 1.5 0 0.0 2019 87 145,796 92.4 1.1 0 0.0 2020 51 126,580 26.0 0.5 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2021 6 12,625 34.1 5.7 0 0.0 2019 1 12,362 10.1 10.1 0 0.0 2010 2 12,211 18.3 9.2 0 0.0	2011	37	113,332	120.0	3.2	0	0.0
2014 68 131,840 166.8 2.5 0 0.0 2015 69 137,830 146.4 2.1 0 0.0 2016 87 147,118 180.3 2.1 0 0.0 2017 102 148,426 180.4 1.8 0 0.0 2018 85 150,515 129.6 1.5 0 0.0 2019 87 145,796 92.4 1.1 0 0.0 2020 51 126,580 26.0 0.5 0 0.0 2021 6 14,561 0.9 0 0 0 2021 6 14,561 0.9 0 0 0 2008 9 13,064 43.4 4.8 0 0.0 0 2010 6 12,625 34.1 10.1 0 0.0 0 2011 2 12,211 18.3 9.2 0 0.0	2012	51	107,092	140.6	2.8	0	0.0
2015 69 137,830 146.4 2.1 0 0.0 2016 87 147,118 180.3 2.1 0 0.0 2017 102 148,426 180.4 1.8 0 0.0 2018 85 150,515 129.6 1.5 0 0.0 2019 87 145,796 92.4 1.1 0 0.0 2020 51 126,580 26.0 0.5 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2010 6 12,625 34.1 5.7 0 0.0 2011 2 12,211 18.3 9.2 0 0.0 2012 </td <td>2013</td> <td>56</td> <td>123,833</td> <td>124.1</td> <td>2.2</td> <td>0</td> <td>0.0</td>	2013	56	123,833	124.1	2.2	0	0.0
2016 87 147,118 180.3 2.1 0 0.0 2017 102 148,426 180.4 1.8 0 0.0 2018 85 150,515 129.6 1.5 0 0.0 2019 87 145,796 92.4 1.1 0 0.0 2020 51 126,580 26.0 0.5 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2021 6 14,561 0.9 0.2 0 0.0 2012 6 14,562 10.1 10.1 0 0.0 2019 1 12,362 10.1 10.1 0 0.0 2011 2 12,211 18.3 9.2 0 0.0 2012 6 12,718 28.1 4.7 0 0.0 2014 </td <td>2014</td> <td>68</td> <td>131,840</td> <td>166.8</td> <td>2.5</td> <td>0</td> <td>0.0</td>	2014	68	131,840	166.8	2.5	0	0.0
2017102148,426180.41.800.0201885150,515129.61.500.0201987145,79692.41.100.0202051126,58026.00.500.02021614,5610.90.200.0WHIE2008913,06443.44.800.02010612,62534.15.700.02011212,21118.39.200.02012612,62534.15.700.02013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.500.00.0201819,1631.500.00.0201937,1662.10.700.0202024,3431.70.800.0	2015	69	137,830	146.4	2.1	0	0.0
201885150,515129.61.500.0201987145,79692.41.100.0202051126,58026.00.500.02021614,5610.90.200.0White2008913,06443.44.800.02010612,26234.15.700.02011212,21118.39.200.02012612,71828.14.700.02013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2016	87	147,118	180.3	2.1	0	0.0
201987145,79692.41.100.0202051126,58026.00.500.02021614,5610.90.200.0White2008913,06443.44.800.02009112,36210.110.100.02010612,62534.15.700.02011212,21118.39.200.02012612,71828.14.700.02013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2017	102	148,426	180.4	1.8	0	0.0
202051126,58026.00.500.02021614,5610.90.200.0White2008913,06443.44.800.02009112,36210.110.100.02010612,62534.15.700.02011212,21118.39.200.02012612,71828.14.700.02013512,60527.55.500.02014413,12212.73.200.02015612,5227.61.500.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2018	85	150,515	129.6	1.5	0	0.0
2021614,5610.90.200.0White2008913,06443.44.800.02009112,36210.110.100.02010612,62534.15.700.02011212,21118.39.200.02012612,71828.14.700.02013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2019	87	145,796	92.4	1.1	0	0.0
White 2008 9 13,064 43.4 4.8 0 0.0 2009 1 12,362 10.1 10.1 0 0.0 2010 6 12,625 34.1 5.7 0 0.0 2011 2 12,211 18.3 9.2 0 0.0 2012 6 12,718 28.1 4.7 0 0.0 2013 5 12,605 27.5 5.5 0 0.0 2014 4 13,122 12.7 3.2 0 0.0 2015 6 12,662 25.1 4.2 0 0.0 2016 8 13,069 15.4 1.9 0 0.0 2017 5 12,522 7.6 1.5 0 0.0 2018 1 9,163 1.5 1.5 0 0.0 2019 3 7,166 2.1 0.7 0 0.0	2020	51	126,580	26.0	0.5	0	0.0
2008913,064 43.4 4.8 00.0 2009 112,36210.110.100.0 2010 612,625 34.1 5.7 00.0 2011 212,21118.3 9.2 00.0 2012 612,71828.1 4.7 00.0 2013 512,60527.55.500.0 2014 413,12212.7 3.2 00.0 2015 612,66225.1 4.2 00.0 2016 813,06915.41.900.0 2017 512,5227.61.500.0 2018 19,1631.51.500.0 2019 37,1662.10.700.0 2020 24,3431.70.800.0	2021	6	14,561	0.9	0.2	0	0.0
2009112,36210.110.100.02010612,62534.15.700.02011212,21118.39.200.02012612,71828.14.700.02013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	White						
2010612,62534.15.700.02011212,21118.39.200.02012612,71828.14.700.02013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2008	9	13,064	43.4	4.8	0	0.0
2011212,21118.39.200.02012612,71828.14.700.02013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2009	1	12,362	10.1	10.1	0	0.0
2012612,71828.14.700.02013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2010	6	12,625	34.1	5.7	0	0.0
2013512,60527.55.500.02014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2011	2	12,211	18.3	9.2	0	0.0
2014413,12212.73.200.02015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2012	6	12,718	28.1	4.7	0	0.0
2015612,66225.14.200.02016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2013	5	12,605	27.5	5.5	0	0.0
2016813,06915.41.900.02017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2014	4	13,122	12.7	3.2	0	0.0
2017512,5227.61.500.0201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2015	6	12,662	25.1	4.2	0	0.0
201819,1631.51.500.0201937,1662.10.700.0202024,3431.70.800.0	2016	8	13,069	15.4	1.9	0	0.0
2019 3 7,166 2.1 0.7 0 0.0 2020 2 4,343 1.7 0.8 0 0.0	2017	5	12,522	7.6	1.5	0	0.0
2020 2 4,343 1.7 0.8 0 0.0	2018	1	9,163	1.5	1.5	0	0.0
	2019	3	7,166	2.1	0.7	0	0.0
2021 1 970 0.2 0.2 0.0	2020	2	4,343	1.7	0.8	0	0.0
	2021	1	970	0.2	0.2	0	0.0



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Pro	esent, Clinical Cha	aracteristics: Present				
American Indian	or Alaska Native	•				
2008	0	3	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	2	0.0	-	0	N/A
2011	0	5	0.0	-	0	N/A
2012	0	3	0.0	-	0	N/A
2013	0	3	0.0	-	0	N/A
2014	0	2	0.0	-	0	N/A
2015	0	4	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Asian						
2008	0	20	0.0	-	0	N/A
2009	0	19	0.0	-	0	N/A
2010	0	30	0.0	-	0	N/A
2011	0	25	0.0	-	0	N/A
2012	0	34	0.0	-	0	N/A
2013	0	26	0.0	-	0	N/A
2014	0	18	0.0	-	0	N/A
2015	0	23	0.0	-	0	N/A
2016	0	16	0.0	-	0	N/A
2017	0	14	0.0	-	0	N/A
2018	0	10	0.0	-	0	N/A
2019	0	10	0.0	-	0	N/A
2020	0	10	0.0	-	0	N/A
2021	0	3	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Black or Africar	n American					
2008	0	12	0.0	-	0	N/A
2009	0	25	0.0	-	0	N/A
2010	0	21	0.0	-	0	N/A
2011	0	18	0.0	-	0	N/A
2012	0	24	0.0	-	0	N/A
2013	1	19	1.3	1.3	0	0.0
2014	1	40	5.8	5.8	0	0.0
2015	2	36	5.3	2.6	0	0.0
2016	0	33	0.0	-	0	N/A
2017	1	41	2.0	2.0	0	0.0
2018	0	22	0.0	-	0	N/A
2019	0	11	0.0	-	0	N/A
2020	0	4	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Native Hawaiia	n or Other Pacific	Islander				
2008	0	8	0.0	-	0	N/A
2009	1	5	10.0	10.0	0	0.0
2010	0	17	0.0	-	0	N/A
2011	0	17	0.0	-	0	N/A
2012	0	21	0.0	-	0	N/A
2013	0	31	0.0	-	0	N/A
2014	0	13	0.0	-	0	N/A
2015	0	10	0.0	-	0	N/A
2016	0	14	0.0	-	0	N/A
2017	0	9	0.0	-	0	N/A
2018	0	3	0.0	-	0	N/A
2019	0	14	0.0	-	0	N/A
2020	1	9	0.1	0.1	0	0.0
2021	0	1	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	6	1,643	24.8	4.1	0	0.0
2009	7	1,505	22.2	3.2	0	0.0
2010	9	1,257	13.0	1.4	0	0.0
2011	4	1,160	13.6	3.4	0	0.0
2012	2	1,101	9.4	4.7	0	0.0
2013	2	1,083	0.7	0.3	0	0.0
2014	5	1,280	18.9	3.8	0	0.0
2015	9	1,119	25.5	2.8	0	0.0
2016	8	1,024	18.7	2.3	0	0.0
2017	3	1,020	8.8	2.9	0	0.0
2018	6	957	9.1	1.5	0	0.0
2019	13	881	16.2	1.2	0	0.0
2020	5	732	1.1	0.2	0	0.0
2021	1	83	0.2	0.2	0	0.0
White						
2008	1	91	11.1	11.1	0	0.0
2009	0	106	0.0	-	0	N/A
2010	0	107	0.0	-	0	N/A
2011	0	98	0.0	-	0	N/A
2012	0	116	0.0	-	0	N/A
2013	0	100	0.0	-	0	N/A
2014	2	73	12.0	6.0	0	0.0
2015	1	66	4.7	4.7	0	0.0
2016	0	51	0.0	-	0	N/A
2017	1	55	3.4	3.4	0	0.0
2018	1	63	0.4	0.4	0	0.0
2019	0	41	0.0	-	0	N/A
2020	0	28	0.0	-	0	N/A
2021	1	4	0.4	0.4	0	0.0



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Valganciclovir	Treatment for Infai	nts with CMV or cCMV				
Overall						
American India	an or Alaska Native					
2008	0	641	0.0	-	0	N/A
2009	0	569	0.0	-	0	N/A
2010	0	779	0.0	-	0	N/A
2011	0	951	0.0	-	0	N/A
2012	0	1,229	0.0	-	0	N/A
2013	0	1,234	0.0	-	0	N/A
2014	0	675	0.0	-	0	N/A
2015	0	395	0.0	-	0	N/A
2016	0	337	0.0	-	0	N/A
2017	0	345	0.0	-	0	N/A
2018	0	299	0.0	-	0	N/A
2019	0	311	0.0	-	0	N/A
2020	0	231	0.0	-	0	N/A
2021	0	47	0.0	-	0	N/A
Asian						
2008	0	4,679	0.0	-	0	N/A
2009	1	3,761	0.5	0.5	0	0.0
2010	1	3,631	0.3	0.3	0	0.0
2011	3	3,721	1.5	0.5	0	0.0
2012	0	3,979	0.0	-	0	N/A
2013	0	3,601	0.0	-	0	N/A
2014	1	3,841	0.5	0.5	0	0.0
2015	1	3,909	0.5	0.5	0	0.0
2016	0	4,329	0.0	-	0	N/A
2017	3	4,944	0.9	0.3	1	3,333.3
2018	0	4,865	0.0	-	0	N/A
2019	2	4,558	1.0	0.5	0	0.0
2020	1	3,787	0.5	0.5	0	0.0
2021	0	700	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Black or Africa	n American					
2008	3	16,073	1.5	0.5	0	0.0
2009	4	15,812	2.0	0.5	0	0.0
2010	8	15,408	3.9	0.5	0	0.0
2011	4	16,040	1.1	0.3	1	2,500.0
2012	5	16,502	2.1	0.4	0	0.0
2013	3	16,271	1.5	0.5	0	0.0
2014	7	15,241	2.2	0.3	3	4,285.7
2015	8	15,170	1.8	0.2	4	5,000.0
2016	10	15,346	3.4	0.3	4	4,000.0
2017	12	15,091	3.5	0.3	5	4,166.7
2018	12	11,385	3.7	0.3	3	2,500.0
2019	7	10,100	1.6	0.2	4	5,714.3
2020	3	5,406	0.6	0.2	0	0.0
2021	0	554	0.0	-	0	N/A
Native Hawaiid	an or Other Pacific	Islander				
2008	0	1,587	0.0	-	0	N/A
2009	1	1,486	0.5	0.5	0	0.0
2010	0	1,409	0.0	-	0	N/A
2011	1	1,470	0.1	0.1	1	10,000.0
2012	2	1,500	1.0	0.5	0	0.0
2013	0	1,412	0.0	-	0	N/A
2014	0	1,293	0.0	-	0	N/A
2015	0	1,352	0.0	-	0	N/A
2016	0	1,496	0.0	-	0	N/A
2017	0	1,391	0.0	-	0	N/A
2018	1	1,389	0.1	0.1	1	10,000.0
2019	1	1,362	0.5	0.5	0	0.0
2020	2	1,245	0.5	0.2	1	5,000.0
2021	0	236	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	85	483,458	31.5	0.4	3	352.9
2009	77	459,818	31.2	0.4	4	519.5
2010	89	402,103	36.1	0.4	4	449.4
2011	66	374,433	25.9	0.4	9	1,363.6
2012	65	359,065	24.9	0.4	8	1,230.8
2013	87	421,917	29.9	0.3	15	1,724.1
2014	107	445,819	37.0	0.3	18	1,682.2
2015	101	463,196	31.3	0.3	28	2,772.3
2016	122	477,378	36.8	0.3	30	2,459.0
2017	141	464,688	46.0	0.3	34	2,411.3
2018	122	459,840	40.1	0.3	26	2,131.1
2019	136	440,690	42.5	0.3	34	2,500.0
2020	86	380,697	22.4	0.3	24	2,790.7
2021	12	48,332	1.1	0.1	3	2,500.0
White						
2008	13	50,850	5.4	0.4	4	3,076.9
2009	6	44,668	2.2	0.4	0	0.0
2010	8	42,676	3.5	0.4	1	1,250.0
2011	5	43,747	2.2	0.4	0	0.0
2012	8	42,886	2.7	0.3	2	2,500.0
2013	6	40,849	2.8	0.5	0	0.0
2014	7	38,363	2.2	0.3	2	2,857.1
2015	8	36,625	3.3	0.4	2	2,500.0
2016	13	36,949	3.1	0.2	8	6,153.8
2017	8	34,900	2.9	0.4	3	3,750.0
2018	4	26,302	1.2	0.3	2	5,000.0
2019	3	21,812	0.7	0.2	1	3,333.3
2020	2	11,349	0.1	0.1	2	10,000.0
2021	2	2,551	0.6	0.3	0	0.0



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Ab	sent, Clinical Cha	racteristics: Absent				
American Indian	or Alaska Native	2				
2008	0	471	0.0	-	0	N/A
2009	0	411	0.0	-	0	N/A
2010	0	576	0.0	-	0	N/A
2011	0	690	0.0	-	0	N/A
2012	0	907	0.0	-	0	N/A
2013	0	888	0.0	-	0	N/A
2014	0	458	0.0	-	0	N/A
2015	0	228	0.0	-	0	N/A
2016	0	213	0.0	-	0	N/A
2017	0	217	0.0	-	0	N/A
2018	0	187	0.0	-	0	N/A
2019	0	193	0.0	-	0	N/A
2020	0	141	0.0	-	0	N/A
2021	0	26	0.0	-	0	N/A
Asian						
2008	0	2,962	0.0	-	0	N/A
2009	0	2,200	0.0	-	0	N/A
2010	0	2,006	0.0	-	0	N/A
2011	1	2,086	0.5	0.5	0	0.0
2012	0	2,101	0.0	-	0	N/A
2013	0	1,918	0.0	-	0	N/A
2014	0	1,902	0.0	-	0	N/A
2015	0	2,106	0.0	-	0	N/A
2016	0	2,221	0.0	-	0	N/A
2017	0	2,694	0.0	-	0	N/A
2018	0	2,729	0.0	-	0	N/A
2019	1	2,523	0.5	0.5	0	0.0
2020	0	1,993	0.0	-	0	N/A
2021	0	364	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Black or Africar	n American					
2008	1	13,692	0.5	0.5	0	0.0
2009	2	13,144	1.0	0.5	0	0.0
2010	4	12,740	2.0	0.5	0	0.0
2011	1	13,423	0.1	0.1	1	10,000.0
2012	4	13,670	1.6	0.4	0	0.0
2013	1	13,239	0.5	0.5	0	0.0
2014	1	12,036	0.5	0.5	0	0.0
2015	1	11,695	0.5	0.5	0	0.0
2016	5	11,716	2.2	0.4	0	0.0
2017	5	11,389	2.1	0.4	1	2,000.0
2018	2	8,719	0.6	0.3	1	5,000.0
2019	4	7,879	1.1	0.3	2	5,000.0
2020	0	3,988	0.0	-	0	N/A
2021	0	374	0.0	-	0	N/A
Native Hawaiia	n or Other Pacific	Islander				
2008	0	984	0.0	-	0	N/A
2009	0	884	0.0	-	0	N/A
2010	0	732	0.0	-	0	N/A
2011	1	677	0.1	0.1	1	10,000.0
2012	0	602	0.0	-	0	N/A
2013	0	599	0.0	-	0	N/A
2014	0	519	0.0	-	0	N/A
2015	0	727	0.0	-	0	N/A
2016	0	731	0.0	-	0	N/A
2017	0	695	0.0	-	0	N/A
2018	0	750	0.0	-	0	N/A
2019	0	852	0.0	-	0	N/A
2020	0	730	0.0	-	0	N/A
2021	0	128	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	31	344,719	10.2	0.3	1	322.6
2009	22	318,914	8.7	0.4	0	0.0
2010	29	278,052	11.7	0.4	0	0.0
2011	25	261,035	10.1	0.4	3	1,200.0
2012	9	252,114	3.8	0.4	0	0.0
2013	28	298,390	10.0	0.4	4	1,428.6
2014	33	314,003	13.7	0.4	0	0.0
2015	22	325,851	9.3	0.4	1	454.5
2016	27	330,909	11.0	0.4	2	740.7
2017	31	316,975	10.9	0.4	5	1,612.9
2018	25	310,047	9.2	0.4	3	1,200.0
2019	33	295,794	13.2	0.4	3	909.1
2020	26	254,816	7.0	0.3	7	2,692.3
2021	5	33,832	0.3	0.1	1	2,000.0
White						
2008	3	37,864	1.5	0.5	0	0.0
2009	5	32,356	1.7	0.3	0	0.0
2010	2	30,100	0.8	0.4	0	0.0
2011	3	31,590	1.2	0.4	0	0.0
2012	2	30,226	1.0	0.5	0	0.0
2013	0	28,298	0.0	-	0	N/A
2014	1	25,299	0.5	0.5	0	0.0
2015	1	24,044	0.5	0.5	0	0.0
2016	4	23,954	0.8	0.2	3	7,500.0
2017	2	22,461	1.0	0.5	0	0.0
2018	2	17,183	1.0	0.5	0	0.0
2019	0	14,699	0.0	-	0	N/A
2020	0	7,040	0.0	-	0	N/A
2021	0	1,581	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Pr	esent, Clinical Cha	aracteristics: Absent				
American Indiar	n or Alaska Native					
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	4	0.0	-	0	N/A
2011	0	5	0.0	-	0	N/A
2012	0	11	0.0	-	0	N/A
2013	0	6	0.0	-	0	N/A
2014	0	4	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	3	0.0	-	0	N/A
2017	0	2	0.0	-	0	N/A
2018	0	2	0.0	-	0	N/A
2019	0	5	0.0	-	0	N/A
2020	0	1	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Asian						
2008	0	25	0.0	-	0	N/A
2009	0	23	0.0	-	0	N/A
2010	0	24	0.0	-	0	N/A
2011	0	28	0.0	-	0	N/A
2012	0	13	0.0	-	0	N/A
2013	0	24	0.0	-	0	N/A
2014	0	14	0.0	-	0	N/A
2015	0	9	0.0	-	0	N/A
2016	0	13	0.0	-	0	N/A
2017	1	11	0.1	0.1	1	10,000.0
2018	0	15	0.0	-	0	N/A
2019	0	26	0.0	-	0	N/A
2020	0	9	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Black or African	American					
2008	0	32	0.0	-	0	N/A
2009	0	50	0.0	-	0	N/A
2010	0	63	0.0	-	0	N/A
2011	0	45	0.0	-	0	N/A
2012	0	44	0.0	-	0	N/A
2013	0	35	0.0	-	0	N/A
2014	0	43	0.0	-	0	N/A
2015	0	62	0.0	-	0	N/A
2016	0	49	0.0	-	0	N/A
2017	0	31	0.0	-	0	N/A
2018	0	28	0.0	-	0	N/A
2019	0	24	0.0	-	0	N/A
2020	0	12	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Native Hawaiia	n or Other Pacific	Islander				
2008	0	6	0.0	-	0	N/A
2009	0	12	0.0	-	0	N/A
2010	0	19	0.0	-	0	N/A
2011	0	13	0.0	-	0	N/A
2012	0	12	0.0	-	0	N/A
2013	0	9	0.0	-	0	N/A
2014	0	10	0.0	-	0	N/A
2015	0	10	0.0	-	0	N/A
2016	0	13	0.0	-	0	N/A
2017	0	16	0.0	-	0	N/A
2018	1	12	0.1	0.1	1	10,000.0
2019	0	26	0.0	-	0	N/A
2020	0	17	0.0	-	0	N/A
2021	0	3	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	0	2,701	0.0	-	0	N/A
2009	3	2,364	1.2	0.4	0	0.0
2010	3	2,056	1.5	0.5	0	0.0
2011	0	1,959	0.0	-	0	N/A
2012	4	1,704	2.0	0.5	0	0.0
2013	1	1,916	0.1	0.1	1	10,000.0
2014	1	2,137	0.0	0.0	0	0.0
2015	2	1,913	0.3	0.2	1	5,000.0
2016	2	1,678	0.5	0.3	1	5,000.0
2017	5	1,557	1.1	0.2	2	4,000.0
2018	6	1,498	2.1	0.3	1	1,666.7
2019	3	1,337	0.6	0.2	0	0.0
2020	4	1,257	0.5	0.1	2	5,000.0
2021	0	123	0.0	-	0	N/A
White						
2008	0	201	0.0	-	0	N/A
2009	0	213	0.0	-	0	N/A
2010	0	191	0.0	-	0	N/A
2011	0	167	0.0	-	0	N/A
2012	0	174	0.0	-	0	N/A
2013	1	157	0.5	0.5	0	0.0
2014	0	97	0.0	-	0	N/A
2015	0	99	0.0	-	0	N/A
2016	1	84	0.1	0.1	1	10,000.0
2017	0	69	0.0	-	0	N/A
2018	0	70	0.0	-	0	N/A
2019	0	42	0.0	-	0	N/A
2020	0	17	0.0	-	0	N/A
2021	0	5	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: A	bsent, Clinical Cha	racteristics: Present				
American India	n or Alaska Native	,				
2008	0	170	0.0	-	0	N/A
2009	0	159	0.0	-	0	N/A
2010	0	201	0.0	-	0	N/A
2011	0	262	0.0	-	0	N/A
2012	0	317	0.0	-	0	N/A
2013	0	348	0.0	-	0	N/A
2014	0	216	0.0	-	0	N/A
2015	0	167	0.0	-	0	N/A
2016	0	123	0.0	-	0	N/A
2017	0	130	0.0	-	0	N/A
2018	0	110	0.0	-	0	N/A
2019	0	114	0.0	-	0	N/A
2020	0	95	0.0	-	0	N/A
2021	0	21	0.0	-	0	N/A
Asian						
2008	0	1,735	0.0	-	0	N/A
2009	1	1,559	0.5	0.5	0	0.0
2010	1	1,614	0.3	0.3	0	0.0
2011	2	1,619	1.0	0.5	0	0.0
2012	0	1,877	0.0	-	0	N/A
2013	0	1,680	0.0	-	0	N/A
2014	1	1,946	0.5	0.5	0	0.0
2015	1	1,810	0.5	0.5	0	0.0
2016	0	2,122	0.0	-	0	N/A
2017	2	2,267	0.8	0.4	0	0.0
2018	0	2,148	0.0	-	0	N/A
2019	1	2,050	0.5	0.5	0	0.0
2020	1	1,819	0.5	0.5	0	0.0
2021	0	336	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Black or African	American					
2008	2	2,412	1.0	0.5	0	0.0
2009	2	2,691	1.0	0.5	0	0.0
2010	4	2,680	2.0	0.5	0	0.0
2011	3	2,634	1.0	0.3	0	0.0
2012	1	2,852	0.5	0.5	0	0.0
2013	1	3,061	0.5	0.5	0	0.0
2014	5	3,225	1.5	0.3	2	4,000.0
2015	5	3,486	1.2	0.2	3	6,000.0
2016	5	3,629	1.2	0.2	4	8,000.0
2017	6	3,713	1.3	0.2	3	5,000.0
2018	10	2,688	3.2	0.3	2	2,000.0
2019	3	2,231	0.6	0.2	2	6,666.7
2020	3	1,419	0.6	0.2	0	0.0
2021	0	181	0.0	-	0	N/A
Native Hawaiia	n or Other Pacific	Islander				
2008	0	606	0.0	-	0	N/A
2009	0	595	0.0	-	0	N/A
2010	0	674	0.0	-	0	N/A
2011	0	785	0.0	-	0	N/A
2012	2	887	1.0	0.5	0	0.0
2013	0	797	0.0	-	0	N/A
2014	0	775	0.0	-	0	N/A
2015	0	631	0.0	-	0	N/A
2016	0	761	0.0	-	0	N/A
2017	0	693	0.0	-	0	N/A
2018	0	641	0.0	-	0	N/A
2019	1	497	0.5	0.5	0	0.0
2020	1	522	0.4	0.4	0	0.0
2021	0	106	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	48	138,008	18.3	0.4	2	416.7
2009	45	140,540	18.6	0.4	3	666.7
2010	48	123,933	18.7	0.4	4	833.3
2011	37	113,332	14.4	0.4	5	1,351.4
2012	50	107,092	19.0	0.4	6	1,200.0
2013	56	123,833	19.3	0.3	9	1,607.1
2014	68	131,840	22.9	0.3	13	1,911.8
2015	68	137,830	19.1	0.3	22	3,235.3
2016	86	147,118	24.4	0.3	22	2,558.1
2017	102	148,426	33.7	0.3	24	2,352.9
2018	85	150,515	27.2	0.3	19	2,235.3
2019	87	145,796	27.1	0.3	21	2,413.8
2020	51	126,580	14.1	0.3	13	2,549.0
2021	6	14,561	0.6	0.1	2	3,333.3
White						
2008	9	13,064	3.8	0.4	3	3,333.3
2009	1	12,362	0.5	0.5	0	0.0
2010	6	12,625	2.6	0.4	1	1,666.7
2011	2	12,211	1.0	0.5	0	0.0
2012	6	12,718	1.7	0.3	2	3,333.3
2013	5	12,605	2.3	0.5	0	0.0
2014	4	13,122	1.0	0.3	1	2,500.0
2015	6	12,662	2.7	0.4	1	1,666.7
2016	8	13,069	2.3	0.3	4	5,000.0
2017	5	12,522	1.9	0.4	2	4,000.0
2018	1	9,163	0.1	0.1	1	10,000.0
2019	3	7,166	0.7	0.2	1	3,333.3
2020	2	4,343	0.1	0.1	2	10,000.0
2021	1	970	0.2	0.2	0	0.0



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Pro	esent, Clinical Cha	aracteristics: Present				
American Indian	or Alaska Native	•				
2008	0	3	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	2	0.0	-	0	N/A
2011	0	5	0.0	-	0	N/A
2012	0	3	0.0	-	0	N/A
2013	0	3	0.0	-	0	N/A
2014	0	2	0.0	-	0	N/A
2015	0	4	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Asian						
2008	0	20	0.0	-	0	N/A
2009	0	19	0.0	-	0	N/A
2010	0	30	0.0	-	0	N/A
2011	0	25	0.0	-	0	N/A
2012	0	34	0.0	-	0	N/A
2013	0	26	0.0	-	0	N/A
2014	0	18	0.0	-	0	N/A
2015	0	23	0.0	-	0	N/A
2016	0	16	0.0	-	0	N/A
2017	0	14	0.0	-	0	N/A
2018	0	10	0.0	-	0	N/A
2019	0	10	0.0	-	0	N/A
2020	0	10	0.0	-	0	N/A
2021	0	3	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Black or African	American					
2008	0	12	0.0	-	0	N/A
2009	0	25	0.0	-	0	N/A
2010	0	21	0.0	-	0	N/A
2011	0	18	0.0	-	0	N/A
2012	0	24	0.0	-	0	N/A
2013	1	19	0.5	0.5	0	0.0
2014	1	40	0.2	0.2	1	10,000.0
2015	2	36	0.1	0.1	1	5,000.0
2016	0	33	0.0	-	0	N/A
2017	1	41	0.1	0.1	1	10,000.0
2018	0	22	0.0	-	0	N/A
2019	0	11	0.0	-	0	N/A
2020	0	4	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Native Hawaiia	n or Other Pacific	Islander				
2008	0	8	0.0	-	0	N/A
2009	1	5	0.5	0.5	0	0.0
2010	0	17	0.0	-	0	N/A
2011	0	17	0.0	-	0	N/A
2012	0	21	0.0	-	0	N/A
2013	0	31	0.0	-	0	N/A
2014	0	13	0.0	-	0	N/A
2015	0	10	0.0	-	0	N/A
2016	0	14	0.0	-	0	N/A
2017	0	9	0.0	-	0	N/A
2018	0	3	0.0	-	0	N/A
2019	0	14	0.0	-	0	N/A
2020	1	9	0.0	0.0	1	10,000.0
2021	0	1	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	6	1,643	3.0	0.5	0	0.0
2009	7	1,505	2.6	0.4	1	1,428.6
2010	9	1,257	4.3	0.5	0	0.0
2011	4	1,160	1.4	0.3	1	2,500.0
2012	2	1,101	0.1	0.1	2	10,000.0
2013	2	1,083	0.4	0.2	1	5,000.0
2014	5	1,280	0.3	0.1	5	10,000.0
2015	9	1,119	2.7	0.3	4	4,444.4
2016	7	1,024	0.9	0.1	5	7,142.9
2017	3	1,020	0.4	0.1	3	10,000.0
2018	6	957	1.6	0.3	3	5,000.0
2019	13	881	1.6	0.1	10	7,692.3
2020	5	732	0.7	0.1	2	4,000.0
2021	1	83	0.2	0.2	0	0.0
White						
2008	1	91	0.1	0.1	1	10,000.0
2009	0	106	0.0	-	0	N/A
2010	0	107	0.0	-	0	N/A
2011	0	98	0.0	-	0	N/A
2012	0	116	0.0	-	0	N/A
2013	0	100	0.0	-	0	N/A
2014	2	73	0.6	0.3	1	5,000.0
2015	1	66	0.1	0.1	1	10,000.0
2016	0	51	0.0	-	0	N/A
2017	1	55	0.0	0.0	1	10,000.0
2018	1	63	0.1	0.1	1	10,000.0
2019	0	41	0.0	-	0	N/A
2020	0	28	0.0	-	0	N/A
2021	1	4	0.4	0.4	0	0.0



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Treatment With	nin 45 Days from D	Diagnosis				
American India	n or Alaska Native					
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Asian						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	1	0.0	-	0	N/A
2017	1	1	3.8	3.8	0	0.0
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Black or Africa	n American					
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	1	2	8.3	8.3	0	0.0
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	4	4	19.9	5.0	0	0.0
2016	2	2	6.2	3.1	0	0.0
2017	3	5	6.6	2.2	0	0.0
2018	2	2	1.9	0.9	0	0.0
2019	3	3	2.0	0.7	0	0.0
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Native Hawaiid	n or Other Pacific	Islander				
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	1	1	2.9	2.9	0	0.0
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	1	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	1	1	0.1	0.1	0	0.0
2021	0	0	0.0	-	0	N/A



		New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009130.40.400.02010347.62.500.020113513.54.500.0201291024.52.700.02013111427.22.500.02014151739.12.600.02015243256.42.300.02016243063.72.700.02018212432.71.600.02019273831.71.200.02020202411.80.600.02021330.70.200.02020202411.80.600.02021000.0-0N/A2011000.0-0N/A2012229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A2014122.95.900.02015010.0-0N/A2014125.95.900.02015010.0-00.0 <th>Unknown</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>	Unknown						
2010347.62.500.020113513.54.500.0201291024.52.700.02013111427.22.500.02014151739.12.600.02015243256.42.300.02016243063.72.700.02017243143.31.800.02018212432.71.600.02019273831.71.200.0202020241.80.600.02021330.70.200.020202021.71.900.02030010.0-0N/A204100.0-0N/A20522295.000.02053010.0-0N/A20541.80.0-0N/A2055010.0-0N/A2054010.0-0N/A2055010.0-00.02055010.0-00.02056010.0-00.020550 <td>2008</td> <td>0</td> <td>1</td> <td>0.0</td> <td>-</td> <td>0</td> <td>N/A</td>	2008	0	1	0.0	-	0	N/A
2011 3 5 13.5 4.5 0 0.0 2012 9 10 24.5 2.7 0 0.0 2013 11 14 27.2 2.5 0 0.0 2014 15 17 39.1 2.6 0 0.0 2015 24 32 56.4 2.3 0 0.0 2016 24 30 63.7 2.7 0 0.0 2017 24 31 43.3 1.8 0 0.0 2018 21 24 32.7 1.6 0 0.0 2019 27 38 31.7 1.2 0 0.0 0.0 2020 20 24 1.1.8 0.6 0 0.0 0.0 2021 3 0.7 0.2 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	2009	1	3	0.4	0.4	0	0.0
2012 9 10 24.5 2.7 0 0.0 2013 11 14 27.2 2.5 0 0.0 2014 15 17 39.1 2.6 0 0.0 2015 24 32 56.4 2.3 0 0.0 2016 24 30 63.7 2.7 0 0.0 2017 24 31 43.3 1.8 0 0.0 2018 21 24 31.7 1.2 0 0.0 2019 27 38 31.7 1.2 0 0.0 2020 20 24 11.8 0.6 0 0.0 2021 3 3 0.7 0.2 0 0.0 2020 20 2.4 11.8 0.6 0 0.0 2010 0 0 0 - 0 N/A 2011 0 0 - <td>2010</td> <td>3</td> <td>4</td> <td>7.6</td> <td>2.5</td> <td>0</td> <td>0.0</td>	2010	3	4	7.6	2.5	0	0.0
2013 11 14 27.2 2.5 0 0.0 2014 15 17 39.1 2.6 0 0.0 2015 24 32 56.4 2.3 0 0.0 2016 24 30 63.7 2.7 0 0.0 2017 24 31 43.3 1.8 0 0.0 2018 21 24 32.7 1.6 0 0.0 2019 27 38 31.7 1.2 0 0.0 2020 20 24 11.8 0.6 0 0.0 2021 3 3 0.7 0.2 0 0.0 2020 20 24 11.8 0.6 0 0.0 2010 0 0 0.0 - 0 N/A 2011 0 0 0 - 0 N/A 2012 2 9.9 5.0	2011	3	5	13.5	4.5	0	0.0
2014 15 17 39.1 2.6 0 0.0 2015 24 32 56.4 2.3 0 0.0 2016 24 30 63.7 2.7 0 0.0 2017 24 31 43.3 1.8 0 0.0 2018 21 24 32.7 1.6 0 0.0 2019 27 38 31.7 1.2 0 0.0 2021 2 24 1.8 0.6 0 0.0 2021 3 3 0.7 0.2 0 0.0 2021 3 3 0.7 0.2 0 0.0 2021 0 1 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 2011 0 0.0 - 0 N/A 2012 2 2 9.9 5.0 0	2012	9	10	24.5	2.7	0	0.0
2015 24 32 56.4 2.3 0 0.0 2016 24 30 63.7 2.7 0 0.0 2017 24 31 43.3 1.8 0 0.0 2018 21 24 32.7 1.6 0 0.0 2019 27 38 31.7 1.2 0 0.0 2020 20 24 11.8 0.6 0 0.0 2021 3 3 0.7 0.2 0 0.0 2021 3 3 0.7 0.2 0 0.0 2021 3 3 0.7 0.2 0 0.0 2021 2 2 1.0.0 - 0 N/A 2010 0 0.0 0.0 - 0 N/A 2011 0 0.0 - 0 N/A 2012 2 9.9 5.0 0	2013	11	14	27.2	2.5	0	0.0
2016 24 30 63.7 2.7 0 0.0 2017 24 31 43.3 1.8 0 0.0 2018 21 24 32.7 1.6 0 0.0 2019 27 38 31.7 1.2 0 0.0 2020 20 24 11.8 0.6 0 0.0 2021 3 3 0.7 0.2 0 0.0 2021 3 0.7 0.2 0 0.0 0.0 2021 3 0.7 0.2 0 0.0 0.0 2010 0 1 0.0 - 0 N/A 2010 0 0.0 - 0 N/A 0 0.0 2011 0 0 0.0 - 0 N/A 2012 2 9.9 5.0 0 0.0 0.0 2013 0 1	2014	15	17	39.1	2.6	0	0.0
2017 24 31 43.3 1.8 0 0.0 2018 21 24 32.7 1.6 0 0.0 2019 27 38 31.7 1.2 0 0.0 2020 20 24 11.8 0.6 0 0.0 2021 3 3 0.7 0.2 0 0.0 2020 20 24 11.8 0.6 0 0.0 2021 3 3 0.7 0.2 0 0.0 2021 2 2 21.7 10.9 0 0.0 2008 2 2 2 21.7 10.9 0 0.0 2010 0 0 0.0 -1 0 N/A 2011 0 0 0.0 -1 0 N/A 2012 2 2 9.9 5.0 0 0.0 2013 0 1 0.0 -1 0 0.0 2014 1 2 5.9 5.9 0 0 0.0 2015 0 1 0.0 -1 0.0 0.0 0.0 2016 6 7 18.7 3.1 0 0.0 0.0 2018 2 2 1.9 0.0 0.0 0.0 2014 1 3 0.4 0.4 0.4 0.0 0.0 2014 1 3 0.4 0.4 0.0 0.0	2015	24	32	56.4	2.3	0	0.0
2018212432.71.600.02019273831.71.200.02020202411.80.600.02021330.70.200.0White20082221.710.900.02009010.0-0N/A2011000.0-0N/A2012229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02019130.40.400.02019130.40.400.0	2016	24	30	63.7	2.7	0	0.0
2019273831.71.200.02020202411.80.600.02021330.70.200.0WHIE2008222.1.710.900.02009010.0-0N/A2010000.0-0N/A2011000.0-0N/A2012229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.00.00.02019130.40.400.02019221.70.800.0	2017	24	31	43.3	1.8	0	0.0
2020202411.80.600.02021330.70.200.0White20082221.710.900.02009010.0-0N/A2010000.0-0N/A2011000.0-0N/A2012229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A2017224.42.200.02018221.91.000.02019130.40.400.0	2018	21	24	32.7	1.6	0	0.0
2021330.70.200.0White20082221.710.900.02009010.0-0N/A2010000.0-0N/A2011000.0-0N/A2012229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2019	27	38	31.7	1.2	0	0.0
White 2008 2 2 21.7 10.9 0 0.0 2009 0 1 0.0 - 0 N/A 2010 0 0 0.0 - 0 N/A 2011 0 0 0.0 - 0 N/A 2012 2 2 9.9 5.0 0 0.0 2013 0 1 0.0 - 0 N/A 2014 1 2 5.9 5.9 0 0.0 2015 0 1 0.0 - 0 N/A 2016 6 7 18.7 3.1 0 0.0 2017 2 2 4.4 2.2 0 0.0 2018 2 2 1.9 1.0 0 0.0 2019 1 3 0.4 0.4 0 0.0 2020 2 2	2020	20	24	11.8	0.6	0	0.0
200822 21.7 10.9 0 0.0 2009 01 0.0 -0N/A 2010 00 0.0 -0N/A 2011 00 0.0 -0N/A 2012 229.9 5.0 0 0.0 2013 01 0.0 -0N/A 2014 12 5.9 5.9 0 0.0 2015 01 0.0 -0N/A 2016 67 18.7 3.1 0 0.0 2017 22 4.4 2.2 0 0.0 2018 22 1.9 1.0 0 0.0 2019 13 0.4 0.4 0 0.0 2020 22 1.7 0.8 0 0.0	2021	3	3	0.7	0.2	0	0.0
2009010.0-0N/A2010000.0-0N/A2011000.0-0N/A2012229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	White						
2010000.0-0N/A2011000.0-0N/A2012229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2008	2	2	21.7	10.9	0	0.0
2011000.0-0N/A201229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2009	0	1	0.0	-	0	N/A
2012229.95.000.02013010.0-0N/A2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2010	0	0	0.0	-	0	N/A
2013010.0-0N/A2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2011	0	0	0.0	-	0	N/A
2014125.95.900.02015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2012	2	2	9.9	5.0	0	0.0
2015010.0-0N/A20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2013	0	1	0.0	-	0	N/A
20166718.73.100.02017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2014	1	2	5.9	5.9	0	0.0
2017224.42.200.02018221.91.000.02019130.40.400.02020221.70.800.0	2015	0	1	0.0	-	0	N/A
2018221.91.000.02019130.40.400.02020221.70.800.0	2016	6	7	18.7	3.1	0	0.0
2019 1 3 0.4 0.4 0 0.0 2020 2 2 1.7 0.8 0 0.0	2017	2	2	4.4	2.2	0	0.0
2020 2 2 1.7 0.8 0 0.0	2018	2	2	1.9	1.0	0	0.0
	2019	1	3	0.4	0.4	0	0.0
2021 0 0 0.0 - 0 N/A	2020	2	2	1.7	0.8	0	0.0
	2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Treatment With	in 180 Days from	Diagnosis				
American India	n or Alaska Native	2				
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Asian						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	1	0.0	-	0	N/A
2016	0	1	0.0	-	0	N/A
2017	1	1	3.8	3.8	0	0.0
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Black or Africa	n American					
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	1	2	8.3	8.3	0	0.0
2012	0	1	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	3	3	16.4	5.5	0	0.0
2015	4	4	19.9	5.0	0	0.0
2016	4	4	10.4	2.6	0	0.0
2017	5	8	11.5	2.3	0	0.0
2018	3	3	3.8	1.3	0	0.0
2019	4	4	2.6	0.6	0	0.0
2020	0	0	0.0	-	0	N/A
2021	0	0	0.0	-	0	N/A
Native Hawaiid	an or Other Pacific	Islander				
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	1	1	2.9	2.9	0	0.0
2012	0	0	0.0	-	0	N/A
2013	0	1	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	0	0.0	-	0	N/A
2016	0	0	0.0	-	0	N/A
2017	0	2	0.0	-	0	N/A
2018	1	1	3.0	3.0	0	0.0
2019	0	0	0.0	-	0	N/A
2020	1	1	0.1	0.1	0	0.0
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ³	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	3	8	14.0	4.7	0	0.0
2009	4	11	15.8	3.9	0	0.0
2010	4	15	7.8	1.9	0	0.0
2011	9	14	33.8	3.8	0	0.0
2012	9	16	24.5	2.7	0	0.0
2013	15	25	30.4	2.0	0	0.0
2014	19	33	44.2	2.3	0	0.0
2015	29	48	70.0	2.4	0	0.0
2016	33	52	90.2	2.7	0	0.0
2017	34	54	69.3	2.0	0	0.0
2018	26	38	41.5	1.6	0	0.0
2019	34	58	40.0	1.2	0	0.0
2020	24	33	14.9	0.6	0	0.0
2021	3	3	0.7	0.2	0	0.0
White						
2008	4	6	24.1	6.0	0	0.0
2009	0	2	0.0	-	0	N/A
2010	1	2	10.7	10.7	0	0.0
2011	0	0	0.0	-	0	N/A
2012	2	2	9.9	5.0	0	0.0
2013	0	1	0.0	-	0	N/A
2014	2	3	12.7	6.4	0	0.0
2015	2	4	9.2	4.6	0	0.0
2016	8	10	22.3	2.8	0	0.0
2017	3	4	4.9	1.6	0	0.0
2018	2	3	1.9	1.0	0	0.0
2019	1	4	0.4	0.4	0	0.0
2020	2	3	1.7	0.8	0	0.0
2021	0	0	0.0	-	0	N/A

			1.2
Table 10. Summary of Exposures of Interest in the Sentinel Distributed Database (SDD) between Januar	v 1. 2008 and Ma	v 31. 2021. by Race and Year', 2

¹Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

²Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

³Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Cytomegalovir	us (CMV) Infection	or Congenital CMV (cC	MV)			
Overall						
Yes						
2008	0	7,652	0.0	-	0	N/A
2009	0	5,645	0.0	-	0	N/A
2010	1	4,911	2.6	2.6	0	0.0
2011	0	4,668	0.0	-	0	N/A
2012	2	4,596	5.5	2.7	0	0.0
2013	2	3,988	9.9	4.9	0	0.0
2014	0	3,687	0.0	-	0	N/A
2015	0	3,985	0.0	-	0	N/A
2016	1	4,209	3.9	3.9	0	0.0
2017	1	4,195	1.9	1.9	0	0.0
2018	1	4,447	2.9	2.9	0	0.0
2019	2	4,598	3.9	2.0	0	0.0
2020	2	3,813	1.2	0.6	0	0.0
2021	0	585	0.0	-	0	N/A
No						
2008	14	53,464	93.4	6.7	0	0.0
2009	11	54,068	57.5	5.2	0	0.0
2010	13	53,505	76.7	5.9	0	0.0
2011	12	55,640	55.5	4.6	0	0.0
2012	12	55,600	44.2	3.7	0	0.0
2013	6	53,372	42.1	7.0	0	0.0
2014	13	50,306	57.1	4.4	0	0.0
2015	14	48,597	54.2	3.9	0	0.0
2016	17	49,278	41.8	2.5	0	0.0
2017	17	47,111	36.7	2.2	0	0.0
2018	8	34,994	16.4	2.1	0	0.0
2019	9	29,031	5.7	0.6	0	0.0
2020	4	13,637	2.2	0.5	0	0.0
2021	1	2,473	0.4	0.4	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	87	496,172	215.1	2.5	0	0.0
2009	78	466,401	209.9	2.7	0	0.0
2010	92	407,590	282.9	3.1	0	0.0
2011	67	380,054	206.0	3.1	0	0.0
2012	67	364,965	196.6	2.9	0	0.0
2013	88	427,924	214.9	2.4	0	0.0
2014	109	451,239	271.2	2.5	0	0.0
2015	105	468,065	239.2	2.3	0	0.0
2016	129	482,348	270.6	2.1	0	0.0
2017	146	470,053	270.7	1.9	0	0.0
2018	130	464,639	187.7	1.4	0	0.0
2019	138	445,204	142.5	1.0	0	0.0
2020	88	385,265	43.7	0.5	0	0.0
2021	13	49,362	1.8	0.1	0	0.0
Hearing Loss: A	bsent, Clinical Cha	racteristics: Absent				
Yes						
2008	0	5,424	0.0	-	0	N/A
2009	0	3,791	0.0	-	0	N/A
2010	0	3,256	0.0	-	0	N/A
2011	0	2,966	0.0	-	0	N/A
2012	0	2,848	0.0	-	0	N/A
2013	2	2,336	9.9	4.9	0	0.0
2014	0	2,117	0.0	-	0	N/A
2015	0	2,425	0.0	-	0	N/A
2016	1	2,539	3.9	3.9	0	0.0
2017	0	2,614	0.0	-	0	N/A
2018	0	2,840	0.0	-	0	N/A
2019	0	2,983	0.0	-	0	N/A
2020	0	2,522	0.0	-	0	N/A
2021	0	321	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
No						
2008	4	40,083	32.7	8.2	0	0.0
2009	6	40,087	25.8	4.3	0	0.0
2010	4	38,804	21.2	5.3	0	0.0
2011	5	41,204	20.8	4.2	0	0.0
2012	6	40,159	16.7	2.8	0	0.0
2013	1	38,067	6.7	6.7	0	0.0
2014	2	34,058	8.2	4.1	0	0.0
2015	2	32,757	7.6	3.8	0	0.0
2016	7	32,683	18.0	2.6	0	0.0
2017	6	31,032	14.0	2.3	0	0.0
2018	4	23,212	7.9	2.0	0	0.0
2019	3	19,831	2.2	0.7	0	0.0
2020	0	8,056	0.0	-	0	N/A
2021	0	1,516	0.0	-	0	N/A
Unknown						
2008	31	355,185	87.0	2.8	0	0.0
2009	23	324,031	66.3	2.9	0	0.0
2010	31	282,146	98.4	3.2	0	0.0
2011	26	265,331	72.3	2.8	0	0.0
2012	9	256,613	26.5	2.9	0	0.0
2013	26	302,929	79.0	3.0	0	0.0
2014	33	318,042	78.4	2.4	0	0.0
2015	22	329,469	49.8	2.3	0	0.0
2016	28	334,522	62.2	2.2	0	0.0
2017	32	320,785	66.9	2.1	0	0.0
2018	25	313,563	38.7	1.5	0	0.0
2019	35	299,126	33.5	1.0	0	0.0
2020	26	258,130	14.2	0.5	0	0.0
2021	5	34,468	0.5	0.1	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: P	Present, Clinical Cha	aracteristics: Absent				
Yes						
2008	0	29	0.0	-	0	N/A
2009	0	20	0.0	-	0	N/A
2010	0	26	0.0	-	0	N/A
2011	0	31	0.0	-	0	N/A
2012	0	22	0.0	-	0	N/A
2013	0	22	0.0	-	0	N/A
2014	0	11	0.0	-	0	N/A
2015	0	9	0.0	-	0	N/A
2016	0	14	0.0	-	0	N/A
2017	0	11	0.0	-	0	N/A
2018	0	18	0.0	-	0	N/A
2019	0	19	0.0	-	0	N/A
2020	0	12	0.0	-	0	N/A
2021	0	1	0.0	-	0	N/A
No						
2008	0	157	0.0	-	0	N/A
2009	0	226	0.0	-	0	N/A
2010	0	241	0.0	-	0	N/A
2011	0	199	0.0	-	0	N/A
2012	0	211	0.0	-	0	N/A
2013	1	192	8.2	8.2	0	0.0
2014	0	137	0.0	-	0	N/A
2015	0	152	0.0	-	0	N/A
2016	1	133	1.9	1.9	0	0.0
2017	1	112	3.8	3.8	0	0.0
2018	1	103	3.0	3.0	0	0.0
2019	0	95	0.0	-	0	N/A
2020	0	37	0.0	-	0	N/A
2021	0	7	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	0	2,779	0.0	-	0	N/A
2009	3	2,416	13.4	4.5	0	0.0
2010	3	2,090	11.3	3.8	0	0.0
2011	0	1,987	0.0	-	0	N/A
2012	4	1,725	9.4	2.4	0	0.0
2013	1	1,933	2.4	2.4	0	0.0
2014	1	2,157	0.0	0.0	0	0.0
2015	2	1,932	6.0	3.0	0	0.0
2016	2	1,693	2.4	1.2	0	0.0
2017	5	1,563	8.1	1.6	0	0.0
2018	6	1,504	7.1	1.2	0	0.0
2019	3	1,346	0.6	0.2	0	0.0
2020	4	1,264	2.0	0.5	0	0.0
2021	0	123	0.0	-	0	N/A
Hearing Loss: A	bsent, Clinical Cha	racteristics: Present				
Yes						
2008	0	2,234	0.0	-	0	N/A
2009	0	1,863	0.0	-	0	N/A
2010	0	1,670	0.0	-	0	N/A
2011	0	1,686	0.0	-	0	N/A
2012	2	1,743	5.5	2.7	0	0.0
2013	0	1,645	0.0	-	0	N/A
2014	0	1,575	0.0	-	0	N/A
2015	0	1,565	0.0	-	0	N/A
2016	0	1,672	0.0	-	0	N/A
2017	1	1,578	1.9	1.9	0	0.0
2018	1	1,607	2.9	2.9	0	0.0
2019	2	1,613	3.9	2.0	0	0.0
2020	1	1,305	1.2	1.2	0	0.0
2021	0	266	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
No						
2008	9	13,456	49.6	5.5	0	0.0
2009	4	14,046	21.7	5.4	0	0.0
2010	9	14,727	55.5	6.2	0	0.0
2011	7	14,493	34.7	5.0	0	0.0
2012	6	15,499	27.5	4.6	0	0.0
2013	4	15,369	27.2	6.8	0	0.0
2014	8	16,327	31.0	3.9	0	0.0
2015	11	15,934	41.9	3.8	0	0.0
2016	9	16,676	21.9	2.4	0	0.0
2017	9	16,166	16.8	1.9	0	0.0
2018	3	11,843	5.5	1.8	0	0.0
2019	6	9,251	3.5	0.6	0	0.0
2020	4	5,640	2.2	0.5	0	0.0
2021	0	953	0.0	-	0	N/A
Unknown						
2008	50	140,305	103.2	2.1	0	0.0
2009	45	141,997	107.9	2.4	0	0.0
2010	50	125,330	162.8	3.3	0	0.0
2011	37	114,664	120.0	3.2	0	0.0
2012	52	108,501	151.3	2.9	0	0.0
2013	58	125,310	131.5	2.3	0	0.0
2014	70	133,222	173.9	2.5	0	0.0
2015	70	139,087	152.7	2.2	0	0.0
2016	91	148,474	187.4	2.1	0	0.0
2017	105	150,007	183.4	1.7	0	0.0
2018	92	151,815	132.4	1.4	0	0.0
2019	87	146,990	92.3	1.1	0	0.0
2020	53	127,833	26.5	0.5	0	0.0
2021	7	14,956	1.1	0.2	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Pro	esent, Clinical Cha	aracteristics: Present				
Yes						
2008	0	26	0.0	-	0	N/A
2009	0	16	0.0	-	0	N/A
2010	1	10	2.6	2.6	0	0.0
2011	0	14	0.0	-	0	N/A
2012	0	27	0.0	-	0	N/A
2013	0	17	0.0	-	0	N/A
2014	0	7	0.0	-	0	N/A
2015	0	12	0.0	-	0	N/A
2016	0	10	0.0	-	0	N/A
2017	0	15	0.0	-	0	N/A
2018	0	9	0.0	-	0	N/A
2019	0	16	0.0	-	0	N/A
2020	1	8	0.1	0.1	0	0.0
2021	0	1	0.0	-	0	N/A
No						
2008	1	90	11.1	11.1	0	0.0
2009	1	109	10.0	10.0	0	0.0
2010	0	144	0.0	-	0	N/A
2011	0	129	0.0	-	0	N/A
2012	0	147	0.0	-	0	N/A
2013	0	143	0.0	-	0	N/A
2014	3	120	17.9	6.0	0	0.0
2015	1	120	4.7	4.7	0	0.0
2016	0	95	0.0	-	0	N/A
2017	1	99	2.0	2.0	0	0.0
2018	0	75	0.0	-	0	N/A
2019	0	53	0.0	-	0	N/A
2020	0	35	0.0	-	0	N/A
2021	1	5	0.4	0.4	0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	6	1,661	24.8	4.1	0	0.0
2009	7	1,535	22.2	3.2	0	0.0
2010	8	1,280	10.5	1.3	0	0.0
2011	4	1,180	13.6	3.4	0	0.0
2012	2	1,125	9.4	4.7	0	0.0
2013	3	1,102	1.9	0.6	0	0.0
2014	5	1,299	18.9	3.8	0	0.0
2015	11	1,126	30.8	2.8	0	0.0
2016	8	1,033	18.7	2.3	0	0.0
2017	4	1,025	12.2	3.0	0	0.0
2018	7	971	9.5	1.4	0	0.0
2019	13	888	16.2	1.2	0	0.0
2020	5	740	1.1	0.2	0	0.0
2021	1	85	0.2	0.2	0	0.0
	Freatment for Infai	nts with CMV or cCMV				
Overall						
Yes						
2008	0	7,652	0.0	-	0	N/A
2009	0	5,645	0.0	-	0	N/A
2010	1	4,911	0.5	0.5	0	0.0
2011	0	4,668	0.0	-	0	N/A
2012	2	4,596	1.0	0.5	0	0.0
2013	2	3,988	1.0	0.5	0	0.0
2014	0	3,687	0.0	-	0	N/A
2015	0	3,985	0.0	-	0	N/A
2016	1	4,209	0.1	0.1	1	10,000.0
2017	1	4,195	0.5	0.5	0	0.0
2018	1	4,447	0.5	0.5	0	0.0
2019	2	4,598	1.0	0.5	0	0.0
2020	2	3,813	0.5	0.3	1	5,000.0
	0	585	0.0		0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
No						
2008	14	53,464	5.9	0.4	4	2,857.1
2009	11	54,068	5.0	0.5	0	0.0
2010	13	53,505	6.2	0.5	0	0.0
2011	12	55,640	4.4	0.4	2	1,666.7
2012	12	55,600	4.2	0.4	2	1,666.7
2013	6	53,372	3.0	0.5	0	0.0
2014	13	50,306	4.4	0.3	4	3,076.9
2015	14	48,597	5.4	0.4	4	2,857.1
2016	17	49,278	5.0	0.3	9	5,294.1
2017	17	47,111	5.5	0.3	7	4,117.6
2018	8	34,994	2.4	0.3	4	5,000.0
2019	9	29,031	1.8	0.2	5	5,555.6
2020	4	13,637	0.6	0.2	2	5,000.0
2021	1	2,473	0.4	0.4	0	0.0
Unknown						
2008	87	496,172	32.5	0.4	3	344.8
2009	78	466,401	31.3	0.4	4	512.8
2010	92	407,590	37.1	0.4	5	543.5
2011	67	380,054	26.4	0.4	9	1,343.3
2012	66	364,965	25.4	0.4	8	1,212.1
2013	88	427,924	30.2	0.3	15	1,704.5
2014	109	451,239	37.5	0.3	19	1,743.1
2015	104	468,065	31.5	0.3	30	2,884.6
2016	127	482,348	38.4	0.3	32	2,519.7
2017	146	470,053	47.4	0.3	36	2,465.8
2018	130	464,639	42.2	0.3	28	2,153.8
2019	138	445,204	43.5	0.3	34	2,463.8
2020	88	385,265	22.9	0.3	24	2,727.3
2021	13	49,362	1.3	0.1	3	2,307.7



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: Ab	sent, Clinical Cha	racteristics: Absent				
Yes						
2008	0	5,424	0.0	-	0	N/A
2009	0	3,791	0.0	-	0	N/A
2010	0	3,256	0.0	-	0	N/A
2011	0	2,966	0.0	-	0	N/A
2012	0	2,848	0.0	-	0	N/A
2013	2	2,336	1.0	0.5	0	0.0
2014	0	2,117	0.0	-	0	N/A
2015	0	2,425	0.0	-	0	N/A
2016	1	2,539	0.1	0.1	1	10,000.0
2017	0	2,614	0.0	-	0	N/A
2018	0	2,840	0.0	-	0	N/A
2019	0	2,983	0.0	-	0	N/A
2020	0	2,522	0.0	-	0	N/A
2021	0	321	0.0	-	0	N/A
No						
2008	4	40,083	2.0	0.5	0	0.0
2009	6	40,087	2.5	0.4	0	0.0
2010	4	38,804	2.0	0.5	0	0.0
2011	5	41,204	1.4	0.3	2	4,000.0
2012	6	40,159	2.5	0.4	0	0.0
2013	1	38,067	0.5	0.5	0	0.0
2014	2	34,058	1.0	0.5	0	0.0
2015	2	32,757	1.0	0.5	0	0.0
2016	7	32,683	2.4	0.3	2	2,857.1
2017	6	31,032	2.6	0.4	1	1,666.7
2018	4	23,212	1.5	0.4	1	2,500.0
2019	3	19,831	0.6	0.2	2	6,666.7
2020	0	8,056	0.0	-	0	N/A
2021	0	1,516	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	31	355,185	10.2	0.3	1	322.6
2009	23	324,031	8.9	0.4	0	0.0
2010	31	282,146	12.5	0.4	0	0.0
2011	26	265,331	10.6	0.4	3	1,153.8
2012	9	256,613	3.8	0.4	0	0.0
2013	26	302,929	9.0	0.3	4	1,538.5
2014	33	318,042	13.7	0.4	0	0.0
2015	22	329,469	9.3	0.4	1	454.5
2016	28	334,522	11.5	0.4	2	714.3
2017	32	320,785	11.4	0.4	5	1,562.5
2018	25	313,563	9.2	0.4	3	1,200.0
2019	35	299,126	14.2	0.4	3	857.1
2020	26	258,130	7.0	0.3	7	2,692.3
2021	5	34,468	0.3	0.1	1	2,000.0
Hearing Loss: Pr	esent, Clinical Cha	aracteristics: Absent				
Yes						
2008	0	29	0.0	-	0	N/A
2009	0	20	0.0	-	0	N/A
2010	0	26	0.0	-	0	N/A
2011	0	31	0.0	-	0	N/A
2012	0	22	0.0	-	0	N/A
2013	0	22	0.0	-	0	N/A
2014	0	11	0.0	-	0	N/A
2015	0	9	0.0	-	0	N/A
2016	0	14	0.0	-	0	N/A
2017	0	11	0.0	-	0	N/A
2018	0	18	0.0	-	0	N/A
2019	0	19	0.0	-	0	N/A
2020	0	12	0.0	-	0	N/A
2021	0	1	0.0		0	N/A



No - 0 2008 0 157 0.0 - 0 2009 0 226 0.0 - 0 2010 0 241 0.0 - 0 2011 0 199 0.0 - 0 2012 0 211 0.0 - 0 2013 1 192 0.5 0.5 0 2014 0 137 0.0 - 0 2015 0 152 0.0 - 0 2016 1 133 0.1 0.1 1 2017 1 112 0.1 0.1 1 2018 1 103 0.1 0.1 1 2019 0 95 0.0 - 0 2020 0 37 0.0 - 0 2010 3 2,090 1.5 0.5 0 </th <th>per 10,000 New Infants</th> <th>New Episodes with an Event</th> <th>Average Person-Years at Risk</th> <th>Years at Risk</th> <th>Eligible Members²</th> <th>New Users</th> <th></th>	per 10,000 New Infants	New Episodes with an Event	Average Person-Years at Risk	Years at Risk	Eligible Members ²	New Users	
2009 0 226 0.0 - 0 2010 0 241 0.0 - 0 2011 0 199 0.0 - 0 2012 0 211 0.0 - 0 2013 1 192 0.5 0.5 0 2014 0 137 0.0 - 0 2015 0 152 0.0 - 0 2016 1 133 0.1 0.1 1 2018 1 103 0.1 0.1 1 2019 0 95 0.0 - 0 2020 0 37 0.0 - 0 2021 0 7 0.0 - 0 2020 3 2,416 1.2 0.4 0 2010 3 2,090 1.5 0.5 0 2011 0 1,937							No
2010 0 241 0.0 - 0 2011 0 199 0.0 - 0 2012 0 211 0.0 - 0 2013 1 192 0.5 0.5 0 2014 0 137 0.0 - 0 2015 0 152 0.0 - 0 2016 1 133 0.1 0.1 1 2017 1 112 0.1 0.1 1 2019 0 95 0.0 - 0 2020 0 37 0.0 - 0 2021 0 7 0.0 - 0 2020 3 2,416 1.2 0.4 0 2010 3 2,090 1.5 0.5 0 2011 0 1,987 0.0 - 0 2012 4 1,725	N/A	0	-	0.0	157	0	2008
201101990.0-0 2012 0 211 0.0-0 2013 11920.50.50 2014 01370.0-0 2015 01520.0-0 2016 11330.10.11 2017 11120.10.11 2018 11030.10.11 2019 0950.0-0 2020 0370.0-0 2021 070.0-0 2020 0370.0-0 2021 070.0-0 2021 01.50.50 2010 32,9001.50.50 2011 01,9870.0-0 2012 41,7252.00.50 2013 11,9330.10.11 2014 12,1570.00.00 2015 21,9320.30.21 2016 21,6930.50.31 2017 51,5631.10.22 2018 61,5042.10.31	N/A	0	-	0.0	226	0	2009
2012 0 211 0.0 - 0 2013 1 192 0.5 0.5 0 2014 0 137 0.0 - 0 2015 0 152 0.0 - 0 2016 1 133 0.1 0.1 1 2017 1 112 0.1 0.1 1 2018 1 03 0.1 0.1 1 2019 0 95 0.0 - 0 2020 0 37 0.0 - 0 2021 0 7 0.0 - 0 2020 0 37 0.0 - 0 2021 0 7 0.0 - 0 2020 0 37 0.0 - 0 2010 3 2,416 1.2 0.4 0 2011 0 1,987	N/A	0	-	0.0	241	0	2010
2013 1 192 0.5 0.5 0 2014 0 137 0.0 - 0 2015 0 152 0.0 - 0 2016 1 133 0.1 0.1 1 2017 1 112 0.1 0.1 1 2018 1 103 0.1 0.1 1 2019 0 95 0.0 - 0 2020 0 37 0.0 - 0 2021 0 7 0.0 - 0 2020 0 37 0.0 - 0 2021 0 7 0.0 - 0 2020 3 2,779 0.0 - 0 2008 0 2,779 0.0 - 0 2011 0 1,987 0.0 - 0 2012 4 1,725	N/A	0	-	0.0	199	0	2011
2014 0 137 0.0 - 0 2015 0 152 0.0 - 0 2016 1 133 0.1 0.1 1 2017 1 112 0.1 0.1 1 2018 1 103 0.1 0.1 1 2019 0 95 0.0 - 0 2020 0 37 0.0 - 0 2021 0 7 0.0 - 0 2020 0 37 0.0 - 0 2021 0 7 0.0 - 0 2010 3 2,416 1.2 0.4 0 2010 3 2,090 1.5 0.5 0 2011 0 1,987 0.0 - 0 2012 4 1,725 2.0 0.5 0 2013 1 1,933 <td>N/A</td> <td>0</td> <td>-</td> <td>0.0</td> <td>211</td> <td>0</td> <td>2012</td>	N/A	0	-	0.0	211	0	2012
201501520.0-0 2016 11330.10.11 2017 11120.10.11 2018 11030.10.11 2019 0950.0-0 2020 0370.0-0 2021 070.0-0 2021 070.0-0 2021 02,7790.0-0 2008 02,7790.0-0 2009 32,4161.20.40 2010 32,0901.50.50 2011 01,9870.0-0 2012 41,7252.00.50 2013 11,9330.10.11 2014 12,1570.00.00 2015 21,9320.30.21 2016 21,6930.50.31 2017 51,5631.10.22 2018 61,5042.10.31	0.0	0	0.5	0.5	192	1	2013
201611330.10.11201711120.10.11201811030.10.1120190950.0-020200370.0-02021070.0-0Umage: Second	N/A	0	-	0.0	137	0	2014
201711120.10.11201811030.10.1120190950.0-020200370.0-02021070.0-0Umbody200802,7790.0-0200932,4161.20.40201032,0901.50.50201101,9870.0-0201241,7252.00.50201311,9330.10.11201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	N/A	0	-	0.0	152	0	2015
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	10,000.0	1	0.1	0.1	133	1	2016
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	10,000.0	1	0.1	0.1	112	1	2017
20200370.0-02021070.0-0Unknown-0200802,7790.0-0200932,4161.20.40201032,0901.50.50201101,9870.0-0201241,7252.00.50201311,9330.10.11201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	10,000.0	1	0.1	0.1	103	1	2018
2021070.0-0Unknown200802,7790.0-0200932,4161.20.40201032,0901.50.50201101,9870.0-0201241,7252.00.50201311,9330.10.11201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	N/A	0	-	0.0	95	0	2019
Unknown 2008 0 2,779 0.0 - 0 2009 3 2,416 1.2 0.4 0 2010 3 2,090 1.5 0.5 0 2011 0 1,987 0.0 - 0 2012 4 1,725 2.0 0.5 0 2013 1 1,933 0.1 0.1 1 2014 1 2,157 0.0 0.0 0 2015 2 1,932 0.3 0.2 1 2016 2 1,693 0.5 0.3 1 2017 5 1,563 1.1 0.2 2 2018 6 1,504 2.1 0.3 1	N/A	0	-	0.0	37	0	2020
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	N/A	0	-	0.0	7	0	2021
200932,4161.20.40201032,0901.50.50201101,9870.0-0201241,7252.00.50201311,9330.10.11201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31							Unknown
201032,0901.50.50201101,9870.0-0201241,7252.00.50201311,9330.10.11201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	N/A	0	-	0.0	2,779	0	2008
201101,9870.0-0201241,7252.00.50201311,9330.10.11201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	0.0	0	0.4	1.2	2,416	3	2009
201241,7252.00.50201311,9330.10.11201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	0.0	0	0.5	1.5	2,090	3	2010
201311,9330.10.11201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	N/A	0	-	0.0	1,987	0	2011
201412,1570.00.00201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	0.0	0	0.5	2.0	1,725	4	2012
201521,9320.30.21201621,6930.50.31201751,5631.10.22201861,5042.10.31	10,000.0	1	0.1	0.1	1,933	1	2013
201621,6930.50.31201751,5631.10.22201861,5042.10.31	0.0	0	0.0	0.0	2,157	1	2014
201751,5631.10.22201861,5042.10.31	5,000.0	1	0.2	0.3	1,932	2	2015
2018 6 1,504 2.1 0.3 1	5,000.0	1	0.3	0.5	1,693	2	2016
	4,000.0	2	0.2	1.1	1,563	5	2017
2019 3 1.346 0.6 0.2 0	1,666.7	1	0.3	2.1	1,504	6	2018
	0.0	0	0.2	0.6	1,346	3	2019
2020 4 1,264 0.5 0.1 2	5,000.0	2	0.1	0.5	1,264	4	2020
2021 0 123 0.0 - 0	N/A	0	-	0.0	123	0	2021



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Hearing Loss: A	bsent, Clinical Cha	racteristics: Present				
Yes						
2008	0	2,234	0.0	-	0	N/A
2009	0	1,863	0.0	-	0	N/A
2010	0	1,670	0.0	-	0	N/A
2011	0	1,686	0.0	-	0	N/A
2012	2	1,743	1.0	0.5	0	0.0
2013	0	1,645	0.0	-	0	N/A
2014	0	1,575	0.0	-	0	N/A
2015	0	1,565	0.0	-	0	N/A
2016	0	1,672	0.0	-	0	N/A
2017	1	1,578	0.5	0.5	0	0.0
2018	1	1,607	0.5	0.5	0	0.0
2019	2	1,613	1.0	0.5	0	0.0
2020	1	1,305	0.5	0.5	0	0.0
2021	0	266	0.0	-	0	N/A
No						
2008	9	13,456	3.8	0.4	3	3,333.3
2009	4	14,046	2.0	0.5	0	0.0
2010	9	14,727	4.2	0.5	0	0.0
2011	7	14,493	3.0	0.4	0	0.0
2012	6	15,499	1.7	0.3	2	3,333.3
2013	4	15,369	2.0	0.5	0	0.0
2014	8	16,327	2.5	0.3	2	2,500.0
2015	11	15,934	4.3	0.4	3	2,727.3
2016	9	16,676	2.5	0.3	6	6,666.7
2017	9	16,166	2.7	0.3	4	4,444.4
2018	3	11,843	0.8	0.3	2	6,666.7
2019	6	9,251	1.3	0.2	3	5,000.0
2020	4	5,640	0.6	0.2	2	5,000.0
2021	0	953	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	50	140,305	19.3	0.4	2	400.0
2009	45	141,997	18.6	0.4	3	666.7
2010	50	125,330	19.3	0.4	5	1,000.0
2011	37	114,664	14.4	0.4	5	1,351.4
2012	51	108,501	19.5	0.4	6	1,176.5
2013	58	125,310	20.1	0.3	9	1,551.7
2014	70	133,222	23.5	0.3	14	2,000.0
2015	69	139,087	19.1	0.3	23	3,333.3
2016	90	148,474	25.5	0.3	24	2,666.7
2017	105	150,007	34.5	0.3	25	2,381.0
2018	92	151,815	29.2	0.3	20	2,173.9
2019	87	146,990	27.1	0.3	21	2,413.8
2020	53	127,833	14.7	0.3	13	2,452.8
2021	7	14,956	0.8	0.1	2	2,857.1
Hearing Loss: P	resent, Clinical Cha	aracteristics: Present				
Yes						
2008	0	26	0.0	-	0	N/A
2009	0	16	0.0	-	0	N/A
2010	1	10	0.5	0.5	0	0.0
2011	0	14	0.0	-	0	N/A
2012	0	27	0.0	-	0	N/A
2013	0	17	0.0	-	0	N/A
2014	0	7	0.0	-	0	N/A
2015	0	12	0.0	-	0	N/A
2016	0	10	0.0	-	0	N/A
2017	0	15	0.0	-	0	N/A
2018	0	9	0.0	-	0	N/A
2019	0	16	0.0	-	0	N/A
2020	1	8	0.0	0.0	1	10,000.0
2021	0	1	0.0	-	0	N/A



2008 1 90 0.1 0.1 1 10,000.0 2009 1 109 0.5 0.5 0 0.0 2010 0 144 0.0 - 0 N/A 2011 0 129 0.0 - 0 N/A 2012 0 147 0.0 - 0 N/A 2013 0 143 0.0 - 0 N/A 2014 3 120 0.8 0.3 2 6,666.7 2015 1 120 0.1 0.1 1 10,000.0 2016 0 95 0.0 - 0 N/A 2017 1 99 0.1 0.1 1 10,000.0 2018 0 75 0.0 - 0 N/A 2019 0 53 0.0 - 0 N/A 2020 0 35 0.0 <th></th> <th>New Users</th> <th>Eligible Members²</th> <th>Years at Risk</th> <th>Average Person-Years at Risk</th> <th>New Episodes with an Event</th> <th>Events per 10,000 New Infants</th>		New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
2009 1 109 0.5 0.5 0 0.0 2010 0 144 0.0 - 0 N/A 2011 0 129 0.0 - 0 N/A 2012 0 147 0.0 - 0 N/A 2013 0 143 0.0 - 0 N/A 2014 3 120 0.8 0.3 2 6,666.7 2015 1 120 0.1 0.1 1 10,000.0 2016 0 95 0.0 - 0 N/A 2017 1 99 0.1 0.1 1 0,000.0 2018 0 75 0.0 - 0 N/A 2020 0 35 0.0 - 0 0 2021 1 5 0.4 0.4 0 0.0 2020 7 1,55 2.6	No						
201001440.0-0N/A201101290.0-0N/A201201470.0-0N/A201301430.0-0N/A201431200.80.326,666.7201511200.10.1110,000.020160950.0-0N/A20171990.10.1110,000.020180750.0-0N/A20200530.0-0N/A2021150.40.400.020200350.6-00.02021150.40.400.0202031,6613.00.500.0201081,2803.80.500.0201141,1801.40.312,500.0201221,2550.10.1210,000.0201331,1020.90.313,333.3201451,2990.30.151,429.52015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.02013 <td< td=""><td>2008</td><td>1</td><td>90</td><td>0.1</td><td>0.1</td><td>1</td><td>10,000.0</td></td<>	2008	1	90	0.1	0.1	1	10,000.0
2011 0 129 0.0 - 0 N/A 2012 0 147 0.0 - 0 N/A 2013 0 143 0.0 - 0 N/A 2014 3 120 0.8 0.3 2 66667. 2015 1 120 0.1 0.1 1 10,000.0 2016 0 95 0.0 - 0 N/A 2017 1 99 0.1 0.1 1 10,000.0 2018 0 75 0.0 - 0 N/A 2020 0 53 0.0 - 0 N/A 2021 1 5 0.4 0 0 0 2020 1 35 0.6 0.4 1 1,428.6 2010 8 1,280 3.8 0.5 0 0.0 2011 1,180 1.4 0.3 </td <td>2009</td> <td>1</td> <td>109</td> <td>0.5</td> <td>0.5</td> <td>0</td> <td>0.0</td>	2009	1	109	0.5	0.5	0	0.0
2012 0 147 0.0 - 0 N/A 2013 0 143 0.0 - 0 N/A 2014 3 120 0.8 0.3 2 6,666.7 2015 1 120 0.1 0.1 1 10,000.0 2016 0 95 0.0 - 0 N/A 2017 1 99 0.1 0.1 1 10,000.0 2018 0 75 0.0 - 0 N/A 2020 0 35 0.0 - 0 N/A 2021 1 5 0.0 - 0 N/A 2020 0 35 0.0 - 0 N/A 2021 1 5 0.0 0.0 0 0 2009 7 1,535 2.6 0.4 1 1,428.6 2010 8 1,280 3.8	2010	0	144	0.0	-	0	N/A
2013 0 143 0.0 - 0 N/A 2014 3 120 0.8 0.3 2 6,666.7 2015 1 120 0.1 0.1 1 10,000.0 2016 0 95 0.0 - 0 N/A 2017 1 99 0.1 0.1 1 10,000.0 2018 0 75 0.0 - 0 N/A 2019 0 53 0.0 - 0 N/A 2021 1 5 0.4 0.4 0 0.0 2021 1 5 0.4 0.4 0 0.0 2021 1 5 0.4 0.4 0 0.0 2008 6 1,661 3.0 0.5 0 0.0 2010 8 1,280 3.8 0.5 0 0.0 2011 4 1,180 1.4	2011	0	129	0.0	-	0	N/A
2014 3 120 0.8 0.3 2 6,666.7 2015 1 120 0.1 0.1 1 10,000.0 2016 0 95 0.0 - 0 N/A 2017 1 99 0.1 0.1 1 10,000.0 2018 0 75 0.0 - 0 N/A 2019 0 53 0.0 - 0 N/A 2020 0 35 0.0 - 0 N/A 2021 1 5 0.4 0.4 0 0.0 Introver Introver Introver Introver Introver Introver Introver Introver <thintrover< th=""> 2008 6 1,661 3.0 0.5 0 0.0 0.0 2010 8 1,280 3.8 0.5 0 0.0 0.0 2012 2 1,125 0.1 0.1</thintrover<>	2012	0	147	0.0	-	0	N/A
2015 1 120 0.1 0.1 1 10,000.0 2016 0 95 0.0 - 0 N/A 2017 1 99 0.1 0.1 1 10,000.0 2018 0 75 0.0 - 0 N/A 2019 0 53 0.0 - 0 N/A 2020 0 35 0.0 - 0 N/A 2021 1 5 0.4 0.4 0 0.0 2021 1 5 0.4 0.4 0 0.0 2021 1 5 0.4 0.4 0 0.0 2010 8 1,280 3.8 0.5 0 0.0 2011 4 1,180 1.4 0.3 1 2,500.0 2012 2 1,125 0.1 0.1 2 10,000.0 2013 3 1,025 <	2013	0	143	0.0	-	0	N/A
2016 0 95 0.0 - 0 N/A 2017 1 99 0.1 0.1 1 10,000.0 2018 0 75 0.0 - 0 N/A 2019 0 53 0.0 - 0 N/A 2020 0 35 0.0 - 0 N/A 2021 1 5 0.4 0.4 0.0 0.0 2021 1 5 0.4 0.4 0.4 0.0 0.0 2021 1 5 0.4 0.4 0.4 0.0 0.0 2017 1 55 0.4 0.4 1 1.428.6 2009 7 1,535 2.6 0.4 1 1.428.6 2010 8 1,280 3.8 0.5 0 0.0 2011 4 1,180 1.4 0.3 1 3.333.3 2014	2014	3	120	0.8	0.3	2	6,666.7
20171990.10.1110,000.020180750.0-0N/A20190530.0-0N/A20200350.0-0N/A2021150.40.400.0JakawaJakawaJakawa1,613.00.500.0Jakawa0.500.0Jong71,5352.60.411,428.6201081,2803.80.500.00.0201141,1801.40.312,500.00.0201221,1250.10.1210,000.0201331,1020.90.313,33.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2015	1	120	0.1	0.1	1	10,000.0
20180750.0-0N/A20190530.0-0N/A20200350.0-0N/A2021150.40.400.0201861,6613.00.500.0200861,6613.00.500.0200971,5352.60.411,428.6201081,2803.80.500.0201141,1801.40.312,500.0201221,1250.10.1210,000.0201331,1020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2016	0	95	0.0	-	0	N/A
20190530.0-0N/A20200350.0-0N/A2021150.40.400.0Intervent200861.6613.00.500.0200971.5352.60.411.428.6201081.2803.80.500.0201141.1801.40.312.500.0201221.1250.10.1210,000.0201331.1020.90.313,333.3201451.2990.30.1510,000.02015111.1262.80.354,545.5201671.0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2017	1	99	0.1	0.1	1	10,000.0
20200350.0-0N/A2021150.40.400.0201051,6613.00.500.0200971,5352.60.411,428.6201081,2803.80.500.0201141,1801.40.312,500.0201221,1250.10.1210,000.0201331,020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.141,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2018	0	75	0.0	-	0	N/A
2021150.40.400.0Unknown200861,6613.00.500.0200971,5352.60.411,428.6201081,2803.80.500.0201141,1801.40.312,500.0201221,1250.10.1210,000.0201331,1020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2019	0	53	0.0	-	0	N/A
Unknown 2008 61,6613.00.500.0 2009 71,5352.60.411,428.6 2010 81,2803.80.500.0 2011 41,1801.40.312,500.0 2012 21,1250.10.1210,000.0 2013 31,1020.90.313,333.3 2014 51,2990.30.1510,000.0 2015 111,1262.80.354,545.5 2016 71,0330.90.157,142.9 2017 41,0250.40.1410,000.0 2018 79711.70.245,714.3 2019 138881.60.1107,692.3 2020 57400.70.124,000.0	2020	0	35	0.0	-	0	N/A
200861,6613.00.500.0200971,5352.60.411,428.6201081,2803.80.500.0201141,1801.40.312,500.0201221,1250.10.1210,000.0201331,1020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2021	1	5	0.4	0.4	0	0.0
200971,5352.60.411,428.6201081,2803.80.500.0201141,1801.40.312,500.0201221,1250.10.1210,000.0201331,1020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	Unknown						
201081,2803.80.500.0201141,1801.40.312,500.0201221,1250.10.1210,000.0201331,1020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2008	6	1,661	3.0	0.5	0	0.0
201141,1801.40.312,500.0201221,1250.10.1210,000.0201331,1020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2009	7	1,535	2.6	0.4	1	1,428.6
201221,1250.10.1210,000.0201331,1020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2010	8	1,280	3.8	0.5	0	0.0
201331,1020.90.313,333.3201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2011	4	1,180	1.4	0.3	1	2,500.0
201451,2990.30.1510,000.02015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2012	2	1,125	0.1	0.1	2	10,000.0
2015111,1262.80.354,545.5201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2013	3	1,102	0.9	0.3	1	3,333.3
201671,0330.90.157,142.9201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2014	5	1,299	0.3	0.1	5	10,000.0
201741,0250.40.1410,000.0201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2015	11	1,126	2.8	0.3	5	4,545.5
201879711.70.245,714.32019138881.60.1107,692.3202057400.70.124,000.0	2016	7	1,033	0.9	0.1	5	7,142.9
2019 13 888 1.6 0.1 10 7,692.3 2020 5 740 0.7 0.1 2 4,000.0	2017	4	1,025	0.4	0.1	4	10,000.0
2020 5 740 0.7 0.1 2 4,000.0	2018	7	971	1.7	0.2	4	5,714.3
2020 5 740 0.7 0.1 2 4,000.0	2019	13	888	1.6		10	
	2020		740	0.7		2	4,000.0
	2021	1	85	0.2		0	0.0



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Treatment With	in 45 Days from D	Diagnosis				
Yes						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	1	0.0	-	0	N/A
2016	1	1	3.9	3.9	0	0.0
2017	0	0	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	1	1	0.1	0.1	0	0.0
2021	0	0	0.0	-	0	N/A
No						
2008	2	2	21.7	10.9	0	0.0
2009	0	1	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	2	2	11.1	5.6	0	0.0
2012	2	2	9.9	5.0	0	0.0
2013	0	1	0.0	-	0	N/A
2014	0	1	0.0	-	0	N/A
2015	2	2	8.4	4.2	0	0.0
2016	6	8	15.9	2.7	0	0.0
2017	5	8	11.4	2.3	0	0.0
2018	2	2	2.9	1.4	0	0.0
2019	4	6	2.4	0.6	0	0.0
2020	2	2	1.7	0.8	0	0.0
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
Unknown						
2008	0	1	0.0	-	0	N/A
2009	1	3	0.4	0.4	0	0.0
2010	3	4	7.6	2.5	0	0.0
2011	3	6	13.5	4.5	0	0.0
2012	9	10	24.5	2.7	0	0.0
2013	11	14	27.2	2.5	0	0.0
2014	16	18	45.0	2.8	0	0.0
2015	26	34	67.9	2.6	0	0.0
2016	25	31	68.8	2.8	0	0.0
2017	25	32	46.7	1.9	0	0.0
2018	23	26	33.6	1.5	0	0.0
2019	27	38	31.7	1.2	0	0.0
2020	20	24	11.8	0.6	0	0.0
2021	3	3	0.7	0.2	0	0.0
Treatment With	in 180 Days from	Diagnosis				
Yes						
2008	0	0	0.0	-	0	N/A
2009	0	0	0.0	-	0	N/A
2010	0	0	0.0	-	0	N/A
2011	0	0	0.0	-	0	N/A
2012	0	0	0.0	-	0	N/A
2013	0	0	0.0	-	0	N/A
2014	0	0	0.0	-	0	N/A
2015	0	1	0.0	-	0	N/A
2016	1	1	3.9	3.9	0	0.0
2017	0	1	0.0	-	0	N/A
2018	0	0	0.0	-	0	N/A
2019	0	0	0.0	-	0	N/A
2020	1	1	0.1	0.1	0	0.0
2021	0	0	0.0	-	0	N/A



	New Users	Eligible Members ²	Years at Risk	Average Person-Years at Risk	New Episodes with an Event	Events per 10,000 New Infants
No						
2008	4	6	24.1	6.0	0	0.0
2009	0	2	0.0	-	0	N/A
2010	0	1	0.0	-	0	N/A
2011	2	2	11.1	5.6	0	0.0
2012	2	2	9.9	5.0	0	0.0
2013	0	2	0.0	-	0	N/A
2014	4	5	23.3	5.8	0	0.0
2015	4	6	17.6	4.4	0	0.0
2016	9	12	23.3	2.6	0	0.0
2017	7	12	16.4	2.3	0	0.0
2018	4	4	7.8	2.0	0	0.0
2019	5	8	3.0	0.6	0	0.0
2020	2	2	1.7	0.8	0	0.0
2021	0	0	0.0	-	0	N/A
Unknown						
2008	3	8	14.0	4.7	0	0.0
2009	4	11	15.8	3.9	0	0.0
2010	5	16	18.5	3.7	0	0.0
2011	9	15	33.8	3.8	0	0.0
2012	9	17	24.5	2.7	0	0.0
2013	15	25	30.4	2.0	0	0.0
2014	20	34	50.0	2.5	0	0.0
2015	31	50	81.6	2.6	0	0.0
2016	35	54	95.7	2.7	0	0.0
2017	36	56	73.2	2.0	0	0.0
2018	28	41	42.4	1.5	0	0.0
2019	34	58	40.0	1.2	0	0.0
2020	24	34	14.9	0.6	0	0.0
2021	3	3	0.7	0.2	0	0.0

¹Counts of events and proportions of events per 10,000 new infants were not estimated (reported as 0) in cohorts examining clinical characteristics of infants with CMV at ≤45 days of age and VGCV treatment within 45/180 days from CMV diagnosis.

²Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.



DP ID	Start Date	End Date
DP01	01/01/2008	12/31/2020
DP02	01/01/2000	04/30/2021
DP03	01/01/2000	06/30/2020
DP04	01/01/2004	05/31/2021
DP05	01/01/2007	02/28/2021
DP06	01/01/2000	12/31/2019
DP07	01/01/2005	10/31/2020
DP08	01/01/2000	02/28/2021
DP09	01/01/2000	05/31/2021
DP10	01/01/2006	03/31/2021
DP11	01/01/2008	12/31/2020
DP12	01/01/2000	02/28/2021

Appendix A. Start and End Dates for Each Data Partner	DD) as of Rec	uset Distribution	Dato	(December 9	2021)
Appendix A. Start and End Dates for Each Data Partner	DF	j as ui neu	Juest Distribution	Date	(December 9,	2021)

The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.



Census Bureau Region	States and Territories
Northeast	Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, Pennsylvania
Midwest	Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, South Dakota
South	Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, Texas
West	Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming, Alaska, California, Hawaii, Washington, Oregon
Other	Northern Mariana Islands, Marshall Islands, Puerto Rico, US Virgin Islands, American Samoa, Micronesia, Guam, Palau
Missing	Missing
Invalid	Recorded geographic location does not match any identifiers per the Sentinel Common Data Model definition



Appendix C. List of Generic and Brand Names of Medical Products Used to Define Outcome and Inclusion Criteria in this Request

Generic Name	Brand Name	
Valganciclovir/Ganciclovir		
ganciclovir	Cytovene	
ganciclovir	ganciclovir	
ganciclovir sodium	Cytovene	
ganciclovir sodium	ganciclovir sodium	
valganciclovir HCl	Valcyte	
valganciclovir HCl	valganciclovir	



Appendix D. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Codes Used to Define Cytomegalovirus (CMV) Infection or Congenital CMV (cCMV) Events in this Request

Code	Description	Code Category	Code Type				
Cytomeg	alovirus Infection (CMV)						
078.5	Cytomegaloviral disease	Diagnosis	ICD-9-CM				
B25.0	Cytomegaloviral pneumonitis	Diagnosis	ICD-10-CM				
B25.1	Cytomegaloviral hepatitis	Diagnosis	ICD-10-CM				
B25.2	Cytomegaloviral pancreatitis	Diagnosis	ICD-10-CM				
B25.8	Other cytomegaloviral diseases	Diagnosis	ICD-10-CM				
B25.9	Cytomegaloviral disease, unspecified	Diagnosis	ICD-10-CM				
Congenit	Congenital Cytomegalovirus (cCMV)						
771.1	Congenital cytomegalovirus infection	Diagnosis	ICD-9-CM				
P35.1	Congenital cytomegalovirus infection	Diagnosis	ICD-10-CM				



Code	Description	Code Category	Code Type
Hearing L	•		71.2
388.01	Presbyacusis	Diagnosis	ICD-9-CM
388.2	Unspecified sudden hearing loss	Diagnosis	ICD-9-CM
389.1	Sensorineural hearing loss	Diagnosis	ICD-9-CM
389.10	Unspecified sensorineural hearing loss	Diagnosis	ICD-9-CM
389.11	Sensory hearing loss, bilateral	Diagnosis	ICD-9-CM
389.12	Neural hearing loss, bilateral	Diagnosis	ICD-9-CM
389.13	Neural hearing loss, unilateral	Diagnosis	ICD-9-CM
389.14	Central hearing loss	Diagnosis	ICD-9-CM
389.15	Sensorineural hearing loss, unilateral	Diagnosis	ICD-9-CM
389.16	Sensorineural hearing loss, asymmetrical	Diagnosis	ICD-9-CM
389.17	Sensory hearing loss, unilateral	Diagnosis	ICD-9-CM
389.18	Sensorineural hearing loss, bilateral	Diagnosis	ICD-9-CM
389.2	Mixed conductive and sensorineural hearing loss	Diagnosis	ICD-9-CM
389.20	Mixed hearing loss, unspecified	Diagnosis	ICD-9-CM
389.21	Mixed hearing loss, unilateral	Diagnosis	ICD-9-CM
389.22	Mixed hearing loss, bilateral	Diagnosis	ICD-9-CM
389.7	Deaf, nonspeaking, not elsewhere classifiable	Diagnosis	ICD-9-CM
389.8	Other specified forms of hearing loss	Diagnosis	ICD-9-CM
389.9	Unspecified hearing loss	Diagnosis	ICD-9-CM
69710	IMPLANT/REPLACE HEARING AID	Procedure	CPT-4
69930	IMPLANT COCHLEAR DEVICE	Procedure	CPT-4
92510	AURAL REHABILITATION FOLLOWING COCHLEAR IMPLANT (INCLUDES EVALUATION OF AURAL REHABILITATION STATUS	Procedure	CPT-4
92601	COCHLEAR IMPLT F/UP EXAM <7	Procedure	CPT-4
92602	REPROGRAM COCHLEAR IMPLT <7	Procedure	CPT-4
92630	AUD REHAB PRE-LING HEAR LOSS	Procedure	CPT-4
92633	AUD REHAB POSTLING HEAR LOSS	Procedure	CPT-4
95.48	Fitting of hearing aid	Procedure	ICD-9-CM
F0DZ05Z	Tinnitus Masker Device Fitting using Hearing Aid Selection / Fitting / Test Equipment	Procedure	ICD-10-PCS
FODZOZZ	Tinnitus Masker Device Fitting	Procedure	ICD-10-PCS
F0DZ11Z	Monaural Hearing Aid Device Fitting using Audiometer	Procedure	ICD-10-PCS
F0DZ12Z	Monaural Hearing Aid Device Fitting using Sound Field / Booth	Procedure	ICD-10-PCS
F0DZ15Z	Monaural Hearing Aid Device Fitting using Hearing Aid Selection / Fitting / Test Equipmen	Procedure	ICD-10-PCS
F0DZ1KZ	Monaural Hearing Aid Device Fitting using Audiovisual Equipment	Procedure	ICD-10-PCS
F0DZ1LZ	Monaural Hearing Aid Device Fitting using Assistive Listening Equipment	Procedure	ICD-10-PCS
F0DZ1ZZ	Monaural Hearing Aid Device Fitting	Procedure	ICD-10-PCS
F0DZ21Z	Binaural Hearing Aid Device Fitting using Audiometer	Procedure	ICD-10-PCS
F0DZ22Z	Binaural Hearing Aid Device Fitting using Sound Field / Booth	Procedure	ICD-10-PCS
F0DZ25Z	Binaural Hearing Aid Device Fitting using Hearing Aid Selection / Fitting / Test Equipment	Procedure	ICD-10-PCS
F0DZ2KZ	Binaural Hearing Aid Device Fitting using Audiovisual Equipment	Procedure	ICD-10-PCS
F0DZ2LZ	Binaural Hearing Aid Device Fitting using Assistive Listening Equipment	Procedure	ICD-10-PCS
F0DZ2ZZ	Binaural Hearing Aid Device Fitting	Procedure	ICD-10-PCS
F0DZ51Z	Assistive Listening Device Device Fitting using Audiometer	Procedure	ICD-10-PCS



Code	Description	Code Category	Code Type
F0DZ52Z	Assistive Listening Device Device Fitting using Sound Field / Booth	Procedure	ICD-10-PCS
F0DZ55Z	Assistive Listening Device Device Fitting using Hearing Aid Selection / Fitting / Test Equipn	Procedure	ICD-10-PCS
F0DZ5KZ	Assistive Listening Device Device Fitting using Audiovisual Equipment	Procedure	ICD-10-PCS
F0DZ5LZ	Assistive Listening Device Device Fitting using Assistive Listening Equipment	Procedure	ICD-10-PCS
F0DZ5ZZ	Assistive Listening Device Device Fitting	Procedure	ICD-10-PCS
H90.3	Sensorineural hearing loss, bilateral	Diagnosis	ICD-10-CM
H90.4	Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.41	Sensorineural hearing loss, unilateral, right ear, with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.42	Sensorineural hearing loss, unilateral, left ear, with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.5	Unspecified sensorineural hearing loss	Diagnosis	ICD-10-CM
H90.6	Mixed conductive and sensorineural hearing loss, bilateral	Diagnosis	ICD-10-CM
H90.7	Mixed conductive and sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.71	Mixed conductive and sensorineural hearing loss, unilateral, right ear, with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.72	Mixed conductive and sensorineural hearing loss, unilateral, left ear, with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.8	Mixed conductive and sensorineural hearing loss, unspecified	Diagnosis	ICD-10-CM
H90.A21	Sensorineural hearing loss, unilateral, right ear, with restricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.A22	Sensorineural hearing loss, unilateral, left ear, with restricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.A31	Mixed conductive and sensorineural hearing loss, unilateral, right ear with restricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.A32	Mixed conductive and sensorineural hearing loss, unilateral, left ear with restricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H91.0	Ototoxic hearing loss	Diagnosis	ICD-10-CM
H91.01	Ototoxic hearing loss, right ear	Diagnosis	ICD-10-CM
H91.02	Ototoxic hearing loss, left ear	Diagnosis	ICD-10-CM
H91.03	Ototoxic hearing loss, bilateral	Diagnosis	ICD-10-CM
H91.09	Ototoxic hearing loss, unspecified ear	Diagnosis	ICD-10-CM
H91.1	Presbycusis	Diagnosis	ICD-10-CM
H91.10	Presbycusis, unspecified ear	Diagnosis	ICD-10-CM
H91.11	Presbycusis, right ear	Diagnosis	ICD-10-CM
H91.12	Presbycusis, left ear	Diagnosis	ICD-10-CM
H91.13	Presbycusis, bilateral	Diagnosis	ICD-10-CM
H91.2	Sudden idiopathic hearing loss	Diagnosis	ICD-10-CM
H91.20	Sudden idiopathic hearing loss, unspecified ear	Diagnosis	ICD-10-CM
H91.21	Sudden idiopathic hearing loss, right ear	Diagnosis	ICD-10-CM
H91.22	Sudden idiopathic hearing loss, left ear	Diagnosis	ICD-10-CM
H91.23	Sudden idiopathic hearing loss, bilateral	Diagnosis	ICD-10-CM
H91.3	Deaf nonspeaking, not elsewhere classified	Diagnosis	ICD-10-CM
H91.8	Other specified hearing loss	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
H91.8X	Other specified hearing loss	Diagnosis	ICD-10-CN
H91.8X1	Other specified hearing loss, right ear	Diagnosis	ICD-10-CN
191.8X2	Other specified hearing loss, left ear	Diagnosis	ICD-10-CN
H91.8X3	Other specified hearing loss, bilateral	Diagnosis	ICD-10-CN
H91.8X9	Other specified hearing loss, unspecified ear	Diagnosis	ICD-10-CN
H91.9	Unspecified hearing loss	Diagnosis	ICD-10-CN
H91.90	Unspecified hearing loss, unspecified ear	Diagnosis	ICD-10-CN
191.91	Unspecified hearing loss, right ear	Diagnosis	ICD-10-CN
191.92	Unspecified hearing loss, left ear	Diagnosis	ICD-10-CN
191.93	Unspecified hearing loss, bilateral	Diagnosis	ICD-10-CN
/53.2	Adjustment hearing aid	Procedure	ICD-9-CN
246.1	Encounter for fitting and adjustment of hearing aid	Procedure	ICD-10-PC
laundice			
774	Other perinatal jaundice	Diagnosis	ICD-9-CN
774.0	Perinatal jaundice from hereditary hemolytic anemias	Diagnosis	ICD-9-CN
74.1	Perinatal jaundice from other excessive hemolysis	Diagnosis	ICD-9-CN
74.2	Neonatal jaundice associated with preterm delivery	Diagnosis	ICD-9-CN
774.3	Neonatal jaundice due to delayed conjugation from other causes	Diagnosis	ICD-9-CN
74.30	Neonatal jaundice due to delayed conjugation, cause unspecified	Diagnosis	ICD-9-CN
74.31	Neonatal jaundice due to delayed conjugation in diseases classified elsewhere	Diagnosis	ICD-9-CN
74.39	Other neonatal jaundice due to delayed conjugation from other causes	Diagnosis	ICD-9-CN
74.4	Perinatal jaundice due to hepatocellular damage	Diagnosis	ICD-9-CN
774.5	Perinatal jaundice from other causes	Diagnosis	ICD-9-CN
774.6	Unspecified fetal and neonatal jaundice	Diagnosis	ICD-9-CN
P58.0	Neonatal jaundice due to bruising	Diagnosis	ICD-10-CM
P58.1	Neonatal jaundice due to bleeding	Diagnosis	ICD-10-CM
P58.2	Neonatal jaundice due to infection	Diagnosis	ICD-10-CM
P58.3	Neonatal jaundice due to polycythemia	Diagnosis	ICD-10-CM
P58.41	Neonatal jaundice due to drugs or toxins transmitted from mother	Diagnosis	ICD-10-CM
P58.42	Neonatal jaundice due to drugs or toxins given to newborn	Diagnosis	ICD-10-CM
P58.5	Neonatal jaundice due to swallowed maternal blood	Diagnosis	ICD-10-CI
·58.8	Neonatal jaundice due to other specified excessive hemolysis	Diagnosis	ICD-10-CM
·58.9	Neonatal jaundice due to excessive hemolysis, unspecified	Diagnosis	ICD-10-CI
·59.0	Neonatal jaundice associated with preterm delivery	Diagnosis	ICD-10-CM
^{959.1}	Inspissated bile syndrome	Diagnosis	ICD-10-CM
·59.20	Neonatal jaundice from unspecified hepatocellular damage	Diagnosis	ICD-10-CI
P59.29	Neonatal jaundice from other hepatocellular damage	Diagnosis	ICD-10-C
^{259.3}	Neonatal jaundice from breast milk inhibitor	Diagnosis	ICD-10-CI
^{259.8}	Neonatal jaundice from other specified causes	Diagnosis	ICD-10-CM
p59.9	Neonatal jaundice, unspecified	Diagnosis	ICD-10-CN
Petechiae			
772.6	Fetal and neonatal cutaneous hemorrhage	Diagnosis	ICD-9-CN
782.7	Spontaneous ecchymoses	Diagnosis	ICD-9-CN
P54.5	Neonatal cutaneous hemorrhage	Diagnosis	ICD-10-CN
R23.3	Spontaneous ecchymoses	Diagnosis	ICD-10-CN



Code	Description	Code Category	Code Type
Hepatom	egaly		
573.1	Hepatitis in viral diseases classified elsewhere	Diagnosis	ICD-9-CM
789.1	Hepatomegaly	Diagnosis	ICD-9-CM
B25.1	Cytomegaloviral hepatitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Splenome	egaly		
289.51	Chronic congestive splenomegaly	Diagnosis	ICD-9-CM
289.53	Neutropenic splenomegaly	Diagnosis	ICD-9-CM
789.2	Splenomegaly	Diagnosis	ICD-9-CM
D73.2	Chronic congestive splenomegaly	Diagnosis	ICD-10-CM
D73.81	Neutropenic splenomegaly	Diagnosis	ICD-10-CM
R16.1	Splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Microcep	haly		
742.1	Microcephalus	Diagnosis	ICD-9-CM
Q02	Microcephaly	Diagnosis	ICD-10-CM
Thrombo	cytopenia		
287.3	Primary thrombocytopenia	Diagnosis	ICD-9-CM
287.30	Primary thrombocytopenia, unspecified	Diagnosis	ICD-9-CM
287.31	Immune thrombocytopenic purpura	Diagnosis	ICD-9-CM
287.33	Congenital and hereditary thrombocytopenic purpura	Diagnosis	ICD-9-CM
287.39	Other primary thrombocytopenia	Diagnosis	ICD-9-CM
287.4	Secondary thrombocytopenia	Diagnosis	ICD-9-CM
287.49	Other secondary thrombocytopenia	Diagnosis	ICD-9-CM
287.5	Unspecified thrombocytopenia	Diagnosis	ICD-9-CM
776.1	Transient neonatal thrombocytopenia	Diagnosis	ICD-9-CM
776.2	Disseminated intravascular coagulation in newborn	Diagnosis	ICD-9-CM
D69.42	Congenital and hereditary thrombocytopenia purpura	Diagnosis	ICD-10-CM
D69.49	Other primary thrombocytopenia	Diagnosis	ICD-10-CM
D69.51	Posttransfusion purpura	Diagnosis	ICD-10-CM
D69.59	Other secondary thrombocytopenia	Diagnosis	ICD-10-CM
D69.6	Thrombocytopenia, unspecified	Diagnosis	ICD-10-CM
P60	Disseminated intravascular coagulation of newborn	Diagnosis	ICD-10-CM
P61.0	Transient neonatal thrombocytopenia	Diagnosis	ICD-10-CM
Chorioret			
363.0	Focal chorioretinitis and focal retinochoroiditis	Diagnosis	ICD-9-CM
363.00	Unspecified focal chorioretinitis	Diagnosis	ICD-9-CM
363.01	Focal choroiditis and chorioretinitis, juxtapapillary	Diagnosis	ICD-9-CM
363.03	Focal choroiditis and chorioretinitis of other posterior pole	Diagnosis	ICD-9-CM
363.04	Focal choroiditis and chorioretinitis, peripheral	Diagnosis	ICD-9-CM
363.05	Focal retinitis and retinochoroiditis, juxtapapillary	Diagnosis	ICD-9-CM
363.06	Focal retinitis and retinochoroiditis, macular or paramacular	Diagnosis	ICD-9-CM
363.07	Focal retinitis and retinochoroiditis of other posterior pole	Diagnosis	ICD-9-CM
363.08	Focal retinitis and retinochoroiditis, peripheral	Diagnosis	ICD-9-CM



Code	Description	Code Category	Code Type
363.1	Disseminated chorioretinitis and disseminated retino-choroiditis	Diagnosis	ICD-9-CM
363.10	Unspecified disseminated chorioretinitis	Diagnosis	ICD-9-CM
363.11	Disseminated choroiditis and chorioretinitis, posterior pole	Diagnosis	ICD-9-CM
363.12	Disseminated choroiditis and chorioretinitis, peripheral	Diagnosis	ICD-9-CM
363.13	Disseminated choroiditis and chorioretinitis, generalized	Diagnosis	ICD-9-CM
363.14	Disseminated retinitis and retinochoroiditis, metastatic	Diagnosis	ICD-9-CM
363.15	Disseminated retinitis and retinochoroiditis, pigment epitheliopathy	Diagnosis	ICD-9-CM
363.2	Other and unspecified forms of chorioretinitis and retinochoroiditis	Diagnosis	ICD-9-CM
363.20	Unspecified chorioretinitis	Diagnosis	ICD-9-CM
363.21	Pars planitis	Diagnosis	ICD-9-CM
363.22	Harada's disease	Diagnosis	ICD-9-CM
363.3	Chorioretinal scars	Diagnosis	ICD-9-CM
363.30	Unspecified chorioretinal scar	Diagnosis	ICD-9-CM
363.31	Solar retinopathy	Diagnosis	ICD-9-CM
363.32	Other macular chorioretinal scars	Diagnosis	ICD-9-CM
363.33	Other chorioretinal scars of posterior pole	Diagnosis	ICD-9-CM
363.34	Peripheral chorioretinal scars	Diagnosis	ICD-9-CM
363.35	Disseminated chorioretinal scars	Diagnosis	ICD-9-CM
H30.0	Focal chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.00	Unspecified focal chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.001	Unspecified focal chorioretinal inflammation, right eye	Diagnosis	ICD-10-CM
H30.002	Unspecified focal chorioretinal inflammation, left eye	Diagnosis	ICD-10-CM
H30.003	Unspecified focal chorioretinal inflammation, bilateral	Diagnosis	ICD-10-CM
H30.009	Unspecified focal chorioretinal inflammation, unspecified eye	Diagnosis	ICD-10-CM
H30.01	Focal chorioretinal inflammation, juxtapapillary	Diagnosis	ICD-10-CM
H30.011	Focal chorioretinal inflammation, juxtapapillary, right eye	Diagnosis	ICD-10-CM
H30.012	Focal chorioretinal inflammation, juxtapapillary, left eye	Diagnosis	ICD-10-CM
H30.013	Focal chorioretinal inflammation, juxtapapillary, bilateral	Diagnosis	ICD-10-CM
H30.019	Focal chorioretinal inflammation, juxtapapillary, unspecified eye	Diagnosis	ICD-10-CM
H30.02	Focal chorioretinal inflammation of posterior pole	Diagnosis	ICD-10-CM
H30.021	Focal chorioretinal inflammation of posterior pole, right eye	Diagnosis	ICD-10-CM
H30.022	Focal chorioretinal inflammation of posterior pole, left eye	Diagnosis	ICD-10-CM
H30.023	Focal chorioretinal inflammation of posterior pole, bilateral	Diagnosis	ICD-10-CM
H30.029	Focal chorioretinal inflammation of posterior pole, unspecified eye	Diagnosis	ICD-10-CM
H30.03	Focal chorioretinal inflammation, peripheral	Diagnosis	ICD-10-CM
H30.031	Focal chorioretinal inflammation, peripheral, right eye	Diagnosis	ICD-10-CM
H30.032	Focal chorioretinal inflammation, peripheral, left eye	Diagnosis	ICD-10-CM
H30.033	Focal chorioretinal inflammation, peripheral, bilateral	Diagnosis	ICD-10-CM
H30.039	Focal chorioretinal inflammation, peripheral, unspecified eye	Diagnosis	ICD-10-CM
H30.04	Focal chorioretinal inflammation, macular or paramacular	Diagnosis	ICD-10-CM
H30.041	Focal chorioretinal inflammation, macular or paramacular, right eye	Diagnosis	ICD-10-CM
H30.042	Focal chorioretinal inflammation, macular or paramacular, left eye	Diagnosis	ICD-10-CM
H30.043	Focal chorioretinal inflammation, macular or paramacular, bilateral	Diagnosis	ICD-10-CM
H30.049	Focal chorioretinal inflammation, macular or paramacular, unspecified eye	Diagnosis	ICD-10-CM
H30.1	Disseminated chorioretinal inflammation	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
H30.10	Unspecified disseminated chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.101	Unspecified disseminated chorioretinal inflammation, right eye	Diagnosis	ICD-10-CM
H30.102	Unspecified disseminated chorioretinal inflammation, left eye	Diagnosis	ICD-10-CM
H30.103	Unspecified disseminated chorioretinal inflammation, bilateral	Diagnosis	ICD-10-CM
H30.109	Unspecified disseminated chorioretinal inflammation, unspecified eye	Diagnosis	ICD-10-CM
H30.11	Disseminated chorioretinal inflammation of posterior pole	Diagnosis	ICD-10-CM
H30.111	Disseminated chorioretinal inflammation of posterior pole, right eye	Diagnosis	ICD-10-CM
H30.112	Disseminated chorioretinal inflammation of posterior pole, left eye	Diagnosis	ICD-10-CM
H30.113	Disseminated chorioretinal inflammation of posterior pole, bilateral	Diagnosis	ICD-10-CM
H30.119	Disseminated chorioretinal inflammation of posterior pole, unspecified eye	Diagnosis	ICD-10-CM
H30.12	Disseminated chorioretinal inflammation, peripheral	Diagnosis	ICD-10-CM
H30.121	Disseminated chorioretinal inflammation, peripheral right eye	Diagnosis	ICD-10-CM
H30.122	Disseminated chorioretinal inflammation, peripheral, left eye	Diagnosis	ICD-10-CM
H30.123	Disseminated chorioretinal inflammation, peripheral, bilateral	Diagnosis	ICD-10-CM
H30.129	Disseminated chorioretinal inflammation, peripheral, unspecified eye	Diagnosis	ICD-10-CM
H30.13	Disseminated chorioretinal inflammation, generalized	Diagnosis	ICD-10-CM
H30.131	Disseminated chorioretinal inflammation, generalized, right eye	Diagnosis	ICD-10-CM
H30.132	Disseminated chorioretinal inflammation, generalized, left eye	Diagnosis	ICD-10-CM
H30.133	Disseminated chorioretinal inflammation, generalized, bilateral	Diagnosis	ICD-10-CM
H30.139	Disseminated chorioretinal inflammation, generalized, unspecified eye	Diagnosis	ICD-10-CM
H30.14	Acute posterior multifocal placoid pigment epitheliopathy	Diagnosis	ICD-10-CM
H30.141	Acute posterior multifocal placoid pigment epitheliopathy, right eye	Diagnosis	ICD-10-CM
H30.142	Acute posterior multifocal placoid pigment epitheliopathy, left eye	Diagnosis	ICD-10-CM
H30.143	Acute posterior multifocal placoid pigment epitheliopathy, bilateral	Diagnosis	ICD-10-CM
H30.149	Acute posterior multifocal placoid pigment epitheliopathy, unspecified eye	Diagnosis	ICD-10-CM
H30.89	Other chorioretinal inflammations	Diagnosis	ICD-10-CM
H30.891	Other chorioretinal inflammations, right eye	Diagnosis	ICD-10-CM
H30.892	Other chorioretinal inflammations, left eye	Diagnosis	ICD-10-CM
H30.893	Other chorioretinal inflammations, bilateral	Diagnosis	ICD-10-CM
H30.899	Other chorioretinal inflammations, unspecified eye	Diagnosis	ICD-10-CM
H30.9	Unspecified chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.90	Unspecified chorioretinal inflammation, unspecified eye	Diagnosis	ICD-10-CM
H30.91	Unspecified chorioretinal inflammation, right eye	Diagnosis	ICD-10-CM
H30.92	Unspecified chorioretinal inflammation, left eye	Diagnosis	ICD-10-CM
H30.93	Unspecified chorioretinal inflammation, bilateral	Diagnosis	ICD-10-CM
H31.00	Unspecified chorioretinal scars	Diagnosis	ICD-10-CM
H31.001	Unspecified chorioretinal scars, right eye	Diagnosis	ICD-10-CM
H31.002	Unspecified chorioretinal scars, left eye	Diagnosis	ICD-10-CM
H31.003	Unspecified chorioretinal scars, bilateral	Diagnosis	ICD-10-CM
H31.009	Unspecified chorioretinal scars, unspecified eye	Diagnosis	ICD-10-CM
H31.011	Macula scars of posterior pole (postinflammatory) (post-traumatic), right eye	Diagnosis	ICD-10-CM
H31.012	Macula scars of posterior pole (postinflammatory) (post-traumatic), left eye	Diagnosis	ICD-10-CM
H31.013	Macula scars of posterior pole (postinflammatory) (post-traumatic), bilateral	Diagnosis	ICD-10-CM
H31.019	Macula scars of posterior pole (postinflammatory) (post-traumatic), unspecified eye	Diagnosis	ICD-10-CM
H31.021	Solar retinopathy, right eye	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
H31.022	Solar retinopathy, left eye	Diagnosis	ICD-10-CM
H31.023	Solar retinopathy, bilateral	Diagnosis	ICD-10-CM
H31.029	Solar retinopathy, unspecified eye	Diagnosis	ICD-10-CM
H31.091	Other chorioretinal scars, right eye	Diagnosis	ICD-10-CM
H31.092	Other chorioretinal scars, left eye	Diagnosis	ICD-10-CM
H31.093	Other chorioretinal scars, bilateral	Diagnosis	ICD-10-CM
H31.099	Other chorioretinal scars, unspecified eye	Diagnosis	ICD-10-CM
Brain Abn	ormality		
330.3	Cerebral degeneration of childhood in other diseases classified elsewhere	Diagnosis	ICD-9-CM
331.3	Communicating hydrocephalus	Diagnosis	ICD-9-CM
331.4	Obstructive hydrocephalus	Diagnosis	ICD-9-CM
331.5	Idiopathic normal pressure hydrocephalus [INPH]	Diagnosis	ICD-9-CM
331.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CM
348.89	Other conditions of brain	Diagnosis	ICD-9-CM
348.9	Unspecified condition of brain	Diagnosis	ICD-9-CM
742.2	Congenital reduction deformities of brain	Diagnosis	ICD-9-CM
742.3	Congenital hydrocephalus	Diagnosis	ICD-9-CM
742.4	Other specified congenital anomalies of brain	Diagnosis	ICD-9-CM
742.9	Unspecified congenital anomaly of brain, spinal cord, and nervous system	Diagnosis	ICD-9-CM
793.0	Nonspecific (abnormal) findings on radiological and other examination of skull and head	Diagnosis	ICD-9-CM
G91.0	Communicating hydrocephalus	Diagnosis	ICD-10-CM
G91.1	Obstructive hydrocephalus	Diagnosis	ICD-10-CM
G91.2	(Idiopathic) normal pressure hydrocephalus	Diagnosis	ICD-10-CM
G91.4	Hydrocephalus in diseases classified elsewhere	Diagnosis	ICD-10-CM
G91.8	Other hydrocephalus	Diagnosis	ICD-10-CM
G91.9	Hydrocephalus, unspecified	Diagnosis	ICD-10-CM
G93.89	Other specified disorders of brain	Diagnosis	ICD-10-CM
G93.9	Disorder of brain, unspecified	Diagnosis	ICD-10-CM
Q03.8	Other congenital hydrocephalus	Diagnosis	ICD-10-CM
Q03.9	Congenital hydrocephalus, unspecified	Diagnosis	ICD-10-CM
Q04.0	Congenital malformations of corpus callosum	Diagnosis	ICD-10-CM
Q04.3	Other reduction deformities of brain	Diagnosis	ICD-10-CM
Q04.4	Septo-optic dysplasia of brain	Diagnosis	ICD-10-CM
Q04.5	Megalencephaly	Diagnosis	ICD-10-CM
Q04.6	Congenital cerebral cysts	Diagnosis	ICD-10-CM
Q04.8	Other specified congenital malformations of brain	Diagnosis	ICD-10-CM
Q04.9	Congenital malformation of brain, unspecified	Diagnosis	ICD-10-CM
R90.82	White matter disease, unspecified	Diagnosis	ICD-10-CM
R93.0	Abnormal findings on diagnostic imaging of skull and head, not elsewhere classified	Diagnosis	ICD-10-CM
	in Abnormality	- 35110313	
G91.3	Post-traumatic hydrocephalus, unspecified	Diagnosis	ICD-10-CM
Q03.0	Malformations of aqueduct of Sylvius	Diagnosis	ICD-10-CM
Q03.1	Atresia of foramina of Magendie and Luschka	Diagnosis	ICD-10-CM
Q04.1	Arhinencephaly	Diagnosis	ICD-10-CM
Q04.2	Holoprosencephaly	Diagnosis	ICD-10-CM



Appendix E. List of Current Procedural Terminology, Fourth Edition (CPT-4), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Inclusion and Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Cytomeg	alovirus Infection (CMV)		
078.5	Cytomegaloviral disease	Diagnosis	ICD-9-CM
B25.0	Cytomegaloviral pneumonitis	Diagnosis	ICD-10-CM
B25.1	Cytomegaloviral hepatitis	Diagnosis	ICD-10-CM
B25.2	Cytomegaloviral pancreatitis	Diagnosis	ICD-10-CM
B25.8	Other cytomegaloviral diseases	Diagnosis	ICD-10-CM
B25.9	Cytomegaloviral disease, unspecified	Diagnosis	ICD-10-CM
Congenit	al Cytomegalovirus (cCMV)		
771.1	Congenital cytomegalovirus infection	Diagnosis	ICD-9-CM
P35.1	Congenital cytomegalovirus infection	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
Hearing L	oss		
388.01	Presbyacusis	Diagnosis	ICD-9-CM
388.2	Unspecified sudden hearing loss	Diagnosis	ICD-9-CM
389.1	Sensorineural hearing loss	Diagnosis	ICD-9-CM
389.10	Unspecified sensorineural hearing loss	Diagnosis	ICD-9-CM
389.11	Sensory hearing loss, bilateral	Diagnosis	ICD-9-CM
389.12	Neural hearing loss, bilateral	Diagnosis	ICD-9-CM
389.13	Neural hearing loss, unilateral	Diagnosis	ICD-9-CM
389.14	Central hearing loss	Diagnosis	ICD-9-CM
389.15	Sensorineural hearing loss, unilateral	Diagnosis	ICD-9-CM
389.16	Sensorineural hearing loss, asymmetrical	Diagnosis	ICD-9-CM
389.17	Sensory hearing loss, unilateral	Diagnosis	ICD-9-CM
389.18	Sensorineural hearing loss, bilateral	Diagnosis	ICD-9-CM
389.2	Mixed conductive and sensorineural hearing loss	Diagnosis	ICD-9-CM
389.20	Mixed hearing loss, unspecified	Diagnosis	ICD-9-CM
389.21	Mixed hearing loss, unilateral	Diagnosis	ICD-9-CM
389.22	Mixed hearing loss, bilateral	Diagnosis	ICD-9-CM
389.7	Deaf, nonspeaking, not elsewhere classifiable	Diagnosis	ICD-9-CM
389.8	Other specified forms of hearing loss	Diagnosis	ICD-9-CM
389.9	Unspecified hearing loss	Diagnosis	ICD-9-CM
69710	IMPLANT/REPLACE HEARING AID	Procedure	CPT-4
69930	IMPLANT COCHLEAR DEVICE	Procedure	CPT-4
92510	AURAL REHABILITATION FOLLOWING COCHLEAR IMPLANT (INCLUDES EVALUATION OF	Procedure	CPT-4
	AURAL REHABILITATION STATUS		
92601	COCHLEAR IMPLT F/UP EXAM <7	Procedure	CPT-4
92602	REPROGRAM COCHLEAR IMPLT <7	Procedure	CPT-4
92630	AUD REHAB PRE-LING HEAR LOSS	Procedure	CPT-4
92633	AUD REHAB POSTLING HEAR LOSS	Procedure	CPT-4
95.48	Fitting of hearing aid	Procedure	ICD-9-CM
	Tinnitus Masker Device Fitting using Hearing Aid Selection / Fitting / Test Equipment	Procedure	ICD-10-PCS
	Tinnitus Masker Device Fitting	Procedure	ICD-10-PCS
	Monaural Hearing Aid Device Fitting using Audiometer	Procedure	ICD-10-PCS
	Monaural Hearing Aid Device Fitting using Sound Field / Booth	Procedure	ICD-10-PCS
	Monaural Hearing Aid Device Fitting using Hearing Aid Selection / Fitting / Test Equipment		ICD-10-PCS
	Monaural Hearing Aid Device Fitting using Audiovisual Equipment	Procedure	ICD-10-PCS
ODZ1LZ	Monaural Hearing Aid Device Fitting using Assistive Listening Equipment	Procedure	ICD-10-PCS
FODZ1ZZ	Monaural Hearing Aid Device Fitting	Procedure	ICD-10-PCS
F0DZ21Z	Binaural Hearing Aid Device Fitting using Audiometer	Procedure	ICD-10-PCS
=0DZ22Z	Binaural Hearing Aid Device Fitting using Sound Field / Booth	Procedure	ICD-10-PCS
FODZ25Z	Binaural Hearing Aid Device Fitting using Hearing Aid Selection / Fitting / Test Equipment	Procedure	ICD-10-PCS
FODZ2KZ	Binaural Hearing Aid Device Fitting using Audiovisual Equipment	Procedure	ICD-10-PCS
FODZ2LZ	Binaural Hearing Aid Device Fitting using Assistive Listening Equipment	Procedure	ICD-10-PCS
FODZ2ZZ	Binaural Hearing Aid Device Fitting	Procedure	ICD-10-PCS



Code	Description	Code Category	Code Type
F0DZ51Z	Assistive Listening Device Device Fitting using Audiometer	Procedure	ICD-10-PCS
F0DZ52Z	Assistive Listening Device Device Fitting using Sound Field / Booth	Procedure	ICD-10-PCS
F0DZ55Z	Assistive Listening Device Device Fitting using Hearing Aid Selection / Fitting / Test Equipme	Procedure	ICD-10-PCS
F0DZ5KZ	Assistive Listening Device Device Fitting using Audiovisual Equipment	Procedure	ICD-10-PCS
F0DZ5LZ	Assistive Listening Device Device Fitting using Assistive Listening Equipment	Procedure	ICD-10-PCS
F0DZ5ZZ	Assistive Listening Device Device Fitting	Procedure	ICD-10-PCS
H90.3	Sensorineural hearing loss, bilateral	Diagnosis	ICD-10-CM
H90.4	Sensorineural hearing loss, unilateral with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.41	Sensorineural hearing loss, unilateral, right ear, with unrestricted hearing on the contralate	Diagnosis	ICD-10-CM
H90.42	Sensorineural hearing loss, unilateral, left ear, with unrestricted hearing on the contralater	Diagnosis	ICD-10-CM
H90.5	Unspecified sensorineural hearing loss	Diagnosis	ICD-10-CM
H90.6	Mixed conductive and sensorineural hearing loss, bilateral	Diagnosis	ICD-10-CM
H90.7	Mixed conductive and sensorineural hearing loss, unilateral with unrestricted hearing on tl	Diagnosis	ICD-10-CM
H90.71	Mixed conductive and sensorineural hearing loss, unilateral, right ear, with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.72	Mixed conductive and sensorineural hearing loss, unilateral, left ear, with unrestricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.8	Mixed conductive and sensorineural hearing loss, unspecified	Diagnosis	ICD-10-CM
H90.A21	Sensorineural hearing loss, unilateral, right ear, with restricted hearing on the	Diagnosis	ICD-10-CM
	contralateral side		
H90.A22	Sensorineural hearing loss, unilateral, left ear, with restricted hearing on the contralateral side	Diagnosis	ICD-10-CM
H90.A31	Mixed conductive and sensorineural hearing loss, unilateral, right ear with restricted	Diagnosis	ICD-10-CM
	hearing on the contralateral side	-	
H90.A32	Mixed conductive and sensorineural hearing loss, unilateral, left ear with restricted hearing	Diagnosis	ICD-10-CM
H91.0	Ototoxic hearing loss	Diagnosis	ICD-10-CM
H91.01	Ototoxic hearing loss, right ear	Diagnosis	ICD-10-CM
H91.02	Ototoxic hearing loss, left ear	Diagnosis	ICD-10-CM
H91.03	Ototoxic hearing loss, bilateral	Diagnosis	ICD-10-CM
H91.09	Ototoxic hearing loss, unspecified ear	Diagnosis	ICD-10-CM
H91.1	Presbycusis	Diagnosis	ICD-10-CM
H91.10	Presbycusis, unspecified ear	Diagnosis	ICD-10-CM
H91.11	Presbycusis, right ear	Diagnosis	ICD-10-CM
H91.12	Presbycusis, left ear	Diagnosis	ICD-10-CM
H91.13	Presbycusis, bilateral	Diagnosis	ICD-10-CM
H91.2	Sudden idiopathic hearing loss	Diagnosis	ICD-10-CM
H91.20	Sudden idiopathic hearing loss, unspecified ear	Diagnosis	ICD-10-CM
H91.21	Sudden idiopathic hearing loss, right ear	Diagnosis	ICD-10-CM
H91.22	Sudden idiopathic hearing loss, left ear	Diagnosis	ICD-10-CM
H91.23	Sudden idiopathic hearing loss, bilateral	Diagnosis	ICD-10-CM
H91.3	Deaf nonspeaking, not elsewhere classified	Diagnosis	ICD-10-CM
H91.8	Other specified hearing loss	Diagnosis	ICD-10-CM
H91.8X	Other specified hearing loss	Diagnosis	ICD-10-CM
H91.8X1	Other specified hearing loss, right ear	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
191.8X2	Other specified hearing loss, left ear	Diagnosis	ICD-10-CM
191.8X3	Other specified hearing loss, bilateral	Diagnosis	ICD-10-CM
191.8X9	Other specified hearing loss, unspecified ear	Diagnosis	ICD-10-CM
1 91.9	Unspecified hearing loss	Diagnosis	ICD-10-CN
1 91.90	Unspecified hearing loss, unspecified ear	Diagnosis	ICD-10-CN
1 91.91	Unspecified hearing loss, right ear	Diagnosis	ICD-10-CN
191.92	Unspecified hearing loss, left ear	Diagnosis	ICD-10-CN
191.93	Unspecified hearing loss, bilateral	Diagnosis	ICD-10-CM
/53.2	Adjustment hearing aid	Procedure	ICD-9-CM
246.1	Encounter for fitting and adjustment of hearing aid	Procedure	ICD-10-PCS
aundice			
74	Other perinatal jaundice	Diagnosis	ICD-9-CM
774.0	Perinatal jaundice from hereditary hemolytic anemias	Diagnosis	ICD-9-CM
774.1	Perinatal jaundice from other excessive hemolysis	Diagnosis	ICD-9-CM
74.2	Neonatal jaundice associated with preterm delivery	Diagnosis	ICD-9-CM
74.3	Neonatal jaundice due to delayed conjugation from other causes	Diagnosis	ICD-9-CM
74.30	Neonatal jaundice due to delayed conjugation, cause unspecified	Diagnosis	ICD-9-CM
74.31	Neonatal jaundice due to delayed conjugation in diseases classified elsewhere	Diagnosis	ICD-9-CM
74.39	Other neonatal jaundice due to delayed conjugation from other causes	Diagnosis	ICD-9-CM
74.4	Perinatal jaundice due to hepatocellular damage	Diagnosis	ICD-9-CM
74.5	Perinatal jaundice from other causes	Diagnosis	ICD-9-CM
74.6	Unspecified fetal and neonatal jaundice	Diagnosis	ICD-9-CM
·58.0	Neonatal jaundice due to bruising	Diagnosis	ICD-10-CN
P58.1	Neonatal jaundice due to bleeding	Diagnosis	ICD-10-CN
·58.2	Neonatal jaundice due to infection	Diagnosis	ICD-10-CN
·58.3	Neonatal jaundice due to polycythemia	Diagnosis	ICD-10-CN
⁹ 58.41	Neonatal jaundice due to drugs or toxins transmitted from mother	Diagnosis	ICD-10-CN
^{58.42}	Neonatal jaundice due to drugs or toxins given to newborn	Diagnosis	ICD-10-CN
P58.5	Neonatal jaundice due to swallowed maternal blood	Diagnosis	ICD-10-CN
58.8	Neonatal jaundice due to other specified excessive hemolysis	Diagnosis	ICD-10-CN
58.9	Neonatal jaundice due to excessive hemolysis, unspecified	Diagnosis	ICD-10-CN
·59.0	Neonatal jaundice associated with preterm delivery	Diagnosis	ICD-10-CN
^{959.1}	Inspissated bile syndrome	Diagnosis	ICD-10-CN
^{59.20}	Neonatal jaundice from unspecified hepatocellular damage	Diagnosis	ICD-10-CN
·59.29	Neonatal jaundice from other hepatocellular damage	Diagnosis	ICD-10-CN
59.3	Neonatal jaundice from breast milk inhibitor	Diagnosis	ICD-10-CN
·59.8	Neonatal jaundice from other specified causes	Diagnosis	ICD-10-CN
59.9	Neonatal jaundice, unspecified	Diagnosis	ICD-10-CN
Petechiae	<u> </u>		
72.6	Fetal and neonatal cutaneous hemorrhage	Diagnosis	ICD-9-CM
82.7	Spontaneous ecchymoses	Diagnosis	ICD-9-CM
P54.5	Neonatal cutaneous hemorrhage	Diagnosis	ICD-10-CN
23.3	Spontaneous ecchymoses	Diagnosis	ICD-10-CN



Code	Description	Code Category	Code Type
573.1	Hepatitis in viral diseases classified elsewhere	Diagnosis	ICD-9-CM
789.1	Hepatomegaly	Diagnosis	ICD-9-CM
B25.1	Cytomegaloviral hepatitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Splenom	egaly		
289.51	Chronic congestive splenomegaly	Diagnosis	ICD-9-CM
289.53	Neutropenic splenomegaly	Diagnosis	ICD-9-CM
789.2	Splenomegaly	Diagnosis	ICD-9-CM
D73.2	Chronic congestive splenomegaly	Diagnosis	ICD-10-CM
D73.81	Neutropenic splenomegaly	Diagnosis	ICD-10-CM
R16.1	Splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Microce	phaly		
742.1	Microcephalus	Diagnosis	ICD-9-CM
Q02	Microcephaly	Diagnosis	ICD-10-CM
Thrombo	ocytopenia		
287.3	Primary thrombocytopenia	Diagnosis	ICD-9-CM
287.30	Primary thrombocytopenia, unspecified	Diagnosis	ICD-9-CM
287.31	Immune thrombocytopenic purpura	Diagnosis	ICD-9-CM
287.33	Congenital and hereditary thrombocytopenic purpura	Diagnosis	ICD-9-CM
287.39	Other primary thrombocytopenia	Diagnosis	ICD-9-CM
287.4	Secondary thrombocytopenia	Diagnosis	ICD-9-CM
287.49	Other secondary thrombocytopenia	Diagnosis	ICD-9-CM
287.5	Unspecified thrombocytopenia	Diagnosis	ICD-9-CM
776.1	Transient neonatal thrombocytopenia	Diagnosis	ICD-9-CM
776.2	Disseminated intravascular coagulation in newborn	Diagnosis	ICD-9-CM
D69.42	Congenital and hereditary thrombocytopenia purpura	Diagnosis	ICD-10-CM
D69.49	Other primary thrombocytopenia	Diagnosis	ICD-10-CM
D69.51	Posttransfusion purpura	Diagnosis	ICD-10-CM
D69.59	Other secondary thrombocytopenia	Diagnosis	ICD-10-CM
D69.6	Thrombocytopenia, unspecified	Diagnosis	ICD-10-CM
P60	Disseminated intravascular coagulation of newborn	Diagnosis	ICD-10-CM
P61.0	Transient neonatal thrombocytopenia	Diagnosis	ICD-10-CM
Choriore	tinitis		
363.0	Focal chorioretinitis and focal retinochoroiditis	Diagnosis	ICD-9-CM
363.00	Unspecified focal chorioretinitis	Diagnosis	ICD-9-CM
363.01	Focal choroiditis and chorioretinitis, juxtapapillary	Diagnosis	ICD-9-CM
363.03	Focal choroiditis and chorioretinitis of other posterior pole	Diagnosis	ICD-9-CM
363.04	Focal choroiditis and chorioretinitis, peripheral	Diagnosis	ICD-9-CM
363.05	Focal retinitis and retinochoroiditis, juxtapapillary	Diagnosis	ICD-9-CM
363.06	Focal retinitis and retinochoroiditis, macular or paramacular	Diagnosis	ICD-9-CM
363.07	Focal retinitis and retinochoroiditis of other posterior pole	Diagnosis	ICD-9-CM
-	Focal retinitis and retinochoroiditis, peripheral	Diagnosis	ICD-9-CM



Code	Description	Code Category	Code Type
363.1	Disseminated chorioretinitis and disseminated retino-choroiditis	Diagnosis	ICD-9-CM
363.10	Unspecified disseminated chorioretinitis	Diagnosis	ICD-9-CM
363.11	Disseminated choroiditis and chorioretinitis, posterior pole	Diagnosis	ICD-9-CM
363.12	Disseminated choroiditis and chorioretinitis, peripheral	Diagnosis	ICD-9-CM
363.13	Disseminated choroiditis and chorioretinitis, generalized	Diagnosis	ICD-9-CM
363.14	Disseminated retinitis and retinochoroiditis, metastatic	Diagnosis	ICD-9-CM
363.15	Disseminated retinitis and retinochoroiditis, pigment epitheliopathy	Diagnosis	ICD-9-CM
363.2	Other and unspecified forms of chorioretinitis and retinochoroiditis	Diagnosis	ICD-9-CM
363.20	Unspecified chorioretinitis	Diagnosis	ICD-9-CM
363.21	Pars planitis	Diagnosis	ICD-9-CM
363.22	Harada's disease	Diagnosis	ICD-9-CM
363.3	Chorioretinal scars	Diagnosis	ICD-9-CM
363.30	Unspecified chorioretinal scar	Diagnosis	ICD-9-CM
363.31	Solar retinopathy	Diagnosis	ICD-9-CM
363.32	Other macular chorioretinal scars	Diagnosis	ICD-9-CM
363.33	Other chorioretinal scars of posterior pole	Diagnosis	ICD-9-CM
363.34	Peripheral chorioretinal scars	Diagnosis	ICD-9-CM
363.35	Disseminated chorioretinal scars	Diagnosis	ICD-9-CM
H30.0	Focal chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.00	Unspecified focal chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.001	Unspecified focal chorioretinal inflammation, right eye	Diagnosis	ICD-10-CM
H30.002	Unspecified focal chorioretinal inflammation, left eye	Diagnosis	ICD-10-CM
H30.003	Unspecified focal chorioretinal inflammation, bilateral	Diagnosis	ICD-10-CM
H30.009	Unspecified focal chorioretinal inflammation, unspecified eye	Diagnosis	ICD-10-CM
H30.01	Focal chorioretinal inflammation, juxtapapillary	Diagnosis	ICD-10-CM
H30.011	Focal chorioretinal inflammation, juxtapapillary, right eye	Diagnosis	ICD-10-CM
H30.012	Focal chorioretinal inflammation, juxtapapillary, left eye	Diagnosis	ICD-10-CM
H30.013	Focal chorioretinal inflammation, juxtapapillary, bilateral	Diagnosis	ICD-10-CM
H30.019	Focal chorioretinal inflammation, juxtapapillary, unspecified eye	Diagnosis	ICD-10-CM
H30.02	Focal chorioretinal inflammation of posterior pole	Diagnosis	ICD-10-CM
H30.021	Focal chorioretinal inflammation of posterior pole, right eye	Diagnosis	ICD-10-CM
H30.022	Focal chorioretinal inflammation of posterior pole, left eye	Diagnosis	ICD-10-CM
H30.023	Focal chorioretinal inflammation of posterior pole, bilateral	Diagnosis	ICD-10-CM
H30.029	Focal chorioretinal inflammation of posterior pole, unspecified eye	Diagnosis	ICD-10-CM
H30.03	Focal chorioretinal inflammation, peripheral	Diagnosis	ICD-10-CM
H30.031	Focal chorioretinal inflammation, peripheral, right eye	Diagnosis	ICD-10-CM
H30.032	Focal chorioretinal inflammation, peripheral, left eye	Diagnosis	ICD-10-CM
H30.033	Focal chorioretinal inflammation, peripheral, bilateral	Diagnosis	ICD-10-CM
H30.039	Focal chorioretinal inflammation, peripheral, unspecified eye	Diagnosis	ICD-10-CM
H30.04	Focal chorioretinal inflammation, macular or paramacular	Diagnosis	ICD-10-CM
H30.041	Focal chorioretinal inflammation, macular or paramacular, right eye	Diagnosis	ICD-10-CM
H30.042	Focal chorioretinal inflammation, macular or paramacular, left eye	Diagnosis	ICD-10-CM
H30.043	Focal chorioretinal inflammation, macular or paramacular, bilateral	Diagnosis	ICD-10-CM
H30.049	Focal chorioretinal inflammation, macular or paramacular, unspecified eye	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
H30.1	Disseminated chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.10	Unspecified disseminated chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.101	Unspecified disseminated chorioretinal inflammation, right eye	Diagnosis	ICD-10-CM
H30.102	Unspecified disseminated chorioretinal inflammation, left eye	Diagnosis	ICD-10-CM
H30.103	Unspecified disseminated chorioretinal inflammation, bilateral	Diagnosis	ICD-10-CM
H30.109	Unspecified disseminated chorioretinal inflammation, unspecified eye	Diagnosis	ICD-10-CM
H30.11	Disseminated chorioretinal inflammation of posterior pole	Diagnosis	ICD-10-CM
H30.111	Disseminated chorioretinal inflammation of posterior pole, right eye	Diagnosis	ICD-10-CM
H30.112	Disseminated chorioretinal inflammation of posterior pole, left eye	Diagnosis	ICD-10-CM
H30.113	Disseminated chorioretinal inflammation of posterior pole, bilateral	Diagnosis	ICD-10-CM
H30.119	Disseminated chorioretinal inflammation of posterior pole, unspecified eye	Diagnosis	ICD-10-CM
H30.12	Disseminated chorioretinal inflammation, peripheral	Diagnosis	ICD-10-CM
H30.121	Disseminated chorioretinal inflammation, peripheral right eye	Diagnosis	ICD-10-CM
H30.122	Disseminated chorioretinal inflammation, peripheral, left eye	Diagnosis	ICD-10-CM
H30.123	Disseminated chorioretinal inflammation, peripheral, bilateral	Diagnosis	ICD-10-CM
H30.129	Disseminated chorioretinal inflammation, peripheral, unspecified eye	Diagnosis	ICD-10-CM
H30.13	Disseminated chorioretinal inflammation, generalized	Diagnosis	ICD-10-CM
H30.131	Disseminated chorioretinal inflammation, generalized, right eye	Diagnosis	ICD-10-CM
H30.132	Disseminated chorioretinal inflammation, generalized, left eye	Diagnosis	ICD-10-CM
H30.133	Disseminated chorioretinal inflammation, generalized, bilateral	Diagnosis	ICD-10-CM
H30.139	Disseminated chorioretinal inflammation, generalized, unspecified eye	Diagnosis	ICD-10-CM
H30.14	Acute posterior multifocal placoid pigment epitheliopathy	Diagnosis	ICD-10-CM
H30.141	Acute posterior multifocal placoid pigment epitheliopathy, right eye	Diagnosis	ICD-10-CM
H30.142	Acute posterior multifocal placoid pigment epitheliopathy, left eye	Diagnosis	ICD-10-CM
H30.143	Acute posterior multifocal placoid pigment epitheliopathy, bilateral	Diagnosis	ICD-10-CM
H30.149	Acute posterior multifocal placoid pigment epitheliopathy, unspecified eye	Diagnosis	ICD-10-CM
H30.89	Other chorioretinal inflammations	Diagnosis	ICD-10-CM
H30.891	Other chorioretinal inflammations, right eye	Diagnosis	ICD-10-CM
H30.892	Other chorioretinal inflammations, left eye	Diagnosis	ICD-10-CM
H30.893	Other chorioretinal inflammations, bilateral	Diagnosis	ICD-10-CM
H30.899	Other chorioretinal inflammations, unspecified eye	Diagnosis	ICD-10-CM
H30.9	Unspecified chorioretinal inflammation	Diagnosis	ICD-10-CM
H30.90	Unspecified chorioretinal inflammation, unspecified eye	Diagnosis	ICD-10-CM
H30.91	Unspecified chorioretinal inflammation, right eye	Diagnosis	ICD-10-CM
H30.92	Unspecified chorioretinal inflammation, left eye	Diagnosis	ICD-10-CM
H30.93	Unspecified chorioretinal inflammation, bilateral	Diagnosis	ICD-10-CM
H31.00	Unspecified chorioretinal scars	Diagnosis	ICD-10-CM
H31.001	Unspecified chorioretinal scars, right eye	Diagnosis	ICD-10-CM
H31.002	Unspecified chorioretinal scars, left eye	Diagnosis	ICD-10-CM
H31.003	Unspecified chorioretinal scars, bilateral	Diagnosis	ICD-10-CM
H31.009	Unspecified chorioretinal scars, unspecified eye	Diagnosis	ICD-10-CM
H31.011	Macula scars of posterior pole (postinflammatory) (post-traumatic), right eye	Diagnosis	ICD-10-CM
H31.011	Macula scars of posterior pole (postinianinatory) (post-traumatic), left eye	Diagnosis	ICD-10-CM
H31.012	Macula scars of posterior pole (postinflammatory) (post-traumatic), lett eye	Diagnosis	ICD-10-CM



Code	Description	Code Category	Code Type
H31.019	Macula scars of posterior pole (postinflammatory) (post-traumatic), unspecified eye	Diagnosis	ICD-10-CN
H31.021	Solar retinopathy, right eye	Diagnosis	ICD-10-CN
131.022	Solar retinopathy, left eye	Diagnosis	ICD-10-CN
131.023	Solar retinopathy, bilateral	Diagnosis	ICD-10-CN
131.029	Solar retinopathy, unspecified eye	Diagnosis	ICD-10-CN
131.091	Other chorioretinal scars, right eye	Diagnosis	ICD-10-CN
131.092	Other chorioretinal scars, left eye	Diagnosis	ICD-10-CN
131.093	Other chorioretinal scars, bilateral	Diagnosis	ICD-10-CN
131.099	Other chorioretinal scars, unspecified eye	Diagnosis	ICD-10-CN
Brain Abr	ormality		
30.3	Cerebral degeneration of childhood in other diseases classified elsewhere	Diagnosis	ICD-9-CM
331.3	Communicating hydrocephalus	Diagnosis	ICD-9-CM
31.4	Obstructive hydrocephalus	Diagnosis	ICD-9-CM
31.5	Idiopathic normal pressure hydrocephalus [INPH]	Diagnosis	ICD-9-CM
31.7	Cerebral degeneration in diseases classified elsewhere	Diagnosis	ICD-9-CN
48.89	Other conditions of brain	Diagnosis	ICD-9-CN
48.9	Unspecified condition of brain	Diagnosis	ICD-9-CN
42.2	Congenital reduction deformities of brain	Diagnosis	ICD-9-CN
42.3	Congenital hydrocephalus	Diagnosis	ICD-9-CN
42.4	Other specified congenital anomalies of brain	Diagnosis	ICD-9-CN
42.9	Unspecified congenital anomaly of brain, spinal cord, and nervous system	Diagnosis	ICD-9-CN
93.0	Nonspecific (abnormal) findings on radiological and other examination of skull and head	Diagnosis	ICD-9-CN
691.0	Communicating hydrocephalus	Diagnosis	ICD-10-CN
691.1	Obstructive hydrocephalus	Diagnosis	ICD-10-CN
691.2	(Idiopathic) normal pressure hydrocephalus	Diagnosis	ICD-10-CN
691.4	Hydrocephalus in diseases classified elsewhere	Diagnosis	ICD-10-CN
i91.8	Other hydrocephalus	Diagnosis	ICD-10-CN
691.9	Hydrocephalus, unspecified	Diagnosis	ICD-10-CN
693.89	Other specified disorders of brain	Diagnosis	ICD-10-CN
693.9	Disorder of brain, unspecified	Diagnosis	ICD-10-CN
203.8	Other congenital hydrocephalus	Diagnosis	ICD-10-CN
203.9	Congenital hydrocephalus, unspecified	Diagnosis	ICD-10-CN
204.0	Congenital malformations of corpus callosum	Diagnosis	ICD-10-CN
204.3	Other reduction deformities of brain	Diagnosis	ICD-10-CN
204.4	Septo-optic dysplasia of brain	Diagnosis	ICD-10-CN
204.5	Megalencephaly	Diagnosis	ICD-10-CN
204.6	Congenital cerebral cysts	Diagnosis	ICD-10-CN
204.8	Other specified congenital malformations of brain	Diagnosis	ICD-10-CN
04.9	Congenital malformation of brain, unspecified	Diagnosis	ICD-10-CN
890.82	White matter disease, unspecified	Diagnosis	ICD-10-CN
93.0	Abnormal findings on diagnostic imaging of skull and head, not elsewhere classified	Diagnosis	ICD-10-CN
ther Bra	in Abnormality		
691.3	Post-traumatic hydrocephalus, unspecified	Diagnosis	ICD-10-CN
203.0	Malformations of aqueduct of Sylvius	Diagnosis	ICD-10-CN



Code	Description	Code Category	Code Type
Q03.1	Atresia of foramina of Magendie and Luschka	Diagnosis	ICD-10-CM
204.1	Arhinencephaly	Diagnosis	ICD-10-CM
204.2	Holoprosencephaly	Diagnosis	ICD-10-CM
Cytome	galovirus Infection (CMV)		
078.5	Cytomegaloviral disease	Diagnosis	ICD-9-CM
325.0	Cytomegaloviral pneumonitis	Diagnosis	ICD-10-CM
325.1	Cytomegaloviral hepatitis	Diagnosis	ICD-10-CN
325.2	Cytomegaloviral pancreatitis	Diagnosis	ICD-10-CN
325.8	Other cytomegaloviral diseases	Diagnosis	ICD-10-CN
325.9	Cytomegaloviral disease, unspecified	Diagnosis	ICD-10-CN
Congeni	tal Cytomegalovirus (cCMV)		
771.1	Congenital cytomegalovirus infection	Diagnosis	ICD-9-CM
P35.1	Congenital cytomegalovirus infection	Diagnosis	ICD-10-CN
CMV PC	R Test (Blood, Urine, Saliva)		
37483	Infectious agent detection by nucleic acid (DNA or RNA); central nervous system	Procedure	CPT-4
	pathogen (eg, Neisseria meningitidis, Streptococcus pneumoniae, Listeria, Haemophilus		
	influenzae, E. coli, Streptococcus agalactiae, enterovirus, human parechovirus, herpes		
	simplex virus type 1 and 2, human herpesvirus 6, cytomegalovirus, varicella zoster virus,		
	Cryptococcus), includes multiplex reverse transcription, when performed, and multiplex		
	amplified probe technique, multiple types or subtypes, 12-25 targets		
37495	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, direct probe	Procedure	CPT-4
	technique		
87496	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, amplified	Procedure	CPT-4
	probe technique		
87497	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, quantification	Procedure	CPT-4
37910	Infectious agent genotype analysis by nucleic acid (DNA or RNA); cytomegalovirus	Procedure	CPT-4
	tigen or Antibody Testing		••••
36644	Antibody; cytomegalovirus (CMV)	Procedure	CPT-4
36645	Antibody; cytomegalovirus (CMV), IgM	Procedure	CPT-4
37198	Cytomegalovirus, direct fluorescent antibody (DFA)	Procedure	CPT-4
37271	Infectious agent antigen detection by immunofluorescent technique; Cytomegalovirus,	Procedure	CPT-4
	direct fluorescent antibody (DFA)		
87332	Infectious agent antigen detection by immunoassay technique, (eg, enzyme	Procedure	CPT-4
	immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA],		-
	immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step		
CMV Cu			
37252	Virus isolation; tissue culture inoculation, observation, and presumptive identification by	Procedure	CPT-4
	cytopathic effect		
37254	Virus isolation; centrifuge enhanced (shell vial) technique, includes identification with	Procedure	CPT-4
	immunofluorescence stain, each virus		
lead Co	omputed Tomography (CT)		
70450	Computed tomography, head or brain; without contrast material	Procedure	CPT-4
70460	Computed tomography, head or brain; with contrast material(s)	Procedure	CPT-4
5400	compared tomography, neuron stant, with contrast materiality	insecure	



Code	Description	Code Category	Code Type
70470	Computed tomography, head or brain; without contrast material, followed by contrast material(s) and furthe sections	Procedure	CPT-4
70480	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material	Procedure	CPT-4
70481	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; with contrast material(s)	Procedure	CPT-4
70482	Computed tomography, orbit, sella, or posterior fossa or outer, middle, or inner ear; without contrast material, followed by contrast material(s) and further sections	Procedure	CPT-4
0351	CT Scan-Head Scan	Procedure	Revenue
Brain MR			
70551	Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material	Procedure	CPT-4
70552	Magnetic resonance (eg, proton) imaging, brain (including brain stem); with contrast material(s)	Procedure	CPT-4
70553	Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences	Procedure	CPT-4
0611	Magnetic Resonance Technology-MRI-Brain/Brain Stem	Procedure	Revenue
88.91	Magnetic resonance imaging of brain and brain stem	Procedure	ICD-9-PCS
3030Y0Z	Magnetic Resonance Imaging (MRI) of Brain using Other Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
B030YZZ	Magnetic Resonance Imaging (MRI) of Brain using Other Contrast	Procedure	ICD-10-PCS
B030ZZZ	Magnetic Resonance Imaging (MRI) of Brain	Procedure	ICD-10-PCS
B33RY0Z	Magnetic Resonance Imaging (MRI) of Intracranial Arteries using Other Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
B33RYZZ	Magnetic Resonance Imaging (MRI) of Intracranial Arteries using Other Contrast	Procedure	ICD-10-PCS
B33RZZZ	Magnetic Resonance Imaging (MRI) of Intracranial Arteries	Procedure	ICD-10-PCS
Head Ultr			
76536	Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation	Procedure	HCPCS
76536	US SOFT TISSUE HEAD & NECK REAL TIME IMGE DOCM	Procedure	CPT-4
38.71	DIAGNOSTIC ULTRASOUND OF HEAD AND NECK	Procedure	ICD-9-PCS
3040ZZZ	Ultrasonography of Brain	Procedure	ICD-10-PCS
BH4CZZZ	Ultrasonography of Head and Neck	Procedure	ICD-10-PCS
	Ultrasonography of Neck	Procedure	ICD-10-PCS
Neutrope			
288.0	Neutropenia	Diagnosis	ICD-9-CM
288.00	Neutropenia, unspecified	Diagnosis	ICD-9-CM
288.01	Congenital neutropenia	Diagnosis	ICD-9-CM
288.03	Drug induced neutropenia	Diagnosis	ICD-9-CM
288.04	Neutropenia due to infection	Diagnosis	ICD-9-CM
288.09	Other neutropenia	Diagnosis	ICD-9-CM
776.7	Transient neonatal neutropenia	Diagnosis	ICD-9-CM
D70	Neutropenia	Diagnosis	ICD-10-CN
D70.0	Congenital agranulocytosis	Diagnosis	ICD-10-CM



D70.2 Other drug-induced agranulocytosis Diagnosis D70.3 Neutropenia due to infection Diagnosis D70.8 Other neutropenia Diagnosis D70.9 Neutropenia, unspecified Diagnosis P61.5 Transient neonatal neutropenia Diagnosis D3023001 Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open Approach Procedure 3023011 Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open Approach Procedure 3023301 Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open Approach Procedure 3023011 Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open Approach Procedure 3024001 Transfusion of Nonautologous Red Blood Cells into Central Vein, Open Approach Procedure 3024001 Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous Approach Procedure 3024301 Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous Approach Procedure 3025001 Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open Approach Procedure 3025001 Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open Approach Procedure 3025011 Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open Approach Procedure <	ICD-10-CI ICD-10-CI ICD-10-CI ICD-10-CI ICD-10-CI ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
D70.8Other neutropeniaDiagnosisD70.9Neutropenia, unspecifiedDiagnosisD70.9Neutropenia, unspecifiedDiagnosisReceipt of R8C TransfusionDiagnosis80230N1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open ApproachProcedure30230N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Open ApproachProcedure30231N1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Percutaneous ApproachProcedure30230N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30250P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Percutaneous ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30260N1Tran	ICD-10-Cf ICD-10-Cf ICD-10-Cf ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
D70.9Neutropenia, unspecifiedDiagnosisP61.5Transient neonatal neutropeniaDiagnosisReceipt of RBC Transfusion30230N1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open ApproachProcedure30230N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Open ApproachProcedure302311Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Percutaneous ApproachProcedure30230P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure3024301Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure3024301Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure3024301Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure3024301Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure3025001Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure3025001Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure3025001Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure3025001Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure3025301Transfusion of Nonautologous Red Blood Cells into Central Artery, P	ICD-10-Cf ICD-10-Cf ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
P61.5Transient neonatal neutropeniaDiagnosisReceipt of RBC Transfusion30230N1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open ApproachProcedure30230P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Percutaneous ApproachProcedure30231N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Percutaneous ApproachProcedure30230P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Percutaneous ApproachProcedure30240N1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure30250P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Open ApproachProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30260P1 </td <td>ICD-10-Cf ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC</td>	ICD-10-Cf ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
Receipt of RBC Transfusion30230N1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open ApproachProcedure30230N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Open ApproachProcedure30233N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Percutaneous ApproachProcedure30233N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Percutaneous ApproachProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30243P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30250P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous Approach <td>ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC</td>	ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
30230N1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Open ApproachProcedure30230P1Transfusion of Nonautologous Rrozen Red Cells into Peripheral Vein, Open ApproachProcedure30233P1Transfusion of Nonautologous Rrozen Red Cells into Peripheral Vein, Percutaneous ApproachProcedure30233P1Transfusion of Nonautologous Rrozen Red Cells into Peripheral Vein, Open ApproachProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253N1Transfusion of Nonautologous Rozen Red Cells into Central Artery, PercutaneousProcedure30253N1Transfusion of Nonautologous Rozen Red Cells into Central Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Rozen Red Cells into Central Artery, PercutaneousProcedure30260N1Transfusion of Nonautologous Rozen Red Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautolog	ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
30230P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Open ApproachProcedure30233N1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Percutaneous ApproachProcedure30233P1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Percutaneous ApproachProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedureApproachTransfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusi	ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
30233N1Transfusion of Nonautologous Red Blood Cells into Peripheral Vein, Percutaneous ApproacProcedure30233P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30243N1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure30250N1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, PercutaneousProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30260N1Transfus	ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
30233P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Vein, Percutaneous ApproaProcedure30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30243N1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, PercutaneousProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1 <td< td=""><td>ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC</td></td<>	ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
30240N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Open ApproachProcedure30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30243P1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30250P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedureApproachProcedureProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutan	ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
30240P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Open ApproachProcedure30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30243P1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30250P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, PercutaneousProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure302611Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30262011Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263011Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263011 <td>ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC</td>	ICD-10-PC ICD-10-PC ICD-10-PC ICD-10-PC
30243N1Transfusion of Nonautologous Red Blood Cells into Central Vein, Percutaneous ApproachProcedure30243P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30250P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253N1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, PercutaneousProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30273N1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProc	ICD-10-PC ICD-10-PC ICD-10-PC
30243P1Transfusion of Nonautologous Frozen Red Cells into Central Vein, Percutaneous ApproachProcedure30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30250P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30273N1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory, Percutaneous @ Red Blood CellsProcedure30273PAdministration @ Circulatory @ Transfusion @ Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of	ICD-10-PC ICD-10-PC
30250N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Open ApproachProcedure30250P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Open ApproachProcedure30253P1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, PercutaneousProcedure30253P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous ApproachProcedure30273N1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory, Percutaneous ApproachProcedure30273P1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedure Secure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedure Secure30273P1Transfusion of	ICD-10-PC
30250P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Open ApproachProcedure30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Percutaneous ApproachProcedure30253P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Percutaneous ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30273N1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory, Percutaneous ApproachProcedure30273P1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedures of Conception, Circulatory, Procedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous ApproachProcedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutane	
30253N1Transfusion of Nonautologous Red Blood Cells into Peripheral Artery, Percutaneous ApproachProcedure30253P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Percutaneous ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous ApproachProcedure30263P1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous ApproachProcedure30273N1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @Procedure30273N2Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory, Percutaneous ApproachProcedure30273P1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @Procedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedure So Conception, Circulatory, Procedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous ApproachProcedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutan	ICD-10-PC
ApproachProcedure30253P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Percutaneous ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260P1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263P1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263P1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous ApproachProcedure30273NAdministration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @Procedure30273N1Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, Percutaneous ApproachProcedure30273P1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @Procedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory @Procedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous ApproachProcedure	
30253P1Transfusion of Nonautologous Frozen Red Cells into Peripheral Artery, Percutaneous ApproachProcedure30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260P1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263P1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous ApproachProcedure30273NAdministration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @Procedure30273N1Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, Percutaneous ApproachProcedure30273P1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @Procedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory @Procedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedure So Conception, Circulatory, ProcedureProcedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous ApproachProcedure	ICD-10-PC
30260N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Open ApproachProcedure30260P1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Open ApproachProcedure30263N1Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous ApproachProcedure30263P1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous ApproachProcedure30263P1Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous ApproachProcedure30273N1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @Procedure30273N1Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, Percutaneous ApproachProcedure30273P1Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @Procedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous @ Frozen Red CellsProcedure30273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous ApproachProcedure	ICD-10-PC
 30260P1 Transfusion of Nonautologous Frozen Red Cells into Central Artery, Open Approach 30263N1 Transfusion of Nonautologous Red Blood Cells into Central Artery, Percutaneous Approach 30263P1 Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous Approach 30273N Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Procedure 30273N1 Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, 30273P Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ 30273P Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, 30273P1 Procedure 	ICD-10-PC
 30263P1 Transfusion of Nonautologous Frozen Red Cells into Central Artery, Percutaneous Approac Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Procedure Percutaneous @ Red Blood Cells 30273N1 Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, Percutaneous Approach 30273P Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Procedure Percutaneous Approach 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Procedure Percutaneous @ Frozen Red Cells 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Procedure Percutaneous Approach 	ICD-10-PC
 Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Procedure Percutaneous @ Red Blood Cells Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, Percutaneous Approach Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Procedure Percutaneous @ Frozen Red Cells Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous @ Frozen Red Cells Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous Approach 	ICD-10-PC
Percutaneous @ Red Blood Cells 30273N1 Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, Percutaneous Approach 30273P Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Procedure Percutaneous @ Frozen Red Cells 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Procedure Percutaneous Approach Procedure	ICD-10-PC
30273N1 Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, Percutaneous Approach Procedure 30273P Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Procedure 30273P1 Frozen Red Cells Procedure 30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Percutaneous Approach Procedure	ICD-10-PC
30273PAdministration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ProcedurePercutaneous @ Frozen Red Cells80273P1Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory,ProcedurePercutaneous ApproachProcedureProcedure	ICD-10-PC
30273P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Procedure Percutaneous Approach	ICD-10-PC
	ICD-10-PC
30277N Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Via Procedure Natural or Artificial Opening @ Red Blood Cells	ICD-10-PC
30277N1 Transfusion of Nonautologous Red Blood Cells into Products of Conception, Circulatory, Procedure Via Natural or Artificial Opening	ICD-10-PC
0277P Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Via Procedure Natural or Artificial Opening @ Frozen Red Cells	ICD-10-PC
0277P1 Transfusion of Nonautologous Frozen Red Cells into Products of Conception, Circulatory, Procedure Via Natural or Artificial Opening	ICD-10-PC
904 Transfusion of packed cells Procedure	ICD-9-CN
C1016Whole blood or red blood cells, leukoreduced, frozen, deglycerol, washed, each unitProcedureC1020Each unit red blood cells, frozen/deglycerolized/washed, leukocyte-reduced, irradiatedProcedure	HCPCS HCPCS



Code	Description	Code Category	Code Type
C1021	Red blood cells, leukocyte-reduced, cmv negative, irradiated, each unit	Procedure	HCPCS
C9504	RED BLD CELLS DEGLYCEROLIZED EA UNI	Procedure	HCPCS
C9505	Red blood cells, irradiated, each unit	Procedure	HCPCS
P9016	Red blood cells, leukocytes reduced, each unit	Procedure	HCPCS
P9021	Red blood cells, each unit	Procedure	HCPCS
P9022	Red blood cells, washed, each unit	Procedure	HCPCS
P9038	Red blood cells, irradiated, each unit	Procedure	HCPCS
P9039	RBCS DEGLYCEROLIZED EACH UNIT	Procedure	HCPCS
P9040	Red blood cells, leukocytes reduced, irradiated, each unit	Procedure	HCPCS
9051	Whole blood or red blood cells, leukocytes reduced, cmv-negative, each unit	Procedure	HCPCS
P9054	Each unit whole blood or red blood cells, leukocytes reduced, frozen, deglycerol, washed	Procedure	HCPCS
9057	Red blood cells, frozen/deglycerolized/washed, leukocytes reduced, irradiated, each unit	Procedure	HCPCS
P9058	Red blood cells, leukocytes reduced, cmv-negative, irradiated, each unit	Procedure	HCPCS
Receipt o	f Platelet Transfusion		
30230R	Administration @ Circulatory @ Transfusion @ Peripheral Vein @ Open @ Platelets	Procedure	ICD-10-PC
30230R1	Transfusion of Nonautologous Platelets into Peripheral Vein, Open Approach	Procedure	ICD-10-PC
30233R	Administration @ Circulatory @ Transfusion @ Peripheral Vein @ Percutaneous @ Platelet	Procedure	ICD-10-PC
30233R1	Transfusion of Nonautologous Platelets into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PC
30240R	Administration @ Circulatory @ Transfusion @ Central Vein @ Open @ Platelets	Procedure	ICD-10-PC
30240R1	Transfusion of Nonautologous Platelets into Central Vein, Open Approach	Procedure	ICD-10-PC
30243R	Administration @ Circulatory @ Transfusion @ Central Vein @ Percutaneous @ Platelets	Procedure	ICD-10-PC
80243R1	Transfusion of Nonautologous Platelets into Central Vein, Percutaneous Approach	Procedure	ICD-10-PC
30250R	Administration @ Circulatory @ Transfusion @ Peripheral Artery @ Open @ Platelets	Procedure	ICD-10-PC
30250R1	Transfusion of Nonautologous Platelets into Peripheral Artery, Open Approach	Procedure	ICD-10-PC
30253R	Administration @ Circulatory @ Transfusion @ Peripheral Artery @ Percutaneous @ Platel	Procedure	ICD-10-PC
30253R1	Transfusion of Nonautologous Platelets into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PC
30260R	Administration @ Circulatory @ Transfusion @ Central Artery @ Open @ Platelets	Procedure	ICD-10-PC
30260R1	Transfusion of Nonautologous Platelets into Central Artery, Open Approach	Procedure	ICD-10-PC
30263R	Administration @ Circulatory @ Transfusion @ Central Artery @ Percutaneous @ Platelets	Procedure	ICD-10-PC
30263R1	Transfusion of Nonautologous Platelets into Central Artery, Percutaneous Approach	Procedure	ICD-10-PC
30273R	Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Percutaneous @ Platelets	Procedure	ICD-10-PC
80273R1	Transfusion of Nonautologous Platelets into Products of Conception, Circulatory, Percutaneous Approach	Procedure	ICD-10-PC
80277R	Administration @ Circulatory @ Transfusion @ Products of Conception, Circulatory @ Via Natural or Artificial Opening @ Platelets	Procedure	ICD-10-PC
0277R1	Transfusion of Nonautologous Platelets into Products of Conception, Circulatory, Via Natural or Artificial Opening	Procedure	ICD-10-PC
905	Platelet transfusion	Procedure	ICD-9-CN
C1011	Platelet, hla-matched leukoreduced, apheresis/pheresis, each unit	Procedure	HCPCS
C1012	Platelet concentrate, leukoreduced, aprieresis, prieresis, each unit	Procedure	HCPCS
C1012	Platelet, hla-matched leukoreduced, apheresis/pheresis, each unitytes reduced	Procedure	HCPCS
C1015	Platelet, leukoreduced, apheresis, pheresis, each unit	Procedure	HCPCS
	רומנכוכו, וכעולטו בעערבע, מטוובו באא טוובו באא, במלוו עווונ	FIOLEUUIE	nurus



Code	Description	Code Category	Code Type
C1017	Platelet, leukoreduced, cmv-negative, apheresis/pheresis, each unit	Procedure	HCPCS
C1019	Platelet, leukoreduced, irradiated, apheresis/pheresis, each unit	Procedure	HCPCS
C9500	Platelets, irradiated, each unit	Procedure	HCPCS
C9501	Platelets, pheresis, each unit	Procedure	HCPCS
C9502	PLATELETS PHERESIS IRRADIATED EA UN	Procedure	HCPCS
P9019	Platelets, each unit	Procedure	HCPCS
P9031	Platelets, leukocytes reduced, each unit	Procedure	HCPCS
P9032	Platelets, irradiated, each unit	Procedure	HCPCS
P9033	Platelets, leukocytes reduced, irradiated, each unit	Procedure	HCPCS
P9034	Platelets, pheresis, each unit	Procedure	HCPCS
P9035	Platelets, pheresis, leukocytes reduced, each unit	Procedure	HCPCS
P9036	PLATELETS PHERESIS IRRADATD EA UNIT	Procedure	HCPCS
P9037	Platelets, pheresis, leukocytes reduced, irradiated, each unit	Procedure	HCPCS
P9052	PLT HLA-MATCHD LEUKOCYTES RDUC EACH	Procedure	HCPCS
P9053	PLT PHERES LEUKOCYT RDUC CMV-NEG EA	Procedure	HCPCS
P9055	PLT LEUKOCYT RDUC CMV-NEG APH/PHERS	Procedure	HCPCS
P9072	PLT PHRS PATH RDUC/RPD BACT TST E U	Procedure	HCPCS
Q9988	PLATELETS PATHOGEN REDUCED EA UNIT	Procedure	HCPCS
Receipt	of GCSF Transfusion		
C9058	Injection, pegfilgrastim-bmez, biosimilar, (Ziextenzo) 0.5 mg	Procedure	HCPCS
C9119	Injection, pegfilgrastim, per 6 mg single dose vial	Procedure	HCPCS
J1440	Injection, filgrastim (G-CSF), 300 mcg	Procedure	HCPCS
J1441	Injection, filgrastim (G-CSF), 480 mcg	Procedure	HCPCS
J1442	Injection, filgrastim (G-CSF), excludes biosimilars, 1 mcg	Procedure	HCPCS
J1446	Injection, TBO-filgrastim, 5 micrograms	Procedure	HCPCS
J1447	Injection, tbo-filgrastim, 1 mcg	Procedure	HCPCS
J2505	Injection, pegfilgrastim, 6 mg	Procedure	HCPCS
Q4053	Injection, pegfilgrastim, 1 mg	Procedure	HCPCS
Q5101	Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg	Procedure	HCPCS
Q5108	Injection, pegfilgrastim-jmdb, biosimilar, (Fulphila), 0.5 mg	Procedure	HCPCS
Q5110	Injection, filgrastim-aafi, biosimilar, (Nivestym), 1 mcg	Procedure	HCPCS
Q5111	Injection, pegfilgrastim-cbqv, biosimilar, (Udenyca), 0.5 mg	Procedure	HCPCS
Q5120	Injection, pegfilgrastim-bmez, biosimilar, (ZIEXTENZO), 0.5 mg	Procedure	HCPCS
S0135	Injection pegfilgrastim, 6 mg	Procedure	HCPCS



				egalovirus Infection (C				-		GVC) use in children with	
Query Period: January 1, 2008 - May 31, 2021 Coverage Requirement: Medical and Drug Coverage Pre-Index Enrollment Requirement: No pre-enrollment requirement Post-Index Enrollment Requirement: 0 days Enrollment Gap: 0 days Age Groups: ≤45 days (For CMV index); 0 < 6 months, 6 months < 1 year, 1 < 2 years, 2 < 3 years, 3 < 4 years, 4 - 5 years (For VGCV index) Distribution of Index-Defining Codes: Valganciclovir, Ganciclovir Censor Output Cate Yes (Overall, censor days by 1-14, 15 - 30, 31 - 90, 91 - 180, 181 - 365, and >365) - For valganciclovir assessments only Stratifications: Sex, Year, Ethnicity, Region, Sex & Year, Ethnicity & Year, Race & Year, Region & Year Freeze Data: Yes										and >365) - For	
Scenario	Index	Cohort Definition	-	Maximum Exposure Episode Duration		Treatment	Exposure Episode	Minimum Exposure Episode Duration	Minimum Days Supplied	Censor Treatment Episode at Evidence of:	Flag for PEPR
1	cCMV or CMV	First valid exposure episodes during query period;	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Yes
2	cCMV or CMV	First valid exposure episodes during query period;	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
3	cCMV or CMV	First valid exposure episodes during query period;	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
4	cCMV or CMV	First valid exposure episodes during query period;	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
5	cCMV or CMV	First valid exposure episodes during query period;	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	



						Ехро	sure				
Scenario	Index	Cohort Definition	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration	Minimum Days Supplied	Censor Treatment Episode at Evidence of:	Flag for PEPR
6	cCMV or CMV	First valid exposure episodes during query period;	Yes	180	N/A	N/A	N/A	N/A	N/A	N/A	Yes
7	cCMV or CMV	First valid exposure episodes during query period;	Yes	180	N/A	N/A	N/A	N/A	N/A	N/A	
8	cCMV or CMV	First valid exposure episodes during query period;	Yes	180	N/A	N/A	N/A	N/A	N/A	N/A	
9	cCMV or CMV	First valid exposure episodes during query period;	Yes	180	N/A	N/A	N/A	N/A	N/A	N/A	
10	cCMV or CMV	First valid exposure episodes during query period;	Yes	180	Any care settng	N/A	N/A	N/A	N/A	N/A	
11	cCMV or CMV	First valid exposure episodes during query period;	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Yes
12	cCMV or CMV	First valid exposure episodes during query period;	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	Yes
13	VGVC or GGVC	First valid exposure episodes during query period;		N/A	Any care settng	30 days	30 days	1 day	1 day	*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	Yes



_	Exposure										
Scenario	Index	Cohort Definition	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Treatment Episode Gap	Exposure Episode Extension	Minimum Exposure Episode Duration	Minimum Days Supplied	Censor Treatment Episode at Evidence of:	Flag for PEPR
14	VGVC or GGVC	First valid exposure episodes during query period;		N/A	Any care settng	30 days	30 days	1 day	1 day	*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	Yes
15	VGVC or GGVC	First valid exposure episodes during query period;		N/A	Any care settng	30 days	30 days	1 day	1 day	*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	Yes
16	VGVC or GGVC	First valid exposure episodes during query period;		N/A	Any care settng	30 days	30 days	1 day	1 day	*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	Yes
17	VGVC or GGVC	First valid exposure episodes during query period;		N/A	Any care settng	30 days	30 days	1 day	1 day	*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	Yes
18	VGVC or GGVC	First valid exposure episodes during query period;		N/A	Any care settng	30 days	30 days	1 day	1 day	*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	
19	VGVC or GGVC	First valid exposure episodes during query period;		N/A	Any care settng	30 days	30 days	1 day	1 day	*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	Yes



						Ехро	osure				
Scenario	Index	Cohort Definition	Build Episodes on Point Exposure?	Maximum Exposure Episode Duration	Care Setting	Treatment Episode Gap	· ·	Minimum Exposure Episode Duration	Minimum Days Supplied	Censor Treatment Episode at Evidence of:	Flag for PEPR
20	VGVC or GGVC	First valid exposure episodes during query period;	N/A		Any care settng					*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	
21	VGVC or GGVC	First valid exposure episodes during query period;	N/A		Any care settng					*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	
22	VGVC or GGVC	First valid exposure episodes during query period;	N/A		Any care settng					*Death; *DP end date; *Query end date; *Episode End Date *Disenrollment	



		Inclusion/Exclusion	Criteria	
Scenario	Inclusion/ Exclusion Group	Criteria	Evaluation Period Start	Evaluation Period End
1	N/A	N/A	N/A	N/A
2 ——	Hearing Loss	Exclusion	Ever (prior to index)	15 days
-	Clinical Characteristics	Exclusion	Ever (prior to index)	15 days
3	Hearing Loss	Inclusion	Ever (prior to index)	15 days
5	Clinical Characteristics	Exclusion	Ever (prior to index)	15 days
1	Hearing Loss	Exclusion	Ever (prior to index)	15 days
4	Clinical Characteristics	Inclusion	Ever (prior to index)	15 days
5	Hearing Loss	Inclusion	Ever (prior to index)	15 days
5	Clinical Characteristics	Inclusion	Ever (prior to index)	15 days
6	N/A	N/A	N/A	N/A
7	Hearing Loss	Exclusion	Ever (prior to index)	1E days
,	Clinical Characteristics	Exclusion	– Ever (prior to index)	15 days
8 ——	Hearing Loss	Inclusion	Ever (prior to index)	1E days
0	Clinical Characteristics	Exclusion	– Ever (prior to index)	15 days
9 —	Hearing Loss	Exclusion		15 davia
9	Clinical Characteristics	Inclusion	 Ever (prior to index) 	15 days
10	Hearing Loss	Inclusion	Free (action to indee)	45 days
10	Clinical Characteristics	Inclusion	– Ever (prior to index)	15 days
11	VGVC or GGVC	Inclusion	0 days	45 days
12	VGVC or GGVC	Inclusion	0 days	180 days
13	cCMV	Inclusion	Ever (prior to index)	45 days
	cCMV	Inclusion	Ever (prior to index)	45 days
14	Hearing Loss	Exclusion	Ever (prior to index)	0 days
	Clinical Characteristics	Exclusion	Ever (prior to index)	0 days



r		Inclusion/Exclusion	Criteria	
cenario	Inclusion/ Exclusion Group	Criteria	Evaluation Period Start	Evaluation Period End
	cCMV	Inclusion	Ever (prior to index)	45 days
15	Hearing Loss	Inclusion	Ever (prior to index)	0 days
	Clinical Characteristics	Exclusion	Ever (prior to index)	0 days
	cCMV	Inclusion	Ever (prior to index)	45 days
16	Hearing Loss	Exclusion	Ever (prior to index)	0 days
	Clinical Characteristics	Inclusion	Ever (prior to index)	0 days
	cCMV	Inclusion	Ever (prior to index)	45 days
17	Hearing Loss	Inclusion	Ever (prior to index)	0 days
	Clinical Characteristics	Inclusion	Ever (prior to index)	0 days
18 ——	cCMV	Inclusion	Ever (prior to index)	0 days
10	No Hematologic Outcomes	Exclusion	0 days	180 days
19 ———	cCMV	Inclusion	Ever (prior to index)	0 days
19	Any Hematologic Outcomes	Inclusion	0 days	180 days
20	cCMV or CMV	Inclusion	-45 days	0 days
21	cCMV or CMV	Inclusion	-45 days	0 days
22	cCMV or CMV	Inclusion	-45 days	0 days



			Covariates			
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period
1	Clinical characteristics, Lab tests, Radiology, CMV culture	N/A	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
2 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
3	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
3 -	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified



		Covariates									
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period					
4 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified					
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified					
E	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified					
5	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified					



			Covariates			
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period
6	Clinical characteristics, Lab tests,	N/A	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
6	Radiology, CMV culture	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
7 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified



			Covariates			
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period
8	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
9	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified



			Covariates			
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period
10	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
10	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
11	Clinical characteristics, Lab tests,	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
11	Radiology, CMV culture	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified



			Covariates			
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period
12	Clinical characteristics, Lab tests, Radiology, CMV culture	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
		Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
13	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
		Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified



	Covariates							
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period		
14 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified		
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified		
15 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified		
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified		



		Covariates				
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period
16 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
17 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified



		Covariates							
Scenario	Covariates	Principal Diagnosis Position	Exclude Evidence of Days Supply if Event Washout Includes Dispensings	Event De-Duplication	Forced Supply to Attach to Dispensings	Blackout Period			
18 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified			
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	attached to the NDC to	Numeric specified			
19 -	N/A	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified			
	Selected clinical characteristics include Jaundice, Petechiae, Hepatomegaly, Splenomegaly, Microcephaly, Thrombocytopenia, Chorioretinitis, Brain abnormality	Only applicable for Inpatient and Institutional stays: *Principal; *Secondary; *Unknown	*Washout lookback period should search for evidence of days supply; *Washout lookback period should search for only evidence of a dispensing date	*Count all occurrences of an HOI during exposure period *De-duplicates occurrences of the same event code and code type on the same day *De-duplicates occurrences of the same event group on the same day	Numeric specified; Indicates a forced supply that should be attached to the NDC to replace the event code's RxSup value	Numeric specified			

International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology (CPT) codes are provided by Optum360.

National Drug Codes (NDCs) are checked against First Data Bank's "National Drug Data File (NDDF®) Plus."



Trends in Rates of Congenital CMV Overall and by Selected Demographic Characteristics


Cohort A

- Index on date of CMV diagnosis
- Restricted to infants 45 days old or younger
- No pre-index enrollment requirement
- Repeat, with stratification by Disease Severity

<u>Cohort Definition</u> First valid exposure episode; no cohort re-entry

Stratifications

Year, Sex, Ethnicity, Race, Geographic location, Sex*Year, Geographic location*Year, Race*Year, Ethnicity*Year





Trends in Prevalence of Valganciclovir Use Among Infants With Congenital CMV Overall and by Selected Demographic Characteristics

Cohort A with Valganciclovir Treatment


- Index on date of CMV diagnosis
- Restricted to infants 45 days old or younger
- No Pre-index requirement
- Event: Valganciclovir/Ganciclovir Treatment

Cohort Definition

First valid exposure episode; no cohort re-entry


Stratifications

Year, Sex, Ethnicity, Race, Geographic location, Sex*year, Ethnicity*year, Race*year, Geographic location*year



















Clinical Testing and Clinical Characteristics of Infants with Valganciclovir-Treated Congenital CMV Disease (Sensitivity Analysis: Valganciclovir Use Within the First 180 Days from CMV Diagnosis)